{
    "5e6157cb1af46fc13000000e_1": [
        {
            "start_logit": 14.34375,
            "end_logit": 15.25,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8076171875,
            "end_logit": 15.25,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.34375,
            "end_logit": -2.26171875,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -2.712890625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -5.9453125,
            "text": "Rett syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 15.25,
            "text": "methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 15.25,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 15.25,
            "text": "Mutations in the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 15.25,
            "text": "protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 15.25,
            "text": "with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 15.25,
            "text": "commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.25,
            "text": "associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.25,
            "text": "are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.25,
            "text": "2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.25,
            "text": "gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 15.25,
            "text": "binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.25,
            "text": "the methyl-CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.25,
            "text": "(MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.25,
            "text": ") are commonly associated with Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.25,
            "text": "CpG-binding protein-2 gene (MECP2) are commonly associated with Rett syndrome",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_2": [
        {
            "start_logit": 14.28125,
            "end_logit": 15.1484375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": 15.1484375,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.28125,
            "end_logit": -2.3046875,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -3.23828125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 15.1484375,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.0859375,
            "text": "Rett syndrome (RS) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.3515625,
            "text": "Rett syndrome (RS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.4921875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.7421875,
            "text": "Rett syndrome (RS",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.7578125,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeC",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.7890625,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.8671875,
            "text": "Rett syndrome (RS) is a debilitating",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.921875,
            "text": "Rett syndrome (RS) is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.921875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.9296875,
            "text": "Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls",
            "probability": 0.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": -8.0859375,
            "text": "syndrome (RS) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": -9.3515625,
            "text": "syndrome (RS)",
            "probability": 0.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": -9.4921875,
            "text": "syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": -9.7421875,
            "text": "syndrome (RS",
            "probability": 0.0
        },
        {
            "start_logit": -1.943359375,
            "end_logit": -9.7578125,
            "text": "syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG-binding protein MeC",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_3": [
        {
            "start_logit": 14.34375,
            "end_logit": 15.2421875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8349609375,
            "end_logit": 15.2421875,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.34375,
            "end_logit": -2.263671875,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -3.017578125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -7.8203125,
            "text": "Rett syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 15.2421875,
            "text": "disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 15.2421875,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 15.2421875,
            "text": "Mutations in the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 15.2421875,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -8.4765625,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.265625,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 15.2421875,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 15.2421875,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.6875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.2421875,
            "text": "gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.7734375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.2421875,
            "text": "the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.2421875,
            "text": "in the MECP2 gene cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8349609375,
            "end_logit": -7.8203125,
            "text": "syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -1.8349609375,
            "end_logit": -8.4765625,
            "text": "syndrome (RT",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_4": [
        {
            "start_logit": 14.4296875,
            "end_logit": 15.2734375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": 15.2734375,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -2.01171875,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -3.099609375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -5.66015625,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -6.796875,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 15.2734375,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -8.40625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.2265625,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.515625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeC",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.5859375,
            "text": "Rett syndrome is a severe",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.5859375,
            "text": "Rett syndrome is a severe neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.6015625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.9140625,
            "text": "Rett syndrome is a severe neurodevelopmental disorder mainly caused by",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -5.66015625,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -6.796875,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -8.40625,
            "text": "syndrome is a severe neurodevelopmental disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -9.2265625,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -9.515625,
            "text": "syndrome is a severe neurodevelopmental disorder mainly caused by mutations in the transcriptional regulator MeC",
            "probability": 0.0
        },
        {
            "start_logit": -1.732421875,
            "end_logit": -9.5859375,
            "text": "syndrome is a severe",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_5": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.2265625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": 15.2265625,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.203125,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.873046875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -6.86328125,
            "text": "Rett syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.2265625,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.2265625,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.3984375,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 15.2265625,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.2265625,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.765625,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.2265625,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.9375,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.2265625,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.2265625,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 15.2265625,
            "text": "P2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": -6.86328125,
            "text": "syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": -8.3984375,
            "text": "syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -2.203125,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -2.203125,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_6": [
        {
            "start_logit": 14.4609375,
            "end_logit": 15.25,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": 15.25,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -1.896484375,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -2.986328125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -6.75,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 15.25,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.0859375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.4765625,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.890625,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.0546875,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.3671875,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.4140625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.75,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.75,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.78125,
            "text": "Rett syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2",
            "probability": 0.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": -6.75,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": -7.89453125,
            "text": "syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": -8.0859375,
            "text": "syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": -8.4765625,
            "text": "syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -1.830078125,
            "end_logit": -8.890625,
            "text": "syndrome (RTT) is a debilitating neurological disorder caused by mutations in the gene encoding the transcription factor Methyl CpG Binding Protein 2 (MECP2",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_7": [
        {
            "start_logit": 14.4609375,
            "end_logit": 15.2578125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.783203125,
            "end_logit": 15.2578125,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -1.927734375,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -3.0078125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -6.58203125,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -6.859375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.0078125,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 15.2578125,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.0546875,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.2265625,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.3203125,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.4296875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.2265625,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.296875,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.3984375,
            "text": "Rett syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeC",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.46875,
            "text": "Rett syndrome (RTT) is associated",
            "probability": 0.0
        },
        {
            "start_logit": -1.783203125,
            "end_logit": -6.58203125,
            "text": "syndrome (RTT) is associated with mutations in the transcriptional repressor gene MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.783203125,
            "end_logit": -6.859375,
            "text": "syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -1.783203125,
            "end_logit": -8.0078125,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.783203125,
            "end_logit": -8.0546875,
            "text": "syndrome (RTT)",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_8": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.2265625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": 15.2265625,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.203125,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.873046875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -6.86328125,
            "text": "Rett syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.2265625,
            "text": "cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.2265625,
            "text": "Mutations in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.3984375,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 15.2265625,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.2265625,
            "text": "gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.765625,
            "text": "Rett syndrome, a progressive neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.2265625,
            "text": "the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.9375,
            "text": "Rett syndrome, a",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.2265625,
            "text": "MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.2265625,
            "text": "in the MeCP2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 15.2265625,
            "text": "P2 gene cause Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": -6.86328125,
            "text": "syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": -1.8671875,
            "end_logit": -8.3984375,
            "text": "syndrome, a progressive neurodevelopmental disorder.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -2.203125,
            "text": "cause Ret",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -2.203125,
            "text": "Mutations in the MeCP2 gene cause Ret",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_9": [
        {
            "start_logit": 14.3125,
            "end_logit": 15.2109375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": 15.2109375,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3125,
            "end_logit": -2.390625,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -2.716796875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -5.81640625,
            "text": "Rett syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -6.828125,
            "end_logit": 15.2109375,
            "text": "Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 15.2109375,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 15.2109375,
            "text": "mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 15.2109375,
            "text": "in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 15.2109375,
            "text": "protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 15.2109375,
            "text": "disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.2109375,
            "text": "-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.2109375,
            "text": "type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.2109375,
            "text": "binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.2109375,
            "text": "CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.2109375,
            "text": "-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 15.2109375,
            "text": ") mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 15.2109375,
            "text": "(MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 15.2109375,
            "text": "2 (MECP2) mutation type is associated with disease severity in Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.89453125,
            "end_logit": -5.81640625,
            "text": "syndrome.",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_10": [
        {
            "start_logit": 14.34375,
            "end_logit": 15.203125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": 15.203125,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.34375,
            "end_logit": -2.1796875,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -3.22265625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 15.203125,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -8.859375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.15625,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.4609375,
            "text": "Rett syndrome (RTT),",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.5859375,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.5859375,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.609375,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.7109375,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2,",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.828125,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.890625,
            "text": "Rett syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeC",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.921875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": -8.859375,
            "text": "syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": -9.15625,
            "text": "syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": -9.4609375,
            "text": "syndrome (RTT),",
            "probability": 0.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": -9.5859375,
            "text": "syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": -9.5859375,
            "text": "syndrome (RTT), the second most common cause of mental retardation in females, has been associated with mutations in MeCP2",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_11": [
        {
            "start_logit": 14.4921875,
            "end_logit": 15.2734375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.736328125,
            "end_logit": 15.2734375,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -1.8173828125,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -3.015625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.0546875,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.59375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": 15.2734375,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.6015625,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.984375,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.0234375,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.109375,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.296875,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2),",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.328125,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.3515625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.5078125,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.6328125,
            "text": "Rett syndrome (RTT) is a severe",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.640625,
            "text": "Rett syndrome (RTT) is a severe neurodevelopmental disease caused by mutations in methyl-CpG-binding protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.734375,
            "text": "Rett syndrome (RTT) is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.736328125,
            "end_logit": -7.0546875,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.736328125,
            "end_logit": -7.59375,
            "text": "syndrome (RTT)",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_12": [
        {
            "start_logit": 14.4375,
            "end_logit": 15.265625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.7890625,
            "end_logit": 15.265625,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4375,
            "end_logit": -2.001953125,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4375,
            "end_logit": -3.1328125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -7.84765625,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 15.265625,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.09375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.4296875,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.8203125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.8203125,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.8671875,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.9453125,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 15.265625,
            "text": "BACKGROUND  Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.046875,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.484375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.5703125,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MEC",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.6484375,
            "text": "Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": -1.7890625,
            "end_logit": -7.84765625,
            "text": "syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).",
            "probability": 0.0
        },
        {
            "start_logit": -1.7890625,
            "end_logit": -8.09375,
            "text": "syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -1.7890625,
            "end_logit": -8.4296875,
            "text": "syndrome (",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_13": [
        {
            "start_logit": 14.265625,
            "end_logit": 15.21875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8896484375,
            "end_logit": 15.21875,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.408203125,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.921875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 15.21875,
            "text": "the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 15.21875,
            "text": "disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 15.21875,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.1875,
            "text": "Rett syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 15.21875,
            "text": "Mutations in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.15625,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.21875,
            "text": "neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.21875,
            "text": "cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.4765625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.21875,
            "text": "in MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.796875,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 15.21875,
            "text": "MECP2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 15.21875,
            "text": "P2 cause the neurodevelopmental disorder Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8896484375,
            "end_logit": -8.1875,
            "text": "syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": -1.8896484375,
            "end_logit": -8.375,
            "text": "syndrome (RT",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_14": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.1953125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.9833984375,
            "end_logit": 15.1953125,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.228515625,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.494140625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 15.1953125,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 15.1953125,
            "text": "Mutations in the gene encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.9453125,
            "text": "Rett syndrome ,",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.2109375,
            "text": "Rett syndrome , an autism spectrum disorder mainly affecting young females .",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 15.1953125,
            "text": "protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.1953125,
            "text": "of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 15.1953125,
            "text": "methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.1953125,
            "text": "are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.7734375,
            "text": "Rett syndrome , an autism spectrum disorder mainly",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.1953125,
            "text": "encoding the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.1953125,
            "text": "the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.1953125,
            "text": "the methyl-CpG-binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 15.1953125,
            "text": "binding protein MECP2 are the major cause of Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.9833984375,
            "end_logit": -8.9453125,
            "text": "syndrome ,",
            "probability": 0.0
        },
        {
            "start_logit": -1.9833984375,
            "end_logit": -9.2109375,
            "text": "syndrome , an autism spectrum disorder mainly affecting young females .",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -2.494140625,
            "text": "t",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_15": [
        {
            "start_logit": 14.453125,
            "end_logit": 15.28125,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": 15.28125,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.453125,
            "end_logit": -1.904296875,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.453125,
            "end_logit": -3.13671875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 15.28125,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -8.1875,
            "text": "Rett syndrome ( RTT ) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -8.9765625,
            "text": "Rett syndrome ( RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.1796875,
            "text": "Rett syndrome ( RTT )",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.2265625,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.6328125,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.703125,
            "text": "Rett syndrome ( RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.859375,
            "text": "Rett syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -8.1875,
            "text": "syndrome ( RTT ) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -8.9765625,
            "text": "syndrome ( RT",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.1796875,
            "text": "syndrome ( RTT )",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.2265625,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.6328125,
            "text": "syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.6640625,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene encoding the transcriptional repressor methyl-CpG binding protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.703125,
            "text": "syndrome ( RTT",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -9.859375,
            "text": "syndrome ( RTT ) is a severe neurodevelopmental disorder with features of autism that results from mutation of the gene",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_16": [
        {
            "start_logit": 14.484375,
            "end_logit": 15.2734375,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.76953125,
            "end_logit": 15.2734375,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.484375,
            "end_logit": -1.845703125,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.484375,
            "end_logit": -3.2421875,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -6.6484375,
            "text": "Rett syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -8.0859375,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 15.2734375,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -8.4375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -8.6640625,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.2890625,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.53125,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.703125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.71875,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.7578125,
            "text": "Rett syndrome (RTT) is an",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.78125,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeC",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.796875,
            "text": "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder due to",
            "probability": 0.0
        },
        {
            "start_logit": 14.484375,
            "end_logit": -9.8046875,
            "text": "Rett syndrome (RTT) is an X",
            "probability": 0.0
        },
        {
            "start_logit": -1.76953125,
            "end_logit": -6.6484375,
            "text": "syndrome (RTT) is",
            "probability": 0.0
        },
        {
            "start_logit": -1.76953125,
            "end_logit": -8.0859375,
            "text": "syndrome (RTT) is an X-linked neurodevelopmental disorder due to mutations affecting the neural transcription factor MeCP2.",
            "probability": 0.0
        },
        {
            "start_logit": -1.76953125,
            "end_logit": -8.4375,
            "text": "syndrome (RT",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_17": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.296875,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.7138671875,
            "end_logit": 15.296875,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.166015625,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.978515625,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 15.296875,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 15.296875,
            "text": "as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.296875,
            "text": "protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 15.296875,
            "text": "a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.34375,
            "text": "Rett syndrome (RTT).",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.5390625,
            "text": "Rett syndrome (RTT",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 15.296875,
            "text": "Mutations in the transcription factor methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.59375,
            "text": "Rett syndrome (RT",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 15.296875,
            "text": "methyl-CpG-binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 15.296875,
            "text": "binding-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.296875,
            "text": "neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.296875,
            "text": "cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.6953125,
            "text": "Rett syndrome (",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.296875,
            "text": "-protein 2 (MeCP2) cause a delayed-onset neurodevelopmental disorder known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.296875,
            "text": "known as Rett syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.8984375,
            "text": "Rett syndrome (RTT)",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_18": [
        {
            "start_logit": 14.3984375,
            "end_logit": 15.25,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": 15.25,
            "text": "syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.09375,
            "text": "Ret",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.552734375,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -5.69140625,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.25,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.2421875,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.7109375,
            "text": "Rett syndrome is a neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.7109375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.75,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.8359375,
            "text": "Rett syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -5.69140625,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -8.953125,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeCP2",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.2421875,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.3203125,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2 (MeC",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.7109375,
            "text": "syndrome is a neurodevelopmental disorder",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.7109375,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription factor methyl-CpG-binding protein 2",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.75,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding the transcription",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.8359375,
            "text": "syndrome is a neurodevelopmental disorder caused by loss-of-function mutations in the gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -2.552734375,
            "text": "t",
            "probability": 0.0
        }
    ],
    "5e6157cb1af46fc13000000e_19": [
        {
            "start_logit": 14.4296875,
            "end_logit": 15.2265625,
            "text": "Rett syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": 15.2265625,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -2.0859375,
            "text": "Ret",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -2.83203125,
            "text": "Rett",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -7.5859375,
            "text": "Rett syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 15.2265625,
            "text": "t syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -8.296875,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.4296875,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.6796875,
            "text": "Rett syndrome is a mono",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.7109375,
            "text": "Rett syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.84375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.859375,
            "text": "Rett syndrome is a monogenic disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.8984375,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MECP2",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.9453125,
            "text": "Rett syndrome is a monogenic disease due to de novo mutations in either MEC",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -7.5859375,
            "text": "syndrome is",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -8.296875,
            "text": "syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -9.4296875,
            "text": "syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -9.6796875,
            "text": "syndrome is a mono",
            "probability": 0.0
        },
        {
            "start_logit": -1.8681640625,
            "end_logit": -9.7109375,
            "text": "syndrome is a",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": -2.83203125,
            "text": "t",
            "probability": 0.0
        }
    ],
    "58b6bd2622d300530900000c_1": [
        {
            "start_logit": 13.96875,
            "end_logit": 13.3203125,
            "text": "ApoE2",
            "probability": 1.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -2.806640625,
            "text": "ApoE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 13.3203125,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -6.29296875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -6.87109375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.328125,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.9609375,
            "text": "ApoE2 polymorphism",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.4765625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.5390625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R1",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.7890625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia,",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.8984375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -10.0546875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -6.29296875,
            "text": "apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -6.87109375,
            "text": "apoE",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.328125,
            "text": "apoE2",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.6796875,
            "text": "apoE2 isoform is encoded by the R158C allele.",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.953125,
            "text": "apoE2 isoform is encoded by the R158C allele",
            "probability": 0.0
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -6.29296875,
            "text": "2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        }
    ],
    "58b6bd2622d300530900000c_2": [
        {
            "start_logit": 13.96875,
            "end_logit": 13.3203125,
            "text": "ApoE2",
            "probability": 1.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -2.806640625,
            "text": "ApoE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 13.3203125,
            "text": "2",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -6.29296875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -6.87109375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.328125,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.9609375,
            "text": "ApoE2 polymorphism",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.4765625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.5390625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R1",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.7890625,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia,",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.8984375,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -10.0546875,
            "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoprotein",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -6.29296875,
            "text": "apoE2 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -6.87109375,
            "text": "apoE",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.328125,
            "text": "apoE2",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.6796875,
            "text": "apoE2 isoform is encoded by the R158C allele.",
            "probability": 0.0
        },
        {
            "start_logit": -2.08984375,
            "end_logit": -8.953125,
            "text": "apoE2 isoform is encoded by the R158C allele",
            "probability": 0.0
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -6.29296875,
            "text": "2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_1": [
        {
            "start_logit": 8.7109375,
            "end_logit": 11.1171875,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 11.1171875,
            "text": "(SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.1171875,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.1171875,
            "text": "(SR) calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.1171875,
            "text": "calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.1171875,
            "text": ") calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -9.140625,
            "text": "SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -9.140625,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.140625,
            "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -9.140625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -9.140625,
            "text": "(SR) calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -9.140625,
            "text": "calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.5234375,
            "text": "sarcoplasmic reticulum (SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -9.140625,
            "text": ") calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -9.5234375,
            "text": "(SR) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -9.5234375,
            "text": "calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.9140625,
            "text": "sarcoplasmic reticulum (SR",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -9.5234375,
            "text": ") calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -10.0234375,
            "text": "sarcoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -9.9140625,
            "text": "(SR",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_2": [
        {
            "start_logit": 6.69921875,
            "end_logit": 10.109375,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.9970703125
        },
        {
            "start_logit": 0.73583984375,
            "end_logit": 10.109375,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.0025501251220703125
        },
        {
            "start_logit": 6.69921875,
            "end_logit": 1.9091796875,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 0.00027298927307128906
        },
        {
            "start_logit": -6.859375,
            "end_logit": 10.109375,
            "text": "ATPase",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 0.73583984375,
            "end_logit": 1.9091796875,
            "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -9.03125,
            "end_logit": 10.109375,
            "text": "/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 10.109375,
            "text": "Ca(2+)-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -6.23046875,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 10.109375,
            "text": "endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 10.109375,
            "text": "-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.59375,
            "end_logit": 10.109375,
            "text": "o/endoplasmic reticulum Ca(2+)-ATPase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.640625,
            "end_logit": 10.109375,
            "text": "reticulum Ca(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.109375,
            "text": "(2+)-ATPase",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -8.8359375,
            "text": "sarc",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -9.5625,
            "text": "sarco/endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -9.6875,
            "text": "sarco/endoplasmic reticulum Ca(2+)-ATPase (",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 1.9091796875,
            "text": "SERCA",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -9.953125,
            "text": "sarco/endoplasmic reticulum Ca(2+",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -10.125,
            "text": "sarco",
            "probability": 0.0
        },
        {
            "start_logit": 6.69921875,
            "end_logit": -10.5078125,
            "text": "sarco/endoplasmic reticulum Ca(2+)-",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_3": [
        {
            "start_logit": 11.6171875,
            "end_logit": 11.6328125,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -6.87109375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -7.1484375,
            "text": "SERCA, an endoplasmic reticulum (ER",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -7.41796875,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -7.8359375,
            "text": "SERCA, an endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -9.765625,
            "text": "SERCA,",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -9.9765625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.1015625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.109375,
            "text": "SERCA, an endoplasmic",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.2265625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump,",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.2734375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.390625,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.40625,
            "text": "SERCA, an endoplasmic reticulum (ER)",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -10.5234375,
            "text": "SERCA, an endoplasmic reticulum (ER) calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -6.87109375,
            "text": "endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -7.1484375,
            "text": "endoplasmic reticulum (ER",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -7.41796875,
            "text": "endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -7.8359375,
            "text": "endoplasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -6.87109375,
            "text": "an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -7.1484375,
            "text": "an endoplasmic reticulum (ER",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_4": [
        {
            "start_logit": 4.015625,
            "end_logit": 4.3125,
            "text": "SERCA",
            "probability": 0.9873046875
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": 5.40234375,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase",
            "probability": 0.008148193359375
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": 4.3125,
            "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA",
            "probability": 0.0027408599853515625
        },
        {
            "start_logit": -3.94921875,
            "end_logit": 5.40234375,
            "text": "Ca(2+)-ATPase",
            "probability": 0.0010194778442382812
        },
        {
            "start_logit": -3.94921875,
            "end_logit": 4.3125,
            "text": "Ca(2+)-ATPase (SERCA",
            "probability": 0.00034308433532714844
        },
        {
            "start_logit": -8.53125,
            "end_logit": 5.40234375,
            "text": "ATPase",
            "probability": 1.049041748046875e-05
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 4.3125,
            "text": "(SERCA",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 5.40234375,
            "text": "reticulum Ca(2+)-ATPase",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 4.015625,
            "end_logit": -8.21875,
            "text": "SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such as myopathy, heart failure or diabetes.",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -8.53125,
            "end_logit": 4.3125,
            "text": "ATPase (SERCA",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 4.015625,
            "end_logit": -8.390625,
            "text": "SERCA)",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 5.40234375,
            "text": "(2+)-ATPase",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 4.3125,
            "text": "reticulum Ca(2+)-ATPase (SERCA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 5.40234375,
            "text": "-ATPase",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -10.484375,
            "end_logit": 5.40234375,
            "text": ")-ATPase",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 4.3125,
            "text": "(2+)-ATPase (SERCA",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 4.015625,
            "end_logit": -9.6328125,
            "text": "SERCA) is",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 4.3125,
            "text": "-ATPase (SERCA",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.015625,
            "end_logit": -9.9375,
            "text": "SERCA) is the pump crucial for calcium homeostasis and",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.015625,
            "end_logit": -10.0546875,
            "text": "SERCA) is the pump crucial",
            "probability": 5.960464477539062e-07
        }
    ],
    "54db62a3034aea571d000001_5": [
        {
            "start_logit": -1.4384765625,
            "end_logit": 1.2724609375,
            "text": "Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes",
            "probability": 0.333251953125
        },
        {
            "start_logit": -1.4384765625,
            "end_logit": 1.0478515625,
            "text": "Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes).",
            "probability": 0.266357421875
        },
        {
            "start_logit": -2.326171875,
            "end_logit": 1.2724609375,
            "text": "by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes",
            "probability": 0.13720703125
        },
        {
            "start_logit": -2.326171875,
            "end_logit": 1.0478515625,
            "text": "by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes).",
            "probability": 0.109619140625
        },
        {
            "start_logit": -1.4384765625,
            "end_logit": -0.08331298828125,
            "text": "Sarco/Endoplasmic Reticulum Calcium transport ATPases",
            "probability": 0.0859375
        },
        {
            "start_logit": -2.326171875,
            "end_logit": -0.08331298828125,
            "text": "by Sarco/Endoplasmic Reticulum Calcium transport ATPases",
            "probability": 0.03533935546875
        },
        {
            "start_logit": -4.45703125,
            "end_logit": 1.2724609375,
            "text": "SERCA enzymes",
            "probability": 0.0163116455078125
        },
        {
            "start_logit": -4.45703125,
            "end_logit": 1.0478515625,
            "text": "SERCA enzymes).",
            "probability": 0.01300048828125
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 1.2724609375,
            "text": "ATPases (SERCA enzymes",
            "probability": 0.0005545616149902344
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 1.0478515625,
            "text": "ATPases (SERCA enzymes).",
            "probability": 0.00044226646423339844
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 1.0478515625,
            "text": ".",
            "probability": 0.00034999847412109375
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 1.2724609375,
            "text": "(SERCA enzymes",
            "probability": 0.0002275705337524414
        },
        {
            "start_logit": -8.765625,
            "end_logit": 1.2724609375,
            "text": "Calcium is actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes",
            "probability": 0.00021886825561523438
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 1.0478515625,
            "text": "(SERCA enzymes).",
            "probability": 0.00018155574798583984
        },
        {
            "start_logit": -8.765625,
            "end_logit": 1.0478515625,
            "text": "Calcium is actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes).",
            "probability": 0.00017452239990234375
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -0.08331298828125,
            "text": "ATPases",
            "probability": 0.0001436471939086914
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 1.2724609375,
            "text": "Calcium transport ATPases (SERCA enzymes",
            "probability": 0.0001380443572998047
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 1.2724609375,
            "text": "enzymes",
            "probability": 0.00011807680130004883
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 1.0478515625,
            "text": "Calcium transport ATPases (SERCA enzymes).",
            "probability": 0.00011008977890014648
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 1.0478515625,
            "text": "enzymes).",
            "probability": 9.417533874511719e-05
        }
    ],
    "54db62a3034aea571d000001_6": [
        {
            "start_logit": 9.9609375,
            "end_logit": 12.5234375,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 12.5234375,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.5234375,
            "text": "(SERCA",
            "probability": 0.0
        },
        {
            "start_logit": 9.9609375,
            "end_logit": -7.85546875,
            "text": "SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 12.5234375,
            "text": "(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.5234375,
            "text": "calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 12.5234375,
            "text": "plasmic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.5234375,
            "text": "endo)plasmic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.5234375,
            "text": "ic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 12.5234375,
            "text": "o(endo)plasmic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 12.5234375,
            "text": ")plasmic reticulum calcium pump (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -7.85546875,
            "text": "sarco(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -8.546875,
            "text": "sarco(endo)plasmic reticulum calcium pump",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -8.5703125,
            "text": "sarco(endo)plasmic reticulum",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -9.7109375,
            "text": "sarco(endo)plasmic reticulum calcium pump (",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -10.0703125,
            "text": "sarco(endo)plasmic reticulum calcium",
            "probability": 0.0
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -10.203125,
            "text": "sarco(endo)plasm",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -7.85546875,
            "text": "(SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -7.85546875,
            "text": "(endo)plasmic reticulum calcium pump (SERCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -7.85546875,
            "text": "calcium pump (SERCA)",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_7": [
        {
            "start_logit": 11.5546875,
            "end_logit": 10.859375,
            "text": "SERCA",
            "probability": 1.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -3.1796875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -7.10546875,
            "text": "SERCA is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -7.88671875,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.0390625,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.0859375,
            "text": "SERCA is a membrane",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.5,
            "text": "SERCA is a membrane protein that",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.5546875,
            "text": "SERCA is a",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.03125,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.0390625,
            "text": "SERCA is a membrane protein that belongs",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.078125,
            "text": "SERCA is a membrane protein that belongs to the",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.1796875,
            "text": "SERCA is a membrane protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.203125,
            "text": "SERCA is a membrane protein that belongs to the family",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.234375,
            "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -3.1796875,
            "text": "membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -3.1796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -3.1796875,
            "text": "free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -3.1796875,
            "text": "into intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -3.1796875,
            "text": "intracellular stores.",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -3.1796875,
            "text": "pumps free cytosolic calcium into intracellular stores.",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_8": [
        {
            "start_logit": 12.828125,
            "end_logit": 9.4140625,
            "text": "SERCA2a",
            "probability": 1.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -2.2265625,
            "text": "SERCA2a isoform",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": 12.828125,
            "end_logit": -3.599609375,
            "text": "SERCA",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 12.828125,
            "end_logit": -5.296875,
            "text": "SERCA2a isoform in the heart.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.140625,
            "text": "SERCA2a isoform in the",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.3359375,
            "text": "SERCA2a isoform in",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.4140625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": 12.828125,
            "end_logit": -9.6953125,
            "text": "SERCA2a isoform in the heart",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4140625,
            "text": "2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 9.4140625,
            "text": "SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 9.4140625,
            "text": ", and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 9.4140625,
            "text": "the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 9.4140625,
            "text": "different SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.4140625,
            "text": "represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 9.4140625,
            "text": "by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 9.4140625,
            "text": "SERCA is mainly represented by the SERCA2a",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -2.2265625,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -3.599609375,
            "text": "SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.2265625,
            "text": "2a isoform",
            "probability": 0.0
        },
        {
            "start_logit": -6.140625,
            "end_logit": -4.87109375,
            "text": "SERCA",
            "probability": 0.0
        }
    ],
    "54db62a3034aea571d000001_9": [
        {
            "start_logit": 7.59765625,
            "end_logit": 7.0,
            "text": "SERCA",
            "probability": 0.64404296875
        },
        {
            "start_logit": 7.00390625,
            "end_logit": 7.0,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 0.355712890625
        },
        {
            "start_logit": -1.4580078125,
            "end_logit": 7.0,
            "text": "Ca\ufffdz ATPase (SERCA",
            "probability": 7.587671279907227e-05
        },
        {
            "start_logit": 7.00390625,
            "end_logit": -2.20703125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase",
            "probability": 3.5822391510009766e-05
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -3.18359375,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum.",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -7.55078125,
            "text": "SERCA) is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.00390625,
            "end_logit": -6.98046875,
            "text": "The",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -7.921875,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the sarcoplasmic reticulum",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -8.0703125,
            "text": "SERCA)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.00390625,
            "end_logit": -7.55078125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA) is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.00390625,
            "end_logit": -8.0703125,
            "text": "The sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 7.0,
            "text": "(SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.453125,
            "end_logit": 7.0,
            "text": "sarcoplasmic reticulum Ca\ufffdz ATPase (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.15625,
            "end_logit": 7.0,
            "text": "ATPase (SERCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -9.921875,
            "text": "SERCA) is a membrane",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -10.015625,
            "text": "SERCA) is a membrane-bound pump",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.00390625,
            "end_logit": -9.5234375,
            "text": "The sarcoplasmic reticulum Ca",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 7.0,
            "text": "z ATPase (SERCA",
            "probability": 0.0
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -10.375,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration",
            "probability": 0.0
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -10.390625,
            "text": "SERCA) is a membrane-bound pump that utilizes ATP to drive calcium ions from the myocyte cytosol against the higher calcium concentration in the",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_1": [
        {
            "start_logit": 14.03125,
            "end_logit": 15.0546875,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": -2.09375,
            "end_logit": 15.0546875,
            "text": "AA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.03125,
            "end_logit": -1.931640625,
            "text": "AAUA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.22265625,
            "text": "AA",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -4.765625,
            "text": "AAUAAA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -6.21875,
            "text": "AAUAAA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 15.0546875,
            "text": "most canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.0546875,
            "text": "The most canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 15.0546875,
            "text": "canonical AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 15.0546875,
            "text": "UAAA",
            "probability": 0.0
        },
        {
            "start_logit": -2.09375,
            "end_logit": -4.765625,
            "text": "AA hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -2.09375,
            "end_logit": -6.21875,
            "text": "AA hexa",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -1.931640625,
            "text": "most canonical AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -1.931640625,
            "text": "The most canonical AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -1.931640625,
            "text": "canonical AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -1.931640625,
            "text": "UA",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -4.765625,
            "text": "hexamer",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -3.22265625,
            "text": "most canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -3.22265625,
            "text": "The most canonical AA",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -3.22265625,
            "text": "canonical AA",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_2": [
        {
            "start_logit": 14.046875,
            "end_logit": 14.8125,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -0.6787109375,
            "text": "AAUA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.91015625,
            "end_logit": 14.8125,
            "text": "AA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.23046875,
            "text": "AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 14.8125,
            "text": "polyadenylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 14.8125,
            "text": "signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.8125,
            "text": "UAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.8125,
            "text": "ylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -0.6787109375,
            "text": "polyadenylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -0.6787109375,
            "text": "signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -0.6787109375,
            "text": "UA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -0.6787109375,
            "text": "ylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -3.23046875,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -3.23046875,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -3.23046875,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -9.8203125,
            "text": "polyadenylation signal",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -9.8203125,
            "text": "signal",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -10.0546875,
            "text": "polyaden",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -10.1328125,
            "text": "polyadenylation",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -9.8203125,
            "text": "ylation signal",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_3": [
        {
            "start_logit": 14.046875,
            "end_logit": 14.8125,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -0.6787109375,
            "text": "AAUA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.91015625,
            "end_logit": 14.8125,
            "text": "AA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.23046875,
            "text": "AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 14.8125,
            "text": "polyadenylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 14.8125,
            "text": "signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.8125,
            "text": "UAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.8125,
            "text": "ylation signal AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -0.6787109375,
            "text": "polyadenylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -0.6787109375,
            "text": "signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -0.6787109375,
            "text": "UA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -0.6787109375,
            "text": "ylation signal AAUA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -3.23046875,
            "text": "polyadenylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -3.23046875,
            "text": "signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -3.23046875,
            "text": "ylation signal AA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -9.8203125,
            "text": "polyadenylation signal",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -9.8203125,
            "text": "signal",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -10.0546875,
            "text": "polyaden",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -10.1328125,
            "text": "polyadenylation",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -9.8203125,
            "text": "ylation signal",
            "probability": 0.0
        }
    ],
    "550739cf3b8a5dc045000002_4": [
        {
            "start_logit": 14.53125,
            "end_logit": 15.453125,
            "text": "AAUAAA",
            "probability": 1.0
        },
        {
            "start_logit": -1.0546875,
            "end_logit": 15.453125,
            "text": "AA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.53125,
            "end_logit": -1.439453125,
            "text": "AAUA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.53125,
            "end_logit": -1.9228515625,
            "text": "AA",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -7.890625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 15.453125,
            "text": "A polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -8.2421875,
            "text": "AAUAAA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 15.453125,
            "text": "polyadenylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 15.453125,
            "text": "UAAA",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 15.453125,
            "text": "(AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.5625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.828125,
            "text": "AAUAAA) nearby",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.453125,
            "text": "ylation signal (AAUAAA",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.90625,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -10.046875,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -10.0703125,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required for poly(A)",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -10.09375,
            "text": "AAUAAA) nearby the 3' end of pre-mRNA is required",
            "probability": 0.0
        },
        {
            "start_logit": -1.0546875,
            "end_logit": -7.890625,
            "text": "AA) nearby the 3' end of pre-mRNA is required for poly(A) synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -1.0546875,
            "end_logit": -8.2421875,
            "text": "AA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": -1.439453125,
            "text": "A polyadenylation signal (AAUA",
            "probability": 0.0
        }
    ],
    "5e764647c6a8763d23000016_1": [
        {
            "start_logit": 12.328125,
            "end_logit": 12.5234375,
            "text": "CVD 103-HgR",
            "probability": 1.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -3.80078125,
            "text": "CVD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 12.5234375,
            "text": "R",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -5.65234375,
            "text": "CVD 103-HgR (Orochol, Mutachol)",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 12.5234375,
            "text": "-HgR",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -7.265625,
            "text": "CVD 103-HgR (Orochol",
            "probability": 0.0
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 12.5234375,
            "text": "HgR",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 12.5234375,
            "text": "103-HgR",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 12.5234375,
            "text": "vaccine CVD 103-HgR",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.8828125,
            "text": "CVD 103",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.890625,
            "text": "CVD 103-HgR (Orochol, Mutachol),",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.890625,
            "text": "CVD 103-Hg",
            "probability": 0.0
        },
        {
            "start_logit": 12.328125,
            "end_logit": -8.90625,
            "text": "CVD 103-HgR (Orochol, Mutachol",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.5234375,
            "text": "The oral live cholera vaccine CVD 103-HgR",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.5234375,
            "text": "cholera vaccine CVD 103-HgR",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -5.65234375,
            "text": "R (Orochol, Mutachol)",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -3.80078125,
            "text": "vaccine CVD",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -5.65234375,
            "text": "-HgR (Orochol, Mutachol)",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -7.265625,
            "text": "R (Orochol",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": -5.65234375,
            "text": "Orochol, Mutachol)",
            "probability": 0.0
        }
    ],
    "5319a7d2b166e2b806000029_1": [
        {
            "start_logit": 5.44921875,
            "end_logit": 9.96875,
            "text": "Carboxyl terminus of hsc70-interacting protein",
            "probability": 0.98828125
        },
        {
            "start_logit": 5.44921875,
            "end_logit": 5.09765625,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP",
            "probability": 0.00754547119140625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": 5.09765625,
            "text": "CHIP",
            "probability": 0.003482818603515625
        },
        {
            "start_logit": -3.50390625,
            "end_logit": 9.96875,
            "text": "protein",
            "probability": 0.0001277923583984375
        },
        {
            "start_logit": -3.50390625,
            "end_logit": 5.09765625,
            "text": "protein (CHIP",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 9.96875,
            "text": "of hsc70-interacting protein",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 9.96875,
            "text": "interacting protein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 9.96875,
            "text": "terminus of hsc70-interacting protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 9.96875,
            "text": "-interacting protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 9.96875,
            "text": "hsc70-interacting protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -7.03515625,
            "text": "Carboxyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 5.09765625,
            "text": "of hsc70-interacting protein (CHIP",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 5.09765625,
            "text": "(CHIP",
            "probability": 0.0
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -9.1171875,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP)",
            "probability": 0.0
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -9.171875,
            "text": "Carboxyl terminus of hsc70-interacting protein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 5.09765625,
            "text": "interacting protein (CHIP",
            "probability": 0.0
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -9.4140625,
            "text": "Carboxyl terminus of hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -9.8828125,
            "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can",
            "probability": 0.0
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -9.1171875,
            "text": "CHIP)",
            "probability": 0.0
        },
        {
            "start_logit": 5.44921875,
            "end_logit": -9.9296875,
            "text": "Carboxyl terminus of hsc",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_1": [
        {
            "start_logit": 8.7734375,
            "end_logit": 13.7109375,
            "text": "transitional vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": 13.7109375,
            "text": "vertebrae",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 13.7109375,
            "text": "lumbosacral transitional vertebrae",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -8.796875,
            "end_logit": 13.7109375,
            "text": "in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.7109375,
            "text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.7109375,
            "text": "lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 13.7109375,
            "text": "of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.7109375,
            "text": "form of lumbago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 13.7109375,
            "text": "bago in lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.66015625,
            "text": "transitional",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -9.8828125,
            "text": "transitional vertebrae, is an important cause of low back pain in young patients.",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -10.015625,
            "text": "transitional vertebrae,",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -10.1796875,
            "text": "transitional vertebrae, is an important cause of low back pain",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -10.390625,
            "text": "transitional vertebrae, is an important",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -10.421875,
            "text": "transitional vertebrae, is",
            "probability": 0.0
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -10.5078125,
            "text": "transitional vertebrae, is an important cause of low back pain in young",
            "probability": 0.0
        },
        {
            "start_logit": -5.60546875,
            "end_logit": -6.66015625,
            "text": "lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -9.8828125,
            "text": "vertebrae, is an important cause of low back pain in young patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -10.015625,
            "text": "vertebrae,",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": -10.1796875,
            "text": "vertebrae, is an important cause of low back pain",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_2": [
        {
            "start_logit": -10.15625,
            "end_logit": -9.140625,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.08502197265625
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.140625,
            "text": "severe sciatica.",
            "probability": 0.0694580078125
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.140625,
            "text": "characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0672607421875
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.140625,
            "text": "sciatica.",
            "probability": 0.061248779296875
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.140625,
            "text": "Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.061248779296875
        },
        {
            "start_logit": -10.59375,
            "end_logit": -9.140625,
            "text": "have severe sciatica.",
            "probability": 0.054901123046875
        },
        {
            "start_logit": -10.59375,
            "end_logit": -9.140625,
            "text": "lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.054901123046875
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.6015625,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies",
            "probability": 0.0540771484375
        },
        {
            "start_logit": -10.625,
            "end_logit": -9.140625,
            "text": "with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.053253173828125
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -9.140625,
            "text": "lotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.0477294921875
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -9.140625,
            "text": "tolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica.",
            "probability": 0.046234130859375
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -9.140625,
            "text": "often have severe sciatica.",
            "probability": 0.046234130859375
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.7734375,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies and",
            "probability": 0.0447998046875
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.6015625,
            "text": "characteristic lumbosacral anomalies",
            "probability": 0.04278564453125
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.6015625,
            "text": "Bertolotti's syndrome have characteristic lumbosacral anomalies",
            "probability": 0.038330078125
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.7734375,
            "text": "characteristic lumbosacral anomalies and",
            "probability": 0.0360107421875
        },
        {
            "start_logit": -10.15625,
            "end_logit": -10.0234375,
            "text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica",
            "probability": 0.034912109375
        },
        {
            "start_logit": -10.59375,
            "end_logit": -9.6015625,
            "text": "lumbosacral anomalies",
            "probability": 0.034912109375
        },
        {
            "start_logit": -10.625,
            "end_logit": -9.6015625,
            "text": "with Bertolotti's syndrome have characteristic lumbosacral anomalies",
            "probability": 0.0338134765625
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.7734375,
            "text": "Bertolotti's syndrome have characteristic lumbosacral anomalies and",
            "probability": 0.03277587890625
        }
    ],
    "5313058de3eabad02100000e_3": [
        {
            "start_logit": 4.0078125,
            "end_logit": 12.8515625,
            "text": "lumbosacral junction pseudarticulation",
            "probability": 0.88671875
        },
        {
            "start_logit": 4.0078125,
            "end_logit": 10.609375,
            "text": "lumbosacral junction",
            "probability": 0.09417724609375
        },
        {
            "start_logit": 0.150390625,
            "end_logit": 12.8515625,
            "text": "pseudarticulation",
            "probability": 0.0186920166015625
        },
        {
            "start_logit": -4.95703125,
            "end_logit": 12.8515625,
            "text": "ulation",
            "probability": 0.00011289119720458984
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 12.8515625,
            "text": "junction pseudarticulation",
            "probability": 5.5849552154541016e-05
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 10.609375,
            "text": "junction",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 12.8515625,
            "text": "unilateral lumbosacral junction pseudarticulation",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -9.421875,
            "end_logit": 12.8515625,
            "text": "articulation",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -9.65625,
            "end_logit": 12.8515625,
            "text": "symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 10.609375,
            "text": "unilateral lumbosacral junction",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 12.8515625,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 12.8515625,
            "text": "treatment for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.8515625,
            "text": "for symptomatic unilateral lumbosacral junction pseudarticulation",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.65625,
            "end_logit": 10.609375,
            "text": "symptomatic unilateral lumbosacral junction",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 10.609375,
            "text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 10.609375,
            "text": "treatment for symptomatic unilateral lumbosacral junction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.609375,
            "text": "for symptomatic unilateral lumbosacral junction",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.0078125,
            "end_logit": -9.0859375,
            "text": "lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": 4.0078125,
            "end_logit": -9.625,
            "text": "lumbosacral junction pseudarticulation (Bertolotti's syndrome): a case report.",
            "probability": 0.0
        },
        {
            "start_logit": 4.0078125,
            "end_logit": -9.7890625,
            "text": "lumbosacral junction pseudarticulation (",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_4": [
        {
            "start_logit": 5.40625,
            "end_logit": 3.07421875,
            "text": "fifth lumbar vertebra",
            "probability": 0.54931640625
        },
        {
            "start_logit": 5.40625,
            "end_logit": 2.861328125,
            "text": "fifth",
            "probability": 0.44140625
        },
        {
            "start_logit": -1.3251953125,
            "end_logit": 5.5546875,
            "text": "Lumbosacral transitional vertebra",
            "probability": 0.00780487060546875
        },
        {
            "start_logit": -1.3251953125,
            "end_logit": 3.07421875,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 0.0006532669067382812
        },
        {
            "start_logit": -1.3251953125,
            "end_logit": 2.861328125,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth",
            "probability": 0.0005269050598144531
        },
        {
            "start_logit": -5.1328125,
            "end_logit": 5.5546875,
            "text": "transitional vertebra",
            "probability": 0.00017309188842773438
        },
        {
            "start_logit": 5.40625,
            "end_logit": -5.57421875,
            "text": "fifth lumbar",
            "probability": 9.560585021972656e-05
        },
        {
            "start_logit": -4.11328125,
            "end_logit": 3.07421875,
            "text": "vertebra",
            "probability": 4.017353057861328e-05
        },
        {
            "start_logit": -6.75,
            "end_logit": 5.5546875,
            "text": "vertebra",
            "probability": 3.4332275390625e-05
        },
        {
            "start_logit": -5.1328125,
            "end_logit": 3.07421875,
            "text": "transitional vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": -5.1328125,
            "end_logit": 2.861328125,
            "text": "transitional vertebra is an anatomical variation of the fifth",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 3.07421875,
            "text": "lumbar vertebra",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -6.75,
            "end_logit": 3.07421875,
            "text": "vertebra is an anatomical variation of the fifth lumbar vertebra",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -6.890625,
            "end_logit": 3.07421875,
            "text": "the fifth lumbar vertebra",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.75,
            "end_logit": 2.861328125,
            "text": "vertebra is an anatomical variation of the fifth",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -6.890625,
            "end_logit": 2.861328125,
            "text": "the fifth",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 5.40625,
            "end_logit": -10.0625,
            "text": "fifth lumbar vertebra in which an enlarged transverse process can",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.40625,
            "end_logit": -10.2421875,
            "text": "fifth lumbar vertebra in",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.40625,
            "end_logit": -10.34375,
            "text": "fifth lumbar vertebra in which an enlarged transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -1.3251953125,
            "end_logit": -5.57421875,
            "text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5313058de3eabad02100000e_5": [
        {
            "start_logit": 10.1484375,
            "end_logit": 12.8203125,
            "text": "Transitional lumbosacral vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": 12.8203125,
            "text": "vertebrae",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -6.76953125,
            "text": "Transitional lumbosacral vertebrae and",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -7.4765625,
            "text": "Transitional",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 12.8203125,
            "text": "lumbosacral vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -8.3203125,
            "text": "Transitional lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -9.703125,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.1640625,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.1640625,
            "text": "Transitional lumbosacral vertebrae and low back pain",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.203125,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.3125,
            "text": "Transitional lumbosacral vertebrae and low back pain:",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.359375,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.40625,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls",
            "probability": 0.0
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.453125,
            "text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -6.76953125,
            "text": "vertebrae and",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -9.703125,
            "text": "vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -10.1640625,
            "text": "vertebrae and low back pain: diagnostic pitfalls and management",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -10.1640625,
            "text": "vertebrae and low back pain",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -10.203125,
            "text": "vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -3.220703125,
            "end_logit": -10.3125,
            "text": "vertebrae and low back pain:",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_6": [
        {
            "start_logit": 14.328125,
            "end_logit": 15.2421875,
            "text": "facet joint",
            "probability": 1.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": 15.2421875,
            "text": "joint",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.328125,
            "end_logit": -0.73828125,
            "text": "facet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 15.2421875,
            "text": "the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.0625,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 15.2421875,
            "text": "Case report of surgically treated mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.7578125,
            "text": "facet joint contralateral",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.2421875,
            "text": "treated mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.2421875,
            "text": "surgically treated mechanical low back pain from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.2421875,
            "text": "from the facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.1640625,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation (Bertolotti's syndrome).",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.296875,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation (",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.3515625,
            "text": "facet joint contralateral to a unilateral anomalous lumbosacral articulation (Bertolotti's syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -0.73828125,
            "text": "the facet",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -9.0625,
            "text": "joint contralateral to a unilateral anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -0.73828125,
            "text": "Case report of surgically treated mechanical low back pain from the facet",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -9.7578125,
            "text": "joint contralateral",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -0.73828125,
            "text": "treated mechanical low back pain from the facet",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -0.73828125,
            "text": "surgically treated mechanical low back pain from the facet",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -0.73828125,
            "text": "from the facet",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_7": [
        {
            "start_logit": 14.3125,
            "end_logit": 15.2734375,
            "text": "facet joint",
            "probability": 1.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -0.61474609375,
            "text": "facet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 15.2734375,
            "text": "joint",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3125,
            "end_logit": -7.828125,
            "text": "facet joint contralateral to an anomalous lumbosacral articulation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 15.2734375,
            "text": "symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.0703125,
            "text": "facet joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 15.2734375,
            "text": "-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.2734375,
            "text": "L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.2734375,
            "text": "S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.5703125,
            "text": "facet joint contralateral",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.2734375,
            "text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.2734375,
            "text": "a symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.2734375,
            "text": "fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.125,
            "text": "facet joint contralateral to an anomalous lumbosacral",
            "probability": 0.0
        },
        {
            "start_logit": -1.607421875,
            "end_logit": -7.828125,
            "text": "joint contralateral to an anomalous lumbosacral articulation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -0.61474609375,
            "text": "symptomatic L6-S1 facet",
            "probability": 0.0
        },
        {
            "start_logit": -1.607421875,
            "end_logit": -9.0703125,
            "text": "joint contralateral to an anomalous lumbosacral articulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -0.61474609375,
            "text": "-S1 facet",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -0.61474609375,
            "text": "L6-S1 facet",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -0.61474609375,
            "text": "S1 facet",
            "probability": 0.0
        }
    ],
    "5313058de3eabad02100000e_8": [
        {
            "start_logit": 12.09375,
            "end_logit": 14.046875,
            "text": "transitional vertebrae",
            "probability": 1.0
        },
        {
            "start_logit": -3.70703125,
            "end_logit": 14.046875,
            "text": "vertebrae",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 14.046875,
            "text": "lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": 12.09375,
            "end_logit": -4.4609375,
            "text": "transitional",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 14.046875,
            "text": "Bertolotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.046875,
            "text": "with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.046875,
            "text": "back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.046875,
            "text": "the association of back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.046875,
            "text": "of back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.046875,
            "text": "tolotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 14.046875,
            "text": "lotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae",
            "probability": 0.0
        },
        {
            "start_logit": 12.09375,
            "end_logit": -9.421875,
            "text": "transitional vertebrae.",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": -4.4609375,
            "text": "lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -3.70703125,
            "end_logit": -9.421875,
            "text": "vertebrae.",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -4.4609375,
            "text": "Bertolotti's syndrome refers to the association of back pain with lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -4.4609375,
            "text": "with lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -4.4609375,
            "text": "back pain with lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -4.4609375,
            "text": "the association of back pain with lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -4.4609375,
            "text": "of back pain with lumbosacral transitional",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -4.4609375,
            "text": "tolotti's syndrome refers to the association of back pain with lumbosacral transitional",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_1": [
        {
            "start_logit": 13.65625,
            "end_logit": 14.9375,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": 14.9375,
            "text": "DB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.65625,
            "end_logit": -2.890625,
            "text": "mpM",
            "probability": 0.0
        },
        {
            "start_logit": -6.03125,
            "end_logit": 14.9375,
            "text": "oRFsDB",
            "probability": 0.0
        },
        {
            "start_logit": -7.15625,
            "end_logit": 14.9375,
            "text": "FsDB",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -7.09375,
            "text": "mpMoR",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -7.828125,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -7.96875,
            "text": "mpMoRFs",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.171875,
            "text": "mpMoRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.6484375,
            "text": "mpMoRFsDB: a database",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.875,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -10.1171875,
            "text": "mpMoRFsDB: a database of molecular recognition",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -10.1328125,
            "text": "mpMoRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -10.203125,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -7.828125,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -9.171875,
            "text": "DB: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -9.6484375,
            "text": "DB: a database",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -9.875,
            "text": "DB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -10.1171875,
            "text": "DB: a database of molecular recognition",
            "probability": 0.0
        },
        {
            "start_logit": -2.55078125,
            "end_logit": -10.1328125,
            "text": "DB: a database of molecular recognition features",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_2": [
        {
            "start_logit": 13.59375,
            "end_logit": 14.9453125,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": 14.9453125,
            "text": "DB",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.59375,
            "end_logit": -2.818359375,
            "text": "mpM",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 14.9453125,
            "text": "oRFsDB",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 14.9453125,
            "text": "FsDB",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -6.81640625,
            "text": "mpMoR",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -7.51953125,
            "text": "mpMoRFs",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.390625,
            "text": "mpMoRFsDB provides",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.4765625,
            "text": "mpMoRFsDB provides valuable information related to disorder",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.5546875,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.8203125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.8203125,
            "text": "mpMoRFsDB provides valuable information related to disorder-",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.90625,
            "text": "mpMoRFsDB provides valuable",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.921875,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.96875,
            "text": "mpMoRFsDB provides valuable information",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -10.078125,
            "text": "mpMoRFsDB provides valuable information related to disorder-based protein-protein interactions",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -9.390625,
            "text": "DB provides",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -9.4765625,
            "text": "DB provides valuable information related to disorder",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -9.5546875,
            "text": "DB provides valuable information related to disorder-based protein-protein interactions in",
            "probability": 0.0
        },
        {
            "start_logit": -2.6171875,
            "end_logit": -9.8203125,
            "text": "DB provides valuable information related to disorder-based protein-protein interactions in membrane",
            "probability": 0.0
        }
    ],
    "554140ad182542114d000003_3": [
        {
            "start_logit": 14.2109375,
            "end_logit": 15.1796875,
            "text": "mpMoRFsDB",
            "probability": 1.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": 15.1796875,
            "text": "DB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.265625,
            "text": "mpM",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": 15.1796875,
            "text": "oRFsDB",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 15.1796875,
            "text": "FsDB",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -6.9609375,
            "text": "mpMoR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -7.33984375,
            "text": "mpMoRFsDB:",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -7.60546875,
            "text": "mpMoRFs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.0078125,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.0234375,
            "text": "mpMoRFsDB: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.6015625,
            "text": "mpMoRFsDB: a database",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1015625,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1796875,
            "text": "mpMoRFsDB: a database of molecular recognition features",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1875,
            "text": "mpMoRFsDB: a database of molecular recognition",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1875,
            "text": "mpMoRFsDB: a database of molecular recognition features in membrane",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -7.33984375,
            "text": "DB:",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -9.0078125,
            "text": "DB: a database of molecular recognition features in membrane proteins.",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -9.0234375,
            "text": "DB: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -9.6015625,
            "text": "DB: a database",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -10.1015625,
            "text": "DB: a database of molecular recognition features in membrane proteins",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_1": [
        {
            "start_logit": 14.390625,
            "end_logit": 15.515625,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -0.9404296875,
            "end_logit": 15.515625,
            "text": "imaging",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.263671875,
            "text": "magnetic",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.94921875,
            "text": "magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 15.515625,
            "text": "of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 15.515625,
            "text": "resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 15.515625,
            "text": "approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 15.515625,
            "text": "the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.515625,
            "text": "using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.8125,
            "text": "magnetic resonance imaging and",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.4609375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.5,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.515625,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.53125,
            "text": "magnetic resonance imaging and we conduct a systematic review of all",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.546875,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -0.9404296875,
            "end_logit": -9.8125,
            "text": "imaging and",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -2.263671875,
            "text": "of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -0.9404296875,
            "end_logit": -10.4609375,
            "text": "imaging and we conduct a systematic review of all patients reported in the last 60 years",
            "probability": 0.0
        },
        {
            "start_logit": -0.9404296875,
            "end_logit": -10.5,
            "text": "imaging and we conduct a systematic review of all patients reported in the last",
            "probability": 0.0
        },
        {
            "start_logit": -0.9404296875,
            "end_logit": -10.515625,
            "text": "imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        }
    ],
    "5c632542e842deac6700000d_2": [
        {
            "start_logit": 14.5234375,
            "end_logit": 15.59375,
            "text": "magnetic resonance imaging",
            "probability": 1.0
        },
        {
            "start_logit": -0.57470703125,
            "end_logit": 15.59375,
            "text": "imaging",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -1.8603515625,
            "text": "magnetic",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -4.03515625,
            "text": "magnetic resonance",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": 15.59375,
            "text": "of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 15.59375,
            "text": "approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 15.59375,
            "text": "resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.59375,
            "text": "the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.59375,
            "text": "using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.59375,
            "text": "CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 15.59375,
            "text": "novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.59375,
            "text": "we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.59375,
            "text": "Here, we report a patient with CVG-ID that was diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.59375,
            "text": "diagnosed using the novel approach of magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.8671875,
            "text": "magnetic resonance imaging and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.1796875,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.34375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years, discussing the core clinical features of this syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.4375,
            "text": "magnetic resonance imaging and we conduct a systematic review of all patients reported in the last 60 years",
            "probability": 0.0
        },
        {
            "start_logit": -7.9609375,
            "end_logit": -1.8603515625,
            "text": "of magnetic",
            "probability": 0.0
        },
        {
            "start_logit": -0.57470703125,
            "end_logit": -9.8671875,
            "text": "imaging and",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_1": [
        {
            "start_logit": 13.890625,
            "end_logit": 14.828125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": 14.828125,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.890625,
            "end_logit": -3.193359375,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -3.859375,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -7.05078125,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -8.6640625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 14.828125,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.5078125,
            "text": "traseR: an R package for performing trait-",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.5703125,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.5859375,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.6171875,
            "text": "traseR: an R package for performing trait-associated SNP enrichment",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.71875,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.7421875,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.8671875,
            "text": "traseR: an R package for performing trait",
            "probability": 0.0
        },
        {
            "start_logit": 13.890625,
            "end_logit": -9.8984375,
            "text": "traseR: an R package for performing trait-associated SNP",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -7.05078125,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -8.6640625,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -9.5078125,
            "text": "R: an R package for performing trait-",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -9.5703125,
            "text": "R: an",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -9.5859375,
            "text": "R: an R package",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_2": [
        {
            "start_logit": 14.1875,
            "end_logit": 15.109375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": 15.109375,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1875,
            "end_logit": -2.71484375,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -3.068359375,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -6.72265625,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.109375,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.4375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 15.109375,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.5,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.515625,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.609375,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.6796875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -6.72265625,
            "text": "R,",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -9.4375,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -9.5,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -9.515625,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -9.609375,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -2.21484375,
            "end_logit": -9.6796875,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -3.068359375,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -2.71484375,
            "text": "present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_3": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.140625,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 15.140625,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.556640625,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -3.080078125,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -6.65234375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 15.140625,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.4375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.4609375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.46875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.140625,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5859375,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6796875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.140625,
            "text": "we present traseR",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -6.65234375,
            "text": "R,",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -9.4375,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -9.4609375,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -9.46875,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -9.5859375,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -2.1640625,
            "end_logit": -9.6796875,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -2.556640625,
            "text": "present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_4": [
        {
            "start_logit": 14.21875,
            "end_logit": 15.1328125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 15.1328125,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.658203125,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.94921875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -6.859375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 15.1328125,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 15.1328125,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5078125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5234375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.6328125,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.7421875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.7578125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -6.859375,
            "text": "R,",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.5078125,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.5234375,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.6328125,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.7421875,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.7578125,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -2.94921875,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -2.658203125,
            "text": "present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_5": [
        {
            "start_logit": 14.40625,
            "end_logit": 15.234375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": 15.234375,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.40625,
            "end_logit": -2.21875,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -2.919921875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -5.5703125,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -6.78125,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 15.234375,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.25,
            "text": "traseR: an R package for performing trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.4140625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.59375,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.6015625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.6484375,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.65625,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.7265625,
            "text": "traseR: an R package for performing trait-associated SNP",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.8046875,
            "text": "traseR: an R package for performing trait",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.8828125,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.96875,
            "text": "traseR: an R package for performing trait-associated",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -5.5703125,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.78125,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -9.25,
            "text": "R: an R package for performing trait-",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_6": [
        {
            "start_logit": 14.40625,
            "end_logit": 15.234375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": 15.234375,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.40625,
            "end_logit": -2.21875,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -2.919921875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -5.5703125,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -6.78125,
            "text": "traseR:",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 15.234375,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.25,
            "text": "traseR: an R package for performing trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.4140625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.59375,
            "text": "traseR: an",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.6015625,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.6484375,
            "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.65625,
            "text": "traseR: an R package",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.7265625,
            "text": "traseR: an R package for performing trait-associated SNP",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.8046875,
            "text": "traseR: an R package for performing trait",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.8828125,
            "text": "traseR: an R",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.96875,
            "text": "traseR: an R package for performing trait-associated",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -5.5703125,
            "text": "R: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.78125,
            "text": "R:",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -9.25,
            "text": "R: an R package for performing trait-",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_7": [
        {
            "start_logit": 14.21875,
            "end_logit": 15.1328125,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 15.1328125,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.658203125,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.94921875,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -6.859375,
            "text": "traseR,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 15.1328125,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 15.1328125,
            "text": "present traseR",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5078125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5234375,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.6328125,
            "text": "traseR, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.7421875,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.7578125,
            "text": "traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -6.859375,
            "text": "R,",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.5078125,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.5234375,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.6328125,
            "text": "R, an easy-to-use R Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.7421875,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-",
            "probability": 0.0
        },
        {
            "start_logit": -2.1328125,
            "end_logit": -9.7578125,
            "text": "R, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -2.94921875,
            "text": "se",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -2.658203125,
            "text": "present tra",
            "probability": 0.0
        }
    ],
    "587e3129c32c812009000002_8": [
        {
            "start_logit": 14.140625,
            "end_logit": 14.9375,
            "text": "traseR",
            "probability": 1.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": 14.9375,
            "text": "R",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.140625,
            "end_logit": -2.759765625,
            "text": "tra",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -3.2890625,
            "text": "trase",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -4.109375,
            "text": "traseR R",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -7.79296875,
            "text": "traseR R package",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 14.9375,
            "text": "The traseR",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 14.9375,
            "text": "seR",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.34375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.3984375,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohu",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.53125,
            "text": "traseR R package preload",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.5390625,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs are",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.578125,
            "text": "traseR R package preloaded with up-to-date collection of trait-associated SNPs",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -4.109375,
            "text": "R R",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -7.79296875,
            "text": "R R package",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -9.34375,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -9.3984375,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohu",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -9.53125,
            "text": "R R package preload",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -9.5390625,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs are",
            "probability": 0.0
        },
        {
            "start_logit": -2.423828125,
            "end_logit": -9.578125,
            "text": "R R package preloaded with up-to-date collection of trait-associated SNPs",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_1": [
        {
            "start_logit": 13.5546875,
            "end_logit": 14.7578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": 14.7578125,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -3.896484375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -4.75390625,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -6.5078125,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 14.7578125,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.65625,
            "text": "GBshape: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.6796875,
            "text": "GBshape: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.8203125,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.8828125,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.953125,
            "text": "GBshape: a genome",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -10.046875,
            "text": "GBshape: a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -10.09375,
            "text": "GBshape: a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -6.5078125,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -9.65625,
            "text": "e: a genome browser database for DNA shape annotations",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -9.6796875,
            "text": "e: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -9.8203125,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -9.8828125,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -9.953125,
            "text": "e: a genome",
            "probability": 0.0
        },
        {
            "start_logit": -2.595703125,
            "end_logit": -10.046875,
            "text": "e: a genome browse",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_2": [
        {
            "start_logit": 14.390625,
            "end_logit": 15.2578125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": 15.2578125,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.27734375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.55859375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -7.86328125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 15.2578125,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 15.2578125,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.4296875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 15.2578125,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.7734375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.1171875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.3125,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.4453125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.5625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.2578125,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.8046875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.8125,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.86328125,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -8.4296875,
            "text": "e;",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -8.7734375,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_3": [
        {
            "start_logit": 14.1640625,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -2.900390625,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -4.19921875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -5.8984375,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.390625,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.640625,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.65625,
            "text": "GBshape: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.7734375,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.9609375,
            "text": "GBshape: a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.109375,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -5.8984375,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.390625,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.640625,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.65625,
            "text": "e: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.7734375,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.9609375,
            "text": "e: a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -10.109375,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -4.19921875,
            "text": "hap",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_4": [
        {
            "start_logit": 14.265625,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.677734375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -3.658203125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.7421875,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.2421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.46875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.484375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.640625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.7265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.734375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.765625,
            "text": "GBshape can be used to",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8203125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -8.7421875,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.2421875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.46875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.484375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.640625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_5": [
        {
            "start_logit": 14.171875,
            "end_logit": 15.109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 15.109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.171875,
            "end_logit": -2.837890625,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -4.51171875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 15.109375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -7.35546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 15.109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.40625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 15.109375,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.546875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.671875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.03125,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.2578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.28125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.4375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.109375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.625,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -7.35546875,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -8.40625,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -8.546875,
            "text": "e;",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_6": [
        {
            "start_logit": 14.265625,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.677734375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -3.658203125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.7421875,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.2421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.46875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.484375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.640625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.7265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.734375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.765625,
            "text": "GBshape can be used to",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8203125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -8.7421875,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.2421875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.46875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.484375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.640625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_7": [
        {
            "start_logit": 14.265625,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.677734375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -3.658203125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.7421875,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.2421875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.46875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.484375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.640625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.7265625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.734375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.765625,
            "text": "GBshape can be used to",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome brow",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.8203125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -8.7421875,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.2421875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.46875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.484375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.8720703125,
            "end_logit": -9.640625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_8": [
        {
            "start_logit": 14.1640625,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -2.900390625,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -4.19921875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -5.8984375,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.390625,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.640625,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.65625,
            "text": "GBshape: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.7734375,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.9609375,
            "text": "GBshape: a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.109375,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -5.8984375,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.390625,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.640625,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.65625,
            "text": "e: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.7734375,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -9.9609375,
            "text": "e: a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.8798828125,
            "end_logit": -10.109375,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -4.19921875,
            "text": "hap",
            "probability": 0.0
        }
    ],
    "587e1bfdfc7e8dd84f000002_9": [
        {
            "start_logit": 14.171875,
            "end_logit": 15.109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 15.109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.171875,
            "end_logit": -2.837890625,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -4.51171875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": 15.109375,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -7.35546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 15.109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.40625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 15.109375,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.546875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.671875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.03125,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.2578125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.28125,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.4375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.109375,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.625,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -7.35546875,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -8.40625,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -8.546875,
            "text": "e;",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_1": [
        {
            "start_logit": 13.75,
            "end_logit": 14.8515625,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.02734375,
            "end_logit": 14.8515625,
            "text": "patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.75,
            "end_logit": -3.23828125,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -5.41796875,
            "text": "epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 14.8515625,
            "text": "CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -5.9453125,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 14.8515625,
            "text": "an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 14.8515625,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 14.8515625,
            "text": "using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 14.8515625,
            "text": "treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.8515625,
            "text": "for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.8515625,
            "text": "she was treated for CSF leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.8515625,
            "text": "leak using an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -2.02734375,
            "end_logit": -5.41796875,
            "text": "patch.",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -3.23828125,
            "text": "CSF leak using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": -3.23828125,
            "text": "an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -5.41796875,
            "text": "CSF leak using an epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -3.23828125,
            "text": "using an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -5.9453125,
            "text": "CSF leak using an epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -3.23828125,
            "text": "treated for CSF leak using an epidural",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_2": [
        {
            "start_logit": 14.2109375,
            "end_logit": 15.21875,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": 15.21875,
            "text": "patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.578125,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -6.52734375,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 15.21875,
            "text": "invasive measures with epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 15.21875,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.140625,
            "text": "epidural blood patch providing",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.734375,
            "text": "epidural blood patch providing the cornerstone",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.21875,
            "text": "measures with epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 15.21875,
            "text": "with epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.2734375,
            "text": "epidural blood patch providing the cornerstone of the invasive measures",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.6796875,
            "text": "epidural blood patch providing the cornerstone of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.75,
            "text": "epidural blood patch providing the cornerstone of the",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.9296875,
            "text": "epidural blood patch providing the",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1953125,
            "text": "epidural blood patch providing the cornerstone of the invasive",
            "probability": 0.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": -8.140625,
            "text": "patch providing",
            "probability": 0.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": -8.734375,
            "text": "patch providing the cornerstone",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -2.578125,
            "text": "invasive measures with epidural",
            "probability": 0.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": -9.2734375,
            "text": "patch providing the cornerstone of the invasive measures",
            "probability": 0.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": -9.6796875,
            "text": "patch providing the cornerstone of",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_3": [
        {
            "start_logit": 12.84375,
            "end_logit": 14.3671875,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.892578125,
            "end_logit": 14.3671875,
            "text": "patch",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.84375,
            "end_logit": -4.2265625,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 14.3671875,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -6.73828125,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 14.3671875,
            "text": ", epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -7.890625,
            "text": "epidural blood patch should",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.3671875,
            "text": "high-risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 14.3671875,
            "text": "In high-risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -8.640625,
            "text": "epidural blood patch should be performed",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.3671875,
            "text": ", large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.3671875,
            "text": "-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.3671875,
            "text": "-risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.3671875,
            "text": "risk patients , for example, age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.3671875,
            "text": ", postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.3671875,
            "text": "needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.3671875,
            "text": ", age < 50 years, postpartum, large-gauge needle puncture, epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -9.453125,
            "text": "epidural blood patch should be",
            "probability": 0.0
        },
        {
            "start_logit": -2.892578125,
            "end_logit": -7.890625,
            "text": "patch should",
            "probability": 0.0
        },
        {
            "start_logit": -2.892578125,
            "end_logit": -8.640625,
            "text": "patch should be performed",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_4": [
        {
            "start_logit": 13.578125,
            "end_logit": 14.703125,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.095703125,
            "end_logit": 14.703125,
            "text": "patch",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.578125,
            "end_logit": -3.3671875,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 14.703125,
            "text": "acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -6.421875,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 14.703125,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -7.5078125,
            "text": "epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 14.703125,
            "text": "an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 14.703125,
            "text": "than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.703125,
            "text": "parturients were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.703125,
            "text": "ients were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.703125,
            "text": "using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.703125,
            "text": "rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.703125,
            "text": "urients were successfully managed using acupuncture rather than an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": -3.3671875,
            "text": "acupuncture rather than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -2.095703125,
            "end_logit": -7.5078125,
            "text": "patch.",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": -6.421875,
            "text": "acupuncture rather than an epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": -3.3671875,
            "text": "an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": -3.3671875,
            "text": "than an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": -7.32421875,
            "text": "acupuncture",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_5": [
        {
            "start_logit": 12.1171875,
            "end_logit": 13.9453125,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -2.49609375,
            "end_logit": 13.9453125,
            "text": "patch",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.1171875,
            "end_logit": -4.9140625,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 13.9453125,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 12.1171875,
            "end_logit": -6.70703125,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": 12.1171875,
            "end_logit": -6.73828125,
            "text": "epidural blood patch.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 13.9453125,
            "text": "LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 13.9453125,
            "text": "an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 13.9453125,
            "text": "shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 13.9453125,
            "text": "by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 13.9453125,
            "text": "yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 13.9453125,
            "text": "In this case, a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 13.9453125,
            "text": "a 17-yr-old girl had symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 13.9453125,
            "text": "symptoms of a low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 13.9453125,
            "text": "pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 13.9453125,
            "text": "low-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 13.9453125,
            "text": "-pressure headache after LP shunt placement alleviated by an epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -2.49609375,
            "end_logit": -6.73828125,
            "text": "patch.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -4.9140625,
            "text": "LP shunt placement alleviated by an epidural",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -4.9140625,
            "text": "an epidural",
            "probability": 0.0
        }
    ],
    "53262cdcd6d3ac6a34000003_6": [
        {
            "start_logit": 11.15625,
            "end_logit": 14.3359375,
            "text": "epidural blood patch",
            "probability": 1.0
        },
        {
            "start_logit": -3.423828125,
            "end_logit": 14.3359375,
            "text": "patch",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 14.3359375,
            "text": "blood patch",
            "probability": 0.0
        },
        {
            "start_logit": 11.15625,
            "end_logit": -5.640625,
            "text": "epidural",
            "probability": 0.0
        },
        {
            "start_logit": 11.15625,
            "end_logit": -6.5,
            "text": "epidural blood",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 14.3359375,
            "text": "dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.3359375,
            "text": "-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.3359375,
            "text": ") epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.3359375,
            "text": "post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.3359375,
            "text": "-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.3359375,
            "text": ", large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.3359375,
            "text": "-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.3359375,
            "text": "needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 14.3359375,
            "text": "gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural blood patch",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -6.5,
            "text": "blood",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -5.640625,
            "text": "dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -5.640625,
            "text": "-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -5.640625,
            "text": ") epidural",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -5.640625,
            "text": "post-partum, large-gauge-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -5.640625,
            "text": "-needle puncture), patients should be offered early (within 24-48 h of dural puncture) epidural",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_1": [
        {
            "start_logit": 13.1015625,
            "end_logit": 13.828125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -3.572265625,
            "text": "DSM",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": 13.828125,
            "text": "NC",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -7.73828125,
            "text": "DSMNC: a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -7.88671875,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -8.0859375,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -9.9296875,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -9.9375,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -10.15625,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -10.453125,
            "text": "DSMNC: a database of somatic mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -7.73828125,
            "text": "NC: a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -7.88671875,
            "text": "NC:",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -8.0859375,
            "text": "NC: a",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -9.9296875,
            "text": "NC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -9.9375,
            "text": "NC: a database",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -10.15625,
            "text": "NC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -10.453125,
            "text": "NC: a database of somatic mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -7.73828125,
            "text": "a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -7.73828125,
            "text": "of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -7.73828125,
            "text": ": a database of somatic mutations in normal cells.",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_2": [
        {
            "start_logit": 13.8671875,
            "end_logit": 14.921875,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -0.05352783203125,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.583984375,
            "end_logit": 14.921875,
            "text": "NC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -1.765625,
            "text": "DSM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -5.49609375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 14.921875,
            "text": "ial single nucleotide variations (SNVs), occurring in normal cells. Here, we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -8.2890625,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 14.921875,
            "text": "established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -8.7265625,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 14.921875,
            "text": "single nucleotide variations (SNVs), occurring in normal cells. Here, we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.171875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.2734375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.3359375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.65625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": -2.583984375,
            "end_logit": -0.05352783203125,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -2.583984375,
            "end_logit": -5.49609375,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": -0.05352783203125,
            "text": "/dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -0.05352783203125,
            "text": "//dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -0.05352783203125,
            "text": "established DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -0.05352783203125,
            "text": ".big.ac.cn",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_3": [
        {
            "start_logit": 13.1796875,
            "end_logit": 14.3125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -0.7744140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.72265625,
            "end_logit": 14.3125,
            "text": "NC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -3.396484375,
            "text": "DSM",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -4.83203125,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -7.10546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 14.3125,
            "text": "established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -8.296875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -8.328125,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.3125,
            "text": ", we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.234375,
            "text": "DSMNC: a database of somatic mutations in normal cells (",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.390625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.390625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.40625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.609375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/),",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.6640625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.859375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": -3.72265625,
            "end_logit": -0.7744140625,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -3.72265625,
            "end_logit": -4.83203125,
            "text": "NC: a",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -0.7744140625,
            "text": "http://dsmnc.big.ac.cn",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_4": [
        {
            "start_logit": 10.3828125,
            "end_logit": 12.4453125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": 12.4453125,
            "text": "NC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.078125,
            "text": "DSM",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -6.39453125,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -9.0234375,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -9.078125,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -9.890625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -10.0625,
            "text": "DSMNC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -10.15625,
            "text": "DSMNC: a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -10.3203125,
            "text": "DSMNC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct",
            "probability": 0.0
        },
        {
            "start_logit": 10.3828125,
            "end_logit": -10.34375,
            "text": "DSMNC: a database of somatic mutations in normal",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -6.39453125,
            "text": "NC: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -9.0234375,
            "text": "NC: a database of somatic mutations in normal cells.Numerous non-inherited somatic mutations, distinct from those of germ-line origin",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -9.078125,
            "text": "NC:",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -5.35546875,
            "text": "Numerous non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division.",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -6.39453125,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -9.890625,
            "text": "NC: a database",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -10.0625,
            "text": "NC: a database of somatic mutations in normal cells",
            "probability": 0.0
        },
        {
            "start_logit": -5.3984375,
            "end_logit": -10.15625,
            "text": "NC: a database of somatic mutations in normal cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -5.35546875,
            "text": "non-inherited somatic mutations, distinct from those of germ-line origin, occur in somatic cells during DNA replication per cell-division.",
            "probability": 0.0
        }
    ],
    "5c5b268986df2b9174000019_5": [
        {
            "start_logit": 13.1796875,
            "end_logit": 14.3125,
            "text": "DSMNC",
            "probability": 1.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -0.7744140625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.72265625,
            "end_logit": 14.3125,
            "text": "NC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -3.396484375,
            "text": "DSM",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -4.83203125,
            "text": "DSMNC: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -7.10546875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 14.3125,
            "text": "established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -8.296875,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -8.328125,
            "text": "DSMNC:",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.3125,
            "text": ", we established DSMNC",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.234375,
            "text": "DSMNC: a database of somatic mutations in normal cells (",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.390625,
            "text": "DSMNC: a database",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.390625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.40625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.609375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/),",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.6640625,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big",
            "probability": 0.0
        },
        {
            "start_logit": 13.1796875,
            "end_logit": -9.859375,
            "text": "DSMNC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn/)",
            "probability": 0.0
        },
        {
            "start_logit": -3.72265625,
            "end_logit": -0.7744140625,
            "text": "NC: a database of somatic mutations in normal cells (http://dsmnc.big.ac.cn",
            "probability": 0.0
        },
        {
            "start_logit": -3.72265625,
            "end_logit": -4.83203125,
            "text": "NC: a",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -0.7744140625,
            "text": "http://dsmnc.big.ac.cn",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_1": [
        {
            "start_logit": 13.171875,
            "end_logit": 11.9140625,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": 2.0234375,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 5.02467155456543e-05
        },
        {
            "start_logit": 13.171875,
            "end_logit": -4.6953125,
            "text": "Epstein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.33984375,
            "end_logit": 11.9140625,
            "text": "virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -7.52734375,
            "text": "Epstein-Barr virus (",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -8.6484375,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -8.9375,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 11.9140625,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -9.1171875,
            "text": "Epstein-Barr virus (EBV) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 11.9140625,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -9.59375,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -9.6328125,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 13.171875,
            "end_logit": -9.96875,
            "text": "Epstein-Barr virus (EBV) is a highly prevalent",
            "probability": 0.0
        },
        {
            "start_logit": -4.33984375,
            "end_logit": 2.0234375,
            "text": "virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 2.0234375,
            "text": "-Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 2.0234375,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 2.0234375,
            "text": "Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 2.0234375,
            "text": "(EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -4.33984375,
            "end_logit": -7.52734375,
            "text": "virus (",
            "probability": 0.0
        },
        {
            "start_logit": -4.33984375,
            "end_logit": -9.1171875,
            "text": "virus (EBV) is",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_2": [
        {
            "start_logit": 1.74609375,
            "end_logit": -1.7314453125,
            "text": "cytomegalovirus",
            "probability": 0.9873046875
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -7.2421875,
            "text": "cytomegalovirus (",
            "probability": 0.00399017333984375
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -7.2578125,
            "text": "cytomegalovirus (CMV)",
            "probability": 0.003925323486328125
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -7.95703125,
            "text": "cytomegalovirus (CMV",
            "probability": 0.0019512176513671875
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -8.5390625,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection",
            "probability": 0.0010900497436523438
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -9.3125,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV",
            "probability": 0.0005035400390625
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -9.7265625,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection.",
            "probability": 0.0003325939178466797
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -9.7578125,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome",
            "probability": 0.0003211498260498047
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -10.0078125,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis",
            "probability": 0.00025010108947753906
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -10.2890625,
            "text": "cytomegalovirus (CMV) IgM and IgG were positive, suggesting",
            "probability": 0.00018870830535888672
        },
        {
            "start_logit": 1.74609375,
            "end_logit": -10.3046875,
            "text": "cytomegalovirus (CMV) IgM",
            "probability": 0.00018584728240966797
        },
        {
            "start_logit": -9.078125,
            "end_logit": -1.7314453125,
            "text": "her cytomegalovirus",
            "probability": 1.9609928131103516e-05
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -1.7314453125,
            "text": "Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -10.328125,
            "end_logit": -1.7314453125,
            "text": "the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -10.359375,
            "end_logit": -1.7314453125,
            "text": "interestingly her cytomegalovirus",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -1.7314453125,
            "text": ", interestingly her cytomegalovirus",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -1.7314453125,
            "text": "viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -9.078125,
            "end_logit": -7.2421875,
            "text": "her cytomegalovirus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.078125,
            "end_logit": -7.2578125,
            "text": "her cytomegalovirus (CMV)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.078125,
            "end_logit": -7.95703125,
            "text": "her cytomegalovirus (CMV",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a690487b750ff445500001f_3": [
        {
            "start_logit": 12.46875,
            "end_logit": 10.078125,
            "text": "Epstein-Barr virus",
            "probability": 0.96044921875
        },
        {
            "start_logit": 7.92578125,
            "end_logit": 11.140625,
            "text": "infectious mononucleosis",
            "probability": 0.0294647216796875
        },
        {
            "start_logit": 7.92578125,
            "end_logit": 10.078125,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0101776123046875
        },
        {
            "start_logit": 12.46875,
            "end_logit": -4.78515625,
            "text": "Epstein",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.46875,
            "end_logit": -5.2734375,
            "text": "Epstein-Barr virus infection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 11.140625,
            "text": "osis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.46875,
            "end_logit": -6.765625,
            "text": "Epstein-Barr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 10.078125,
            "text": "osis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 10.078125,
            "text": "virus",
            "probability": 0.0
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 10.078125,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -4.78515625,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 10.078125,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -5.2734375,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 12.46875,
            "end_logit": -10.125,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": 12.46875,
            "end_logit": -10.2734375,
            "text": "Epstein-Barr virus infection.",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -6.765625,
            "text": "infectious mononucleosis complicated by spontaneous splenic rupture secondary to Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.140625,
            "text": "diaphragmatic irritation. He was taken to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 10.078125,
            "text": "to Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 11.140625,
            "text": "to theatre for urgent splenectomy. The unifying diagnosis was infectious mononucleosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 11.140625,
            "text": "The unifying diagnosis was infectious mononucleosis",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_4": [
        {
            "start_logit": 13.53125,
            "end_logit": 13.625,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": 13.625,
            "text": "virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.53125,
            "end_logit": -4.00390625,
            "text": "Epstein",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -6.3671875,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 13.625,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.6015625,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 13.625,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.734375,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.96875,
            "text": "Epstein-Barr virus (",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -10.1171875,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 13.625,
            "text": ": Infection with Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.625,
            "text": "Infection with Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": -6.3671875,
            "text": "virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": -4.3671875,
            "end_logit": -5.328125,
            "text": "infectious mononucleosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": -9.734375,
            "text": "virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": -3.1875,
            "end_logit": -9.96875,
            "text": "virus (",
            "probability": 0.0
        },
        {
            "start_logit": -4.3671875,
            "end_logit": -9.90625,
            "text": "infectious mononucleosis (IM) in ~25% cases. The determinants",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -4.00390625,
            "text": ": Infection with Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -4.00390625,
            "text": "Infection with Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -4.3671875,
            "end_logit": -10.15625,
            "text": "infectious mononucleosis (IM",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_5": [
        {
            "start_logit": 14.0703125,
            "end_logit": 14.734375,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": 14.734375,
            "text": "virus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -2.939453125,
            "text": "Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 14.734375,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -6.73046875,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 14.734375,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.2578125,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.5625,
            "text": "Epstein-Barr virus viral load (EBV-VL",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.609375,
            "text": "Epstein-Barr virus viral load",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.7109375,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.765625,
            "text": "Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.734375,
            "text": "of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 14.734375,
            "text": "time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 14.734375,
            "text": "[measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 14.734375,
            "text": "-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 14.734375,
            "text": "/IgG antibodies measured with different assays [measurement of Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": -9.5625,
            "text": "virus viral load (EBV-VL",
            "probability": 0.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": -9.609375,
            "text": "virus viral load",
            "probability": 0.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": -9.7109375,
            "text": "virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values",
            "probability": 0.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": -9.765625,
            "text": "virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_6": [
        {
            "start_logit": 12.3046875,
            "end_logit": 13.0546875,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -0.463623046875,
            "text": "Epstein-Barr virus-related infectious mononucleosis",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.16015625,
            "end_logit": 13.0546875,
            "text": "virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.390625,
            "text": "Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 13.0546875,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 13.0546875,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.91796875,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 13.0546875,
            "text": "positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.0546875,
            "text": "his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.8125,
            "text": "Epstein-Barr virus-",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.0546875,
            "text": ". Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.9453125,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.0546875,
            "text": "total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.0546875,
            "text": "in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.9765625,
            "text": "Epstein-Barr virus-related",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -10.0078125,
            "text": "Epstein-Barr virus-related infectious mononucle",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 13.0546875,
            "text": "lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.0546875,
            "text": "and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -10.09375,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered the most likely",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -10.1875,
            "text": "Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient.",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_7": [
        {
            "start_logit": 13.9921875,
            "end_logit": 14.3125,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": -2.521484375,
            "end_logit": 14.3125,
            "text": "virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -3.033203125,
            "text": "Epstein",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -4.4140625,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 14.3125,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -7.109375,
            "text": "Epstein-Barr virus (EBV",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -7.16796875,
            "text": "Epstein-Barr virus (",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -7.40234375,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 14.3125,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 14.3125,
            "text": ": Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 14.3125,
            "text": "against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.1328125,
            "text": "Epstein-Barr virus (EBV)",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.484375,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.8203125,
            "text": "Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.3125,
            "text": "(HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.3125,
            "text": "and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.3125,
            "text": "antibodies against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.3125,
            "text": "Heterophil antibodies against Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -2.521484375,
            "end_logit": -4.4140625,
            "text": "virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.521484375,
            "end_logit": -7.109375,
            "text": "virus (EBV",
            "probability": 0.0
        }
    ],
    "5a690487b750ff445500001f_8": [
        {
            "start_logit": 14.0703125,
            "end_logit": 14.859375,
            "text": "Epstein-Barr virus",
            "probability": 1.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": 14.859375,
            "text": "virus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -2.794921875,
            "text": "Epstein",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": 14.859375,
            "text": "-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -6.34375,
            "text": "Epstein-Barr",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 14.859375,
            "text": "Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 14.859375,
            "text": "positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -7.95703125,
            "text": "Epstein-Barr virus.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -8.1328125,
            "text": "Epstein-",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.859375,
            "text": "for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.859375,
            "text": "His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.859375,
            "text": "he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.859375,
            "text": "septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.859375,
            "text": "immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.859375,
            "text": "a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.859375,
            "text": "had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 14.859375,
            "text": "and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.859375,
            "text": ", but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 14.859375,
            "text": "but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 14.859375,
            "text": "was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus",
            "probability": 0.0
        }
    ],
    "5c89623bf9c2ba6b28000004_1": [
        {
            "start_logit": 0.5478515625,
            "end_logit": 10.8046875,
            "text": "p.Val7Met",
            "probability": 0.60498046875
        },
        {
            "start_logit": -0.0208892822265625,
            "end_logit": 10.8046875,
            "text": ", p.Val7Met",
            "probability": 0.34228515625
        },
        {
            "start_logit": -2.22265625,
            "end_logit": 10.8046875,
            "text": "(c.19G>A, p.Val7Met",
            "probability": 0.03778076171875
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 10.8046875,
            "text": "Val7Met",
            "probability": 0.0113067626953125
        },
        {
            "start_logit": -5.6015625,
            "end_logit": 10.8046875,
            "text": "Met",
            "probability": 0.001293182373046875
        },
        {
            "start_logit": -5.78125,
            "end_logit": 10.8046875,
            "text": ".Val7Met",
            "probability": 0.0010805130004882812
        },
        {
            "start_logit": -6.75,
            "end_logit": 10.8046875,
            "text": "c.19G>A, p.Val7Met",
            "probability": 0.0004100799560546875
        },
        {
            "start_logit": -7.03125,
            "end_logit": 10.8046875,
            "text": "mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 0.0003097057342529297
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 10.8046875,
            "text": ".19G>A, p.Val7Met",
            "probability": 0.0002467632293701172
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 10.8046875,
            "text": "19G>A, p.Val7Met",
            "probability": 0.00011932849884033203
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 10.8046875,
            "text": "A, p.Val7Met",
            "probability": 9.66787338256836e-05
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 10.8046875,
            "text": ">A, p.Val7Met",
            "probability": 5.257129669189453e-05
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 10.8046875,
            "text": "exon 2 (c.19G>A, p.Val7Met",
            "probability": 1.7881393432617188e-05
        },
        {
            "start_logit": 0.5478515625,
            "end_logit": 0.1824951171875,
            "text": "p.Val7",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 10.8046875,
            "text": "homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -10.1875,
            "end_logit": 10.8046875,
            "text": "a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 1.3172626495361328e-05
        },
        {
            "start_logit": -10.3125,
            "end_logit": 10.8046875,
            "text": "missense mutation in exon 2 (c.19G>A, p.Val7Met",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": -0.0208892822265625,
            "end_logit": 0.1824951171875,
            "text": ", p.Val7",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -2.22265625,
            "end_logit": 0.1824951171875,
            "text": "(c.19G>A, p.Val7",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 0.1824951171875,
            "text": "Val7",
            "probability": 2.980232238769531e-07
        }
    ],
    "56c85ed65795f9a73e000012_1": [
        {
            "start_logit": 12.1796875,
            "end_logit": 10.625,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -8.609375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 10.625,
            "text": "dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -9.6015625,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.0859375,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.171875,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.25,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.3046875,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.3828125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.3984375,
            "text": "inhibits TCR",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.3984375,
            "text": "inhibits TCR-mediated signal transduction,",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.40625,
            "text": "inhibits TCR-",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.4453125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo",
            "probability": 0.0
        },
        {
            "start_logit": 12.1796875,
            "end_logit": -10.4921875,
            "text": "inhibits TCR-mediated signal",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 10.625,
            "text": "that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 10.625,
            "text": ", we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.625,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.625,
            "text": "we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -8.609375,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -9.6015625,
            "text": "dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_2": [
        {
            "start_logit": 11.953125,
            "end_logit": 10.734375,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 10.734375,
            "text": "dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -9.609375,
            "text": "inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -9.796875,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.0703125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.1796875,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.28125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.28125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.3125,
            "text": "inhibits TCR-mediated signal transduction,",
            "probability": 0.0
        },
        {
            "start_logit": 11.953125,
            "end_logit": -10.3203125,
            "text": "inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 10.734375,
            "text": "that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.734375,
            "text": ", we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 10.734375,
            "text": "we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 10.734375,
            "text": "Herein, we show that dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -9.609375,
            "text": "dasatinib inhibits TCR-mediated signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -9.796875,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -10.0703125,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -10.1796875,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -10.28125,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -10.28125,
            "text": "dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_3": [
        {
            "start_logit": 11.7890625,
            "end_logit": 11.4375,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 11.4375,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 11.7890625,
            "end_logit": -8.7421875,
            "text": "inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 11.4375,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 11.7890625,
            "end_logit": -10.2421875,
            "text": "inhibits T-cell activation",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 11.4375,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 11.4375,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.4375,
            "text": "-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.4375,
            "text": "tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.4375,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.4375,
            "text": ", a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -8.7421875,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -10.2421875,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -8.7421875,
            "text": "protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": -8.7421875,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -8.7421875,
            "text": "T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -8.7421875,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -8.7421875,
            "text": "cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -8.7421875,
            "text": "-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -8.7421875,
            "text": "activation and proliferation",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_4": [
        {
            "start_logit": 12.1015625,
            "end_logit": 11.1015625,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": 11.1015625,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.3828125,
            "text": "inhibits T-cell activation and proliferation.",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -9.859375,
            "text": "inhibits T-cell activation",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -10.015625,
            "text": "inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 11.1015625,
            "text": "protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -10.453125,
            "text": "inhibits T-cell activation and",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -10.5,
            "text": "inhibits T",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 11.1015625,
            "text": "molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 11.1015625,
            "text": "a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.1015625,
            "text": "tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.1015625,
            "text": "small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.1015625,
            "text": "-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.1015625,
            "text": ", a small-molecule protein tyrosine kinase inhibitor, inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -8.3828125,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -9.859375,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -10.015625,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -10.4453125,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor,",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -10.453125,
            "text": "Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -10.484375,
            "text": "Das",
            "probability": 0.0
        }
    ],
    "56c85ed65795f9a73e000012_5": [
        {
            "start_logit": 12.234375,
            "end_logit": 10.8671875,
            "text": "inhibits",
            "probability": 1.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -5.2109375,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.0625,
            "end_logit": 10.8671875,
            "text": "Dasatinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -8.8359375,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T cells",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -10.0703125,
            "text": "inhibits the proliferation and function of CD4+CD25+ regulatory T",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -10.3671875,
            "text": "inhibits the proliferation and function of CD4+CD25+",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.8671875,
            "text": "atinib inhibits",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -5.2109375,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -5.2109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.515625,
            "end_logit": -5.2109375,
            "text": "CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -5.2109375,
            "text": "T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -5.2109375,
            "text": "regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -8.8359375,
            "text": "Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -5.2109375,
            "text": "+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -5.2109375,
            "text": "of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -5.2109375,
            "text": "+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -5.2109375,
            "text": "CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -5.2109375,
            "text": "function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -5.2109375,
            "text": "cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -5.2109375,
            "text": "atinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_1": [
        {
            "start_logit": 8.921875,
            "end_logit": 6.14453125,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -9.390625,
            "text": "Liver Injury",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -9.390625,
            "text": "Liver Injury Network",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -10.3828125,
            "text": "Liver Injury Network.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.34375,
            "end_logit": 6.14453125,
            "text": "Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 6.14453125,
            "text": ", prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 6.14453125,
            "text": "Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 6.14453125,
            "text": "prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 6.14453125,
            "text": "need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 6.14453125,
            "text": "transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 6.14453125,
            "text": "the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 6.14453125,
            "text": "-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 6.14453125,
            "text": "for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -9.3671875,
            "text": "drug-induced hepatocellular jaundice",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -9.390625,
            "text": "Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -9.390625,
            "text": "Drug-Induced Liver Injury Network",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": -9.390625,
            "text": ", prospective U.S. Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": -9.390625,
            "text": ", prospective U.S. Drug-Induced Liver Injury Network",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -10.265625,
            "text": "drug-induced hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -9.3671875,
            "text": "Hy's Law of drug-induced hepatocellular jaundice",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_2": [
        {
            "start_logit": 10.9140625,
            "end_logit": 10.8671875,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -9.9375,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.1171875,
            "text": "liver injury patterns were",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.15625,
            "text": "liver injury patterns were found",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.15625,
            "text": "liver injury patterns",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 10.8671875,
            "text": "No additional alleles outside those associated with liver",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.2109375,
            "text": "liver injury",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.25,
            "text": "liver injury patterns were found to",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 10.8671875,
            "text": "additional alleles outside those associated with liver",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.46875,
            "text": "liver injury patterns were found to affect potential severity",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.4765625,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.5859375,
            "text": "liver injury patterns were found to affect potential severity as measured by Hy's Law criteria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9140625,
            "end_logit": -10.609375,
            "text": "liver injury patterns were found to affect",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 10.8671875,
            "text": "alleles outside those associated with liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 10.8671875,
            "text": "with liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 10.8671875,
            "text": "associated with liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -9.9375,
            "text": "potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.9375,
            "text": "No additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -10.1171875,
            "text": "No additional alleles outside those associated with liver injury patterns were",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -9.9375,
            "text": "additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_3": [
        {
            "start_logit": 5.56640625,
            "end_logit": 3.759765625,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -5.23046875,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 0.00012433528900146484
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -9.8515625,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -10.171875,
            "text": "liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -10.2421875,
            "text": "liver aminotransferase levels above the upper limit of normal",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 3.759765625,
            "text": ", liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 3.759765625,
            "text": "through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 3.759765625,
            "text": "Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 3.759765625,
            "text": "We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": 3.759765625,
            "text": "DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.53125,
            "end_logit": 3.759765625,
            "text": "cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.53125,
            "end_logit": -5.23046875,
            "text": "liver",
            "probability": 0.0
        },
        {
            "start_logit": -3.53125,
            "end_logit": -9.8515625,
            "text": "liver disease",
            "probability": 0.0
        },
        {
            "start_logit": -3.53125,
            "end_logit": -10.171875,
            "text": "liver disease.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -5.23046875,
            "text": ", liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -5.23046875,
            "text": "existing liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -5.23046875,
            "text": "above the upper limit of normal, and no pre-existing liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -5.23046875,
            "text": "through 2010, liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -5.23046875,
            "text": "DILI from 2004 through 2010, liver aminotransferase levels above the upper limit of normal, and no pre-existing liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -5.23046875,
            "text": "the upper limit of normal, and no pre-existing liver",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_4": [
        {
            "start_logit": 11.921875,
            "end_logit": 11.015625,
            "text": "Liver",
            "probability": 1.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.25,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.2578125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.28125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.3046875,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.3671875,
            "text": "Liver Failure",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.390625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.40625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.53125,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.5390625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.546875,
            "text": "Liver Failure in",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.5859375,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New",
            "probability": 0.0
        },
        {
            "start_logit": 11.921875,
            "end_logit": -10.625,
            "text": "Liver Failure in Patients With Drug-Induced Liver Injury:",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.015625,
            "text": "Risk of Acute Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.015625,
            "text": "Acute Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.015625,
            "text": "of Acute Liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -10.25,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -10.2578125,
            "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -10.25,
            "text": "Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_5": [
        {
            "start_logit": 11.5703125,
            "end_logit": 11.03125,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 11.03125,
            "text": "Hy's Law, which states that hepatocellular drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 11.03125,
            "text": "drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.0703125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.421875,
            "text": "liver injury (DILI) with jaundice",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.53125,
            "text": "liver injury",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.53125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 11.03125,
            "text": "hepatocellular drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.578125,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.6015625,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF).",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 11.03125,
            "text": "states that hepatocellular drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.7265625,
            "text": "liver injury (DILI) with jaundice indicates a serious reaction, is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.7265625,
            "text": "liver injury (DILI",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 11.03125,
            "text": "that hepatocellular drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 11.03125,
            "text": "induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.03125,
            "text": "-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.03125,
            "text": "which states that hepatocellular drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": -10.0703125,
            "text": "drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -10.359375,
            "text": "Hy's Law",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -10.421875,
            "text": "Hy's Law, which states that hepatocellular drug-induced liver injury (DILI) with jaundice",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_6": [
        {
            "start_logit": 11.3515625,
            "end_logit": 10.328125,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": 11.3515625,
            "end_logit": -9.328125,
            "text": "liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 10.328125,
            "text": "drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.3515625,
            "end_logit": -10.375,
            "text": "liver injury (DILI",
            "probability": 0.0
        },
        {
            "start_logit": 11.3515625,
            "end_logit": -10.375,
            "text": "liver injury (DILI)",
            "probability": 0.0
        },
        {
            "start_logit": 11.3515625,
            "end_logit": -10.546875,
            "text": "liver injury (DIL",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 10.328125,
            "text": "induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 10.328125,
            "text": "identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 10.328125,
            "text": "Hy's law is a method used to identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.328125,
            "text": "used to identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 10.328125,
            "text": "-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 10.328125,
            "text": "to identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 10.328125,
            "text": "'s law is a method used to identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 10.328125,
            "text": "s law is a method used to identify drug-induced liver",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -9.328125,
            "text": "drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -9.328125,
            "text": "injury",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -9.328125,
            "text": "induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.328125,
            "text": "identify drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.328125,
            "text": "Hy's law is a method used to identify drug-induced liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -10.375,
            "text": "drug-induced liver injury (DILI",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_7": [
        {
            "start_logit": 11.84375,
            "end_logit": 11.1484375,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": 11.1484375,
            "text": "Potential severe liver",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 11.1484375,
            "text": "severe liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.640625,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.6484375,
            "text": "liver injury is",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.703125,
            "text": "liver injury is identified in clinical trials by ALT",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.7265625,
            "text": "liver injury",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.734375,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 UL",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.7578125,
            "text": "liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (UL",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.78125,
            "text": "liver injury is identified",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.640625,
            "text": "Potential severe liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.6484375,
            "text": "Potential severe liver injury is",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.703125,
            "text": "Potential severe liver injury is identified in clinical trials by ALT",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.7265625,
            "text": "Potential severe liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.734375,
            "text": "Potential severe liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 UL",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.7578125,
            "text": "Potential severe liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (UL",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -10.78125,
            "text": "Potential severe liver injury is identified",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -10.640625,
            "text": "severe liver injury is identified in clinical trials by ALT>3 \u00d7 upper limits of normal (ULN) and total bilirubin>2 \u00d7 ULN",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -10.6484375,
            "text": "severe liver injury is",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -10.703125,
            "text": "severe liver injury is identified in clinical trials by ALT",
            "probability": 0.0
        }
    ],
    "58f4b25e70f9fc6f0f000011_8": [
        {
            "start_logit": 11.90625,
            "end_logit": 11.1953125,
            "text": "liver",
            "probability": 1.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 11.1953125,
            "text": "Severe liver",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.4140625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.5234375,
            "text": "liver injury",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.5546875,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.5703125,
            "text": "liver injury is identified by the liver chemistry",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.65625,
            "text": "liver injury is",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.6640625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (UL",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.7109375,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.765625,
            "text": "liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.4140625,
            "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.5234375,
            "text": "Severe liver injury",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.5546875,
            "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.5703125,
            "text": "Severe liver injury is identified by the liver chemistry",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.65625,
            "text": "Severe liver injury is",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.6640625,
            "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (UL",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.7109375,
            "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -10.765625,
            "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -10.25,
            "text": "the Food and Drug Administration.",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -10.390625,
            "text": "the Food and Drug Administration",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_1": [
        {
            "start_logit": 11.6796875,
            "end_logit": 11.46875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -8.65625,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 11.46875,
            "text": ", dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 11.46875,
            "text": "DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.46875,
            "text": "Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.46875,
            "text": "approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 11.46875,
            "text": "the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 11.46875,
            "text": ".e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.46875,
            "text": "for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.46875,
            "text": "e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 11.46875,
            "text": "one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.46875,
            "text": "FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.46875,
            "text": "Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.46875,
            "text": "i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.46875,
            "text": "of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.46875,
            "text": "been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": -8.65625,
            "text": ", dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -8.65625,
            "text": "DOACs i.e., dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -8.65625,
            "text": "Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.4609375,
            "text": "DO",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_2": [
        {
            "start_logit": 7.90625,
            "end_logit": 6.3671875,
            "text": "dabigatran",
            "probability": 0.9951171875
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": 7.62890625,
            "text": "apixaban",
            "probability": 0.00406646728515625
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": 6.3671875,
            "text": "apixaban, rivaroxaban, or dabigatran",
            "probability": 0.0011510848999023438
        },
        {
            "start_logit": -3.85546875,
            "end_logit": 7.62890625,
            "text": "ban",
            "probability": 2.7418136596679688e-05
        },
        {
            "start_logit": -3.85546875,
            "end_logit": 6.3671875,
            "text": "ban, rivaroxaban, or dabigatran",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 7.90625,
            "end_logit": -8.078125,
            "text": "dabigatran may",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 7.62890625,
            "text": "xaban",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 7.62890625,
            "text": "anticoagulants such as apixaban",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 6.3671875,
            "text": "xaban, rivaroxaban, or dabigatran",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -9.515625,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -9.7890625,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.90625,
            "end_logit": -9.8828125,
            "text": "dabigatran may be preferred to vitamin K antagonists",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.90625,
            "end_logit": -9.921875,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.90625,
            "end_logit": -9.96875,
            "text": "dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as ida",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 7.62890625,
            "text": "New oral anticoagulants such as apixaban",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 6.3671875,
            "text": "anticoagulants such as apixaban, rivaroxaban, or dabigatran",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.953125,
            "end_logit": 7.62890625,
            "text": "oral anticoagulants such as apixaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 6.3671875,
            "text": "New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 6.3671875,
            "text": ", or dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 6.3671875,
            "text": "or dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_3": [
        {
            "start_logit": 11.71875,
            "end_logit": 11.4296875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.6328125,
            "text": "dabigatran anticoagulant activity,",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.6953125,
            "text": "dabigatran anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.734375,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.0859375,
            "text": "dabigatran anticoagulant activity, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.1640625,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.1640625,
            "text": "dabigatran anticoagulant",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.3359375,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.3671875,
            "text": "dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.4296875,
            "text": ", complete and sustained reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.4296875,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.4296875,
            "text": "and sustained reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.4296875,
            "text": "immediate, complete and sustained reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -9.734375,
            "text": "tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -10.1640625,
            "text": "tolerated in middle-aged, elderly and renally impaired",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -9.6328125,
            "text": ", complete and sustained reversal of dabigatran anticoagulant activity,",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -9.734375,
            "text": "well tolerated in middle-aged, elderly and renally impaired volunteers.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -9.6953125,
            "text": ", complete and sustained reversal of dabigatran anticoagulant activity",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -10.3359375,
            "text": "tolerated in middle-aged, elderly and renally impaired volunteers",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.6328125,
            "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity,",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_4": [
        {
            "start_logit": 11.7578125,
            "end_logit": 11.40625,
            "text": "Dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -9.53125,
            "text": "Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -9.734375,
            "text": "Dabigatran Anticoagulant Activity in",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -9.8203125,
            "text": "Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -10.0546875,
            "text": "Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -10.125,
            "text": "Dabigatran Anticoagulant Activity in a",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 11.40625,
            "text": "Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 11.40625,
            "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 11.40625,
            "text": "of Dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 11.40625,
            "text": "Mediated Reversal of Dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 11.40625,
            "text": "-Mediated Reversal of Dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -9.53125,
            "text": "Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -9.734375,
            "text": "Anticoagulant Activity in",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -9.8203125,
            "text": "Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.8203125,
            "text": ", Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -9.8203125,
            "text": "Phase Ib Study.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -9.53125,
            "text": "Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -9.53125,
            "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -9.53125,
            "text": "of Dabigatran Anticoagulant Activity",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -9.8203125,
            "text": "Double-Blind, Crossover Phase Ib Study.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_5": [
        {
            "start_logit": 11.4375,
            "end_logit": 11.6484375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.8828125,
            "text": "dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.0,
            "text": "dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.03125,
            "text": "dabigatran and two agents, andexanet and ciraparantag",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.1171875,
            "text": "dabigatran and two agents, andexanet and cir",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.6484375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.6484375,
            "text": ", for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.6484375,
            "text": "for each drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.6484375,
            "text": "the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 11.6484375,
            "text": "use of idarucizumab for the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.6484375,
            "text": "the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 11.6484375,
            "text": "drug, including the preferential use of idarucizumab for the reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -9.4921875,
            "text": ", andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -9.4921875,
            "text": "under development for the reversal of rivaroxaban, apixaban, and edoxaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -9.8828125,
            "text": ", andexanet and ciraparantag, currently under development for the reversal of rivaroxaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -9.4921875,
            "text": ", and edoxaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -9.4921875,
            "text": "currently under development for the reversal of rivaroxaban, apixaban, and edoxaban",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -10.0,
            "text": ", andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and ed",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -10.015625,
            "text": ", andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -9.4921875,
            "text": "agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_6": [
        {
            "start_logit": 11.5,
            "end_logit": 11.6328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -7.06640625,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 11.6328125,
            "text": "Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 11.6328125,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 11.6328125,
            "text": "approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.6328125,
            "text": "the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.6328125,
            "text": "targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.6328125,
            "text": "for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.6328125,
            "text": "anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.6328125,
            "text": "effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.6328125,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 11.6328125,
            "text": "rucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 11.6328125,
            "text": "a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 11.6328125,
            "text": "is approved for the urgent reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 11.6328125,
            "text": "of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -7.06640625,
            "text": "Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -7.06640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -7.06640625,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -7.06640625,
            "text": "approved for the urgent reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -7.06640625,
            "text": "the urgent reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_7": [
        {
            "start_logit": 11.6015625,
            "end_logit": 11.515625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.6015625,
            "end_logit": -9.7109375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.515625,
            "text": "treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.515625,
            "text": ": The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 11.515625,
            "text": "with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.515625,
            "text": "The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.515625,
            "text": "bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.515625,
            "text": "of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.515625,
            "text": "CONCLUSIONS: The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.515625,
            "text": "associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.515625,
            "text": "a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.515625,
            "text": "initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.515625,
            "text": "data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.515625,
            "text": "for idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.515625,
            "text": "idarucizumab in treatment of bleeding associated with dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.5234375,
            "text": ": The initial data suggest a definite",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -9.5234375,
            "text": "The initial data suggest a definite",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.7109375,
            "text": "treatment of bleeding associated with dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -9.7109375,
            "text": ": The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.5234375,
            "text": "CONCLUSIONS: The initial data suggest a definite",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_8": [
        {
            "start_logit": 11.59375,
            "end_logit": 11.421875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -9.9140625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT",
            "probability": 0.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -9.9296875,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92",
            "probability": 0.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -9.9375,
            "text": "dabigatran as",
            "probability": 0.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -9.984375,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75",
            "probability": 0.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -10.0390625,
            "text": "dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time",
            "probability": 0.0
        },
        {
            "start_logit": 11.59375,
            "end_logit": -10.15625,
            "text": "dabigatran as assessed by routine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.421875,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.421875,
            "text": "The administration of 5 g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.421875,
            "text": "anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.421875,
            "text": "and completely reversed the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.421875,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.421875,
            "text": "of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.421875,
            "text": "reversed the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -9.234375,
            "text": "to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92 to 27 s).",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.234375,
            "text": "diluted thrombin time from 92 to 27 s).",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.234375,
            "text": "thrombin time from 92 to 27 s).",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -9.9296875,
            "text": "to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time from 92",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -9.984375,
            "text": "to 75",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -10.0390625,
            "text": "to 75 to 26 s, PT from 26 to 11 s and diluted thrombin time",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_9": [
        {
            "start_logit": 11.4765625,
            "end_logit": 11.609375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.2734375,
            "text": "dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.4140625,
            "text": "dabigatran with high affinity, is in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 11.609375,
            "text": "binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.6484375,
            "text": "dabigatran with high affinity, is in development as a specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.953125,
            "text": "dabigatran with high affinity,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.1015625,
            "text": "dabigatran with high affinity",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.140625,
            "text": "dabigatran with high affinity, is in development as a specific antid",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.1640625,
            "text": "dabigatran with high affinity, is in development",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.609375,
            "text": "antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.609375,
            "text": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.609375,
            "text": "monoclonal antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 11.609375,
            "text": "rucizumab, a monoclonal antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -9.2734375,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -9.4140625,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -9.2734375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -9.6484375,
            "text": "binds dabigatran with high affinity, is in development as a specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -9.4140625,
            "text": "dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -9.953125,
            "text": "binds dabigatran with high affinity,",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -9.2734375,
            "text": "high affinity, is in development as a specific antidote for dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_10": [
        {
            "start_logit": 11.46875,
            "end_logit": 11.6328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.46875,
            "end_logit": -9.7265625,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.6328125,
            "text": "to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.6328125,
            "text": "antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.6328125,
            "text": "the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.6328125,
            "text": "safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.6328125,
            "text": "of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.6328125,
            "text": "in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.6328125,
            "text": ", tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 11.6328125,
            "text": "tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.6328125,
            "text": "specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.6328125,
            "text": "idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 11.6328125,
            "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.6328125,
            "text": "healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.6328125,
            "text": "and pharmacokinetics of idarucizumab, a specific antidote to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -9.5625,
            "text": "antidote",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.5625,
            "text": "the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -9.7265625,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -9.7265625,
            "text": "antidote to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.7265625,
            "text": "the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_11": [
        {
            "start_logit": 11.5078125,
            "end_logit": 11.6171875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.15625,
            "text": "dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -9.25,
            "text": "dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.015625,
            "text": "dabigatran and to review the pharmacology",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.6171875,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.6171875,
            "text": "anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.6171875,
            "text": "antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 11.6171875,
            "text": "the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 11.6171875,
            "text": "humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.21875,
            "end_logit": 11.6171875,
            "text": "monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2890625,
            "end_logit": 11.6171875,
            "text": "for the anticoagulant activity of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.15625,
            "text": "of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.25,
            "text": "of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.15625,
            "text": "anticoagulant activity of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -9.15625,
            "text": "antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.25,
            "text": "anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -9.15625,
            "text": "the anticoagulant activity of dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.875,
            "text": "of",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -9.25,
            "text": "the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": -9.15625,
            "text": "humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_12": [
        {
            "start_logit": 14.4765625,
            "end_logit": 13.0703125,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -0.2900390625,
            "text": "Dabigatran",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -4.40625,
            "end_logit": 13.0703125,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 13.0703125,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.2265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.5546875,
            "text": "Dabigatran etexilate is",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 13.0703125,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3046875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3046875,
            "text": "Dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.65625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.796875,
            "text": "Dabigatran etexilate is an oral",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.828125,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.90625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.9140625,
            "text": "Dabigatran etexilate is an",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.921875,
            "text": "Dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.9765625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.0390625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by ida",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.1015625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idaruc",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.1015625,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 13.0703125,
            "text": "ilate",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_13": [
        {
            "start_logit": 11.6640625,
            "end_logit": 11.53125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.546875,
            "text": "dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.6484375,
            "text": "dabigatran, anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.8671875,
            "text": "dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.9609375,
            "text": "dabigatran, anticoagulation can be rapidly",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -10.1015625,
            "text": "dabigatran, anticoagulation can be rapidly reversed with idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -10.125,
            "text": "dabigatran, anticoagulation can be rapidly reversed with idaruc",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -10.1328125,
            "text": "dabigatran, anticoagulation can",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -10.1796875,
            "text": "dabigatran, anticoagulation can be rapidly reversed",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 11.53125,
            "text": "In ICH related to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.53125,
            "text": "to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.53125,
            "text": "ICH related to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.53125,
            "text": "related to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.546875,
            "text": "In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.6484375,
            "text": "In ICH related to dabigatran, anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -9.546875,
            "text": "to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -9.6484375,
            "text": "to dabigatran, anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.8671875,
            "text": "In ICH related to dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.8984375,
            "text": "In ICH",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.9609375,
            "text": "In ICH related to dabigatran, anticoagulation can be rapidly",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_14": [
        {
            "start_logit": 14.4453125,
            "end_logit": 11.40625,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": 2.01171875,
            "text": "dabigatran",
            "probability": 8.350610733032227e-05
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -7.91015625,
            "text": "dabigatran etexilate.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -8.671875,
            "text": "dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 11.40625,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -5.99609375,
            "end_logit": 11.40625,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.9296875,
            "text": "dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 11.40625,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 11.40625,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 11.40625,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.40625,
            "text": "Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 11.40625,
            "text": "rucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 11.40625,
            "text": "reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.375,
            "end_logit": 11.40625,
            "text": "agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.40625,
            "end_logit": 11.40625,
            "text": "a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 2.01171875,
            "text": "for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 2.01171875,
            "text": "Idarucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 2.01171875,
            "text": "rucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 2.01171875,
            "text": "reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.375,
            "end_logit": 2.01171875,
            "text": "agent for dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_15": [
        {
            "start_logit": 11.5078125,
            "end_logit": 11.6328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -8.4921875,
            "text": "dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.0,
            "text": "dabigatran within",
            "probability": 0.0
        },
        {
            "start_logit": 11.5078125,
            "end_logit": -10.2265625,
            "text": "dabigatran within minutes",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.6328125,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.6328125,
            "text": "the anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.6328125,
            "text": "anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.6328125,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.6328125,
            "text": "reversed the anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 11.6328125,
            "text": "rucizumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 11.6328125,
            "text": "effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 11.6328125,
            "text": "izumab completely reversed the anticoagulant effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -8.4921875,
            "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -8.4921875,
            "text": "the anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -8.4921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -8.4921875,
            "text": "within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -8.4921875,
            "text": "anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -8.4921875,
            "text": "minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -8.4921875,
            "text": "of dabigatran within minutes.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -8.4921875,
            "text": "reversed the anticoagulant effect of dabigatran within minutes.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_16": [
        {
            "start_logit": 14.4765625,
            "end_logit": 13.0703125,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -0.2900390625,
            "text": "Dabigatran",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -4.40625,
            "end_logit": 13.0703125,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 13.0703125,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.2265625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.5546875,
            "text": "Dabigatran etexilate is",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 13.0703125,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3046875,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3046875,
            "text": "Dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.65625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.796875,
            "text": "Dabigatran etexilate is an oral",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.828125,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.90625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.9140625,
            "text": "Dabigatran etexilate is an",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.921875,
            "text": "Dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.9765625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.0390625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by ida",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.1015625,
            "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idaruc",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.1015625,
            "text": "Dabigatran etexilate is an oral thrombin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 13.0703125,
            "text": "ilate",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_17": [
        {
            "start_logit": 14.375,
            "end_logit": 11.0703125,
            "text": "dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 14.375,
            "end_logit": 2.341796875,
            "text": "dabigatran",
            "probability": 0.0001634359359741211
        },
        {
            "start_logit": 14.375,
            "end_logit": -8.921875,
            "text": "dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -8.9296875,
            "text": "dabigatran etexilate.",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": 11.0703125,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -6.4375,
            "end_logit": 11.0703125,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.9453125,
            "text": "dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 11.0703125,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 11.0703125,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 11.0703125,
            "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.0703125,
            "text": "for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.0703125,
            "text": "Idarucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 11.0703125,
            "text": "rucizumab is a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 11.0703125,
            "text": "reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.3828125,
            "end_logit": 11.0703125,
            "text": "a reversal agent for dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 2.341796875,
            "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 2.341796875,
            "text": "for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 2.341796875,
            "text": "Idarucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 2.341796875,
            "text": "rucizumab is a reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 2.341796875,
            "text": "reversal agent for dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_18": [
        {
            "start_logit": 11.5,
            "end_logit": 11.59375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -7.53515625,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.59375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.59375,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.59375,
            "text": "antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.59375,
            "text": "anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 11.59375,
            "text": "for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 11.59375,
            "text": "monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": 11.59375,
            "text": "humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.265625,
            "end_logit": 11.59375,
            "text": "effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2734375,
            "end_logit": 11.59375,
            "text": "rucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 11.59375,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.328125,
            "end_logit": 11.59375,
            "text": "of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.34375,
            "end_logit": 11.59375,
            "text": "reversal of the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -7.53515625,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -7.53515625,
            "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -7.53515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": -7.53515625,
            "text": "antibody fragment for reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -7.53515625,
            "text": "anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": -7.53515625,
            "text": "for reversal of the anticoagulant effects of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_19": [
        {
            "start_logit": 11.4140625,
            "end_logit": 11.640625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.5234375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.640625,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.640625,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 11.640625,
            "text": "targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.640625,
            "text": "to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 11.640625,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 11.640625,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.5,
            "end_logit": 11.640625,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.515625,
            "end_logit": 11.640625,
            "text": "specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.5390625,
            "end_logit": 11.640625,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -6.5234375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -6.5234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -6.5234375,
            "text": "antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": -6.5234375,
            "text": "targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -6.5234375,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": -6.5234375,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": -6.5234375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.5,
            "end_logit": -6.5234375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.515625,
            "end_logit": -6.5234375,
            "text": "specifically targeted to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_20": [
        {
            "start_logit": 11.4140625,
            "end_logit": 11.640625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -6.5234375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.640625,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.640625,
            "text": "antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 11.640625,
            "text": "targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.640625,
            "text": "to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 11.640625,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 11.640625,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.5,
            "end_logit": 11.640625,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.515625,
            "end_logit": 11.640625,
            "text": "specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.5390625,
            "end_logit": 11.640625,
            "text": "a monoclonal antibody fragment specifically targeted to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -6.5234375,
            "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -6.5234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -6.5234375,
            "text": "antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": -6.5234375,
            "text": "targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -6.5234375,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": -6.5234375,
            "text": "monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": -6.5234375,
            "text": "rucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.5,
            "end_logit": -6.5234375,
            "text": "izumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.515625,
            "end_logit": -6.5234375,
            "text": "specifically targeted to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_21": [
        {
            "start_logit": 13.75,
            "end_logit": 8.875,
            "text": "dabigatran etexilate",
            "probability": 0.9931640625
        },
        {
            "start_logit": 13.75,
            "end_logit": 3.87109375,
            "text": "dabigatran",
            "probability": 0.00669097900390625
        },
        {
            "start_logit": 13.75,
            "end_logit": -6.75390625,
            "text": "dabigatran etexilate and neutralizes its activity.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.75,
            "end_logit": -8.5703125,
            "text": "dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.25,
            "text": "dabigatran etexilate and",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.765625,
            "text": "dabigatran etexilate and neutral",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.7734375,
            "text": "dabigatran etexilate and neutralizes its activity",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.8046875,
            "text": "dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 8.875,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.875,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 8.875,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 8.875,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 8.875,
            "text": "binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 8.875,
            "text": "Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 8.875,
            "text": "antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 8.875,
            "text": "directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 8.875,
            "text": "rucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 8.875,
            "text": "monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 8.875,
            "text": ", a monoclonal antibody fragment, directly binds dabigatran etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 3.87109375,
            "text": "binds dabigatran",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_22": [
        {
            "start_logit": 11.6171875,
            "end_logit": 11.5546875,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -8.046875,
            "text": "dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -9.9140625,
            "text": "dabigatran with high affinity",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 11.5546875,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.5546875,
            "text": "binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.5546875,
            "text": "antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 11.5546875,
            "text": "rucizumab is an antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 11.5546875,
            "text": "an antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.265625,
            "end_logit": 11.5546875,
            "text": "izumab is an antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.3828125,
            "end_logit": 11.5546875,
            "text": "is an antibody fragment that binds dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -8.046875,
            "text": "Idarucizumab is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -8.046875,
            "text": "binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -8.046875,
            "text": "antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -8.046875,
            "text": "high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -8.046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -8.046875,
            "text": "rucizumab is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.125,
            "end_logit": -8.046875,
            "text": "with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": -8.046875,
            "text": "an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.265625,
            "end_logit": -8.046875,
            "text": "izumab is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.3828125,
            "end_logit": -8.046875,
            "text": "is an antibody fragment that binds dabigatran with high affinity.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_23": [
        {
            "start_logit": 11.8671875,
            "end_logit": 11.234375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -4.34765625,
            "text": "dabigatran etexilate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -9.3203125,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -9.4609375,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -9.984375,
            "text": "dabigatran et",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.0078125,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.0078125,
            "text": "dabigatran etexila",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.1484375,
            "text": "dabigatran etexilate using",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.3671875,
            "text": "dabigatran etexilate using idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.3671875,
            "text": "dabigatran etexilate using idarucizumab was safe and successful with no recombinant",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.3828125,
            "text": "dabigatran etexilate using idarucizumab was safe and successful",
            "probability": 0.0
        },
        {
            "start_logit": 11.8671875,
            "end_logit": -10.3828125,
            "text": "dabigatran etexilate using idaruc",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.234375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.234375,
            "text": "CONCLUSION Reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.234375,
            "text": "Reversal of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -4.34765625,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -4.34765625,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": -4.34765625,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -4.34765625,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -4.34765625,
            "text": "of dabigatran etexilate",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_24": [
        {
            "start_logit": 11.546875,
            "end_logit": 11.515625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -8.7578125,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 11.515625,
            "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.515625,
            "text": ", monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.515625,
            "text": "to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.515625,
            "text": "antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 11.515625,
            "text": "humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.515625,
            "text": "monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 11.515625,
            "text": "binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 11.515625,
            "text": "Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 11.515625,
            "text": "the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.515625,
            "text": "treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.515625,
            "text": "specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 11.515625,
            "text": "only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 11.515625,
            "text": "novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 11.515625,
            "text": "is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -8.7578125,
            "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -8.7578125,
            "text": ", monoclonal antibody fragment that specifically binds to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -8.7578125,
            "text": "to dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -8.7578125,
            "text": "antibody fragment that specifically binds to dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_25": [
        {
            "start_logit": 11.65625,
            "end_logit": 11.515625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -8.609375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.515625,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 11.515625,
            "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.515625,
            "text": "approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.515625,
            "text": "antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.515625,
            "text": "anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.515625,
            "text": "for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.515625,
            "text": "(minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.515625,
            "text": "the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.515625,
            "text": ", the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.515625,
            "text": "rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.515625,
            "text": ") reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.515625,
            "text": "minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.515625,
            "text": "effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.515625,
            "text": "monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.515625,
            "text": "of anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -8.609375,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -8.609375,
            "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -8.609375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_26": [
        {
            "start_logit": 11.453125,
            "end_logit": 11.6328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.3046875,
            "text": "dabigatran, which was recently approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.34375,
            "text": "dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.6328125,
            "text": ", dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.75,
            "text": "dabigatran, which was recently approved for use in the USA",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 11.6328125,
            "text": "direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.046875,
            "text": "dabigatran, which",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.6328125,
            "text": "the direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.6328125,
            "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.6328125,
            "text": "antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.6328125,
            "text": "targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.6328125,
            "text": "specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 11.6328125,
            "text": "thrombin inhibitor, dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -9.3046875,
            "text": ", dabigatran, which was recently approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -9.34375,
            "text": ", dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -9.3046875,
            "text": "direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -9.34375,
            "text": "direct thrombin inhibitor, dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.3046875,
            "text": "approved for use in the USA.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -9.75,
            "text": ", dabigatran, which was recently approved for use in the USA",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -9.609375,
            "text": "direct thrombin inhibitor",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_27": [
        {
            "start_logit": 11.640625,
            "end_logit": 11.6640625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.3984375,
            "text": "dabigatran, is the first specific antidote for a NOAC",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.7421875,
            "text": "dabigatran, is the first specific antidote",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.84375,
            "text": "dabigatran, is the first specific antidote for a NO",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -10.0625,
            "text": "dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -10.0859375,
            "text": "dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -10.2578125,
            "text": "dabigatran, is the first specific antid",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.6640625,
            "text": "targeting dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -10.328125,
            "text": "dabigatran, is the first specific antidote for a NOAC to be",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -10.375,
            "text": "dabigatran, is the first specific antidote for a NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.6640625,
            "text": "antibody fragment targeting dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.6640625,
            "text": "Idarucizumab, an antibody fragment targeting dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -9.3984375,
            "text": "NOAC",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -9.84375,
            "text": "NO",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -10.0625,
            "text": "NOAC to be approved, but real-world experience is limited.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -9.3984375,
            "text": "targeting dabigatran, is the first specific antidote for a NOAC",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -10.328125,
            "text": "NOAC to be",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.3984375,
            "text": "antibody fragment targeting dabigatran, is the first specific antidote for a NOAC",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -10.375,
            "text": "NOAC to",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -9.7421875,
            "text": "targeting dabigatran, is the first specific antidote",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_28": [
        {
            "start_logit": 11.7109375,
            "end_logit": 11.4375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -7.203125,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -7.30859375,
            "text": "dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.0234375,
            "text": "dabigatran, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.6015625,
            "text": "dabigatran, and reversed the effects of the drug on coagulation variables",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.734375,
            "text": "dabigatran, and reversed the effects of the drug",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.9609375,
            "text": "dabigatran, and reversed",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.0,
            "text": "dabigatran, and reversed the effects of the drug on",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.0859375,
            "text": "dabigatran, and reversed the effects of the drug on coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.4375,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.4375,
            "text": "plasma concentrations of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.4375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 11.4375,
            "text": "concentrations of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 11.4375,
            "text": "neutralised plasma concentrations of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.21875,
            "end_logit": 11.4375,
            "text": "rucizumab neutralised plasma concentrations of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -7.203125,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -7.203125,
            "text": "plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -7.203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -7.30859375,
            "text": "Idarucizumab neutralised plasma concentrations of dabigatran,",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -7.203125,
            "text": "coagulation variables.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_29": [
        {
            "start_logit": 11.484375,
            "end_logit": 11.6328125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.37109375,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.6328125,
            "text": "antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.6328125,
            "text": "developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.6328125,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.6328125,
            "text": "anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.6328125,
            "text": "the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.6328125,
            "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 11.6328125,
            "text": "an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 11.6328125,
            "text": "to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 11.6328125,
            "text": "effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 11.6328125,
            "text": "rucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.3203125,
            "end_logit": 11.6328125,
            "text": "reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.40625,
            "end_logit": 11.6328125,
            "text": ", an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -7.37109375,
            "text": "antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -7.37109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -7.37109375,
            "text": "developed to reverse the anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -7.37109375,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -7.37109375,
            "text": "anticoagulant effects of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -7.37109375,
            "text": "the anticoagulant effects of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_30": [
        {
            "start_logit": 11.1171875,
            "end_logit": 11.734375,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -8.6953125,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.2734375,
            "text": "dabigatran and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.671875,
            "text": "dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -9.859375,
            "text": "dabigatran and, unlike PCCs",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -10.1015625,
            "text": "dabigatran and, unlike PCC",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -10.1328125,
            "text": "dabigatran and, unlike PCCs, was",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.734375,
            "text": "effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.734375,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.734375,
            "text": "Idarucizumab also reversed the effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 11.734375,
            "text": "the effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 11.734375,
            "text": "reversed the effects of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -8.6953125,
            "text": "effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -8.6953125,
            "text": "of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -8.6953125,
            "text": "over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -8.6953125,
            "text": "thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -8.6953125,
            "text": "PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -8.6953125,
            "text": "Idarucizumab also",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -8.6953125,
            "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -8.6953125,
            "text": "associated with over-correction of thrombin generation.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_31": [
        {
            "start_logit": 14.53125,
            "end_logit": 13.234375,
            "text": "Dabigatran etexilate",
            "probability": 1.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -0.265869140625,
            "text": "Dabigatran",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -3.908203125,
            "end_logit": 13.234375,
            "text": "te",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -7.8203125,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -8.9921875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.046875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.5390625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time,",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.7109375,
            "text": "Dabigatran etexilate (DE) dose-dependently",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.71875,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.890625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.890625,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -9.9609375,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -10.0078125,
            "text": "Dabigatran etexilate (DE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.53125,
            "end_logit": -10.0234375,
            "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 13.234375,
            "text": "etexilate",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 13.234375,
            "text": "exilate",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 13.234375,
            "text": "ilate",
            "probability": 0.0
        },
        {
            "start_logit": -3.908203125,
            "end_logit": -7.8203125,
            "text": "te (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.",
            "probability": 0.0
        },
        {
            "start_logit": -3.908203125,
            "end_logit": -8.9921875,
            "text": "te (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which",
            "probability": 0.0
        },
        {
            "start_logit": -3.908203125,
            "end_logit": -9.046875,
            "text": "te (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_32": [
        {
            "start_logit": 11.6171875,
            "end_logit": 11.53125,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": 11.6171875,
            "end_logit": -8.6953125,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.53125,
            "text": "of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.53125,
            "text": "effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.53125,
            "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 11.53125,
            "text": "safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 11.53125,
            "text": "the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 11.53125,
            "text": "its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 11.53125,
            "text": "addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 11.53125,
            "text": "we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 11.53125,
            "text": "discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.21875,
            "end_logit": 11.53125,
            "text": ", tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.234375,
            "end_logit": 11.53125,
            "text": "idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.234375,
            "end_logit": 11.53125,
            "text": "for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 11.53125,
            "text": "this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.6953125,
            "text": "of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -8.6953125,
            "text": "effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -8.6953125,
            "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -8.6953125,
            "text": "safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": -8.6953125,
            "text": "the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.",
            "probability": 0.0
        }
    ],
    "5a7237672dc08e987e000008_33": [
        {
            "start_logit": 11.5546875,
            "end_logit": 11.6015625,
            "text": "dabigatran",
            "probability": 1.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 11.6015625,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.078125,
            "text": "dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 11.6015625,
            "text": "for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 11.6015625,
            "text": "recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.6015625,
            "text": "potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 11.6015625,
            "text": "approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.6015625,
            "text": "Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.6015625,
            "text": "until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.6015625,
            "text": "The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.6015625,
            "text": "Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.6015625,
            "text": "the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.6015625,
            "text": "a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.6015625,
            "text": "of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.6015625,
            "text": "This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.6015625,
            "text": "and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.6015625,
            "text": ", a potential reversal agent for dabigatran",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": -9.078125,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran.",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": -9.8359375,
            "text": "Food and Drug Administration approval of idarucizumab, a potential reversal",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -9.078125,
            "text": "for dabigatran.",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_1": [
        {
            "start_logit": 12.171875,
            "end_logit": 8.2734375,
            "text": "lectin complement pathway",
            "probability": 0.998046875
        },
        {
            "start_logit": 12.171875,
            "end_logit": 1.8623046875,
            "text": "lectin",
            "probability": 0.00164794921875
        },
        {
            "start_logit": 12.171875,
            "end_logit": -0.0284423828125,
            "text": "lectin complement",
            "probability": 0.00024890899658203125
        },
        {
            "start_logit": 12.171875,
            "end_logit": -8.296875,
            "text": "lectin complement pathway and SLE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.171875,
            "end_logit": -8.6640625,
            "text": "lectin complement pathway and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.171875,
            "end_logit": -8.984375,
            "text": "lectin complement pathway and SLE.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 8.2734375,
            "text": "complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 8.2734375,
            "text": "pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 8.2734375,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 8.2734375,
            "text": "part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 8.2734375,
            "text": "of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 8.2734375,
            "text": "the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 8.2734375,
            "text": "aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 8.2734375,
            "text": "an association exists between the ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 8.2734375,
            "text": "ficolins that are part of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.3046875,
            "end_logit": -0.0284423828125,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 1.8623046875,
            "text": "the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 1.8623046875,
            "text": "part of the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 1.8623046875,
            "text": "of the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 1.8623046875,
            "text": "the ficolins that are part of the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_2": [
        {
            "start_logit": 13.421875,
            "end_logit": 14.140625,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -0.6796875,
            "text": "lectin complement",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.421875,
            "end_logit": -1.474609375,
            "text": "lectin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.337890625,
            "end_logit": 14.140625,
            "text": "pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.78125,
            "end_logit": 14.140625,
            "text": "complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 14.140625,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.1640625,
            "text": "lectin complement pathway (LCP",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.421875,
            "text": "lectin complement pathway (LC",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.140625,
            "text": "ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.140625,
            "text": "the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.140625,
            "text": ": To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -10.078125,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH)",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.140625,
            "text": "of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.140625,
            "text": "To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -10.203125,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -10.21875,
            "text": "lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and outcome.",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -10.3515625,
            "text": "lectin complement pathway (LCP),",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -10.359375,
            "text": "lectin complement pathway (LCP), in",
            "probability": 0.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": -0.6796875,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -0.6796875,
            "text": "the lectin complement",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_3": [
        {
            "start_logit": 10.0625,
            "end_logit": 7.66796875,
            "text": "lectin complement pathway",
            "probability": 0.97412109375
        },
        {
            "start_logit": 10.0625,
            "end_logit": 4.03125,
            "text": "lectin",
            "probability": 0.0255584716796875
        },
        {
            "start_logit": 10.0625,
            "end_logit": -1.5859375,
            "text": "lectin complement",
            "probability": 9.292364120483398e-05
        },
        {
            "start_logit": -5.03515625,
            "end_logit": 7.66796875,
            "text": "complement pathway",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.0625,
            "end_logit": -9.0625,
            "text": "lectin complement pathway activation in patients with subarachnoid hemorrhage.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0625,
            "end_logit": -9.9140625,
            "text": "lectin complement pathway activation",
            "probability": 0.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -9.984375,
            "text": "lectin complement pathway activation in",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.66796875,
            "text": "pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 7.66796875,
            "text": "mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 7.66796875,
            "text": "Ficolin-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 7.66796875,
            "text": "-3-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 7.66796875,
            "text": "-mediated lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 4.03125,
            "text": "mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 4.03125,
            "text": "Ficolin-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -1.5859375,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 4.03125,
            "text": "-3-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 4.03125,
            "text": "-mediated lectin",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -1.5859375,
            "text": "mediated lectin complement",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -1.5859375,
            "text": "Ficolin-3-mediated lectin complement",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -1.5859375,
            "text": "-3-mediated lectin complement",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_4": [
        {
            "start_logit": 10.6328125,
            "end_logit": 11.25,
            "text": "lectin complement pathway",
            "probability": 1.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -0.323974609375,
            "text": "lectin",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -1.84375,
            "text": "lectin complement",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 11.25,
            "text": "pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 11.25,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -6.01953125,
            "text": "lectin complement pathway initiators.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 11.25,
            "text": "Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.5703125,
            "text": "lectin complement pathway initiators",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.25,
            "text": "complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": 10.6328125,
            "end_logit": -9.6953125,
            "text": "lectin complement pathway initiator",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.25,
            "text": "collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.25,
            "text": "the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.25,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.25,
            "text": ", Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.25,
            "text": "among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 11.25,
            "text": "only collagenase proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.25,
            "text": "proteolytic resistant molecule among the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -1.84375,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -0.323974609375,
            "text": "Ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -0.323974609375,
            "text": "complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_5": [
        {
            "start_logit": 11.8828125,
            "end_logit": 6.80859375,
            "text": "lectin complement pathway",
            "probability": 0.9912109375
        },
        {
            "start_logit": 11.8828125,
            "end_logit": 1.91796875,
            "text": "lectin",
            "probability": 0.007450103759765625
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -0.1163330078125,
            "text": "lectin complement",
            "probability": 0.0009775161743164062
        },
        {
            "start_logit": 11.8828125,
            "end_logit": -5.1328125,
            "text": "lectin complement pathway.",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 6.80859375,
            "text": "complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 6.80859375,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 6.80859375,
            "text": "pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 6.80859375,
            "text": "Ficolin-3 (Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 6.80859375,
            "text": "in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 6.80859375,
            "text": "or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 6.80859375,
            "text": "-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 6.80859375,
            "text": "Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 6.80859375,
            "text": "H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 6.80859375,
            "text": "ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 6.80859375,
            "text": "pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 6.80859375,
            "text": "(Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 6.80859375,
            "text": "kata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 1.91796875,
            "text": "the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -0.1163330078125,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 1.91796875,
            "text": "Ficolin-3 (Hakata antigen or H-ficolin) is a soluble pattern recognition molecule in the lectin",
            "probability": 0.0
        }
    ],
    "56c1d856ef6e394741000032_6": [
        {
            "start_logit": 11.6328125,
            "end_logit": 6.2265625,
            "text": "lectin complement pathway",
            "probability": 0.97705078125
        },
        {
            "start_logit": 11.6328125,
            "end_logit": 2.4296875,
            "text": "lectin",
            "probability": 0.0219268798828125
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -0.92236328125,
            "text": "lectin complement",
            "probability": 0.0007681846618652344
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -8.1953125,
            "text": "lectin complement pathway and",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.953125,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP-1, -2 and -3 and two nonenzymatic proteins.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -10.1875,
            "text": "lectin complement pathway and form complexes with serine proteases",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -10.2734375,
            "text": "lectin complement pathway and form complexes with serine proteases named MASP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 6.2265625,
            "text": "complement pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 6.2265625,
            "text": "pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 6.2265625,
            "text": "the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 6.2265625,
            "text": "Ficolin-1, -2 and -3 are recognition molecules in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 6.2265625,
            "text": "in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 6.2265625,
            "text": "-2 and -3 are recognition molecules in the lectin complement pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 2.4296875,
            "text": "the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 2.4296875,
            "text": "Ficolin-1, -2 and -3 are recognition molecules in the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -5.5390625,
            "end_logit": -0.92236328125,
            "text": "complement",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 2.4296875,
            "text": "in the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 2.4296875,
            "text": "-2 and -3 are recognition molecules in the lectin",
            "probability": 0.0
        },
        {
            "start_logit": -7.96484375,
            "end_logit": -0.92236328125,
            "text": "the lectin complement",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -0.92236328125,
            "text": "Ficolin-1, -2 and -3 are recognition molecules in the lectin complement",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_1": [
        {
            "start_logit": 14.3359375,
            "end_logit": 15.296875,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": 15.296875,
            "text": "c",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -2.607421875,
            "text": "Deep",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -4.2578125,
            "text": "DeepLo",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -8.7578125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.0,
            "text": "DeepLoc:",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 15.296875,
            "text": "Loc",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.3203125,
            "text": "DeepLoc: prediction",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.578125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.734375,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.09375,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -8.7578125,
            "text": "c: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.0,
            "text": "c:",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.3203125,
            "text": "c: prediction",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.578125,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.734375,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -10.09375,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -4.2578125,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -8.7578125,
            "text": "Loc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -8.7578125,
            "text": ": prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        }
    ],
    "5a7639419e632bc066000005_2": [
        {
            "start_logit": 14.3359375,
            "end_logit": 15.296875,
            "text": "DeepLoc",
            "probability": 1.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": 15.296875,
            "text": "c",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -2.607421875,
            "text": "Deep",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -4.2578125,
            "text": "DeepLo",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -8.7578125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.0,
            "text": "DeepLoc:",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 15.296875,
            "text": "Loc",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.3203125,
            "text": "DeepLoc: prediction",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.578125,
            "text": "DeepLoc: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.734375,
            "text": "DeepLoc: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.09375,
            "text": "DeepLoc: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -8.7578125,
            "text": "c: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.0,
            "text": "c:",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.3203125,
            "text": "c: prediction",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.578125,
            "text": "c: prediction of protein subcellular localization using deep learning",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -9.734375,
            "text": "c: prediction of protein subcellular localization",
            "probability": 0.0
        },
        {
            "start_logit": -1.46484375,
            "end_logit": -10.09375,
            "text": "c: prediction of protein subcellular localization using",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -4.2578125,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -8.7578125,
            "text": "Loc: prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -8.7578125,
            "text": ": prediction of protein subcellular localization using deep learning.",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_1": [
        {
            "start_logit": 14.6328125,
            "end_logit": 15.4921875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -0.99169921875,
            "end_logit": 15.4921875,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -1.4296875,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -3.25,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 15.4921875,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 15.4921875,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 15.4921875,
            "text": "Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 15.4921875,
            "text": ": Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.4765625,
            "text": "interleukin-17A monoclonal antibody.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.4921875,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.4921875,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.5703125,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.4921875,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.4921875,
            "text": "BACKGROUND: Secukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.4921875,
            "text": "ukinumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.4921875,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.9921875,
            "text": "interleukin-17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.4921875,
            "text": "is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.4921875,
            "text": "inumab is a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -1.4296875,
            "text": "human anti-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_2": [
        {
            "start_logit": 14.609375,
            "end_logit": 15.4765625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.0498046875,
            "end_logit": 15.4765625,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.609375,
            "end_logit": -1.525390625,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.609375,
            "end_logit": -3.736328125,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 15.4765625,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 15.4765625,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 15.4765625,
            "text": "Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 15.4765625,
            "text": ": Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 15.4765625,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.4765625,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.4765625,
            "text": "BACKGROUND: Secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 15.4765625,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.4765625,
            "text": "ukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.4765625,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.046875,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.171875,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.1953125,
            "text": "interleukin-17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.3359375,
            "text": "interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": -1.525390625,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.0498046875,
            "end_logit": -10.046875,
            "text": "17A monoclonal",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_3": [
        {
            "start_logit": 14.625,
            "end_logit": 15.4765625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": 15.4765625,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.625,
            "end_logit": -1.4833984375,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.625,
            "end_logit": -3.634765625,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.4765625,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 15.4765625,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 15.4765625,
            "text": "secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 15.4765625,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 15.4765625,
            "text": "We evaluated secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 15.4765625,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.4765625,
            "text": "fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.4765625,
            "text": "a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.8359375,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.4765625,
            "text": "ukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 15.4765625,
            "text": "evaluated secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.9921875,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -10.0078125,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -10.1328125,
            "text": "interleukin-17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -1.4833984375,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -9.8359375,
            "text": "17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_4": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.4140625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": 15.4140625,
            "text": "17A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.662109375,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -3.404296875,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 15.4140625,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 15.4140625,
            "text": "Anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.4921875,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 15.4140625,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.8125,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.96875,
            "text": "interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.15625,
            "text": "interleukin-17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.25,
            "text": "interleukin-17A monoclonal antibody secukinumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.3125,
            "text": "interleukin-17A monoclonal antibody sec",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -9.4921875,
            "text": "17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -9.8125,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -9.96875,
            "text": "17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -10.15625,
            "text": "17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -10.25,
            "text": "17A monoclonal antibody secukinumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -1.662109375,
            "text": "Anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.251953125,
            "end_logit": -10.3125,
            "text": "17A monoclonal antibody sec",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_5": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.453125,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.109375,
            "end_logit": 15.453125,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.666015625,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -3.611328125,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 15.453125,
            "text": "human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 15.453125,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 15.453125,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.453125,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.453125,
            "text": "secukinumab, a fully human anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.09375,
            "text": "interleukin-17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.140625,
            "text": "interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.2890625,
            "text": "interleukin-17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.515625,
            "text": "interleukin-17A monoclonal antibody, in",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -1.666015625,
            "text": "human anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -1.109375,
            "end_logit": -10.09375,
            "text": "17A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -1.109375,
            "end_logit": -10.140625,
            "text": "17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -1.109375,
            "end_logit": -10.2890625,
            "text": "17A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -1.109375,
            "end_logit": -10.515625,
            "text": "17A monoclonal antibody, in",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -1.666015625,
            "text": "anti-interleukin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -1.666015625,
            "text": "-interleukin",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_6": [
        {
            "start_logit": 14.4921875,
            "end_logit": 15.4921875,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -0.97607421875,
            "end_logit": 15.4921875,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -1.79296875,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -4.46484375,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 15.4921875,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 15.4921875,
            "text": "human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 15.4921875,
            "text": "targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.4921875,
            "text": "secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.4921875,
            "text": "doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.4921875,
            "text": ": To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.4921875,
            "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.4921875,
            "text": "for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.4921875,
            "text": "safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.96875,
            "text": "interleukin-17A blockade",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.171875,
            "text": "interleukin-17A blockade, in patients with noninfectious uveitis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.2734375,
            "text": "interleukin-17A blockade, in",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.390625,
            "text": "interleukin-17A blockade, in patients with noninfectious uveitis",
            "probability": 0.0
        },
        {
            "start_logit": -0.97607421875,
            "end_logit": -9.96875,
            "text": "17A blockade",
            "probability": 0.0
        },
        {
            "start_logit": -0.97607421875,
            "end_logit": -10.171875,
            "text": "17A blockade, in patients with noninfectious uveitis.",
            "probability": 0.0
        },
        {
            "start_logit": -0.97607421875,
            "end_logit": -10.2734375,
            "text": "17A blockade, in",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_7": [
        {
            "start_logit": 14.5,
            "end_logit": 15.40625,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": 15.40625,
            "text": "17A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.5,
            "end_logit": -1.86328125,
            "text": "interleukin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5,
            "end_logit": -4.06640625,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.40625,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -9.375,
            "text": "interleukin-17A-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -9.828125,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -9.8828125,
            "text": "interleukin-17A-blocking",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -10.0859375,
            "text": "interleukin-17A-blocking antibody",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 15.40625,
            "text": "Treatment with the interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -10.109375,
            "text": "interleukin-17A-blocking antibody secukinumab does",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -10.15625,
            "text": "interleukin-17A-blocking antibody secukinumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -10.2421875,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -10.2421875,
            "text": "interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -9.375,
            "text": "17A-",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -9.828125,
            "text": "17A-blocking antibody secukinumab does not interfere",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -9.8828125,
            "text": "17A-blocking",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -10.0859375,
            "text": "17A-blocking antibody",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -10.109375,
            "text": "17A-blocking antibody secukinumab does",
            "probability": 0.0
        },
        {
            "start_logit": -1.1884765625,
            "end_logit": -10.15625,
            "text": "17A-blocking antibody secukinumab",
            "probability": 0.0
        }
    ],
    "54e0d7471388e8454a000015_8": [
        {
            "start_logit": 14.3828125,
            "end_logit": 15.53125,
            "text": "interleukin-17A",
            "probability": 1.0
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": 15.53125,
            "text": "17A",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -2.1171875,
            "text": "interleukin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -3.861328125,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -7.51953125,
            "text": "interleukin-17A (",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.015625,
            "text": "interleukin-17A (IL-17A)",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 15.53125,
            "text": "-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.59375,
            "text": "interleukin-17A (IL",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.75,
            "text": "interleukin-17A (IL-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.53125,
            "text": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.53125,
            "text": "-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.53125,
            "text": "anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.5859375,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.609375,
            "text": "interleukin-17A (IL-17A) monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.53125,
            "text": "the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.53125,
            "text": "to the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.53125,
            "text": "the anti-interleukin-17A",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.984375,
            "text": "interleukin-17A (IL-17A) monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -10.0703125,
            "text": "interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab",
            "probability": 0.0
        },
        {
            "start_logit": -0.6513671875,
            "end_logit": -7.51953125,
            "text": "17A (",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_1": [
        {
            "start_logit": 14.203125,
            "end_logit": 14.9296875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.064453125,
            "end_logit": 14.9296875,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.203125,
            "end_logit": -2.193359375,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.734375,
            "end_logit": 14.9296875,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -6.2421875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 14.9296875,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.03125,
            "text": "Alzheimer's disease mouse model.",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.109375,
            "text": "Alzheimer's disease mouse model",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.1484375,
            "text": "Alzheimer's disease mouse",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.9296875,
            "text": "the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.9296875,
            "text": "approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.9296875,
            "text": "The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.703125,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.9296875,
            "text": "in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.9296875,
            "text": "offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 14.9296875,
            "text": "new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 14.9296875,
            "text": "presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.9296875,
            "text": "of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 14.9296875,
            "text": "cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 14.9296875,
            "text": "novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_2": [
        {
            "start_logit": 12.3671875,
            "end_logit": 9.234375,
            "text": "Alzheimer's disease",
            "probability": 0.98193359375
        },
        {
            "start_logit": 12.3671875,
            "end_logit": 5.2578125,
            "text": "Alzheimer's disease (AD)",
            "probability": 0.0185394287109375
        },
        {
            "start_logit": 12.3671875,
            "end_logit": -5.328125,
            "text": "Alzheimer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.3671875,
            "end_logit": -7.8671875,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.234375,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.3671875,
            "end_logit": -9.765625,
            "text": "Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 9.234375,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 9.234375,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 9.234375,
            "text": "of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.359375,
            "end_logit": 5.2578125,
            "text": "disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 5.2578125,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 5.2578125,
            "text": "'s disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 5.2578125,
            "text": "s disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 5.2578125,
            "text": "of Alzheimer's disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -3.806640625,
            "text": "APP/Lo",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -3.806640625,
            "text": "Lo",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -7.1875,
            "text": "APP/Lo mice",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -3.806640625,
            "text": "/Lo",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -3.806640625,
            "text": "old APP/Lo",
            "probability": 0.0
        },
        {
            "start_logit": -6.640625,
            "end_logit": -8.0,
            "text": "APP/Lo mice, carrying the London",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_3": [
        {
            "start_logit": 13.7265625,
            "end_logit": 13.6328125,
            "text": "Alzheimer's disease",
            "probability": 0.92578125
        },
        {
            "start_logit": 10.734375,
            "end_logit": 13.6328125,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.04681396484375
        },
        {
            "start_logit": 10.734375,
            "end_logit": 13.09375,
            "text": "Val717Ile",
            "probability": 0.027099609375
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -3.259765625,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.75390625,
            "end_logit": 13.6328125,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 13.6328125,
            "text": "Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 13.09375,
            "text": "Ile",
            "probability": 0.0
        },
        {
            "start_logit": 10.734375,
            "end_logit": -3.259765625,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 13.6328125,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -7.05078125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 13.6328125,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 10.734375,
            "end_logit": -4.37890625,
            "text": "Val",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -8.96875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 13.6328125,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.09375,
            "text": "Alzheimer's disease.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 13.6328125,
            "text": "7Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 13.6328125,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 13.09375,
            "text": "The London APP mutation (Val717Ile",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 13.09375,
            "text": "7Ile",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 13.6328125,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_4": [
        {
            "start_logit": 7.984375,
            "end_logit": 10.0078125,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 10.0078125,
            "text": "for AD",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 10.0078125,
            "text": "mutation was responsible for AD",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 10.0078125,
            "text": "responsible for AD",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 10.0078125,
            "text": "this mutation was responsible for AD",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 10.0078125,
            "text": ", this mutation was responsible for AD",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -9.546875,
            "text": "AD in 3 out of 7",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -9.6015625,
            "text": "AD in",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -9.8671875,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far.",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -10.0,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -10.078125,
            "text": "AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -10.09375,
            "text": "AD in 3 out of 7 siblings and",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -10.109375,
            "text": "AD in 3",
            "probability": 0.0
        },
        {
            "start_logit": 7.984375,
            "end_logit": -10.1484375,
            "text": "AD in 3 out of 7 siblings",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -9.546875,
            "text": "for AD in 3 out of 7",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -9.734375,
            "text": "present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -9.6015625,
            "text": "for AD in",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.546875,
            "text": "mutation was responsible for AD in 3 out of 7",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.6015625,
            "text": "mutation was responsible for AD in",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.546875,
            "text": "responsible for AD in 3 out of 7",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_5": [
        {
            "start_logit": 3.791015625,
            "end_logit": 4.13671875,
            "text": "AD",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.61328125,
            "end_logit": 5.1328125,
            "text": "APP(LON",
            "probability": 0.0006046295166015625
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 5.1328125,
            "text": "(APP(LON",
            "probability": 0.00014197826385498047
        },
        {
            "start_logit": -9.265625,
            "end_logit": 5.1328125,
            "text": "mutation (APP(LON",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 5.1328125,
            "text": "the \"London\" mutation (APP(LON",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -9.65625,
            "end_logit": 5.1328125,
            "text": "LON",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -10.03125,
            "end_logit": 5.1328125,
            "text": "\"London\" mutation (APP(LON",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": 5.1328125,
            "text": "(LON",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 3.791015625,
            "end_logit": -9.09375,
            "text": "AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -10.578125,
            "end_logit": 5.1328125,
            "text": "mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 3.791015625,
            "end_logit": -9.4296875,
            "text": "AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP).",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.625,
            "end_logit": 4.13671875,
            "text": "an AD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.61328125,
            "end_logit": -8.5,
            "text": "APP",
            "probability": 0.0
        },
        {
            "start_logit": -4.61328125,
            "end_logit": -9.0234375,
            "text": "APP(LON)",
            "probability": 0.0
        },
        {
            "start_logit": -4.61328125,
            "end_logit": -9.546875,
            "text": "APP(LON)) are examples of these mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -8.5,
            "text": "(APP",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -9.0234375,
            "text": "(APP(LON)",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": -9.546875,
            "text": "(APP(LON)) are examples of these mutants.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -9.09375,
            "text": "of amyloid precursor protein (APP",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -9.4296875,
            "text": "of amyloid precursor protein (APP).",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_6": [
        {
            "start_logit": 4.96484375,
            "end_logit": 7.27734375,
            "text": "AD",
            "probability": 1.0
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -8.140625,
            "text": "AD development",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.96484375,
            "end_logit": -8.6015625,
            "text": "AD development.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 7.27734375,
            "text": "in AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.171875,
            "end_logit": 7.27734375,
            "text": "(LON) in AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 7.27734375,
            "text": "APP(LON) in AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1875,
            "end_logit": 7.27734375,
            "text": "in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.453125,
            "end_logit": -7.75,
            "text": "APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -7.75,
            "text": "APP(SW) and APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -7.75,
            "text": "to silence APP(SW) and APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -7.75,
            "text": "effective to silence APP(SW) and APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": -7.75,
            "text": "(SW) and APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": -7.75,
            "text": "(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": -7.75,
            "text": "sequences that are effective to silence APP(SW) and APP(LON) as",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.734375,
            "text": "APP(LON)",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -8.140625,
            "text": "in AD development",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": -8.140625,
            "text": "(LON) in AD development",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": -8.140625,
            "text": "APP(LON) in AD development",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": -8.140625,
            "text": "in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.8984375,
            "text": "APP(LON) as identified in this study may",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_7": [
        {
            "start_logit": 14.359375,
            "end_logit": 14.8984375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.98046875,
            "end_logit": 14.8984375,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -1.7958984375,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 14.8984375,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -6.09765625,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 14.8984375,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 14.8984375,
            "text": "amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 14.8984375,
            "text": "type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.9296875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 14.8984375,
            "text": "familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 14.8984375,
            "text": "APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.421875,
            "text": "Alzheimer's disease using",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.8984375,
            "text": "variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.8984375,
            "text": "ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.8984375,
            "text": "precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.8984375,
            "text": "-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.8984375,
            "text": "and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -1.7958984375,
            "text": "amyloid precursor protein (APP) variants related to familial Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": -1.7958984375,
            "text": "type amyloid precursor protein (APP) variants related to familial Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": -1.7958984375,
            "text": "familial Alzheimer",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_8": [
        {
            "start_logit": 13.46875,
            "end_logit": 13.8359375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": 5.15625,
            "text": "Alzheimer's disease (V642I",
            "probability": 0.00016868114471435547
        },
        {
            "start_logit": -3.37890625,
            "end_logit": 13.8359375,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -3.353515625,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -6.5234375,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 13.8359375,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -7.19921875,
            "text": "Alzheimer's disease (V",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 13.8359375,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -7.6328125,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -8.2109375,
            "text": "Alzheimer's disease (V642",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 13.8359375,
            "text": "with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.0078125,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.8359375,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2)",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.8515625,
            "text": "Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.8671875,
            "text": "Alzheimer's disease (V642I, so-called London",
            "probability": 0.0
        },
        {
            "start_logit": -1.640625,
            "end_logit": 5.15625,
            "text": "V642I",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 13.8359375,
            "text": "amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 13.8359375,
            "text": "human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.8359375,
            "text": ", 695 isoform) bearing a mutation associated with Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -3.37890625,
            "end_logit": 5.15625,
            "text": "disease (V642I",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_9": [
        {
            "start_logit": 14.1171875,
            "end_logit": 14.6328125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": 14.6328125,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -2.37109375,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.390625,
            "end_logit": 14.6328125,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -5.99609375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.96875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 14.6328125,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.73046875,
            "text": "Alzheimer's disease genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.3828125,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.8671875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.0546875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.0703125,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.3515625,
            "text": "Alzheimer's disease genes:",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.65625,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.65625,
            "text": "Alzheimer's disease genes: the",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.6328125,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -5.99609375,
            "text": "disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -7.73046875,
            "text": "disease genes",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.3828125,
            "text": "disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.8671875,
            "text": "disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_10": [
        {
            "start_logit": 6.3828125,
            "end_logit": 2.08203125,
            "text": "Alzheimers disease (AD",
            "probability": 0.9970703125
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -4.34375,
            "text": "Alzheimers",
            "probability": 0.0016078948974609375
        },
        {
            "start_logit": -0.1650390625,
            "end_logit": 2.08203125,
            "text": "AD",
            "probability": 0.0014247894287109375
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -6.00390625,
            "text": "Alzheimers disease (AD)",
            "probability": 0.0003044605255126953
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -8.609375,
            "text": "Alzheimer",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -9.46875,
            "text": "Alzheimers disease",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -9.5,
            "text": "Alzheimers disease (AD).",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -9.703125,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -9.7421875,
            "text": "Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -0.1650390625,
            "end_logit": -4.30078125,
            "text": "AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -0.1650390625,
            "end_logit": -6.00390625,
            "text": "AD)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -1.9140625,
            "end_logit": -4.30078125,
            "text": "Val717Ile",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.328125,
            "end_logit": 2.08203125,
            "text": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease (AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.546875,
            "end_logit": 2.08203125,
            "text": "(AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 2.08203125,
            "text": "of Alzheimers disease (AD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 2.08203125,
            "text": "disease (AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.328125,
            "end_logit": 2.08203125,
            "text": "s disease (AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.1650390625,
            "end_logit": -8.1171875,
            "text": "AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 2.08203125,
            "text": "amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease (AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.1650390625,
            "end_logit": -9.5,
            "text": "AD).",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_11": [
        {
            "start_logit": 7.19140625,
            "end_logit": 9.96875,
            "text": "Alzheimers",
            "probability": 0.92431640625
        },
        {
            "start_logit": 4.6640625,
            "end_logit": 9.96875,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 0.0740966796875
        },
        {
            "start_logit": 4.6640625,
            "end_logit": 6.2109375,
            "text": "Val717Ile",
            "probability": 0.0017290115356445312
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.96875,
            "text": "s",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.96875,
            "text": "Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.19140625,
            "end_logit": -6.5234375,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 9.96875,
            "text": "7Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.03125,
            "end_logit": 9.96875,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0625,
            "end_logit": 9.96875,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.265625,
            "end_logit": 9.96875,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 9.96875,
            "text": "717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 9.96875,
            "text": "onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 9.96875,
            "text": "London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 9.96875,
            "text": "mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 9.96875,
            "text": "with early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 9.96875,
            "text": "-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 9.96875,
            "text": "early-onset Alzheimers",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 6.2109375,
            "text": "Ile",
            "probability": 0.0
        },
        {
            "start_logit": 4.6640625,
            "end_logit": -6.5234375,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": 7.19140625,
            "end_logit": -9.0546875,
            "text": "Alzheimers disease",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_12": [
        {
            "start_logit": 14.1171875,
            "end_logit": 14.6328125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": 14.6328125,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -2.37109375,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.390625,
            "end_logit": 14.6328125,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -5.99609375,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -6.96875,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -7.828125,
            "end_logit": 14.6328125,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.73046875,
            "text": "Alzheimer's disease genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.3828125,
            "text": "Alzheimer's disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -8.8671875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.0546875,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.0703125,
            "text": "Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.3515625,
            "text": "Alzheimer's disease genes:",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.65625,
            "text": "Alzheimer's disease genes: the amyloid precursor",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.65625,
            "text": "Alzheimer's disease genes: the",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.6328125,
            "text": "Allele-specific silencing of Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -5.99609375,
            "text": "disease genes: the amyloid precursor protein genes with Swedish or London mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -7.73046875,
            "text": "disease genes",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.3828125,
            "text": "disease genes: the amyloid precursor protein",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -8.8671875,
            "text": "disease genes: the amyloid precursor protein genes with Swedish",
            "probability": 0.0
        }
    ],
    "58b6978822d300530900000a_13": [
        {
            "start_logit": 13.7265625,
            "end_logit": 13.6328125,
            "text": "Alzheimer's disease",
            "probability": 0.92578125
        },
        {
            "start_logit": 10.734375,
            "end_logit": 13.6328125,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.04681396484375
        },
        {
            "start_logit": 10.734375,
            "end_logit": 13.09375,
            "text": "Val717Ile",
            "probability": 0.027099609375
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -3.259765625,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.75390625,
            "end_logit": 13.6328125,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 13.6328125,
            "text": "Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": 13.09375,
            "text": "Ile",
            "probability": 0.0
        },
        {
            "start_logit": 10.734375,
            "end_logit": -3.259765625,
            "text": "Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": 13.6328125,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -7.05078125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 13.6328125,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 10.734375,
            "end_logit": -4.37890625,
            "text": "Val",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -8.96875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 13.6328125,
            "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.09375,
            "text": "Alzheimer's disease.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 13.6328125,
            "text": "7Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 13.6328125,
            "text": "APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 13.09375,
            "text": "The London APP mutation (Val717Ile",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 13.09375,
            "text": "7Ile",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 13.6328125,
            "text": "(Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_1": [
        {
            "start_logit": 2.669921875,
            "end_logit": -3.271484375,
            "text": "multiple origins",
            "probability": 0.86865234375
        },
        {
            "start_logit": 2.669921875,
            "end_logit": -5.2578125,
            "text": "multiple",
            "probability": 0.119140625
        },
        {
            "start_logit": 2.669921875,
            "end_logit": -7.58203125,
            "text": "multiple origins.",
            "probability": 0.01163482666015625
        },
        {
            "start_logit": -4.765625,
            "end_logit": -3.271484375,
            "text": "single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 0.0005116462707519531
        },
        {
            "start_logit": -6.34375,
            "end_logit": -3.271484375,
            "text": "using multiple origins",
            "probability": 0.0001055002212524414
        },
        {
            "start_logit": -4.765625,
            "end_logit": -5.2578125,
            "text": "single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 7.027387619018555e-05
        },
        {
            "start_logit": -4.765625,
            "end_logit": -5.90625,
            "text": "single",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": -6.34375,
            "end_logit": -5.2578125,
            "text": "using multiple",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -3.271484375,
            "text": "from single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -4.765625,
            "end_logit": -7.37890625,
            "text": "single origins",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -4.765625,
            "end_logit": -7.58203125,
            "text": "single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -10.28125,
            "end_logit": -3.271484375,
            "text": "most archaea and all eukaryotes replicate using multiple origins",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -3.271484375,
            "text": "eukaryotes replicate using multiple origins",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -3.271484375,
            "text": "archaea and all eukaryotes replicate using multiple origins",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -3.271484375,
            "text": "replicate using multiple origins",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -5.2578125,
            "text": "from single origins, whereas most archaea and all eukaryotes replicate using multiple",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -10.59375,
            "end_logit": -3.271484375,
            "text": "replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -10.625,
            "end_logit": -3.271484375,
            "text": "all eukaryotes replicate using multiple origins",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.34375,
            "end_logit": -7.58203125,
            "text": "using multiple origins.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.65625,
            "end_logit": -3.271484375,
            "text": "archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
            "probability": 1.3709068298339844e-06
        }
    ],
    "52fe58f82059c6d71c00007a_2": [
        {
            "start_logit": 7.75,
            "end_logit": 1.712890625,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 7.75,
            "end_logit": -7.89453125,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 6.711483001708984e-05
        },
        {
            "start_logit": 7.75,
            "end_logit": -9.390625,
            "text": "multiple DNA replication",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 7.75,
            "end_logit": -9.6484375,
            "text": "multiple DNA replication origins are a hallmark",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 7.75,
            "end_logit": -9.828125,
            "text": "multiple DNA replication origins are",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 7.75,
            "end_logit": -10.1484375,
            "text": "multiple DNA",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 7.75,
            "end_logit": -10.1796875,
            "text": "multiple DNA replication origins are a hallmark of Eukaryotes and",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 7.75,
            "end_logit": -10.296875,
            "text": "multiple DNA replication origins are a hallmark of",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -7.89453125,
            "text": "Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -7.89453125,
            "text": "origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -7.89453125,
            "text": "a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -7.89453125,
            "text": "DNA replication origins are a hallmark of Eukaryotes and some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -7.89453125,
            "text": "some Archaea",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.390625,
            "text": "DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -9.6484375,
            "text": "origins are a hallmark",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -9.6484375,
            "text": "a hallmark",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.6484375,
            "text": "DNA replication origins are a hallmark",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -9.828125,
            "text": "origins are",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -10.1796875,
            "text": "Eukaryotes and",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.828125,
            "text": "DNA replication origins are",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_3": [
        {
            "start_logit": 2.158203125,
            "end_logit": -2.78515625,
            "text": "Multiple",
            "probability": 0.92431640625
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -5.6015625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 0.055267333984375
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -7.9453125,
            "text": "Multiple orc/cdc6-associated replication",
            "probability": 0.005283355712890625
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -8.7421875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all",
            "probability": 0.0023822784423828125
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.2578125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in",
            "probability": 0.001422882080078125
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.3515625,
            "text": "Multiple orc/cdc6-associated replication origins",
            "probability": 0.0012950897216796875
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.3984375,
            "text": "Multiple orc/cdc6",
            "probability": 0.0012359619140625
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.421875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarchaeal",
            "probability": 0.0012073516845703125
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.5,
            "text": "Multiple orc/cdc6-associated replication origins were predicted",
            "probability": 0.0011167526245117188
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.5078125,
            "text": "Multiple orc/cdc6-associated replication origins were",
            "probability": 0.0011081695556640625
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.6484375,
            "text": "Multiple orc",
            "probability": 0.0009622573852539062
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.6796875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed",
            "probability": 0.0009326934814453125
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.7265625,
            "text": "Multiple orc/cdc6-",
            "probability": 0.0008902549743652344
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.8046875,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the analyzed haloarch",
            "probability": 0.0008230209350585938
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -9.8203125,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of the",
            "probability": 0.0008106231689453125
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -10.0390625,
            "text": "Multiple orc/cdc6-associated replication origins were predicted in all of",
            "probability": 0.0006513595581054688
        },
        {
            "start_logit": 2.158203125,
            "end_logit": -10.0625,
            "text": "Multiple orc/cdc",
            "probability": 0.0006365776062011719
        },
        {
            "start_logit": -8.90625,
            "end_logit": -5.6015625,
            "text": "haloarchaeal genome",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -5.6015625,
            "text": "replication origins were predicted in all of the analyzed haloarchaeal genome",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -5.6015625,
            "text": "aeal genome",
            "probability": 1.7881393432617188e-07
        }
    ],
    "52fe58f82059c6d71c00007a_4": [
        {
            "start_logit": -1.1640625,
            "end_logit": 1.23828125,
            "text": "multiple",
            "probability": 0.9990234375
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 1.23828125,
            "text": "the multiple",
            "probability": 0.00030040740966796875
        },
        {
            "start_logit": -9.46875,
            "end_logit": 1.23828125,
            "text": "Sulfolobus chromosome implies that the multiple",
            "probability": 0.00024509429931640625
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -7.15234375,
            "text": "multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 0.00022673606872558594
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 1.23828125,
            "text": "chromosome implies that the multiple",
            "probability": 0.00014412403106689453
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 1.23828125,
            "text": "lobus chromosome implies that the multiple",
            "probability": 7.027387619018555e-05
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 1.23828125,
            "text": "bus chromosome implies that the multiple",
            "probability": 6.80685043334961e-05
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 1.23828125,
            "text": "The strong replication-biased structuring of the Sulfolobus chromosome implies that the multiple",
            "probability": 6.103515625e-05
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 1.23828125,
            "text": "strong replication-biased structuring of the Sulfolobus chromosome implies that the multiple",
            "probability": 5.644559860229492e-05
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -9.2265625,
            "text": "multiple replication",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -9.453125,
            "text": "multiple replication origins serve",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -9.5859375,
            "text": "multiple replication origins",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -10.0625,
            "text": "multiple replication origins serve purposes",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -7.15234375,
            "text": "the multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.46875,
            "end_logit": -7.15234375,
            "text": "Sulfolobus chromosome implies that the multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.46875,
            "end_logit": -7.28125,
            "text": "Sulfolobus chromosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -7.15234375,
            "text": "chromosome implies that the multiple replication origins serve purposes other than simply shortening the time required for replication",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -7.28125,
            "text": "chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -7.15234375,
            "text": "required for replication",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -7.15234375,
            "text": "for replication",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_5": [
        {
            "start_logit": -4.79296875,
            "end_logit": -6.2578125,
            "text": "multiple",
            "probability": 0.50048828125
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -6.72265625,
            "text": "multiple replication origin",
            "probability": 0.313232421875
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -7.828125,
            "text": "multiple replication",
            "probability": 0.10333251953125
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -9.3671875,
            "text": "multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 0.0223236083984375
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -9.4765625,
            "text": "multiple replication origin paradigm",
            "probability": 0.02001953125
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -9.78125,
            "text": "multiple replication origin paradigm has also been demonstrated",
            "probability": 0.0146484375
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -10.1640625,
            "text": "multiple replication origin paradigm has also been demonstrated within the",
            "probability": 0.01006317138671875
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -10.203125,
            "text": "multiple replication origin paradigm has",
            "probability": 0.00960540771484375
        },
        {
            "start_logit": -10.046875,
            "end_logit": -6.2578125,
            "text": "the multiple",
            "probability": 0.0025844573974609375
        },
        {
            "start_logit": -10.046875,
            "end_logit": -6.72265625,
            "text": "the multiple replication origin",
            "probability": 0.001644134521484375
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -6.72265625,
            "text": "replication origin",
            "probability": 0.0005679130554199219
        },
        {
            "start_logit": -10.046875,
            "end_logit": -7.828125,
            "text": "the multiple replication",
            "probability": 0.00054168701171875
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -7.828125,
            "text": "replication",
            "probability": 0.00018739700317382812
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.3671875,
            "text": "the multiple replication origin paradigm has also been demonstrated within the archaeal domain of life",
            "probability": 0.00011724233627319336
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.4765625,
            "text": "the multiple replication origin paradigm",
            "probability": 0.00010347366333007812
        },
        {
            "start_logit": -10.046875,
            "end_logit": -9.78125,
            "text": "the multiple replication origin paradigm has also been demonstrated",
            "probability": 7.683038711547852e-05
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -9.3671875,
            "text": "domain of life",
            "probability": 6.99758529663086e-05
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.3671875,
            "text": "archaeal domain of life",
            "probability": 6.67572021484375e-05
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.3671875,
            "text": "of life",
            "probability": 6.276369094848633e-05
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.3671875,
            "text": "within the archaeal domain of life",
            "probability": 5.799531936645508e-05
        }
    ],
    "52fe58f82059c6d71c00007a_6": [
        {
            "start_logit": 9.609375,
            "end_logit": 4.15625,
            "text": "multiple",
            "probability": 1.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -7.98046875,
            "text": "multiple chromosome replication",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.5546875,
            "text": "multiple chromosome replication origins in Sulfolobus",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.984375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -9.296875,
            "text": "multiple chromosome replication origins in",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -9.5,
            "text": "multiple chromosome",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.609375,
            "end_logit": -9.734375,
            "text": "multiple chromosome replication origins in Sulfolobus species",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.0,
            "text": "multiple chromosome replication origins in Sulfolobus species has",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.09375,
            "text": "multiple chromosome replication origins in Sulfolobus species has added yet another eukaryotic trait to the",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.109375,
            "text": "multiple chromosome replication origins",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -8.5546875,
            "text": "Sulfolobus",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -8.984375,
            "text": "Sulfolobus species has added yet another eukaryotic trait to the archaea",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -9.734375,
            "text": "Sulfolobus species",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -10.0,
            "text": "Sulfolobus species has",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -10.09375,
            "text": "Sulfolobus species has added yet another eukaryotic trait to the",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -7.98046875,
            "text": "chromosome replication",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -8.5546875,
            "text": "bus",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -8.5546875,
            "text": "lobus",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -8.5546875,
            "text": "chromosome replication origins in Sulfolobus",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -8.5546875,
            "text": "in Sulfolobus",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_7": [
        {
            "start_logit": 11.703125,
            "end_logit": 6.67578125,
            "text": "multiple",
            "probability": 0.97607421875
        },
        {
            "start_logit": 11.703125,
            "end_logit": 2.951171875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus",
            "probability": 0.023681640625
        },
        {
            "start_logit": 11.703125,
            "end_logit": -6.52734375,
            "text": "multiple replication origins of",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 11.703125,
            "end_logit": -7.62109375,
            "text": "multiple replication origins",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 0.472412109375,
            "end_logit": 2.951171875,
            "text": "Sulfolobus solfataricus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.703125,
            "end_logit": -8.796875,
            "text": "multiple replication",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.703125,
            "end_logit": -8.9296875,
            "text": "multiple replication origins of the archaeon Sulfolobus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.7265625,
            "text": "multiple replication origins of the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.734375,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve method",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.75,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.7734375,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataric",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.8046875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.875,
            "text": "multiple replication origins of the archaeon Sulfo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.96875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -9.9765625,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z curve",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.703125,
            "end_logit": -10.1875,
            "text": "multiple replication origins of the archaeon Sulfolobus solfataricus are suggested by the analysis based on the Z",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.734375,
            "end_logit": 6.67578125,
            "text": "potential multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 6.67578125,
            "text": "the potential multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 2.951171875,
            "text": "potential multiple replication origins of the archaeon Sulfolobus solfataricus",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 2.951171875,
            "text": "s solfataricus",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_8": [
        {
            "start_logit": 5.6796875,
            "end_logit": -4.1328125,
            "text": "multiple",
            "probability": 0.92236328125
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -7.25,
            "text": "multiple replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.040863037109375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -8.5078125,
            "text": "multiple replication",
            "probability": 0.0116119384765625
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -8.7578125,
            "text": "multiple replication origins",
            "probability": 0.00904083251953125
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -9.234375,
            "text": "multiple replication origins have been observed in",
            "probability": 0.005615234375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -9.65625,
            "text": "multiple replication origins have been observed in archaea,",
            "probability": 0.00368499755859375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -9.9140625,
            "text": "multiple replication origins have been observed",
            "probability": 0.00284576416015625
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -10.171875,
            "text": "multiple replication origins have",
            "probability": 0.0021991729736328125
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -10.2421875,
            "text": "multiple replication origins have been observed in archaea, considerably",
            "probability": 0.0020503997802734375
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -7.25,
            "text": "archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -7.25,
            "text": "less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -7.25,
            "text": "been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -7.25,
            "text": "is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -7.25,
            "text": "processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -7.25,
            "text": "replication origins have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -7.25,
            "text": "evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -7.25,
            "text": "their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -7.25,
            "text": "have been observed in archaea, considerably less is known about their evolutionary processes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.5078125,
            "text": "replication",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.7578125,
            "text": "replication origins",
            "probability": 0.0
        }
    ],
    "52fe58f82059c6d71c00007a_9": [
        {
            "start_logit": 5.05078125,
            "end_logit": 0.0679931640625,
            "text": "multiple",
            "probability": 0.97314453125
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -3.642578125,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 0.0238494873046875
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -6.921875,
            "text": "multiple orc/cdc6-associated replication",
            "probability": 0.0008978843688964844
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -7.1015625,
            "text": "multiple orc/cdc6-associated replication origins in",
            "probability": 0.0007505416870117188
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -8.6328125,
            "text": "multiple orc/cdc6-associated replication origins",
            "probability": 0.00016164779663085938
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.0546875,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaeal",
            "probability": 0.00010597705841064453
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.078125,
            "text": "multiple orc/cdc6",
            "probability": 0.00010436773300170898
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.3203125,
            "text": "multiple orc/cdc6-associated replication origins in haloarch",
            "probability": 8.130073547363281e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.4453125,
            "text": "multiple orc",
            "probability": 7.170438766479492e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.5546875,
            "text": "multiple orc/cdc6-",
            "probability": 6.431341171264648e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.71875,
            "text": "multiple orc/cdc6-associated",
            "probability": 5.501508712768555e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.8515625,
            "text": "multiple orc/cdc",
            "probability": 4.780292510986328e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -9.953125,
            "text": "multiple orc/cdc6-associated replication origins in haloarchaea",
            "probability": 4.3511390686035156e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -10.1484375,
            "text": "multiple orc/cdc6-associated replication origins in halo",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -10.2421875,
            "text": "multiple orc/",
            "probability": 3.230571746826172e-05
        },
        {
            "start_logit": -8.78125,
            "end_logit": -3.642578125,
            "text": "in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -3.642578125,
            "text": "haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -3.642578125,
            "text": "aeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -3.642578125,
            "text": "orc/cdc6-associated replication origins in haloarchaeal genomes",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": -3.642578125,
            "text": "replication origins in haloarchaeal genomes",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_1": [
        {
            "start_logit": 13.90625,
            "end_logit": 15.0390625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 15.0390625,
            "text": "1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.400390625,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -5.3515625,
            "text": "IL-1\u03b2, IL-6 and IL-8).",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 15.0390625,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.1796875,
            "text": "IL-1\u03b2, IL-6 and IL-8",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.2265625,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 15.0390625,
            "text": "tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 15.0390625,
            "text": "human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.0390625,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.15625,
            "text": "IL-1\u03b2, IL-6 and IL-8)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.0390625,
            "text": "pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.0390625,
            "text": "MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.0390625,
            "text": "cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.0390625,
            "text": "markers of obesity and expression of pro-inflammatory cytokines (IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -5.3515625,
            "text": "1\u03b2, IL-6 and IL-8).",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -8.1796875,
            "text": "1\u03b2, IL-6 and IL-8",
            "probability": 0.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": -9.15625,
            "text": "1\u03b2, IL-6 and IL-8)",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -3.400390625,
            "text": "adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -3.400390625,
            "text": "tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_2": [
        {
            "start_logit": 14.5546875,
            "end_logit": 15.3515625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -1.3544921875,
            "end_logit": 15.3515625,
            "text": "1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.8232421875,
            "text": "IL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -4.58984375,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -7.03125,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance.",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 15.3515625,
            "text": "adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 15.3515625,
            "text": "MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 15.3515625,
            "text": "tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 15.3515625,
            "text": "for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 15.3515625,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -8.8828125,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL-8",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.46875,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.5390625,
            "text": "IL-1\u03b2 and its responsive cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.3515625,
            "text": "human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.625,
            "text": "IL-1\u03b2 and",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 15.3515625,
            "text": "inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.3515625,
            "text": ", the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.3515625,
            "text": "that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -1.3544921875,
            "end_logit": -7.03125,
            "text": "1\u03b2 and its responsive cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3544921875,
            "end_logit": -8.8828125,
            "text": "1\u03b2 and its responsive cytokines IL-6 and IL-8",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_3": [
        {
            "start_logit": 12.3828125,
            "end_logit": 14.640625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -2.3515625,
            "end_logit": 14.640625,
            "text": "1\u03b2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -5.25,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 14.640625,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -7.171875,
            "text": "IL-1\u03b2, and IFN\u03b3.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 14.640625,
            "text": ", IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.640625,
            "text": "/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.640625,
            "text": "Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 14.640625,
            "text": "known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.640625,
            "text": "locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.640625,
            "text": "drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.640625,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.640625,
            "text": "the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -8.9453125,
            "text": "IL-1\u03b2, and IFN\u03b3",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.0546875,
            "text": "IL-1\u03b2, and IFN",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.3984375,
            "text": "IL-1\u03b2, and IFN\u03b3. We",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.4375,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": -2.3515625,
            "end_logit": -7.171875,
            "text": "1\u03b2, and IFN\u03b3.",
            "probability": 0.0
        },
        {
            "start_logit": -2.3515625,
            "end_logit": -8.9453125,
            "text": "1\u03b2, and IFN\u03b3",
            "probability": 0.0
        },
        {
            "start_logit": -2.3515625,
            "end_logit": -9.0546875,
            "text": "1\u03b2, and IFN",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_4": [
        {
            "start_logit": 12.7109375,
            "end_logit": 14.6953125,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": 0.247314453125,
            "text": "IL-1\u03b2, and IFN\u03b3.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 14.6953125,
            "text": "1\u03b2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -4.88671875,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 14.6953125,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 14.6953125,
            "text": ", IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 14.6953125,
            "text": "/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 14.6953125,
            "text": "Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.6953125,
            "text": "known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.6953125,
            "text": "locus 2 (Tpl2, also known as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.6953125,
            "text": "drives the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.6953125,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.6953125,
            "text": "the production of TNF\u03b1, IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -8.875,
            "text": "IL-1\u03b2, and IFN\u03b3",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.1484375,
            "text": "IL-1\u03b2, and IFN",
            "probability": 0.0
        },
        {
            "start_logit": 12.7109375,
            "end_logit": -9.3671875,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 0.247314453125,
            "text": "1\u03b2, and IFN\u03b3.",
            "probability": 0.0
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 0.247314453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 0.247314453125,
            "text": "as Map3k8/Cot) is a potent inflammatory mediator that drives the production of TNF\u03b1, IL-1\u03b2, and IFN\u03b3.",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 0.247314453125,
            "text": ", IL-1\u03b2, and IFN\u03b3.",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_5": [
        {
            "start_logit": 14.046875,
            "end_logit": 15.1640625,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -1.4814453125,
            "end_logit": 15.1640625,
            "text": "1\u03b2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.046875,
            "end_logit": -2.859375,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -5.6875,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -7.1171875,
            "text": "IL-1\u03b2 reporter activity.",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 15.1640625,
            "text": "tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 15.1640625,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.1640625,
            "text": "AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 15.1640625,
            "text": "TPL2 (tumor progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.2265625,
            "text": "IL-1\u03b2 reporter",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 15.1640625,
            "text": "progression locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 15.1640625,
            "text": "EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.4921875,
            "text": "IL-1\u03b2 reporter activity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.1640625,
            "text": "for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.1640625,
            "text": "induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.1640625,
            "text": "locus 2, MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.1640625,
            "text": ", MAP3K8) and found that inhibitors for EPAC and TPL2 reduced AR agonist-induced IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -1.4814453125,
            "end_logit": -7.1171875,
            "text": "1\u03b2 reporter activity.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4814453125,
            "end_logit": -9.2265625,
            "text": "1\u03b2 reporter",
            "probability": 0.0
        },
        {
            "start_logit": -1.4814453125,
            "end_logit": -9.4921875,
            "text": "1\u03b2 reporter activity",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_6": [
        {
            "start_logit": 13.875,
            "end_logit": 14.734375,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -1.87109375,
            "end_logit": 14.734375,
            "text": "1\u03b2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.875,
            "end_logit": -3.447265625,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -7.55859375,
            "text": "IL-1\u03b2,",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -7.8515625,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -7.88671875,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.0546875,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 14.734375,
            "text": "high mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.59375,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were associated with higher",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.75,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1,",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.75,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.828125,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.828125,
            "text": "IL-1\u03b2, IL-6 and IL-8",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.25,
            "text": "IL-1\u03b2, IL-6 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.3359375,
            "text": "IL-1\u03b2, IL-6 and IL-8,",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.734375,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.484375,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.5,
            "text": "IL-1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were associated with",
            "probability": 0.0
        },
        {
            "start_logit": -1.87109375,
            "end_logit": -2.673828125,
            "text": "1\u03b2, IL-6 and IL-8, but not TNF -\u03b1, in human adipose tissue were associated with higher expression of MAP3K8.",
            "probability": 0.0
        },
        {
            "start_logit": -1.87109375,
            "end_logit": -7.55859375,
            "text": "1\u03b2,",
            "probability": 0.0
        }
    ],
    "5fe31317a43ad31278000044_7": [
        {
            "start_logit": 13.703125,
            "end_logit": 15.0234375,
            "text": "IL-1\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -1.3583984375,
            "end_logit": 15.0234375,
            "text": "1\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.703125,
            "end_logit": -0.2998046875,
            "text": "IL-1\u03b2, IL-6 and CXCL1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.703125,
            "end_logit": -2.798828125,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared to WT animals.",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -3.732421875,
            "text": "IL",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -4.63671875,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -7.1328125,
            "text": "IL-",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -7.47265625,
            "text": "IL-1\u03b2,",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": 15.0234375,
            "text": "MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -7.984375,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -8.0078125,
            "text": "IL-1\u03b2, IL-6 and CXCL",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 15.0234375,
            "text": "lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.0234375,
            "text": "-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.0703125,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 15.0234375,
            "text": "Mice lacking MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.1484375,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.2109375,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.0234375,
            "text": "lacking MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.28125,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.328125,
            "text": "IL-1\u03b2, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared to WT",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_1": [
        {
            "start_logit": 6.13671875,
            "end_logit": 3.55859375,
            "text": "SARS-CoV-2",
            "probability": 1.0
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -5.109375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus",
            "probability": 0.00017130374908447266
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -6.40625,
            "text": "SARS-CoV-2.",
            "probability": 4.684925079345703e-05
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -6.796875,
            "text": "SARS",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -7.92578125,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -8.2578125,
            "text": "SARS-CoV",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -9.3515625,
            "text": "SARS-CoV-",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -9.984375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -10.0234375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -10.0234375,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -10.03125,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antiviral",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -10.1640625,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.13671875,
            "end_logit": -10.1875,
            "text": "SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 3.55859375,
            "text": "2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 3.55859375,
            "text": "against SARS-CoV-2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.65625,
            "end_logit": 3.55859375,
            "text": "CoV-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 3.55859375,
            "text": "In the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 3.55859375,
            "text": "race for drugs to be effective against SARS-CoV-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 3.55859375,
            "text": "-CoV-2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 3.55859375,
            "text": "drugs to be effective against SARS-CoV-2",
            "probability": 1.1920928955078125e-07
        }
    ],
    "621ebb733a8413c65300005c_2": [
        {
            "start_logit": 8.421875,
            "end_logit": 4.921875,
            "text": "COVID-19",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.421875,
            "end_logit": -2.2734375,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir),",
            "probability": 0.0007491111755371094
        },
        {
            "start_logit": 8.421875,
            "end_logit": -4.66796875,
            "text": "COVID-19 (",
            "probability": 6.80685043334961e-05
        },
        {
            "start_logit": 8.421875,
            "end_logit": -7.21875,
            "text": "COV",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.890625,
            "text": "COVID",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.421875,
            "end_logit": -8.984375,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.140625,
            "text": "COVID-19 (lopinavir",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.3671875,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.4296875,
            "text": "COVID-19 (lopinavir, ritonavir",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.59375,
            "text": "COVID-19 (lo",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.6484375,
            "text": "COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.71875,
            "text": "COVID-19 (lopin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.421875,
            "end_logit": -9.828125,
            "text": "COVID-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 4.921875,
            "text": "ID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 4.921875,
            "text": "19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 4.921875,
            "text": "treat COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.78125,
            "end_logit": 4.921875,
            "text": "-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 4.921875,
            "text": "repurposed drugs advocated to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 4.921875,
            "text": "to treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -2.2734375,
            "text": "ID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir),",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_3": [
        {
            "start_logit": -0.509765625,
            "end_logit": 4.7265625,
            "text": "COVID-19 patients",
            "probability": 0.9990234375
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 4.7265625,
            "text": "treat COVID-19 patients",
            "probability": 0.00028228759765625
        },
        {
            "start_logit": -9.453125,
            "end_logit": 4.7265625,
            "text": "ID-19 patients",
            "probability": 0.00013017654418945312
        },
        {
            "start_logit": -9.53125,
            "end_logit": 4.7265625,
            "text": "19 patients",
            "probability": 0.00012046098709106445
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 4.7265625,
            "text": "-19 patients",
            "probability": 0.00010061264038085938
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 4.7265625,
            "text": "patients",
            "probability": 9.304285049438477e-05
        },
        {
            "start_logit": -10.1875,
            "end_logit": 4.7265625,
            "text": "favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 6.246566772460938e-05
        },
        {
            "start_logit": -10.296875,
            "end_logit": 4.7265625,
            "text": "(Arbidol) to treat COVID-19 patients",
            "probability": 5.602836608886719e-05
        },
        {
            "start_logit": -10.5625,
            "end_logit": 4.7265625,
            "text": "ifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 4.291534423828125e-05
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 4.7265625,
            "text": "Arbidol) to treat COVID-19 patients",
            "probability": 3.7550926208496094e-05
        },
        {
            "start_logit": -10.71875,
            "end_logit": 4.7265625,
            "text": ": To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 3.6716461181640625e-05
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 4.7265625,
            "text": "safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": -10.890625,
            "end_logit": 4.7265625,
            "text": "novir (Arbidol) to treat COVID-19 patients",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 4.7265625,
            "text": "the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -10.984375,
            "end_logit": 4.7265625,
            "text": "umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 4.7265625,
            "text": "and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -0.509765625,
            "end_logit": -9.234375,
            "text": "COVID-19",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -9.234375,
            "text": "treat COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": -9.234375,
            "text": "ID-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.234375,
            "text": "19",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_4": [
        {
            "start_logit": -5.00390625,
            "end_logit": -6.5625,
            "text": "COVID-19 treatments",
            "probability": 0.7265625
        },
        {
            "start_logit": -5.00390625,
            "end_logit": -7.984375,
            "text": "COVID-19",
            "probability": 0.17529296875
        },
        {
            "start_logit": -5.00390625,
            "end_logit": -10.0703125,
            "text": "COVID-",
            "probability": 0.0216064453125
        },
        {
            "start_logit": -5.00390625,
            "end_logit": -10.078125,
            "text": "COVID",
            "probability": 0.0216064453125
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -6.5625,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments",
            "probability": 0.008941650390625
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -6.66015625,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ)",
            "probability": 0.0080718994140625
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -6.5625,
            "text": "hydroxychloroquine (HCQ) are considered possible COVID-19 treatments",
            "probability": 0.00418853759765625
        },
        {
            "start_logit": -10.171875,
            "end_logit": -6.5625,
            "text": "ID-19 treatments",
            "probability": 0.004123687744140625
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -6.5625,
            "text": "19 treatments",
            "probability": 0.003932952880859375
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -6.66015625,
            "text": "hydroxychloroquine (HCQ)",
            "probability": 0.003753662109375
        },
        {
            "start_logit": -10.578125,
            "end_logit": -6.5625,
            "text": "(HCQ) are considered possible COVID-19 treatments",
            "probability": 0.00274658203125
        },
        {
            "start_logit": -10.578125,
            "end_logit": -6.66015625,
            "text": "(HCQ)",
            "probability": 0.0025005340576171875
        },
        {
            "start_logit": -10.796875,
            "end_logit": -6.5625,
            "text": "ipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments",
            "probability": 0.0022068023681640625
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -7.984375,
            "text": "Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19",
            "probability": 0.00217437744140625
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -6.5625,
            "text": "iravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments",
            "probability": 0.00217437744140625
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -6.5625,
            "text": "-19 treatments",
            "probability": 0.0020427703857421875
        },
        {
            "start_logit": -10.796875,
            "end_logit": -6.66015625,
            "text": "ipiravir (FPV) and hydroxychloroquine (HCQ)",
            "probability": 0.002010345458984375
        },
        {
            "start_logit": -10.890625,
            "end_logit": -6.5625,
            "text": "considered possible COVID-19 treatments",
            "probability": 0.002010345458984375
        },
        {
            "start_logit": -10.890625,
            "end_logit": -6.5625,
            "text": "loroquine (HCQ) are considered possible COVID-19 treatments",
            "probability": 0.002010345458984375
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -6.66015625,
            "text": "iravir (FPV) and hydroxychloroquine (HCQ)",
            "probability": 0.0019779205322265625
        }
    ],
    "621ebb733a8413c65300005c_5": [
        {
            "start_logit": 10.9375,
            "end_logit": 6.5234375,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": 10.9375,
            "end_logit": -4.484375,
            "text": "COVID-19 in many countries.",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 10.9375,
            "end_logit": -5.46484375,
            "text": "COV",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -4.01171875,
            "end_logit": 6.5234375,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.9375,
            "end_logit": -8.5390625,
            "text": "COVID-19 in",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 6.5234375,
            "text": "of COVID-19",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.015625,
            "text": "COVID",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.9375,
            "end_logit": -9.2578125,
            "text": "COVID-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 6.5234375,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 6.5234375,
            "text": "ID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 6.5234375,
            "text": "treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 6.5234375,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 6.5234375,
            "text": "used for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 6.5234375,
            "text": "for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 6.5234375,
            "text": "ipiravir (FVP) has been used for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 6.5234375,
            "text": "been used for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 6.5234375,
            "text": "(FVP) has been used for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 6.5234375,
            "text": "iravir (FVP) has been used for treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -4.01171875,
            "end_logit": -4.484375,
            "text": "Favipiravir (FVP) has been used for treatment of COVID-19 in many countries.",
            "probability": 0.0
        },
        {
            "start_logit": -4.38671875,
            "end_logit": -4.484375,
            "text": "of COVID-19 in many countries.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_6": [
        {
            "start_logit": 3.46875,
            "end_logit": 13.1875,
            "text": "COVID-19 infection",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.1171875,
            "end_logit": 13.1875,
            "text": "infection",
            "probability": 0.0005068778991699219
        },
        {
            "start_logit": -4.44140625,
            "end_logit": 13.1875,
            "text": "severe COVID-19 infection",
            "probability": 0.00036787986755371094
        },
        {
            "start_logit": -8.03125,
            "end_logit": 13.1875,
            "text": "-19 infection",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 13.1875,
            "text": "ID-19 infection",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 13.1875,
            "text": "Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 13.1875,
            "text": "19 infection",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -8.9140625,
            "end_logit": 13.1875,
            "text": "treating patients with severe COVID-19 infection",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 13.1875,
            "text": "with severe COVID-19 infection",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -10.0,
            "end_logit": 13.1875,
            "text": "patients with severe COVID-19 infection",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.34375,
            "end_logit": 13.1875,
            "text": "the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.1875,
            "text": "To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.1875,
            "text": "standard therapy in treating patients with severe COVID-19 infection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.53125,
            "end_logit": 13.1875,
            "text": "compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 13.1875,
            "text": "therapy in treating patients with severe COVID-19 infection",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.1875,
            "text": "ipiravir compared to the standard therapy in treating patients with severe COVID-19 infection",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.1875,
            "text": "in treating patients with severe COVID-19 infection",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 3.46875,
            "end_logit": -4.24609375,
            "text": "COVID-19 infection.",
            "probability": 0.0
        },
        {
            "start_logit": 3.46875,
            "end_logit": -9.8046875,
            "text": "COV",
            "probability": 0.0
        },
        {
            "start_logit": 3.46875,
            "end_logit": -10.1484375,
            "text": "COVID-19",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_7": [
        {
            "start_logit": -1.3828125,
            "end_logit": 13.03125,
            "text": "COVID-19 infections",
            "probability": 0.88330078125
        },
        {
            "start_logit": -3.54296875,
            "end_logit": 13.03125,
            "text": "severe COVID-19 infections",
            "probability": 0.10150146484375
        },
        {
            "start_logit": -5.59375,
            "end_logit": 13.03125,
            "text": "infections",
            "probability": 0.0131072998046875
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 13.03125,
            "text": "19 infections",
            "probability": 0.0005450248718261719
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 13.03125,
            "text": "ID-19 infections",
            "probability": 0.00037479400634765625
        },
        {
            "start_logit": -9.34375,
            "end_logit": 13.03125,
            "text": "with severe COVID-19 infections",
            "probability": 0.0003082752227783203
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 13.03125,
            "text": "-19 infections",
            "probability": 0.00023448467254638672
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.03125,
            "text": "patients with severe COVID-19 infections",
            "probability": 8.040666580200195e-05
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.03125,
            "text": "standard of care in patients with severe COVID-19 infections",
            "probability": 7.259845733642578e-05
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.03125,
            "text": "in patients with severe COVID-19 infections",
            "probability": 6.306171417236328e-05
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 13.03125,
            "text": "Favipiravir versus standard of care in patients with severe COVID-19 infections",
            "probability": 6.115436553955078e-05
        },
        {
            "start_logit": -11.078125,
            "end_logit": 13.03125,
            "text": "versus standard of care in patients with severe COVID-19 infections",
            "probability": 5.441904067993164e-05
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 13.03125,
            "text": "of care in patients with severe COVID-19 infections",
            "probability": 5.4001808166503906e-05
        },
        {
            "start_logit": -9.34375,
            "end_logit": -10.1171875,
            "text": "with",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -10.1171875,
            "text": "patients with",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -10.1015625,
            "text": "standard of care in",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -10.1171875,
            "text": "standard of care in patients with",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -10.15625,
            "text": "standard of care",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -10.1015625,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -10.1171875,
            "text": "in patients with",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_8": [
        {
            "start_logit": 3.98828125,
            "end_logit": 9.3984375,
            "text": "COVID-19.",
            "probability": 1.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.3984375,
            "text": ".",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 9.3984375,
            "text": "ID-19.",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 9.3984375,
            "text": "of COVID-19.",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -9.5,
            "end_logit": 9.3984375,
            "text": "treatment of COVID-19.",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 9.3984375,
            "text": "-19.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -10.03125,
            "end_logit": 9.3984375,
            "text": "19.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 9.3984375,
            "text": "Favipiravir in the treatment of COVID-19.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -11.046875,
            "end_logit": 9.3984375,
            "text": "in the treatment of COVID-19.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -11.265625,
            "end_logit": 9.3984375,
            "text": "Molnupiravir/Favipiravir in the treatment of COVID-19.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -11.2734375,
            "end_logit": 9.3984375,
            "text": "ipiravir in the treatment of COVID-19.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -11.3359375,
            "end_logit": 9.3984375,
            "text": "/Favipiravir in the treatment of COVID-19.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -6.45703125,
            "text": "COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -10.0703125,
            "text": "COV",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -10.078125,
            "text": "COVID-",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -10.265625,
            "text": "COVID",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -6.45703125,
            "text": "ID-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": -6.45703125,
            "text": "of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": -6.45703125,
            "text": "treatment of COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -6.45703125,
            "text": "-19",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_9": [
        {
            "start_logit": 12.5390625,
            "end_logit": 14.1484375,
            "text": "influenza infections",
            "probability": 1.0
        },
        {
            "start_logit": -2.986328125,
            "end_logit": 14.1484375,
            "text": "infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -2.28515625,
            "text": "influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.984375,
            "end_logit": 14.1484375,
            "text": "Favipiravir, indicated for the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 14.1484375,
            "text": "treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 14.1484375,
            "text": "emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 14.1484375,
            "text": "of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 14.1484375,
            "text": "new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 14.1484375,
            "text": "the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.1484375,
            "text": "for the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 14.1484375,
            "text": "re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.1484375,
            "text": "ipiravir, indicated for the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 14.1484375,
            "text": "indicated for the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.1484375,
            "text": "and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.1484375,
            "text": "iravir, indicated for the treatment of new and re-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.1484375,
            "text": "-emerging influenza infections",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.5546875,
            "text": "influenza infections,",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.5625,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.65625,
            "text": "influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated.",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.96875,
            "text": "influenza infections, has been suggested",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_10": [
        {
            "start_logit": -6.734375,
            "end_logit": -2.275390625,
            "text": "COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.75927734375
        },
        {
            "start_logit": -9.5625,
            "end_logit": -2.275390625,
            "text": "mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.04486083984375
        },
        {
            "start_logit": -9.828125,
            "end_logit": -2.275390625,
            "text": ".",
            "probability": 0.034393310546875
        },
        {
            "start_logit": -10.296875,
            "end_logit": -2.275390625,
            "text": "ID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0215301513671875
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -2.275390625,
            "text": "19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.018280029296875
        },
        {
            "start_logit": -10.53125,
            "end_logit": -2.275390625,
            "text": "hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0170440673828125
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -2.275390625,
            "text": "favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0158843994140625
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -2.275390625,
            "text": "plus favipiravir.",
            "probability": 0.01198577880859375
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -2.275390625,
            "text": "-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0117950439453125
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -2.275390625,
            "text": "moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.0109100341796875
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -2.275390625,
            "text": "/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.01041412353515625
        },
        {
            "start_logit": -11.1171875,
            "end_logit": -2.275390625,
            "text": "ipiravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.00948333740234375
        },
        {
            "start_logit": -11.1328125,
            "end_logit": -2.275390625,
            "text": "hydroxychloroquine plus favipiravir.",
            "probability": 0.00933837890625
        },
        {
            "start_logit": -11.171875,
            "end_logit": -2.275390625,
            "text": "iravir, and hydroxychloroquine plus favipiravir.",
            "probability": 0.00897979736328125
        },
        {
            "start_logit": -6.734375,
            "end_logit": -6.84765625,
            "text": "COVID-19 patients",
            "probability": 0.0078582763671875
        },
        {
            "start_logit": -6.734375,
            "end_logit": -7.23828125,
            "text": "COVID-19 patients treated with hydroxychloroquine",
            "probability": 0.00531768798828125
        },
        {
            "start_logit": -6.734375,
            "end_logit": -8.9375,
            "text": "COVID-",
            "probability": 0.0009684562683105469
        },
        {
            "start_logit": -6.734375,
            "end_logit": -9.3359375,
            "text": "COVID-19",
            "probability": 0.0006556510925292969
        },
        {
            "start_logit": -6.734375,
            "end_logit": -9.59375,
            "text": "COVID-19 patients treated with hydroxychloroquine,",
            "probability": 0.0005025863647460938
        },
        {
            "start_logit": -6.734375,
            "end_logit": -9.65625,
            "text": "COVID-19 patients treated",
            "probability": 0.00047206878662109375
        }
    ],
    "621ebb733a8413c65300005c_11": [
        {
            "start_logit": 7.421875,
            "end_logit": 8.1875,
            "text": "influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.626953125,
            "end_logit": 8.1875,
            "text": "pandemic influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.0011167526245117188
        },
        {
            "start_logit": 7.421875,
            "end_logit": -4.80078125,
            "text": "influenza A/California/04/2009 (H1N1)",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 7.421875,
            "end_logit": -5.265625,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 8.1875,
            "text": "infections",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.421875,
            "end_logit": -5.82421875,
            "text": "influenza A/California/04/2009 (H1N1) virus",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.35546875,
            "text": "influenza",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 8.1875,
            "text": "virus infections",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 8.1875,
            "text": ") virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.671875,
            "end_logit": 8.1875,
            "text": "treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.9453125,
            "text": "influenza A/California/04/2009 (H1N1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 8.1875,
            "text": "of pandemic influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.421875,
            "end_logit": -8.2578125,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.421875,
            "end_logit": -9.046875,
            "text": "influenza A/California/04/2009 (H1N1) virus infections in mice",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.046875,
            "end_logit": 8.1875,
            "text": "favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 8.1875,
            "text": "A/California/04/2009 (H1N1) virus infections",
            "probability": 0.0
        },
        {
            "start_logit": 7.421875,
            "end_logit": -9.40625,
            "text": "influenza A",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 8.1875,
            "text": "(H1N1) virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 8.1875,
            "text": "/California/04/2009 (H1N1) virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 8.1875,
            "text": "/04/2009 (H1N1) virus infections",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_12": [
        {
            "start_logit": 9.8125,
            "end_logit": 5.16796875,
            "text": "COVID-19",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.8125,
            "end_logit": -1.5341796875,
            "text": "COVID-19.",
            "probability": 0.0012264251708984375
        },
        {
            "start_logit": 9.8125,
            "end_logit": -6.4609375,
            "text": "COV",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 9.8125,
            "end_logit": -9.1171875,
            "text": "COVID-",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.8125,
            "end_logit": -9.4296875,
            "text": "COVID",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.984375,
            "end_logit": 5.16796875,
            "text": "with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 5.16796875,
            "text": "19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 5.16796875,
            "text": "ID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 5.16796875,
            "text": "Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 5.16796875,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 5.16796875,
            "text": "treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 5.16796875,
            "text": "patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 5.16796875,
            "text": ": Favipiravir possesses high utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 5.16796875,
            "text": "high utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 5.16796875,
            "text": "ipiravir possesses high utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 5.16796875,
            "text": "utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 5.16796875,
            "text": "iravir possesses high utility for treating patients with COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -5.984375,
            "end_logit": -1.5341796875,
            "text": "with COVID-19.",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -1.5341796875,
            "text": "19.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -1.5341796875,
            "text": "ID-19.",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_13": [
        {
            "start_logit": 4.27734375,
            "end_logit": 0.23388671875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus.",
            "probability": 0.701171875
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -0.63330078125,
            "text": "influenza",
            "probability": 0.294677734375
        },
        {
            "start_logit": -0.30322265625,
            "end_logit": -0.63330078125,
            "text": "Favipiravir is active against a broad range of influenza",
            "probability": 0.0030155181884765625
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -7.921875,
            "text": "influenza viruses,",
            "probability": 0.00020110607147216797
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -8.71875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1)",
            "probability": 9.071826934814453e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -8.71875,
            "text": "influenza viruses",
            "probability": 9.071826934814453e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -8.796875,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1",
            "probability": 8.392333984375e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -9.3203125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus",
            "probability": 4.971027374267578e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -9.3984375,
            "text": "influenza viruses, including A(H1N1)pdm09",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -9.6953125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9)",
            "probability": 3.415346145629883e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -9.8828125,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -10.0234375,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -10.0234375,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -10.03125,
            "text": "influenza viruses, including A(H1N1",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": 4.27734375,
            "end_logit": -10.1015625,
            "text": "influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9",
            "probability": 2.276897430419922e-05
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 0.23388671875,
            "text": ".",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -0.30322265625,
            "end_logit": -7.921875,
            "text": "Favipiravir is active against a broad range of influenza viruses,",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -0.30322265625,
            "end_logit": -8.71875,
            "text": "Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1)",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.30322265625,
            "end_logit": -8.71875,
            "text": "Favipiravir is active against a broad range of influenza viruses",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.30322265625,
            "end_logit": -8.796875,
            "text": "Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1",
            "probability": 8.940696716308594e-07
        }
    ],
    "621ebb733a8413c65300005c_14": [
        {
            "start_logit": 13.4609375,
            "end_logit": 14.71875,
            "text": "influenza virus infections",
            "probability": 1.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": 14.71875,
            "text": "infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -2.8671875,
            "text": "influenza",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": 14.71875,
            "text": "Favipiravir is approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": 14.71875,
            "text": "virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 14.71875,
            "text": "treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": 14.71875,
            "text": "of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -6.6328125,
            "text": "influenza virus",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -6.796875,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model.",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 14.71875,
            "text": "approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 14.71875,
            "text": "the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 14.71875,
            "text": "for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.1796875,
            "text": "influenza virus infections and",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.71875,
            "text": "ipiravir is approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.71875,
            "text": "iravir is approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.71875,
            "text": "is approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.609375,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 14.71875,
            "text": "vir is approved in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 14.71875,
            "text": "in Japan for the treatment of influenza virus infections",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -10.0078125,
            "text": "influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_15": [
        {
            "start_logit": 1.6748046875,
            "end_logit": 2.50390625,
            "text": "COVID-19 treatment",
            "probability": 0.480712890625
        },
        {
            "start_logit": 1.1396484375,
            "end_logit": 2.50390625,
            "text": "Favipiravir, an antiviral drug, is being used for COVID-19 treatment",
            "probability": 0.281494140625
        },
        {
            "start_logit": 0.95849609375,
            "end_logit": 2.50390625,
            "text": "antiviral drug, is being used for COVID-19 treatment",
            "probability": 0.2347412109375
        },
        {
            "start_logit": 1.6748046875,
            "end_logit": -4.2109375,
            "text": "COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 0.0005831718444824219
        },
        {
            "start_logit": 1.6748046875,
            "end_logit": -4.234375,
            "text": "COVID-19 treatment,",
            "probability": 0.0005693435668945312
        },
        {
            "start_logit": 1.1396484375,
            "end_logit": -4.09375,
            "text": "Favipiravir, an antiviral",
            "probability": 0.0003840923309326172
        },
        {
            "start_logit": 1.1396484375,
            "end_logit": -4.234375,
            "text": "Favipiravir, an antiviral drug, is being used for COVID-19 treatment,",
            "probability": 0.00033354759216308594
        },
        {
            "start_logit": 0.95849609375,
            "end_logit": -4.09375,
            "text": "antiviral",
            "probability": 0.00032067298889160156
        },
        {
            "start_logit": 0.95849609375,
            "end_logit": -4.2109375,
            "text": "antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety.",
            "probability": 0.00028514862060546875
        },
        {
            "start_logit": 0.95849609375,
            "end_logit": -4.234375,
            "text": "antiviral drug, is being used for COVID-19 treatment,",
            "probability": 0.00027871131896972656
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 2.50390625,
            "text": "treatment",
            "probability": 5.751848220825195e-05
        },
        {
            "start_logit": 1.6748046875,
            "end_logit": -7.46875,
            "text": "COVID-19",
            "probability": 2.2530555725097656e-05
        },
        {
            "start_logit": 1.1396484375,
            "end_logit": -7.46875,
            "text": "Favipiravir, an antiviral drug, is being used for COVID-19",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": -8.953125,
            "end_logit": 2.50390625,
            "text": "ID-19 treatment",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 0.95849609375,
            "end_logit": -7.46875,
            "text": "antiviral drug, is being used for COVID-19",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 2.50390625,
            "text": "19 treatment",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 2.50390625,
            "text": "for COVID-19 treatment",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": -9.28125,
            "end_logit": 2.50390625,
            "text": "-19 treatment",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -9.96875,
            "end_logit": 2.50390625,
            "text": "ipiravir, an antiviral drug, is being used for COVID-19 treatment",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -10.515625,
            "end_logit": 2.50390625,
            "text": "drug, is being used for COVID-19 treatment",
            "probability": 2.4437904357910156e-06
        }
    ],
    "621ebb733a8413c65300005c_16": [
        {
            "start_logit": 5.1171875,
            "end_logit": 7.0234375,
            "text": "influenza",
            "probability": 0.9990234375
        },
        {
            "start_logit": -1.7451171875,
            "end_logit": 7.0234375,
            "text": "pandemic influenza",
            "probability": 0.0010442733764648438
        },
        {
            "start_logit": -2.681640625,
            "end_logit": 7.0234375,
            "text": "Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 0.0004105567932128906
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.24609375,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2.",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 7.0234375,
            "text": "approved for new and reemerging pandemic influenza",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.140625,
            "end_logit": 7.0234375,
            "text": "for new and reemerging pandemic influenza",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.609375,
            "end_logit": 7.0234375,
            "text": "new and reemerging pandemic influenza",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 7.0234375,
            "text": "ipiravir is one such oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.9375,
            "end_logit": 7.0234375,
            "text": "ging pandemic influenza",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.484375,
            "end_logit": 7.0234375,
            "text": "iravir is one such oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.484375,
            "end_logit": 7.0234375,
            "text": "reemerging pandemic influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 7.0234375,
            "text": "merging pandemic influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.578125,
            "end_logit": 7.0234375,
            "text": "drug that was approved for new and reemerging pandemic influenza",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.0234375,
            "text": "oral drug that was approved for new and reemerging pandemic influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 7.0234375,
            "text": "and reemerging pandemic influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -9.6953125,
            "text": "influenza in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -9.96875,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -10.0625,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -10.1796875,
            "text": "influenza in Japan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -10.34375,
            "text": "influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_17": [
        {
            "start_logit": 7.30859375,
            "end_logit": 8.015625,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.998046875
        },
        {
            "start_logit": 0.4619140625,
            "end_logit": 8.015625,
            "text": "Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0010557174682617188
        },
        {
            "start_logit": -0.5283203125,
            "end_logit": 8.015625,
            "text": "COVID-19.",
            "probability": 0.000392913818359375
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -3.24609375,
            "text": "influenza and Ebola",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -4.3515625,
            "text": "influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -5.61328125,
            "text": "influenza",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.4375,
            "end_logit": 8.015625,
            "text": ".",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -6.453125,
            "text": "influenza and Ebola,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.015625,
            "text": "and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 8.015625,
            "text": "treatment of COVID-19.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.3125,
            "end_logit": 8.015625,
            "text": "ID-19.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -7.8984375,
            "text": "influenza and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.609375,
            "end_logit": 8.015625,
            "text": "of COVID-19.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.234375,
            "end_logit": 8.015625,
            "text": "for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.25,
            "end_logit": 8.015625,
            "text": "Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.59375,
            "end_logit": 8.015625,
            "text": "-19.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 8.015625,
            "text": "19.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 8.015625,
            "text": "ipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 8.015625,
            "text": "indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19.",
            "probability": 0.0
        },
        {
            "start_logit": 7.30859375,
            "end_logit": -9.8203125,
            "text": "influenza and Ebola, which",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_18": [
        {
            "start_logit": 11.609375,
            "end_logit": 14.171875,
            "text": "Ebola virus infection",
            "probability": 1.0
        },
        {
            "start_logit": -3.189453125,
            "end_logit": 14.171875,
            "text": "infection",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.703125,
            "end_logit": 14.171875,
            "text": "influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 14.171875,
            "text": "treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -5.47265625,
            "text": "Ebola virus infection. I",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -5.5234375,
            "text": "Ebola",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 14.171875,
            "text": "virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 14.171875,
            "text": "treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.171875,
            "text": "of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.171875,
            "text": "novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.171875,
            "text": "been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.171875,
            "text": "now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.171875,
            "text": "for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.171875,
            "text": "has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.171875,
            "text": "used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.2265625,
            "text": "Ebola virus",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.171875,
            "text": "the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -8.65625,
            "text": "Ebola virus infection.",
            "probability": 0.0
        },
        {
            "start_logit": -3.703125,
            "end_logit": -3.525390625,
            "text": "influenza",
            "probability": 0.0
        },
        {
            "start_logit": -3.189453125,
            "end_logit": -5.47265625,
            "text": "infection. I",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_19": [
        {
            "start_logit": 3.619140625,
            "end_logit": 7.17578125,
            "text": "influenza virus",
            "probability": 0.9921875
        },
        {
            "start_logit": -1.216796875,
            "end_logit": 7.17578125,
            "text": "infections with the influenza virus",
            "probability": 0.00788116455078125
        },
        {
            "start_logit": -5.6328125,
            "end_logit": 7.17578125,
            "text": "treatment of infections with the influenza virus",
            "probability": 9.5367431640625e-05
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -2.876953125,
            "text": "influenza",
            "probability": 4.26173210144043e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 7.17578125,
            "text": "of infections with the influenza virus",
            "probability": 3.790855407714844e-05
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 7.17578125,
            "text": "virus",
            "probability": 3.248453140258789e-05
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.17578125,
            "text": "the influenza virus",
            "probability": 1.436471939086914e-05
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 7.17578125,
            "text": "with the influenza virus",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -9.25,
            "end_logit": 7.17578125,
            "text": "Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 7.17578125,
            "text": "the treatment of infections with the influenza virus",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 7.17578125,
            "text": "advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": 7.17578125,
            "text": "drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 7.17578125,
            "text": "in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 7.17578125,
            "text": "[T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 7.17578125,
            "text": "for the treatment of infections with the influenza virus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 7.17578125,
            "text": "a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 7.17578125,
            "text": "T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -1.216796875,
            "end_logit": -2.876953125,
            "text": "infections with the influenza",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -8.2890625,
            "text": "influenza virus] inhibits in vitro murine norovirus replication",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.619140625,
            "end_logit": -8.7265625,
            "text": "influenza virus] inhibits in vitro murine norovirus replication.",
            "probability": 1.1920928955078125e-07
        }
    ],
    "621ebb733a8413c65300005c_20": [
        {
            "start_logit": 4.73046875,
            "end_logit": 3.1328125,
            "text": "COVID-19",
            "probability": 1.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": 3.1328125,
            "text": "with COVID-19",
            "probability": 0.0003502368927001953
        },
        {
            "start_logit": 4.73046875,
            "end_logit": -8.6875,
            "text": "COVID-",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 4.73046875,
            "end_logit": -8.6875,
            "text": "COV",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 4.73046875,
            "end_logit": -9.2265625,
            "text": "COVID",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 3.1328125,
            "text": "19",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -8.953125,
            "end_logit": 3.1328125,
            "text": "ID-19",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 3.1328125,
            "text": "-19",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.734375,
            "end_logit": 3.1328125,
            "text": "patients with COVID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.828125,
            "end_logit": 3.1328125,
            "text": "treatment option for patients with COVID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 3.1328125,
            "text": "Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 3.1328125,
            "text": "for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.171875,
            "end_logit": 3.1328125,
            "text": "iravir might be a treatment option for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1875,
            "end_logit": 3.1328125,
            "text": "/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 3.1328125,
            "text": "therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 3.1328125,
            "text": "ipiravir might be a treatment option for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.25,
            "end_logit": 3.1328125,
            "text": "Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -8.6875,
            "text": "with COVID-",
            "probability": 0.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -8.6875,
            "text": "with COV",
            "probability": 0.0
        },
        {
            "start_logit": -3.2265625,
            "end_logit": -9.2265625,
            "text": "with COVID",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_21": [
        {
            "start_logit": 9.2578125,
            "end_logit": 1.255859375,
            "text": "COVID-19",
            "probability": 0.9951171875
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.82421875,
            "text": "COVID-19. Recent",
            "probability": 0.0022716522216796875
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -4.86328125,
            "text": "COVID-19.",
            "probability": 0.0021839141845703125
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.296875,
            "text": "COV",
            "probability": 0.00019168853759765625
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.859375,
            "text": "COVID",
            "probability": 4.017353057861328e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -8.9296875,
            "text": "COVID-",
            "probability": 3.743171691894531e-05
        },
        {
            "start_logit": -7.6875,
            "end_logit": 1.255859375,
            "text": "for COVID-19",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 1.255859375,
            "text": "ID-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 1.255859375,
            "text": "19",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 1.255859375,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 1.255859375,
            "text": "vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 1.255859375,
            "text": ", Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 1.255859375,
            "text": "Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 1.255859375,
            "text": "and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 1.255859375,
            "text": "therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 1.255859375,
            "text": "Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -4.82421875,
            "text": "for COVID-19. Recent",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -4.86328125,
            "text": "for COVID-19.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -3.666015625,
            "text": "vir, Favipiravir and Ribavirin might",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -4.82421875,
            "text": "ID-19. Recent",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_22": [
        {
            "start_logit": 10.0625,
            "end_logit": 4.27734375,
            "text": "Covid-19",
            "probability": 1.0
        },
        {
            "start_logit": 10.0625,
            "end_logit": -5.84765625,
            "text": "Covid-19:",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": 10.0625,
            "end_logit": -6.1328125,
            "text": "Cov",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": 10.0625,
            "end_logit": -6.89453125,
            "text": "Covid-19: A Retrospective Study.",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.578125,
            "text": "Covid-19: A Retrospective",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.71875,
            "text": "Covid",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 10.0625,
            "end_logit": -8.921875,
            "text": "Covid-",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 10.0625,
            "end_logit": -9.9765625,
            "text": "Covid-19: A Retrospective Study",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.84375,
            "end_logit": 4.27734375,
            "text": "of Covid-19",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 4.27734375,
            "text": "19",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 4.27734375,
            "text": "id-19",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 4.27734375,
            "text": "-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 4.27734375,
            "text": "Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 4.27734375,
            "text": "Hydroxychloroquine for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 4.27734375,
            "text": "Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 4.27734375,
            "text": "to Hydroxychloroquine for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 4.27734375,
            "text": "Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 4.27734375,
            "text": "for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 4.27734375,
            "text": "ipiravir Compared to Hydroxychloroquine for Management of Covid-19",
            "probability": 0.0
        },
        {
            "start_logit": -4.84375,
            "end_logit": -5.84765625,
            "text": "of Covid-19:",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_23": [
        {
            "start_logit": 5.78125,
            "end_logit": 5.75390625,
            "text": "influenza infec",
            "probability": 1.0
        },
        {
            "start_logit": 5.78125,
            "end_logit": -5.91796875,
            "text": "influenza inf",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 5.78125,
            "end_logit": -7.2421875,
            "text": "influenza",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 5.75390625,
            "text": "of influenza infec",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -9.1875,
            "end_logit": 5.75390625,
            "text": "treatment of influenza infec",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 5.75390625,
            "text": "ec",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 5.75390625,
            "text": "infec",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.796875,
            "end_logit": 5.75390625,
            "text": ": Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.84375,
            "end_logit": 5.75390625,
            "text": "for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 5.75390625,
            "text": "AIM: Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.96875,
            "end_logit": 5.75390625,
            "text": "Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 5.75390625,
            "text": "oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 5.75390625,
            "text": "eltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.078125,
            "end_logit": 5.75390625,
            "text": "ipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.09375,
            "end_logit": 5.75390625,
            "text": "iravir and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.15625,
            "end_logit": 5.75390625,
            "text": "and oseltamivir are antiviral compounds used for the treatment of influenza infec",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -5.91796875,
            "text": "of influenza inf",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": -5.91796875,
            "text": "treatment of influenza inf",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -7.2421875,
            "text": "of influenza",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -5.91796875,
            "text": "inf",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_24": [
        {
            "start_logit": 8.046875,
            "end_logit": 8.0390625,
            "text": "coronavirus disease 2019 (COVID-19)",
            "probability": 0.7158203125
        },
        {
            "start_logit": 8.046875,
            "end_logit": 7.12890625,
            "text": "coronavirus disease 2019",
            "probability": 0.28466796875
        },
        {
            "start_logit": 8.046875,
            "end_logit": -4.67578125,
            "text": "coronavirus disease",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -6.09375,
            "end_logit": 8.0390625,
            "text": "2019 (COVID-19)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 8.0390625,
            "text": "(COVID-19)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 8.0390625,
            "text": ")",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 7.12890625,
            "text": "2019",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 8.0390625,
            "text": "Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.046875,
            "end_logit": -7.3671875,
            "text": "coronavirus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.0390625,
            "text": "managing coronavirus disease 2019 (COVID-19)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 7.12890625,
            "text": "Favipiravir is a promising treatment candidate for managing coronavirus disease 2019",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 8.0390625,
            "text": "COVID-19)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 8.0390625,
            "text": "disease 2019 (COVID-19)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.12890625,
            "text": "managing coronavirus disease 2019",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.12890625,
            "text": "disease 2019",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.046875,
            "end_logit": -9.6171875,
            "text": "coronavirus disease 2019 (COVID-19",
            "probability": 0.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -9.9765625,
            "text": "coronavirus disease 2019 (COVID",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 8.0390625,
            "text": "ipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19)",
            "probability": 0.0
        },
        {
            "start_logit": 8.046875,
            "end_logit": -10.390625,
            "text": "coronavirus disease 2019 (COVID-",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 8.0390625,
            "text": "ID-19)",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_25": [
        {
            "start_logit": 6.96484375,
            "end_logit": 4.1015625,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": -1.9443359375,
            "end_logit": 4.1015625,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 0.00013554096221923828
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -5.33203125,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -7.41015625,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -5.0390625,
            "end_logit": 4.1015625,
            "text": "severe influenza",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -9.171875,
            "text": "influenza,",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -9.640625,
            "text": "influenza, the next pandemic influenza strain, and",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -9.9296875,
            "text": "influenza, the next pandemic influenza strain, and other severe RNA virus infections for",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -9.9375,
            "text": "influenza, the next pandemic influenza strain,",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -10.0859375,
            "text": "influenza, the next pandemic influenza strain, and other",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.96484375,
            "end_logit": -10.203125,
            "text": "influenza, the next pandemic influenza strain",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -8.96875,
            "end_logit": 4.1015625,
            "text": "for severe influenza",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 4.1015625,
            "text": "expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 4.1015625,
            "text": "ipiravir is expected to be an important therapeutic agent for severe influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.453125,
            "end_logit": 4.1015625,
            "text": "therapeutic agent for severe influenza",
            "probability": 0.0
        },
        {
            "start_logit": -1.9443359375,
            "end_logit": -7.41015625,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections",
            "probability": 0.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -5.33203125,
            "text": "severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9443359375,
            "end_logit": -8.59375,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe",
            "probability": 0.0
        },
        {
            "start_logit": -1.9443359375,
            "end_logit": -9.171875,
            "text": "Favipiravir is expected to be an important therapeutic agent for severe influenza,",
            "probability": 0.0
        },
        {
            "start_logit": -1.9443359375,
            "end_logit": -9.4921875,
            "text": "Favipiravir is expected to be an important therapeutic agent for",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_26": [
        {
            "start_logit": 6.16796875,
            "end_logit": 13.84375,
            "text": "pandemic influenza virus infections",
            "probability": 0.857421875
        },
        {
            "start_logit": 4.375,
            "end_logit": 13.84375,
            "text": "influenza virus infections",
            "probability": 0.1422119140625
        },
        {
            "start_logit": -3.33203125,
            "end_logit": 13.84375,
            "text": "infections",
            "probability": 6.41942024230957e-05
        },
        {
            "start_logit": -3.423828125,
            "end_logit": 13.84375,
            "text": "treat pandemic influenza virus infections",
            "probability": 5.841255187988281e-05
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 13.84375,
            "text": "virus infections",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 13.84375,
            "text": "antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -8.953125,
            "end_logit": 13.84375,
            "text": "approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.34375,
            "end_logit": 13.84375,
            "text": "as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 13.84375,
            "text": "to treat pandemic influenza virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.875,
            "end_logit": 13.84375,
            "text": "ipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 13.84375,
            "text": "T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.28125,
            "end_logit": 13.84375,
            "text": "drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 13.84375,
            "text": "been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.84375,
            "text": "known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.84375,
            "text": "iravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 13.84375,
            "text": "705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -5.05078125,
            "text": "pandemic",
            "probability": 0.0
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -6.8984375,
            "text": "pandemic influenza virus infections.",
            "probability": 0.0
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.40234375,
            "text": "pandemic influenza virus",
            "probability": 0.0
        },
        {
            "start_logit": 6.16796875,
            "end_logit": -7.76953125,
            "text": "pandemic influenza",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_27": [
        {
            "start_logit": 8.2265625,
            "end_logit": 1.4111328125,
            "text": "influenza",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -5.57421875,
            "text": "influenza strains",
            "probability": 0.0009217262268066406
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -8.265625,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe.",
            "probability": 6.246566772460938e-05
        },
        {
            "start_logit": -1.708984375,
            "end_logit": 1.4111328125,
            "text": "Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -9.3046875,
            "text": "influenza strains;",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -10.046875,
            "text": "influenza strains; and",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -10.0703125,
            "text": "influenza strains; and several",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -10.2109375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -10.234375,
            "text": "influenza strains; and several phase 2 and 3 clinical trials are",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -4.8984375,
            "end_logit": 1.4111328125,
            "text": "emerging influenza",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -8.640625,
            "end_logit": 1.4111328125,
            "text": "against emerging influenza",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.708984375,
            "end_logit": -5.57421875,
            "text": "Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 1.4111328125,
            "text": "antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 1.4111328125,
            "text": "approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 1.4111328125,
            "text": "use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 1.4111328125,
            "text": "ipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 1.4111328125,
            "text": "(T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 1.4111328125,
            "text": "analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 1.4111328125,
            "text": "-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 1.4111328125,
            "text": "iravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza",
            "probability": 0.0
        }
    ],
    "621ebb733a8413c65300005c_28": [
        {
            "start_logit": 10.6796875,
            "end_logit": 9.4375,
            "text": "influenza",
            "probability": 1.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -8.0625,
            "text": "influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 9.4375,
            "text": "favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -9.171875,
            "text": "influenza and many other RNA viral diseases",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -9.25,
            "text": "influenza and",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": 9.4375,
            "text": "for influenza",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -10.1484375,
            "text": "influenza and many other RNA viral diseases for",
            "probability": 0.0
        },
        {
            "start_logit": 10.6796875,
            "end_logit": -10.2578125,
            "text": "influenza and many other",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 9.4375,
            "text": "ipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.4375,
            "text": "drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 9.4375,
            "text": "iravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 9.4375,
            "text": "promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 9.4375,
            "text": "of antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 9.4375,
            "text": "antiviral activity, favipiravir is a promising drug candidate for influenza",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -8.0625,
            "text": "favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -8.546875,
            "text": "favipiravir is a promising drug candidate for",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -8.0625,
            "text": "for influenza and many other RNA viral diseases for which there are no approved therapies.",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -9.171875,
            "text": "favipiravir is a promising drug candidate for influenza and many other RNA viral diseases",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": -9.25,
            "text": "favipiravir is a promising drug candidate for influenza and",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -8.546875,
            "text": "for",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_1": [
        {
            "start_logit": 7.921875,
            "end_logit": 12.7734375,
            "text": "Status Epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -1.3447265625,
            "end_logit": 12.7734375,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 9.5367431640625e-05
        },
        {
            "start_logit": -5.15625,
            "end_logit": 12.7734375,
            "text": "Epilepticus",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -8.390625,
            "end_logit": 12.7734375,
            "text": "With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 12.7734375,
            "text": "Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.171875,
            "end_logit": 12.7734375,
            "text": "ulsive Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.125,
            "end_logit": 12.7734375,
            "text": "Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.7734375,
            "text": "vulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.7734375,
            "text": "Reevaluation of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 12.7734375,
            "text": "the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.7734375,
            "text": "Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.7734375,
            "text": "of the Critically Ill Patients With Nonconvulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -8.0,
            "text": "Status",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -8.5625,
            "text": "Status Epilepticus by Using Salzburg Consensus Criteria.",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -8.625,
            "text": "Status Epilepticus by",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -8.71875,
            "text": "Status Epilepticus by Using Salzburg Consensus",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -9.890625,
            "text": "Status Epilepticus by Using Sal",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -10.09375,
            "text": "Status Epilepticus by Using Salzburg Consensus Criteria",
            "probability": 0.0
        },
        {
            "start_logit": 7.921875,
            "end_logit": -10.140625,
            "text": "Status Epilepticus by Using Salz",
            "probability": 0.0
        },
        {
            "start_logit": -1.3447265625,
            "end_logit": -8.0,
            "text": "Nonconvulsive Status",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_2": [
        {
            "start_logit": 5.3828125,
            "end_logit": 11.6015625,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 11.6015625,
            "text": "status epilepticus",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 11.6015625,
            "text": "epilepticus",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 11.6015625,
            "text": "ulsive status epilepticus",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -8.65625,
            "end_logit": 11.6015625,
            "text": "with nonconvulsive status epilepticus",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -9.734375,
            "end_logit": 11.6015625,
            "text": "vulsive status epilepticus",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": 11.6015625,
            "text": "the Salzburg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.6015625,
            "text": "critically ill patients with nonconvulsive status epilepticus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.6015625,
            "text": "burg Consensus Criteria (SCC) for determining the prognosis of critically ill patients with nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 11.6015625,
            "text": "patients with nonconvulsive status epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -6.390625,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -7.2578125,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -7.9921875,
            "text": "noncon",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -9.4609375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -9.765625,
            "text": "nonconvulsive status epilepticus (NCSE).",
            "probability": 0.0
        },
        {
            "start_logit": 5.3828125,
            "end_logit": -10.0703125,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -6.390625,
            "text": "status epilepticus (NCS",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -6.390625,
            "text": "epilepticus (NCS",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -7.2578125,
            "text": "status epilepticus (NCSE",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": -7.2578125,
            "text": "epilepticus (NCSE",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_3": [
        {
            "start_logit": 12.2109375,
            "end_logit": 13.5390625,
            "text": "Nonconvulsive Status Epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -4.54296875,
            "end_logit": 13.5390625,
            "text": "Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.80859375,
            "end_logit": 13.5390625,
            "text": "Status Epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -4.60546875,
            "text": "Noncon",
            "probability": 0.0
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 13.5390625,
            "text": "ulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 13.5390625,
            "text": "vulsive Status Epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -8.640625,
            "text": "Nonconvulsive Status",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -8.90625,
            "text": "Nonconvulsive Status Epilepticus:",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -8.9453125,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG Examiner.",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -9.3984375,
            "text": "Nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -9.609375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an Expert EEG",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -9.6953125,
            "text": "Nonconvulsive Status Epilepticus: Validating the Sal",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -9.9609375,
            "text": "Nonconvulsive Status Epilepticus: Validating",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -10.0078125,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salz",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -10.0234375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria Against an",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -10.0859375,
            "text": "Nonconvulsive Status Epilepticus: Validating the",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -10.09375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg Criteria",
            "probability": 0.0
        },
        {
            "start_logit": 12.2109375,
            "end_logit": -10.109375,
            "text": "Nonconvulsive Status Epilepticus: Validating the Salzburg",
            "probability": 0.0
        },
        {
            "start_logit": -4.54296875,
            "end_logit": -8.90625,
            "text": "Epilepticus:",
            "probability": 0.0
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -8.640625,
            "text": "Status",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_4": [
        {
            "start_logit": 12.3828125,
            "end_logit": 13.2578125,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -4.5546875,
            "end_logit": 13.2578125,
            "text": "epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -4.16796875,
            "text": "noncon",
            "probability": 0.0
        },
        {
            "start_logit": -5.23046875,
            "end_logit": 13.2578125,
            "text": "status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 13.2578125,
            "text": "ulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -7.171875,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 13.2578125,
            "text": "for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -8.3203125,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -8.8671875,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 13.2578125,
            "text": "vulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.3125,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.4609375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.6015625,
            "text": "nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.6953125,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Sal",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.7109375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.8515625,
            "text": "nonconvulsive status",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.9453125,
            "text": "nonconvulsive status epilepticus (NCSE),",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.2578125,
            "text": "electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 13.2578125,
            "text": "diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -4.5546875,
            "end_logit": -7.171875,
            "text": "epilepticus (NCS",
            "probability": 0.0
        }
    ],
    "5e48bf5ed14c9f295d000019_5": [
        {
            "start_logit": 12.3828125,
            "end_logit": 13.2578125,
            "text": "nonconvulsive status epilepticus",
            "probability": 1.0
        },
        {
            "start_logit": -4.5546875,
            "end_logit": 13.2578125,
            "text": "epilepticus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -4.16796875,
            "text": "noncon",
            "probability": 0.0
        },
        {
            "start_logit": -5.23046875,
            "end_logit": 13.2578125,
            "text": "status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 13.2578125,
            "text": "ulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -7.171875,
            "text": "nonconvulsive status epilepticus (NCS",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 13.2578125,
            "text": "for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -8.3203125,
            "text": "nonconvulsive status epilepticus (NCSE",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -8.8671875,
            "text": "nonconvulsive status epilepticus (",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 13.2578125,
            "text": "vulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.3125,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount.",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.4609375,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Salzburg criteria is paramount",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.6015625,
            "text": "nonconv",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.6953125,
            "text": "nonconvulsive status epilepticus (NCSE), external validation of the recently proposed Sal",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.7109375,
            "text": "nonconvulsive status epilepticus (NCSE)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.8515625,
            "text": "nonconvulsive status",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.9453125,
            "text": "nonconvulsive status epilepticus (NCSE),",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.2578125,
            "text": "electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 13.2578125,
            "text": "diagnostic accuracy of electroencephalography (EEG) criteria for nonconvulsive status epilepticus",
            "probability": 0.0
        },
        {
            "start_logit": -4.5546875,
            "end_logit": -7.171875,
            "text": "epilepticus (NCS",
            "probability": 0.0
        }
    ],
    "623e02e0f0baec9a1b000005_1": [
        {
            "start_logit": 1.466796875,
            "end_logit": -1.6806640625,
            "text": "ER retention sequence",
            "probability": 0.99609375
        },
        {
            "start_logit": 1.466796875,
            "end_logit": -8.203125,
            "text": "ER retention sequence (",
            "probability": 0.001468658447265625
        },
        {
            "start_logit": 1.466796875,
            "end_logit": -8.6875,
            "text": "ER",
            "probability": 0.0009050369262695312
        },
        {
            "start_logit": 1.466796875,
            "end_logit": -8.9140625,
            "text": "ER retention",
            "probability": 0.0007214546203613281
        },
        {
            "start_logit": 1.466796875,
            "end_logit": -9.390625,
            "text": "ER retention sequence (KDEL)",
            "probability": 0.00044798851013183594
        },
        {
            "start_logit": 1.466796875,
            "end_logit": -10.25,
            "text": "ER retention sequence (KDEL",
            "probability": 0.00018894672393798828
        },
        {
            "start_logit": -10.46875,
            "end_logit": -1.6806640625,
            "text": "retention sequence",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -10.46875,
            "end_logit": -8.203125,
            "text": "retention sequence (",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -8.9140625,
            "text": "retention",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -9.390625,
            "text": "KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -9.390625,
            "text": "retention sequence (KDEL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.390625,
            "text": "EL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -10.25,
            "text": "KDEL",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -10.25,
            "text": "retention sequence (KDEL",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -10.25,
            "text": "EL",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_1": [
        {
            "start_logit": 11.3828125,
            "end_logit": 12.2890625,
            "text": "Anorexia Athletica",
            "probability": 1.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": 12.2890625,
            "text": "a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -5.35546875,
            "text": "Anorexia",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -6.1953125,
            "text": "Anorexia Athletica.",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 12.2890625,
            "text": "Athletica",
            "probability": 0.0
        },
        {
            "start_logit": 11.3828125,
            "end_logit": -8.484375,
            "text": "Anorexia Athletic",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 12.2890625,
            "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 12.2890625,
            "text": "Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 12.2890625,
            "text": "Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.2890625,
            "text": "developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.2890625,
            "text": "ts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 12.2890625,
            "text": "nasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 12.2890625,
            "text": "prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 12.2890625,
            "text": ") constitute a unique metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 12.2890625,
            "text": "metabolic model and they are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 12.2890625,
            "text": "are prone to developing Anorexia Athletica",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -6.1953125,
            "text": "a.",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -6.1953125,
            "text": "Athletica.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -5.35546875,
            "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -5.35546875,
            "text": "Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia",
            "probability": 0.0
        }
    ],
    "53617eeb7d100faa0900000a_2": [
        {
            "start_logit": 11.4765625,
            "end_logit": 12.9140625,
            "text": "anorexia athletica",
            "probability": 1.0
        },
        {
            "start_logit": -3.9453125,
            "end_logit": 12.9140625,
            "text": "a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.46875,
            "end_logit": 12.9140625,
            "text": "athletica",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -5.1484375,
            "text": "anorexia",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -6.79296875,
            "text": "anorexia athletica (AA",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.9140625,
            "text": "with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.0078125,
            "text": "anorexia athletica (",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.9140625,
            "text": "gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 12.9140625,
            "text": "female juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 12.9140625,
            "text": "We studied 13 female juvenile elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 12.9140625,
            "text": "nasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.578125,
            "text": "anorexia athletic",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.9140625,
            "text": "ts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 12.9140625,
            "text": "elite gymnasts with anorexia athletica",
            "probability": 0.0
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -6.79296875,
            "text": "a (AA",
            "probability": 0.0
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -9.0078125,
            "text": "a (",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -6.79296875,
            "text": "athletica (AA",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -5.1484375,
            "text": "with anorexia",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": -9.0078125,
            "text": "athletica (",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -5.1484375,
            "text": "gymnasts with anorexia",
            "probability": 0.0
        }
    ],
    "5c900b9eecadf2e73f000004_1": [
        {
            "start_logit": 12.8828125,
            "end_logit": 15.1328125,
            "text": "Alnylam Pharmaceuticals",
            "probability": 1.0
        },
        {
            "start_logit": -2.125,
            "end_logit": 15.1328125,
            "text": "Pharmaceuticals",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.9375,
            "end_logit": 15.1328125,
            "text": "ylam Pharmaceuticals",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -3.9765625,
            "text": "Alnylam",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 15.1328125,
            "text": "nylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 15.1328125,
            "text": "am Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -4.41015625,
            "text": "Al",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 15.1328125,
            "text": "by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 15.1328125,
            "text": "Patisiran has been developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -7.29296875,
            "text": "Aln",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.1328125,
            "text": "developed by Alnylam Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -9.8828125,
            "text": "Alnylam Pharmaceuticals;",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.046875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.296875,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR)",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.3828125,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA",
            "probability": 0.0
        },
        {
            "start_logit": 12.8828125,
            "end_logit": -10.3984375,
            "text": "Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (",
            "probability": 0.0
        },
        {
            "start_logit": -2.9375,
            "end_logit": -3.9765625,
            "text": "ylam",
            "probability": 0.0
        },
        {
            "start_logit": -6.29296875,
            "end_logit": -3.9765625,
            "text": "nylam",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -3.9765625,
            "text": "am",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -3.9765625,
            "text": "by Alnylam",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_1": [
        {
            "start_logit": 12.9375,
            "end_logit": 14.625,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": 14.625,
            "text": "Sharing",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.9375,
            "end_logit": -3.990234375,
            "text": "Enhancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -7.35546875,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -8.6015625,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.2734375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.4921875,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.53125,
            "text": "Enhancer Sharing Promotes Neighborhoods",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -7.35546875,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -8.6015625,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -10.125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -10.2734375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -10.4921875,
            "text": "Sharing Promotes Neighborhoods of Transcriptional",
            "probability": 0.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": -10.53125,
            "text": "Sharing Promotes Neighborhoods",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -7.35546875,
            "text": "Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -8.6015625,
            "text": "Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -8.6015625,
            "text": "Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -8.6015625,
            "text": "Neighborhoods of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -8.6015625,
            "text": "of Transcriptional Regulation Across Eukaryotes",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_2": [
        {
            "start_logit": 9.625,
            "end_logit": 8.1328125,
            "text": "enhancer sharing",
            "probability": 1.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -5.20703125,
            "text": "enhancer",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 9.625,
            "end_logit": -7.125,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.1328125,
            "text": "sharing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.625,
            "end_logit": -9.2265625,
            "text": "enhancer sharing is commonplace among eukaryotes,",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -9.8046875,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.1171875,
            "text": "enhancer sharing is",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.2734375,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.3203125,
            "text": "enhancer sharing is commonplace among eukaryotes, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.359375,
            "text": "enhancer sharing is commonplace",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.3984375,
            "text": "enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information",
            "probability": 0.0
        },
        {
            "start_logit": 9.625,
            "end_logit": -10.46875,
            "text": "enhancer sharing is commonplace among",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 8.1328125,
            "text": "that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.1328125,
            "text": "We propose that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 8.1328125,
            "text": "propose that enhancer sharing",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -7.125,
            "text": "EP distance is an important layer of information in gene regulation.",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -7.125,
            "text": "sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -5.20703125,
            "text": "that enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -5.20703125,
            "text": "We propose that enhancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -5.20703125,
            "text": "propose that enhancer",
            "probability": 0.0
        }
    ],
    "58c27b7102b8c60953000021_3": [
        {
            "start_logit": 13.5078125,
            "end_logit": 14.7734375,
            "text": "Enhancer Sharing",
            "probability": 1.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": 14.7734375,
            "text": "Sharing",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -3.35546875,
            "text": "Enhancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -6.5859375,
            "text": "Enhancer Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -8.828125,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.6015625,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -10.1484375,
            "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -6.5859375,
            "text": "Sharing Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -8.828125,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -9.6015625,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -10.1484375,
            "text": "Sharing Promotes Neighborhoods of Transcriptional Regulation",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -6.5859375,
            "text": "Promotes",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -8.828125,
            "text": "Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -8.828125,
            "text": "Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -8.828125,
            "text": "Neighborhoods of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -8.828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -9.6015625,
            "text": "Promotes Neighborhoods of Transcriptional Regulation Across",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -8.828125,
            "text": "Eukaryotes.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -9.6015625,
            "text": "Across",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -8.828125,
            "text": "of Transcriptional Regulation Across Eukaryotes.",
            "probability": 0.0
        }
    ],
    "5c8973f3d558e5f232000007_1": [
        {
            "start_logit": 12.453125,
            "end_logit": 14.3671875,
            "text": "Alipogene tiparvovec",
            "probability": 1.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": 1.623046875,
            "text": "Alipogene tiparvovec (Glybera\u00ae)",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -3.001953125,
            "end_logit": 14.3671875,
            "text": "c",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 14.3671875,
            "text": "tiparvovec",
            "probability": 0.0
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 14.3671875,
            "text": "gene tiparvovec",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 14.3671875,
            "text": "pogene tiparvovec",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -5.42578125,
            "text": "Ali",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -5.92578125,
            "text": "Alipo",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 14.3671875,
            "text": "vec",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -7.84765625,
            "text": "Alipogene tiparvovec (Glybera\u00ae) is",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -8.0390625,
            "text": "Alipogene tip",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.3671875,
            "text": "vovec",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -8.7734375,
            "text": "Alipogene",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -9.7421875,
            "text": "Alipogene tiparvove",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -10.0390625,
            "text": "Alipogene tiparvovec (Glybera",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -10.1015625,
            "text": "Alipogene tiparvo",
            "probability": 0.0
        },
        {
            "start_logit": 12.453125,
            "end_logit": -10.125,
            "text": "Alipogene tipar",
            "probability": 0.0
        },
        {
            "start_logit": -3.001953125,
            "end_logit": 1.623046875,
            "text": "c (Glybera\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 1.623046875,
            "text": "tiparvovec (Glybera\u00ae)",
            "probability": 0.0
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 1.623046875,
            "text": "gene tiparvovec (Glybera\u00ae)",
            "probability": 0.0
        }
    ],
    "5c929094ecadf2e73f000019_1": [
        {
            "start_logit": -1.6015625,
            "end_logit": -1.1318359375,
            "text": "activation of retrotransposons.",
            "probability": 0.64697265625
        },
        {
            "start_logit": -1.6015625,
            "end_logit": -1.7626953125,
            "text": "activation",
            "probability": 0.344970703125
        },
        {
            "start_logit": -3.466796875,
            "end_logit": -4.47265625,
            "text": "Senescent cells undergo dramatic alterations to their chromatin landscape that affect genome accessibility and their transcriptional program.",
            "probability": 0.003559112548828125
        },
        {
            "start_logit": -8.140625,
            "end_logit": -1.1318359375,
            "text": "retrotransposons.",
            "probability": 0.0009350776672363281
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.1318359375,
            "text": "the activation of retrotransposons.",
            "probability": 0.000858306884765625
        },
        {
            "start_logit": -1.6015625,
            "end_logit": -7.83203125,
            "text": "activation of retrotransposons",
            "probability": 0.0007939338684082031
        },
        {
            "start_logit": -8.4296875,
            "end_logit": -1.1318359375,
            "text": ".",
            "probability": 0.0006999969482421875
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.7626953125,
            "text": "the activation",
            "probability": 0.0004558563232421875
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -1.1318359375,
            "text": "of centromeres, and changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 0.00016641616821289062
        },
        {
            "start_logit": -1.6015625,
            "end_logit": -9.5859375,
            "text": "activation of retrotranspos",
            "probability": 0.0001379251480102539
        },
        {
            "start_logit": -10.15625,
            "end_logit": -1.1318359375,
            "text": "centromeres, and changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 0.0001245737075805664
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -1.1318359375,
            "text": "in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 0.00010573863983154297
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -1.1318359375,
            "text": "of retrotransposons.",
            "probability": 0.00010246038436889648
        },
        {
            "start_logit": -10.453125,
            "end_logit": -1.1318359375,
            "text": "nuclear lamina interactions, the distension of centromeres, and changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 9.262561798095703e-05
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -1.7626953125,
            "text": "of centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 8.83936882019043e-05
        },
        {
            "start_logit": -10.5,
            "end_logit": -1.1318359375,
            "text": "to the activation of retrotransposons.",
            "probability": 8.83936882019043e-05
        },
        {
            "start_logit": -1.6015625,
            "end_logit": -10.0625,
            "text": "activation of",
            "probability": 8.565187454223633e-05
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -1.1318359375,
            "text": "the distension of centromeres, and changes in chromatin composition that can lead to the activation of retrotransposons.",
            "probability": 8.368492126464844e-05
        },
        {
            "start_logit": -10.15625,
            "end_logit": -1.7626953125,
            "text": "centromeres, and changes in chromatin composition that can lead to the activation",
            "probability": 6.61611557006836e-05
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -1.7626953125,
            "text": "in chromatin composition that can lead to the activation",
            "probability": 5.614757537841797e-05
        }
    ],
    "5fe3130da43ad3127800003f_1": [
        {
            "start_logit": -3.404296875,
            "end_logit": 10.234375,
            "text": "joints",
            "probability": 0.85888671875
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 10.234375,
            "text": "28 joints",
            "probability": 0.114013671875
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 10.234375,
            "text": "in 28 joints",
            "probability": 0.014892578125
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 10.234375,
            "text": "Disease activity score in 28 joints",
            "probability": 0.01111602783203125
        },
        {
            "start_logit": -10.78125,
            "end_logit": 10.234375,
            "text": "activity score in 28 joints",
            "probability": 0.0005383491516113281
        },
        {
            "start_logit": -10.84375,
            "end_logit": 10.234375,
            "text": "score in 28 joints",
            "probability": 0.0005059242248535156
        },
        {
            "start_logit": -3.404296875,
            "end_logit": -9.4140625,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -3.404296875,
            "end_logit": -10.1640625,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -3.404296875,
            "end_logit": -10.21875,
            "text": "joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -3.404296875,
            "end_logit": -10.6328125,
            "text": "joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -9.4140625,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -10.1640625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -10.21875,
            "text": "28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -10.2421875,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -10.6328125,
            "text": "28 joints (DAS",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -9.4140625,
            "text": "in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -9.4140625,
            "text": "Disease activity score in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -10.1640625,
            "text": "in 28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -10.21875,
            "text": "in 28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -10.2421875,
            "text": "in 28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_2": [
        {
            "start_logit": -3.931640625,
            "end_logit": 8.9609375,
            "text": "in 28 joints",
            "probability": 0.6884765625
        },
        {
            "start_logit": -4.85546875,
            "end_logit": 8.9609375,
            "text": "joints",
            "probability": 0.27294921875
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 8.9609375,
            "text": "28 joints",
            "probability": 0.031097412109375
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 8.9609375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.004863739013671875
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 8.9609375,
            "text": "Score in 28 joints",
            "probability": 0.001308441162109375
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 8.9609375,
            "text": "Activity Score in 28 joints",
            "probability": 0.0008997917175292969
        },
        {
            "start_logit": -3.931640625,
            "end_logit": -9.78125,
            "text": "in 28 joints [DAS28]) and the reasons for infliximab discontinuation",
            "probability": 0.0
        },
        {
            "start_logit": -3.931640625,
            "end_logit": -9.84375,
            "text": "in 28 joints [DAS28]) and the reasons for infliximab discontinuation.",
            "probability": 0.0
        },
        {
            "start_logit": -3.931640625,
            "end_logit": -10.15625,
            "text": "in 28 joints [DAS28]) and the reasons",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -7.98828125,
            "text": "ter 7 years",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -9.78125,
            "text": "joints [DAS28]) and the reasons for infliximab discontinuation",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -9.84375,
            "text": "joints [DAS28]) and the reasons for infliximab discontinuation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -8.65625,
            "text": "ter",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -8.671875,
            "text": "ter 7",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -10.15625,
            "text": "joints [DAS28]) and the reasons",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -9.640625,
            "text": "ter 7 years, apart from routine clinical follow-up, treating rheumatologists",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -9.8046875,
            "text": "ter 7 years, apart from routine clinical follow-up, treating rheumatologists were asked to complete a",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -9.828125,
            "text": "ter 7 years, apart from routine clinical follow-up,",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -9.8515625,
            "text": "ter 7 years, apart from routine clinical follow-up",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": -9.875,
            "text": "ter 7 years, apart from routine clinical follow-up, treating rheumatologists were asked to complete a questionnaire",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_3": [
        {
            "start_logit": 2.228515625,
            "end_logit": 12.46875,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.9970703125
        },
        {
            "start_logit": -3.7890625,
            "end_logit": 12.46875,
            "text": "Joints",
            "probability": 0.0024318695068359375
        },
        {
            "start_logit": -7.0625,
            "end_logit": 12.46875,
            "text": "in 28 Joints",
            "probability": 9.21487808227539e-05
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 12.46875,
            "text": "28 Joints",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 12.46875,
            "text": "Score in 28 Joints",
            "probability": 1.800060272216797e-05
        },
        {
            "start_logit": -9.015625,
            "end_logit": 12.46875,
            "text": "Activity Score in 28 Joints",
            "probability": 1.3053417205810547e-05
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 12.46875,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -3.54296875,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -6.5,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA).",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -8.8359375,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -9.125,
            "text": "Disease Activity Score in 28 Joints (",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -9.484375,
            "text": "Disease Activity Score in",
            "probability": 0.0
        },
        {
            "start_logit": -3.7890625,
            "end_logit": -3.54296875,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -9.6953125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -9.78125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -10.03125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -10.0546875,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -10.078125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA)",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -10.1484375,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a",
            "probability": 0.0
        },
        {
            "start_logit": 2.228515625,
            "end_logit": -10.15625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_4": [
        {
            "start_logit": -2.54296875,
            "end_logit": 11.2890625,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.875
        },
        {
            "start_logit": -4.90234375,
            "end_logit": 11.2890625,
            "text": "joints",
            "probability": 0.0823974609375
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 11.2890625,
            "text": "in 28 joints",
            "probability": 0.03277587890625
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.2890625,
            "text": "28 joints",
            "probability": 0.003688812255859375
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 11.2890625,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.00261688232421875
        },
        {
            "start_logit": -8.578125,
            "end_logit": 11.2890625,
            "text": "arthritis (RA) as defined by a Disease Activity Score in 28 joints",
            "probability": 0.002086639404296875
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 11.2890625,
            "text": "Score in 28 joints",
            "probability": 0.0005931854248046875
        },
        {
            "start_logit": -9.9375,
            "end_logit": 11.2890625,
            "text": "a Disease Activity Score in 28 joints",
            "probability": 0.0005359649658203125
        },
        {
            "start_logit": -10.265625,
            "end_logit": 11.2890625,
            "text": "Activity Score in 28 joints",
            "probability": 0.0003859996795654297
        },
        {
            "start_logit": -2.54296875,
            "end_logit": 1.9970703125,
            "text": "rheumatoid arthritis",
            "probability": 8.028745651245117e-05
        },
        {
            "start_logit": -8.578125,
            "end_logit": 1.9970703125,
            "text": "arthritis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -9.515625,
            "text": "rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -9.890625,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints (DAS28) score greater",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.015625,
            "text": "rheumatoid arthritis (RA",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.03125,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.078125,
            "text": "rheumatoid arthritis (RA)",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.0859375,
            "text": "rheumatoid arthritis (RA) as defined",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.0859375,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.21875,
            "text": "rheumatoid arthritis (",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -10.234375,
            "text": "rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints (DAS28) score",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_5": [
        {
            "start_logit": 1.2646484375,
            "end_logit": 13.3828125,
            "text": "28 joints",
            "probability": 0.97802734375
        },
        {
            "start_logit": -2.962890625,
            "end_logit": 13.3828125,
            "text": "joints",
            "probability": 0.0142822265625
        },
        {
            "start_logit": -3.580078125,
            "end_logit": 13.3828125,
            "text": "on 28 joints",
            "probability": 0.007709503173828125
        },
        {
            "start_logit": -9.484375,
            "end_logit": 13.3828125,
            "text": "based on 28 joints",
            "probability": 2.09808349609375e-05
        },
        {
            "start_logit": -10.265625,
            "end_logit": 13.3828125,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.3828125,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.3828125,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -3.59375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -7.37890625,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -3.59375,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arthr",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -8.2265625,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": -3.580078125,
            "end_logit": -3.59375,
            "text": "on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arthr",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -9.5546875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -9.75,
            "text": "28 joints (DAS28) has",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -9.953125,
            "text": "28 joints (DAS28) has been increasingly",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -10.0,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -10.34375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -10.34375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -10.3828125,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of",
            "probability": 0.0
        },
        {
            "start_logit": 1.2646484375,
            "end_logit": -10.390625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_6": [
        {
            "start_logit": -0.10064697265625,
            "end_logit": 13.140625,
            "text": "28 joints",
            "probability": 0.9404296875
        },
        {
            "start_logit": -3.30078125,
            "end_logit": 13.140625,
            "text": "joints",
            "probability": 0.03851318359375
        },
        {
            "start_logit": -3.8984375,
            "end_logit": 13.140625,
            "text": "on 28 joints",
            "probability": 0.0211029052734375
        },
        {
            "start_logit": -9.515625,
            "end_logit": 13.140625,
            "text": "based on 28 joints",
            "probability": 7.665157318115234e-05
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.140625,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 3.8564205169677734e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 13.140625,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 3.6835670471191406e-05
        },
        {
            "start_logit": -10.265625,
            "end_logit": 13.140625,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 3.618001937866211e-05
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -3.189453125,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arthr",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.30078125,
            "end_logit": -3.189453125,
            "text": "joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arthr",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -6.39453125,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -3.8984375,
            "end_logit": -3.189453125,
            "text": "on 28 joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arthr",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -8.296875,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -9.40625,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -3.30078125,
            "end_logit": -6.39453125,
            "text": "joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -9.75,
            "text": "28 joints (DAS28) has been widely",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -9.84375,
            "text": "28 joints (DAS28) has",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -10.1796875,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -3.8984375,
            "end_logit": -6.39453125,
            "text": "on 28 joints (DAS28) has been widely used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -10.2890625,
            "text": "28 joints (DAS28) has been widely used in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -0.10064697265625,
            "end_logit": -10.296875,
            "text": "28 joints (DAS28) has been widely used in clinical practice and research",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_7": [
        {
            "start_logit": -5.42578125,
            "end_logit": 9.4375,
            "text": "joints",
            "probability": 0.60009765625
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.4375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.1622314453125
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.4375,
            "text": "28 joints",
            "probability": 0.1026611328125
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.4375,
            "text": "in 28 joints",
            "probability": 0.07568359375
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 9.4375,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.038818359375
        },
        {
            "start_logit": -9.734375,
            "end_logit": 9.4375,
            "text": "Score in 28 joints",
            "probability": 0.0080718994140625
        },
        {
            "start_logit": -9.875,
            "end_logit": 9.4375,
            "text": "Activity Score in 28 joints",
            "probability": 0.007015228271484375
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 9.4375,
            "text": ": The Disease Activity Score in 28 joints",
            "probability": 0.005092620849609375
        },
        {
            "start_logit": -5.42578125,
            "end_logit": -3.220703125,
            "text": "joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.734375,
            "end_logit": -3.220703125,
            "text": "Disease Activity Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -3.220703125,
            "text": "28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -3.220703125,
            "text": "in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -3.220703125,
            "text": "rheumatoid arthritis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -3.220703125,
            "text": "The Disease Activity Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -3.220703125,
            "text": "in rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.734375,
            "end_logit": -3.220703125,
            "text": "Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.875,
            "end_logit": -3.220703125,
            "text": "Activity Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -3.220703125,
            "text": "used to assess disease activity in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -3.220703125,
            "text": "disease activity in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -3.220703125,
            "text": ": The Disease Activity Score in 28 joints (DAS28), used to assess disease activity in rheumatoid arthritis",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_8": [
        {
            "start_logit": -2.22265625,
            "end_logit": 2.28515625,
            "text": "2-component",
            "probability": 0.4970703125
        },
        {
            "start_logit": -2.2734375,
            "end_logit": 2.28515625,
            "text": "component",
            "probability": 0.47265625
        },
        {
            "start_logit": -5.27734375,
            "end_logit": 2.28515625,
            "text": "the 2-component",
            "probability": 0.0234375
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -3.03515625,
            "text": "2-component Disease Activity Score in 28 joints",
            "probability": 0.0024318695068359375
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -3.03515625,
            "text": "component Disease Activity Score in 28 joints",
            "probability": 0.00231170654296875
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -4.9921875,
            "text": "2",
            "probability": 0.00034356117248535156
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 2.28515625,
            "text": ", the 2-component",
            "probability": 0.00032019615173339844
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 2.28515625,
            "text": ".e., the 2-component",
            "probability": 0.00021004676818847656
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -5.4921875,
            "text": "2-component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein level",
            "probability": 0.00020837783813476562
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -5.4921875,
            "text": "component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein level",
            "probability": 0.00019800662994384766
        },
        {
            "start_logit": -10.09375,
            "end_logit": 2.28515625,
            "text": "joint synovitis, i.e., the 2-component",
            "probability": 0.00018978118896484375
        },
        {
            "start_logit": -5.27734375,
            "end_logit": -3.03515625,
            "text": "the 2-component Disease Activity Score in 28 joints",
            "probability": 0.00011461973190307617
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -6.22265625,
            "text": "2-component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein",
            "probability": 0.00010037422180175781
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -6.22265625,
            "text": "component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein",
            "probability": 9.500980377197266e-05
        },
        {
            "start_logit": -5.27734375,
            "end_logit": -4.9921875,
            "text": "the 2",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -3.03515625,
            "text": "in 28 joints",
            "probability": 1.5974044799804688e-05
        },
        {
            "start_logit": -5.27734375,
            "end_logit": -5.4921875,
            "text": "the 2-component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein level",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -5.27734375,
            "end_logit": -6.22265625,
            "text": "the 2-component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -8.5625,
            "end_logit": -3.03515625,
            "text": "Disease Activity Score in 28 joints",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -9.4140625,
            "text": "2-component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C-reactive protein level)",
            "probability": 4.112720489501953e-06
        }
    ],
    "5fe3130da43ad3127800003f_9": [
        {
            "start_logit": -4.68359375,
            "end_logit": 8.2421875,
            "text": "joints",
            "probability": 0.79931640625
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 8.2421875,
            "text": "in 28 joints",
            "probability": 0.09039306640625
        },
        {
            "start_logit": -6.921875,
            "end_logit": 8.2421875,
            "text": "28 joints",
            "probability": 0.08526611328125
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 8.2421875,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.011810302734375
        },
        {
            "start_logit": -9.796875,
            "end_logit": 8.2421875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.004810333251953125
        },
        {
            "start_logit": -10.109375,
            "end_logit": 8.2421875,
            "text": ": The Disease Activity Score in 28 joints",
            "probability": 0.0035190582275390625
        },
        {
            "start_logit": -10.4375,
            "end_logit": 8.2421875,
            "text": "OBJECTIVE: The Disease Activity Score in 28 joints",
            "probability": 0.0025348663330078125
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 8.2421875,
            "text": "Score in 28 joints",
            "probability": 0.0020198822021484375
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -7.90234375,
            "text": "joints (DAS28) is a key measure in clinical practice and clinic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.0234375,
            "text": "joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.0703125,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -6.86328125,
            "end_logit": -7.90234375,
            "text": "in 28 joints (DAS28) is a key measure in clinical practice and clinic",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -7.90234375,
            "text": "28 joints (DAS28) is a key measure in clinical practice and clinic",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.3046875,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.3671875,
            "text": "joints (DAS28) is a key",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.5234375,
            "text": "joints (DAS28) is a key measure in clinical practice and",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.5390625,
            "text": "joints (DAS28) is a key measure in",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.578125,
            "text": "joints (DAS28) is a key measure",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.6875,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -4.68359375,
            "end_logit": -10.8671875,
            "text": "joints (DAS28)",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_10": [
        {
            "start_logit": -3.361328125,
            "end_logit": 12.09375,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.60009765625
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 12.09375,
            "text": "Joints",
            "probability": 0.342041015625
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 12.09375,
            "text": "28 Joints",
            "probability": 0.0266876220703125
        },
        {
            "start_logit": -7.25,
            "end_logit": 12.09375,
            "text": "in 28 Joints",
            "probability": 0.01226043701171875
        },
        {
            "start_logit": -3.361328125,
            "end_logit": 7.99609375,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.00992584228515625
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 7.99609375,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.0056610107421875
        },
        {
            "start_logit": -9.890625,
            "end_logit": 12.09375,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.0008745193481445312
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 12.09375,
            "text": "Score in 28 Joints",
            "probability": 0.0007777214050292969
        },
        {
            "start_logit": -10.25,
            "end_logit": 12.09375,
            "text": "Activity Score in 28 Joints",
            "probability": 0.0006108283996582031
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 7.99609375,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.00044345855712890625
        },
        {
            "start_logit": -7.25,
            "end_logit": 7.99609375,
            "text": "in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 0.00020372867584228516
        },
        {
            "start_logit": -8.359375,
            "end_logit": 7.99609375,
            "text": "arth",
            "probability": 6.74128532409668e-05
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 7.99609375,
            "text": "in rheumatoid arth",
            "probability": 2.0265579223632812e-05
        },
        {
            "start_logit": -9.890625,
            "end_logit": 7.99609375,
            "text": ": Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 7.99609375,
            "text": "Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 1.2874603271484375e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 7.99609375,
            "text": "Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arth",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -3.361328125,
            "end_logit": -9.1328125,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -3.361328125,
            "end_logit": -9.5,
            "text": "Disease Activity Score in 28 Joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -3.361328125,
            "end_logit": -9.53125,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -9.1328125,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_11": [
        {
            "start_logit": -6.5,
            "end_logit": -0.5830078125,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.44482421875
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -0.5830078125,
            "text": "joints",
            "probability": 0.239990234375
        },
        {
            "start_logit": -6.5,
            "end_logit": -1.9150390625,
            "text": "Disease Activity Score in 28 joints with ESR",
            "probability": 0.11737060546875
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -1.9150390625,
            "text": "joints with ESR",
            "probability": 0.06329345703125
        },
        {
            "start_logit": -8.671875,
            "end_logit": -0.5830078125,
            "text": "in 28 joints",
            "probability": 0.050506591796875
        },
        {
            "start_logit": -8.1015625,
            "end_logit": -1.9150390625,
            "text": "ESR",
            "probability": 0.0236663818359375
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -0.5830078125,
            "text": "28 joints",
            "probability": 0.0208892822265625
        },
        {
            "start_logit": -8.671875,
            "end_logit": -1.9150390625,
            "text": "in 28 joints with ESR",
            "probability": 0.0133819580078125
        },
        {
            "start_logit": -8.96875,
            "end_logit": -1.9150390625,
            "text": "with ESR",
            "probability": 0.00994110107421875
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -0.5830078125,
            "text": "Score in 28 joints",
            "probability": 0.00780487060546875
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -1.9150390625,
            "text": "28 joints with ESR",
            "probability": 0.005535125732421875
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -1.9150390625,
            "text": "Score in 28 joints with ESR",
            "probability": 0.00206756591796875
        },
        {
            "start_logit": -6.5,
            "end_logit": -9.4453125,
            "text": "Disease Activity Score in 28 joints with",
            "probability": 6.318092346191406e-05
        },
        {
            "start_logit": -6.5,
            "end_logit": -9.7109375,
            "text": "Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI",
            "probability": 4.76837158203125e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -9.4453125,
            "text": "joints with",
            "probability": 3.3855438232421875e-05
        },
        {
            "start_logit": -6.5,
            "end_logit": -10.25,
            "text": "Disease Activity Score in 28 joints with ESR (DAS28",
            "probability": 2.8014183044433594e-05
        },
        {
            "start_logit": -6.5,
            "end_logit": -10.2734375,
            "text": "Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CD",
            "probability": 2.7179718017578125e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -9.7109375,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI",
            "probability": 2.5928020477294922e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -10.171875,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -10.1953125,
            "text": "joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine",
            "probability": 1.5974044799804688e-05
        }
    ],
    "5fe3130da43ad3127800003f_12": [
        {
            "start_logit": -3.666015625,
            "end_logit": 13.5546875,
            "text": "joints",
            "probability": 0.7626953125
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 13.5546875,
            "text": "in 28 joints",
            "probability": 0.1431884765625
        },
        {
            "start_logit": -6.125,
            "end_logit": 13.5546875,
            "text": "28 joints",
            "probability": 0.0650634765625
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 13.5546875,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.01509857177734375
        },
        {
            "start_logit": -8.078125,
            "end_logit": 13.5546875,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.0092315673828125
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 13.5546875,
            "text": "Score in 28 joints",
            "probability": 0.0018320083618164062
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 13.5546875,
            "text": ": Simplified Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0010271072387695312
        },
        {
            "start_logit": -10.359375,
            "end_logit": 13.5546875,
            "text": "METHODS: Simplified Disease Activity Index (SDAI) scores, Clinical Disease Activity Index (CDAI) scores, and the Disease Activity Score in 28 joints",
            "probability": 0.0009431838989257812
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.5546875,
            "text": "Activity Score in 28 joints",
            "probability": 0.0008382797241210938
        },
        {
            "start_logit": -3.666015625,
            "end_logit": -9.5703125,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -3.666015625,
            "end_logit": -9.6484375,
            "text": "joints (DAS28) were calculated using data from tocilizumab trials in patients with RA",
            "probability": 0.0
        },
        {
            "start_logit": -3.666015625,
            "end_logit": -9.75,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -3.666015625,
            "end_logit": -9.7890625,
            "text": "joints (DAS28) were",
            "probability": 0.0
        },
        {
            "start_logit": -3.666015625,
            "end_logit": -10.140625,
            "text": "joints (DAS28) were calculated",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -9.328125,
            "text": "in 28",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -9.5703125,
            "text": "in 28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -9.6484375,
            "text": "in 28 joints (DAS28) were calculated using data from tocilizumab trials in patients with RA",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -9.75,
            "text": "in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": -5.33203125,
            "end_logit": -9.7890625,
            "text": "in 28 joints (DAS28) were",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -9.328125,
            "text": "28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_13": [
        {
            "start_logit": 2.666015625,
            "end_logit": 9.984375,
            "text": "Disease activity score in 28 joints",
            "probability": 0.9990234375
        },
        {
            "start_logit": -4.46484375,
            "end_logit": 9.984375,
            "text": "joints",
            "probability": 0.0008006095886230469
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.984375,
            "text": "in 28 joints",
            "probability": 5.602836608886719e-05
        },
        {
            "start_logit": -7.984375,
            "end_logit": 9.984375,
            "text": "28 joints",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -9.609375,
            "end_logit": 9.984375,
            "text": "score in 28 joints",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 9.984375,
            "text": "activity score in 28 joints",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -9.4921875,
            "text": "Disease activity score in 28 joints (DAS28)-remission",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -9.765625,
            "text": "Disease activity score in 28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -9.8203125,
            "text": "Disease activity score in 28",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -9.9140625,
            "text": "Disease activity score in 28 joints (DAS28)",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -9.9921875,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions,",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -10.015625,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -10.0234375,
            "text": "Disease activity score in",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -10.171875,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -10.28125,
            "text": "Disease activity score in 28 joints (DAS28)-remission has not been included among American College of Rheumatology/European League Against Rheumatism definitions",
            "probability": 0.0
        },
        {
            "start_logit": 2.666015625,
            "end_logit": -10.3828125,
            "text": "Disease activity score in 28 joints (DAS28)-remission has",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -3.75390625,
            "text": "high weighting of acute-phase reactants (APR).",
            "probability": 0.0
        },
        {
            "start_logit": -4.46484375,
            "end_logit": -9.4921875,
            "text": "joints (DAS28)-remission",
            "probability": 0.0
        },
        {
            "start_logit": -4.46484375,
            "end_logit": -9.765625,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -3.75390625,
            "text": "Against Rheumatism definitions, because of its association with significant residual disease activity, partly due to high weighting of acute-phase reactants (APR).",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_14": [
        {
            "start_logit": 0.435791015625,
            "end_logit": 12.03125,
            "text": "C-reactive protein",
            "probability": 0.966796875
        },
        {
            "start_logit": -3.263671875,
            "end_logit": 12.03125,
            "text": "with C-reactive protein",
            "probability": 0.023834228515625
        },
        {
            "start_logit": -4.58203125,
            "end_logit": 12.03125,
            "text": "protein",
            "probability": 0.006389617919921875
        },
        {
            "start_logit": -5.6796875,
            "end_logit": 12.03125,
            "text": "joints with C-reactive protein",
            "probability": 0.002132415771484375
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 12.03125,
            "text": "reactive protein",
            "probability": 0.0002161264419555664
        },
        {
            "start_logit": -8.375,
            "end_logit": 12.03125,
            "text": "28 joints with C-reactive protein",
            "probability": 0.00014400482177734375
        },
        {
            "start_logit": -9.171875,
            "end_logit": 12.03125,
            "text": "of 28 joints with C-reactive protein",
            "probability": 6.490945816040039e-05
        },
        {
            "start_logit": -9.359375,
            "end_logit": 12.03125,
            "text": "-reactive protein",
            "probability": 5.3763389587402344e-05
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -0.41162109375,
            "text": "C-reactive protein (DAS)28-CRP",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -3.263671875,
            "end_logit": -0.41162109375,
            "text": "with C-reactive protein (DAS)28-CRP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.58203125,
            "end_logit": -0.41162109375,
            "text": "protein (DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -0.41162109375,
            "text": "joints with C-reactive protein (DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -0.41162109375,
            "text": "(DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -8.453125,
            "text": "C-reactive protein (",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": -0.41162109375,
            "text": "reactive protein (DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -8.8984375,
            "text": "C-reactive protein (DAS)28-CRP)",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -0.41162109375,
            "text": "28 joints with C-reactive protein (DAS)28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -9.2734375,
            "text": "C-reactive protein (DAS",
            "probability": 0.0
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -9.4140625,
            "text": "C",
            "probability": 0.0
        },
        {
            "start_logit": 0.435791015625,
            "end_logit": -9.421875,
            "text": "C-reactive protein (DAS)28-CRP).",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_15": [
        {
            "start_logit": -2.1796875,
            "end_logit": 12.4140625,
            "text": "Disease Activity Score in 28 Joints",
            "probability": 0.80126953125
        },
        {
            "start_logit": -3.751953125,
            "end_logit": 12.4140625,
            "text": "Joints",
            "probability": 0.1666259765625
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 8.15625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.0113372802734375
        },
        {
            "start_logit": -6.4375,
            "end_logit": 12.4140625,
            "text": "28 Joints",
            "probability": 0.0113372802734375
        },
        {
            "start_logit": -7.140625,
            "end_logit": 12.4140625,
            "text": "in 28 Joints",
            "probability": 0.005615234375
        },
        {
            "start_logit": -3.751953125,
            "end_logit": 8.15625,
            "text": "Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.00235748291015625
        },
        {
            "start_logit": -9.875,
            "end_logit": 12.4140625,
            "text": ": Disease Activity Score in 28 Joints",
            "probability": 0.00036454200744628906
        },
        {
            "start_logit": -9.90625,
            "end_logit": 12.4140625,
            "text": "Score in 28 Joints",
            "probability": 0.0003533363342285156
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.4140625,
            "text": "Activity Score in 28 Joints",
            "probability": 0.0002646446228027344
        },
        {
            "start_logit": -6.4375,
            "end_logit": 8.15625,
            "text": "28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 0.00016045570373535156
        },
        {
            "start_logit": -7.140625,
            "end_logit": 8.15625,
            "text": "in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 7.94529914855957e-05
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.15625,
            "text": "art",
            "probability": 5.8591365814208984e-05
        },
        {
            "start_logit": -9.875,
            "end_logit": 8.15625,
            "text": ": Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -9.90625,
            "end_logit": 8.15625,
            "text": "Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -9.921875,
            "end_logit": 8.15625,
            "text": "in rheumatoid art",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 8.15625,
            "text": "Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid art",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -8.6640625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -9.3671875,
            "text": "Disease Activity Score in 28",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -9.4765625,
            "text": "Disease Activity Score in 28 Joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": -9.6328125,
            "text": "Disease Activity Score in 28 Joints (",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_16": [
        {
            "start_logit": -4.328125,
            "end_logit": 10.28125,
            "text": "joints",
            "probability": 0.77392578125
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 10.28125,
            "text": "28 joints",
            "probability": 0.14208984375
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 10.28125,
            "text": "in 28 joints",
            "probability": 0.0673828125
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 10.28125,
            "text": "The Disease Activity Score in 28 joints",
            "probability": 0.005863189697265625
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 10.28125,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.00390625
        },
        {
            "start_logit": -10.25,
            "end_logit": 10.28125,
            "text": ": The Disease Activity Score in 28 joints",
            "probability": 0.0020732879638671875
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 10.28125,
            "text": "OBJECTIVE: The Disease Activity Score in 28 joints",
            "probability": 0.0017614364624023438
        },
        {
            "start_logit": -10.546875,
            "end_logit": 10.28125,
            "text": "Score in 28 joints",
            "probability": 0.0015411376953125
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.28125,
            "text": "Activity Score in 28 joints",
            "probability": 0.0013713836669921875
        },
        {
            "start_logit": -4.328125,
            "end_logit": -9.4453125,
            "text": "joints (DAS28) is a key measure in clinical practice and clini",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.1015625,
            "text": "joints (DAS28) is",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.2421875,
            "text": "joints (DAS28) is a key measure in clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.515625,
            "text": "joints (DAS28) is a key",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.53125,
            "text": "joints (",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.5703125,
            "text": "joints (DAS28) is a key measure in clinical practice and clin",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.65625,
            "text": "joints (DAS28) is a key measure",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.7265625,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.8359375,
            "text": "joints (DAS28) is a key measure in clinical practice and",
            "probability": 0.0
        },
        {
            "start_logit": -4.328125,
            "end_logit": -10.8359375,
            "text": "joints (DAS28) is a key measure in",
            "probability": 0.0
        },
        {
            "start_logit": -6.0234375,
            "end_logit": -9.4453125,
            "text": "28 joints (DAS28) is a key measure in clinical practice and clini",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_17": [
        {
            "start_logit": 0.058349609375,
            "end_logit": 9.6484375,
            "text": "28 joints",
            "probability": 0.90771484375
        },
        {
            "start_logit": -2.8359375,
            "end_logit": 9.6484375,
            "text": "joints",
            "probability": 0.0504150390625
        },
        {
            "start_logit": -3.083984375,
            "end_logit": 9.6484375,
            "text": "including 28 joints",
            "probability": 0.03924560546875
        },
        {
            "start_logit": 0.058349609375,
            "end_logit": 3.521484375,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 0.0019855499267578125
        },
        {
            "start_logit": -2.8359375,
            "end_logit": 3.521484375,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 0.00011026859283447266
        },
        {
            "start_logit": -3.083984375,
            "end_logit": 3.521484375,
            "text": "including 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 8.589029312133789e-05
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 9.6484375,
            "text": "Disease Activity Score including 28 joints",
            "probability": 2.7060508728027344e-05
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.6484375,
            "text": ": The Disease Activity Score including 28 joints",
            "probability": 2.4378299713134766e-05
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 3.521484375,
            "text": "rheumatoid arthritis",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 3.521484375,
            "text": "arthritis",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -2.8359375,
            "end_logit": -2.103515625,
            "text": "joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis (RA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.1875,
            "end_logit": 3.521484375,
            "text": "of rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.80078125,
            "end_logit": -2.103515625,
            "text": "rheumatoid arthritis (RA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 3.521484375,
            "text": "provide a quantifiable measure of rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 3.521484375,
            "text": "quantifiable measure of rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 3.521484375,
            "text": "the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.058349609375,
            "end_logit": -8.9375,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI",
            "probability": 0.0
        },
        {
            "start_logit": 0.058349609375,
            "end_logit": -9.375,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": 0.058349609375,
            "end_logit": -9.4296875,
            "text": "28 joints (DAS28) and",
            "probability": 0.0
        },
        {
            "start_logit": 0.058349609375,
            "end_logit": -9.7578125,
            "text": "28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) were developed in order to provide a quantifiable measure of rheumatoid",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_18": [
        {
            "start_logit": 0.55859375,
            "end_logit": 13.3515625,
            "text": "28 joints",
            "probability": 0.96142578125
        },
        {
            "start_logit": -3.365234375,
            "end_logit": 13.3515625,
            "text": "on 28 joints",
            "probability": 0.01904296875
        },
        {
            "start_logit": -3.39453125,
            "end_logit": 13.3515625,
            "text": "joints",
            "probability": 0.018463134765625
        },
        {
            "start_logit": 0.55859375,
            "end_logit": 5.9609375,
            "text": "28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0005955696105957031
        },
        {
            "start_logit": -9.296875,
            "end_logit": 13.3515625,
            "text": "based on 28 joints",
            "probability": 5.066394805908203e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 13.3515625,
            "text": "The Disease Activity Score based on 28 joints",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.3515625,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 13.3515625,
            "text": ": The Disease Activity Score based on 28 joints",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.3515625,
            "text": "Disease Activity Score based on 28 joints",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -3.365234375,
            "end_logit": 5.9609375,
            "text": "on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": -3.39453125,
            "end_logit": 5.9609375,
            "text": "joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -9.21875,
            "end_logit": 5.9609375,
            "text": "arth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.296875,
            "end_logit": 5.9609375,
            "text": "based on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.59375,
            "end_logit": 5.9609375,
            "text": "of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 5.9609375,
            "text": "rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 5.9609375,
            "text": "The Disease Activity Score based on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 5.9609375,
            "text": "OBJECTIVE: The Disease Activity Score based on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 5.9609375,
            "text": ": The Disease Activity Score based on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 5.9609375,
            "text": "Disease Activity Score based on 28 joints (DAS28) has been increasingly used in clinical practice and research studies of rheumatoid arth",
            "probability": 0.0
        },
        {
            "start_logit": 0.55859375,
            "end_logit": -8.21875,
            "text": "28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_19": [
        {
            "start_logit": 3.49609375,
            "end_logit": 12.1171875,
            "text": "28 joints",
            "probability": 0.83251953125
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": 12.1171875,
            "text": "including 28 joints",
            "probability": 0.165283203125
        },
        {
            "start_logit": -2.59375,
            "end_logit": 12.1171875,
            "text": "joints",
            "probability": 0.0018939971923828125
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 12.1171875,
            "text": "rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.28125,
            "end_logit": 12.1171875,
            "text": "Disease Activity Score including 28 joints",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.1171875,
            "text": "Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -7.86328125,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -8.46875,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI).",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -8.515625,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -7.86328125,
            "text": "including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -9.5078125,
            "text": "28 joints (DAS28) compared",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -9.7578125,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index (CD",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -9.90625,
            "text": "28 joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -9.96875,
            "text": "28 joints (",
            "probability": 0.0
        },
        {
            "start_logit": 3.49609375,
            "end_logit": -10.0,
            "text": "28 joints (DAS28) compared with the Clinical Disease Activity Index",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -8.46875,
            "text": "including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI).",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -8.515625,
            "text": "including 28",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -9.5078125,
            "text": "including 28 joints (DAS28) compared",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -9.7578125,
            "text": "including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CD",
            "probability": 0.0
        },
        {
            "start_logit": 1.8779296875,
            "end_logit": -9.90625,
            "text": "including 28 joints (DAS28",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_20": [
        {
            "start_logit": 10.53125,
            "end_logit": 13.875,
            "text": "C-reactive protein",
            "probability": 1.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": 3.75,
            "text": "C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -3.16796875,
            "end_logit": 13.875,
            "text": "protein",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -3.443359375,
            "end_logit": 13.875,
            "text": "with C-reactive protein",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 3.29296875,
            "end_logit": 3.75,
            "text": "erythrocyte sedimentation rate",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 13.875,
            "text": "reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 13.875,
            "text": "Disease Activity Score in 28 joints calculated with C-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -5.7421875,
            "text": "C",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 13.875,
            "text": "joints calculated with C-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 13.875,
            "text": "-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 13.875,
            "text": "in 28 joints calculated with C-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 13.875,
            "text": ": Disease Activity Score in 28 joints calculated with C-reactive protein",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -7.78515625,
            "text": "C-reactive protein (DAS28-CRP",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -8.9375,
            "text": "C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.015625,
            "text": "C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.109375,
            "text": "C-reactive protein (DAS28-CRP) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -9.640625,
            "text": "C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation",
            "probability": 0.0
        },
        {
            "start_logit": -3.16796875,
            "end_logit": 3.75,
            "text": "protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -10.09375,
            "text": "C-reactive protein (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": 10.53125,
            "end_logit": -10.1484375,
            "text": "C-reactive",
            "probability": 0.0
        }
    ],
    "5fe3130da43ad3127800003f_21": [
        {
            "start_logit": -3.412109375,
            "end_logit": 9.7734375,
            "text": "joints",
            "probability": 0.58837890625
        },
        {
            "start_logit": -4.1015625,
            "end_logit": 9.7734375,
            "text": "28 joints",
            "probability": 0.2958984375
        },
        {
            "start_logit": -5.06640625,
            "end_logit": 9.7734375,
            "text": "in 28 joints",
            "probability": 0.11279296875
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 9.7734375,
            "text": "Disease Activity Score in 28 joints",
            "probability": 0.0020580291748046875
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 9.7734375,
            "text": "the Disease Activity Score in 28 joints",
            "probability": 0.0006575584411621094
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -4.75,
            "text": "joints (DAS28) in early rheumatoid arthritis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.1015625,
            "end_logit": -4.75,
            "text": "28 joints (DAS28) in early rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.06640625,
            "end_logit": -4.75,
            "text": "in 28 joints (DAS28) in early rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -4.75,
            "text": "rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -9.359375,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 0.0
        },
        {
            "start_logit": -4.1015625,
            "end_logit": -9.21875,
            "text": "28",
            "probability": 0.0
        },
        {
            "start_logit": -4.1015625,
            "end_logit": -9.359375,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet.",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.1640625,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.1953125,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.25,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of foref",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.296875,
            "text": "joints (DAS28) in",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.328125,
            "text": "joints (DAS28) in early rheumatoid arthritis (RA) by",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -4.75,
            "text": "Disease Activity Score in 28 joints (DAS28) in early rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -3.412109375,
            "end_logit": -10.515625,
            "text": "joints (DAS28",
            "probability": 0.0
        },
        {
            "start_logit": -4.1015625,
            "end_logit": -10.1640625,
            "text": "28 joints (DAS28) in early rheumatoid arthritis (RA) by adding the \"squeeze test\" of forefeet",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_1": [
        {
            "start_logit": -8.75,
            "end_logit": -3.1953125,
            "text": "elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.29638671875
        },
        {
            "start_logit": -5.25,
            "end_logit": -7.796875,
            "text": "Bacillus anthracis",
            "probability": 0.09844970703125
        },
        {
            "start_logit": -10.234375,
            "end_logit": -3.1953125,
            "text": "/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.067138671875
        },
        {
            "start_logit": -10.5,
            "end_logit": -3.1953125,
            "text": "increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.051513671875
        },
        {
            "start_logit": -10.53125,
            "end_logit": -3.1953125,
            "text": "bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.0499267578125
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -3.1953125,
            "text": "to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.049530029296875
        },
        {
            "start_logit": -10.5625,
            "end_logit": -3.1953125,
            "text": "anthrax toxins and extracellular capsular layer.",
            "probability": 0.048370361328125
        },
        {
            "start_logit": -5.25,
            "end_logit": -8.5859375,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C",
            "probability": 0.04473876953125
        },
        {
            "start_logit": -10.671875,
            "end_logit": -3.1953125,
            "text": "and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.043365478515625
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -3.1953125,
            "text": ".",
            "probability": 0.042999267578125
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -3.1953125,
            "text": "the anthrax toxins and extracellular capsular layer.",
            "probability": 0.041717529296875
        },
        {
            "start_logit": -10.796875,
            "end_logit": -3.1953125,
            "text": "temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer.",
            "probability": 0.03826904296875
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.375,
            "text": "Bacillus anthracis responds to host cues,",
            "probability": 0.02032470703125
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.4921875,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations,",
            "probability": 0.0180816650390625
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.5390625,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2",
            "probability": 0.017242431640625
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.578125,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations",
            "probability": 0.0165863037109375
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.640625,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that",
            "probability": 0.0155792236328125
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.6953125,
            "text": "Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with",
            "probability": 0.01474761962890625
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.8203125,
            "text": "Bacillus anthracis responds to host cues",
            "probability": 0.01302337646484375
        },
        {
            "start_logit": -5.25,
            "end_logit": -9.890625,
            "text": "Bacillus anthrac",
            "probability": 0.01213836669921875
        }
    ],
    "5710a592cf1c32585100002a_2": [
        {
            "start_logit": 12.953125,
            "end_logit": 14.515625,
            "text": "CO(2) /bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": 14.515625,
            "text": "bicarbonate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.931640625,
            "end_logit": 14.515625,
            "text": "elevated CO(2) /bicarbonate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.953125,
            "end_logit": -4.10546875,
            "text": "CO",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 14.515625,
            "text": "(2) /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 14.515625,
            "text": "2) /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 14.515625,
            "text": "/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.515625,
            "text": ") /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -7.82421875,
            "text": "CO(2)",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -8.2578125,
            "text": "CO(",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -8.7109375,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity,",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -8.8046875,
            "text": "CO(2) /",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.1484375,
            "text": "CO(2",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.515625,
            "text": "cultures grown with elevated CO(2) /bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.3828125,
            "text": "CO(2) /bicarbonate exhibited",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.6328125,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.7421875,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.7578125,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.8203125,
            "text": "CO(2) /bicarbonate exhibited increased AtxA",
            "probability": 0.0
        },
        {
            "start_logit": 12.953125,
            "end_logit": -9.859375,
            "text": "CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_3": [
        {
            "start_logit": 11.6328125,
            "end_logit": 10.625,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -6.33984375,
            "text": "CO2,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -7.44921875,
            "text": "CO2, a signal mimicking the host environment.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.625,
            "text": "CO2, a",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.8125,
            "text": "CO2, a signal mimicking the host environment",
            "probability": 0.0
        },
        {
            "start_logit": 11.6328125,
            "end_logit": -9.859375,
            "text": "CO2, a signal",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 10.625,
            "text": "by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 10.625,
            "text": "Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 10.625,
            "text": "virulence genes is triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 10.625,
            "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 10.625,
            "text": "anthracis virulence genes is triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 10.625,
            "text": "is virulence genes is triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 10.625,
            "text": "triggered by CO2",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -6.33984375,
            "text": "by CO2,",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -6.33984375,
            "text": ",",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -6.33984375,
            "text": "Bacillus anthracis virulence genes is triggered by CO2,",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -7.44921875,
            "text": "by CO2, a signal mimicking the host environment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -6.33984375,
            "text": "virulence genes is triggered by CO2,",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -6.33984375,
            "text": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2,",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -6.33984375,
            "text": "anthracis virulence genes is triggered by CO2,",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_4": [
        {
            "start_logit": 11.4375,
            "end_logit": 10.78125,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -4.28515625,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.0703125,
            "text": "CO2 and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.921875,
            "text": "CO2 and in vivo, AtxA is part of the sap",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.9765625,
            "text": "CO2 and in vivo,",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.0546875,
            "text": "CO2 and in vivo, AtxA is part of the",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.1640625,
            "text": "CO2 and in vivo, AtxA",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.171875,
            "text": "CO2 and in vivo",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.1796875,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.21875,
            "text": "CO2 and in vivo, AtxA is",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.296875,
            "text": "CO2 and in vivo, AtxA is part of the sap and eag regulatory",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 10.78125,
            "text": "presence of CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 10.78125,
            "text": "of CO2",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 10.78125,
            "text": "in presence of CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -4.28515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -4.28515625,
            "text": "AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -4.28515625,
            "text": "presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -4.28515625,
            "text": "of CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -4.28515625,
            "text": "eag regulatory network.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": -4.28515625,
            "text": "in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_5": [
        {
            "start_logit": 7.609375,
            "end_logit": 7.55078125,
            "text": "CO2/bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": 7.609375,
            "end_logit": -1.2763671875,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 7.55078125,
            "text": "bicarbonate",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.55078125,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.50390625,
            "text": "CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 7.55078125,
            "text": "not CO2/bicarbonate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 7.55078125,
            "text": "Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -8.453125,
            "text": "CO2/bicarbonate,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 7.55078125,
            "text": "/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.609375,
            "end_logit": -9.640625,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 7.55078125,
            "text": "temperature, not CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.609375,
            "end_logit": -9.8359375,
            "text": "CO2/bicarbonate, affects AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 7.55078125,
            "text": "anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 7.55078125,
            "text": "toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 7.55078125,
            "text": ", not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": -1.2763671875,
            "text": "bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -1.2763671875,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -1.2763671875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -1.2763671875,
            "text": "Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.2763671875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_6": [
        {
            "start_logit": -1.2431640625,
            "end_logit": -0.35009765625,
            "text": "elevated CO2/bicarbonate and temperature.",
            "probability": 0.8642578125
        },
        {
            "start_logit": -3.14453125,
            "end_logit": -0.35009765625,
            "text": "CO2/bicarbonate and temperature.",
            "probability": 0.1292724609375
        },
        {
            "start_logit": -1.2431640625,
            "end_logit": -5.453125,
            "text": "elevated CO2/bicarbonate",
            "probability": 0.005260467529296875
        },
        {
            "start_logit": -3.14453125,
            "end_logit": -5.453125,
            "text": "CO2/bicarbonate",
            "probability": 0.0007877349853515625
        },
        {
            "start_logit": -9.296875,
            "end_logit": -0.35009765625,
            "text": ".",
            "probability": 0.00027441978454589844
        },
        {
            "start_logit": -9.953125,
            "end_logit": -0.35009765625,
            "text": "bicarbonate and temperature.",
            "probability": 0.0001423358917236328
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -0.35009765625,
            "text": "/bicarbonate and temperature.",
            "probability": 0.00010335445404052734
        },
        {
            "start_logit": -10.4375,
            "end_logit": -0.35009765625,
            "text": "temperature.",
            "probability": 8.7738037109375e-05
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -0.35009765625,
            "text": ", and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 7.218122482299805e-05
        },
        {
            "start_logit": -10.703125,
            "end_logit": -0.35009765625,
            "text": ", lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 6.729364395141602e-05
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -0.35009765625,
            "text": "physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 5.97834587097168e-05
        },
        {
            "start_logit": -10.875,
            "end_logit": -0.35009765625,
            "text": "significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 5.6684017181396484e-05
        },
        {
            "start_logit": -10.921875,
            "end_logit": -0.35009765625,
            "text": "expression of the toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 5.4001808166503906e-05
        },
        {
            "start_logit": -10.921875,
            "end_logit": -0.35009765625,
            "text": "toxin genes (pag, lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate and temperature.",
            "probability": 5.4001808166503906e-05
        },
        {
            "start_logit": -9.953125,
            "end_logit": -5.453125,
            "text": "bicarbonate",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -5.453125,
            "text": "/bicarbonate",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -5.453125,
            "text": ", and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.703125,
            "end_logit": -5.453125,
            "text": ", lef, and cya) is enhanced by two physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -5.453125,
            "text": "physiologically significant signals: elevated CO2/bicarbonate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.875,
            "end_logit": -5.453125,
            "text": "significant signals: elevated CO2/bicarbonate",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5710a592cf1c32585100002a_7": [
        {
            "start_logit": -8.21875,
            "end_logit": -8.28125,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C.",
            "probability": 0.179443359375
        },
        {
            "start_logit": -8.15625,
            "end_logit": -9.0625,
            "text": ", the steady-state level of atxA mRNA in",
            "probability": 0.08740234375
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -8.59375,
            "text": "CO2/bicarbonate levels. However",
            "probability": 0.07476806640625
        },
        {
            "start_logit": -8.15625,
            "end_logit": -9.3125,
            "text": ", the steady-state level of atxA mRNA in cells grown in elevated CO2/bicarbonate at 37 degrees C is five- to sixfold",
            "probability": 0.068115234375
        },
        {
            "start_logit": -8.21875,
            "end_logit": -9.3125,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold",
            "probability": 0.06396484375
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -8.765625,
            "text": "CO2/bicarbonate levels.",
            "probability": 0.06396484375
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -9.0625,
            "text": "CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in",
            "probability": 0.04681396484375
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -8.59375,
            "text": "atxA expression is not influenced by CO2/bicarbonate levels. However",
            "probability": 0.041290283203125
        },
        {
            "start_logit": -8.21875,
            "end_logit": -9.765625,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed",
            "probability": 0.040679931640625
        },
        {
            "start_logit": -8.15625,
            "end_logit": -9.8984375,
            "text": ",",
            "probability": 0.03759765625
        },
        {
            "start_logit": -8.21875,
            "end_logit": -9.9140625,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same conditions",
            "probability": 0.035308837890625
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -9.3828125,
            "text": "CO2/bicarbonate",
            "probability": 0.03424072265625
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -8.765625,
            "text": "atxA expression is not influenced by CO2/bicarbonate levels.",
            "probability": 0.03424072265625
        },
        {
            "start_logit": -8.21875,
            "end_logit": -10.03125,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in",
            "probability": 0.03118896484375
        },
        {
            "start_logit": -8.21875,
            "end_logit": -10.03125,
            "text": "elevated CO2/bicarbonate at 37 degrees C is five- to sixfold higher than that observed in cells grown in the same",
            "probability": 0.03118896484375
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -8.28125,
            "text": "to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C.",
            "probability": 0.0292816162109375
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -9.6640625,
            "text": "CO2/bicarbonate levels",
            "probability": 0.025848388671875
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -9.0625,
            "text": "atxA expression is not influenced by CO2/bicarbonate levels. However, the steady-state level of atxA mRNA in",
            "probability": 0.025848388671875
        },
        {
            "start_logit": -10.203125,
            "end_logit": -8.28125,
            "text": "five- to sixfold higher than that observed in cells grown in the same conditions at 28 degrees C.",
            "probability": 0.024658203125
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -8.28125,
            "text": "higher than that observed in cells grown in the same conditions at 28 degrees C.",
            "probability": 0.0242919921875
        }
    ],
    "5710a592cf1c32585100002a_8": [
        {
            "start_logit": -8.046875,
            "end_logit": 4.9453125,
            "text": ", CO2",
            "probability": 0.59130859375
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 4.9453125,
            "text": "CO2",
            "probability": 0.1414794921875
        },
        {
            "start_logit": -10.546875,
            "end_logit": 4.9453125,
            "text": "trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.04852294921875
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 4.9453125,
            "text": "activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.046661376953125
        },
        {
            "start_logit": -10.828125,
            "end_logit": 4.9453125,
            "text": "by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.03662109375
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 4.9453125,
            "text": "the same signal, CO2",
            "probability": 0.035247802734375
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 4.9453125,
            "text": ", atxA, in response to the same signal, CO2",
            "probability": 0.034149169921875
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 4.9453125,
            "text": "transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.033599853515625
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 4.9453125,
            "text": "in trans by the same regulatory gene, atxA, in response to the same signal, CO2",
            "probability": 0.0325927734375
        },
        {
            "start_logit": -10.546875,
            "end_logit": -7.421875,
            "text": "trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -7.421875,
            "text": "activated in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.828125,
            "end_logit": -7.421875,
            "text": "by the same regulatory gene, atxA, in response to the same signal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -7.421875,
            "text": "the same signal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -7.421875,
            "text": ", atxA, in response to the same signal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -7.421875,
            "text": "transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -7.421875,
            "text": "in trans by the same regulatory gene, atxA, in response to the same signal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.75,
            "text": ", lef, and pag, can be viewed as a regulon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -9.75,
            "text": "Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.8515625,
            "text": ", lef, and pag, can be viewed as a regulon,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.8828125,
            "text": ", lef, and pag, can be viewed as a",
            "probability": 5.960464477539063e-08
        }
    ],
    "5710a592cf1c32585100002a_9": [
        {
            "start_logit": -8.265625,
            "end_logit": 1.404296875,
            "text": ".",
            "probability": 0.39599609375
        },
        {
            "start_logit": -8.703125,
            "end_logit": 1.404296875,
            "text": "elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.255615234375
        },
        {
            "start_logit": -10.28125,
            "end_logit": 1.404296875,
            "text": ", atxA.",
            "probability": 0.052734375
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 1.404296875,
            "text": "atxA.",
            "probability": 0.052337646484375
        },
        {
            "start_logit": -10.453125,
            "end_logit": 1.404296875,
            "text": "the toxin gene regulator, atxA.",
            "probability": 0.04443359375
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 1.404296875,
            "text": "toxin gene regulator, atxA.",
            "probability": 0.040771484375
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 1.404296875,
            "text": "toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.03076171875
        },
        {
            "start_logit": -10.90625,
            "end_logit": 1.404296875,
            "text": "growth in elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.028228759765625
        },
        {
            "start_logit": -10.96875,
            "end_logit": 1.404296875,
            "text": "CO2 and the toxin gene regulator, atxA.",
            "probability": 0.0265350341796875
        },
        {
            "start_logit": -11.015625,
            "end_logit": 1.404296875,
            "text": "protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.025299072265625
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 1.404296875,
            "text": "in elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.02471923828125
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 1.404296875,
            "text": "proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA.",
            "probability": 0.022857666015625
        },
        {
            "start_logit": -8.703125,
            "end_logit": -8.3671875,
            "text": "elevated CO2 and the toxin gene regulator, atxA",
            "probability": 1.4662742614746094e-05
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.3359375,
            "text": "elevated CO2",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.8515625,
            "text": "elevated CO2 and",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": -10.28125,
            "end_logit": -8.3671875,
            "text": ", atxA",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -8.3671875,
            "text": "atxA",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -8.703125,
            "end_logit": -10.0546875,
            "text": "elevated CO2 and the toxin",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.3671875,
            "text": "the toxin gene regulator, atxA",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -8.3671875,
            "text": "toxin gene regulator, atxA",
            "probability": 2.3245811462402344e-06
        }
    ],
    "5710a592cf1c32585100002a_10": [
        {
            "start_logit": 2.779296875,
            "end_logit": 9.6328125,
            "text": "acpA",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.6328125,
            "text": "A",
            "probability": 5.817413330078125e-05
        },
        {
            "start_logit": -10.125,
            "end_logit": 9.6328125,
            "text": "and acpA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 9.6328125,
            "text": "activated by both atxA and acpA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -11.0,
            "end_logit": 9.6328125,
            "text": "atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.015625,
            "end_logit": 9.6328125,
            "text": "both atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.0625,
            "end_logit": 9.6328125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 9.6328125,
            "text": "initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -6.0078125,
            "text": "acpA,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -7.40625,
            "text": "acp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 2.201171875,
            "text": "A, and activation appeared to be stimulated by bicarbonate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 2.201171875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 0.89697265625,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.375,
            "text": "acpA, and",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.421875,
            "text": "acpA, and activation appeared to be",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -10.1328125,
            "text": "acpA, and activation appeared",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_11": [
        {
            "start_logit": 5.046875,
            "end_logit": 5.24609375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 5.046875,
            "end_logit": -8.4765625,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.046875,
            "end_logit": -9.609375,
            "text": "CO2 through an AtxA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.046875,
            "end_logit": -10.0234375,
            "text": "CO2 through",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.046875,
            "end_logit": -10.2578125,
            "text": "CO2 through an AtxA-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 5.24609375,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.046875,
            "end_logit": -10.3359375,
            "text": "CO2 through an",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.046875,
            "end_logit": -10.3828125,
            "text": "CO2 through an AtxA-dependent",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.046875,
            "end_logit": -10.3828125,
            "text": "CO2 through an At",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6875,
            "end_logit": 5.24609375,
            "text": "to CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 5.24609375,
            "text": "anthracis genes that respond to CO2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 5.24609375,
            "text": "genes that respond to CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -8.4765625,
            "text": "Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -8.4765625,
            "text": "to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -8.9921875,
            "text": "Bacillus anthracis genes that",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -8.4765625,
            "text": "AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -8.4765625,
            "text": "dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": -8.4765625,
            "text": "anthracis genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": -8.4765625,
            "text": "an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": -8.4765625,
            "text": "genes that respond to CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_12": [
        {
            "start_logit": 2.779296875,
            "end_logit": 9.6328125,
            "text": "acpA",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.6328125,
            "text": "A",
            "probability": 5.817413330078125e-05
        },
        {
            "start_logit": -10.125,
            "end_logit": 9.6328125,
            "text": "and acpA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 9.6328125,
            "text": "activated by both atxA and acpA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -11.0,
            "end_logit": 9.6328125,
            "text": "atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.015625,
            "end_logit": 9.6328125,
            "text": "both atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.0625,
            "end_logit": 9.6328125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 9.6328125,
            "text": "initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -6.0078125,
            "text": "acpA,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -7.40625,
            "text": "acp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 2.201171875,
            "text": "A, and activation appeared to be stimulated by bicarbonate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 2.201171875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 0.89697265625,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.375,
            "text": "acpA, and",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.421875,
            "text": "acpA, and activation appeared to be",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -10.1328125,
            "text": "acpA, and activation appeared",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_13": [
        {
            "start_logit": 9.5390625,
            "end_logit": 8.1796875,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -6.91796875,
            "text": "CO2 through an AtxA-dependent mechanism.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -9.5078125,
            "text": "CO2 through an AtxA-dependent mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -9.515625,
            "text": "CO2 through an AtxA",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -10.109375,
            "text": "CO2 through an AtxA-",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -10.171875,
            "text": "CO2 through",
            "probability": 0.0
        },
        {
            "start_logit": 9.5390625,
            "end_logit": -10.2265625,
            "text": "CO2 through an AtxA-dependent",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 8.1796875,
            "text": "Bacillus anthracis genes that respond to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 8.1796875,
            "text": "to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 8.1796875,
            "text": "anthracis genes that respond to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 8.1796875,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 8.1796875,
            "text": "is genes that respond to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 8.1796875,
            "text": "genes that respond to CO2",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -6.91796875,
            "text": "Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -6.91796875,
            "text": "to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -6.91796875,
            "text": "AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -6.91796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -6.91796875,
            "text": "anthracis genes that respond to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -6.91796875,
            "text": "through an AtxA-dependent mechanism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": -6.91796875,
            "text": "Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_14": [
        {
            "start_logit": -9.3203125,
            "end_logit": 1.4931640625,
            "text": "elevated levels of CO2.",
            "probability": 0.19677734375
        },
        {
            "start_logit": -9.546875,
            "end_logit": 1.4931640625,
            "text": ".",
            "probability": 0.1568603515625
        },
        {
            "start_logit": -9.84375,
            "end_logit": 1.4931640625,
            "text": "Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.11651611328125
        },
        {
            "start_logit": -10.265625,
            "end_logit": 1.4931640625,
            "text": "levels of CO2.",
            "probability": 0.07647705078125
        },
        {
            "start_logit": -10.359375,
            "end_logit": 1.4931640625,
            "text": "B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.069580078125
        },
        {
            "start_logit": -10.421875,
            "end_logit": 1.4931640625,
            "text": "CO2.",
            "probability": 0.06536865234375
        },
        {
            "start_logit": -10.453125,
            "end_logit": 1.4931640625,
            "text": "anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.0633544921875
        },
        {
            "start_logit": -10.734375,
            "end_logit": 1.4931640625,
            "text": "by B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.0478515625
        },
        {
            "start_logit": -10.8125,
            "end_logit": 1.4931640625,
            "text": "toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.04425048828125
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 1.4931640625,
            "text": "enhanced during growth under elevated levels of CO2.",
            "probability": 0.041900634765625
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 1.4931640625,
            "text": "under elevated levels of CO2.",
            "probability": 0.041229248046875
        },
        {
            "start_logit": -10.890625,
            "end_logit": 1.4931640625,
            "text": "growth under elevated levels of CO2.",
            "probability": 0.040924072265625
        },
        {
            "start_logit": -10.9375,
            "end_logit": 1.4931640625,
            "text": ". anthracis is enhanced during growth under elevated levels of CO2.",
            "probability": 0.0390625
        },
        {
            "start_logit": -9.84375,
            "end_logit": -8.53125,
            "text": "Expression of the toxin genes by B. anthracis is",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -10.359375,
            "end_logit": -8.53125,
            "text": "B. anthracis is",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -9.640625,
            "text": "elevated levels of CO2",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -9.84375,
            "end_logit": -9.1171875,
            "text": "Expression of the",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.53125,
            "text": "anthracis is",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -9.7265625,
            "text": "elevated levels of",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -10.734375,
            "end_logit": -8.53125,
            "text": "by B. anthracis is",
            "probability": 2.1457672119140625e-06
        }
    ],
    "5710a592cf1c32585100002a_15": [
        {
            "start_logit": 3.310546875,
            "end_logit": 3.2734375,
            "text": "anthrax toxin synthesis.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 3.310546875,
            "end_logit": -4.296875,
            "text": "anthrax",
            "probability": 0.000514984130859375
        },
        {
            "start_logit": 3.310546875,
            "end_logit": -6.51171875,
            "text": "anthrax toxin",
            "probability": 5.602836608886719e-05
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 3.2734375,
            "text": ".",
            "probability": 5.060434341430664e-05
        },
        {
            "start_logit": 3.310546875,
            "end_logit": -7.90625,
            "text": "anthr",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 3.310546875,
            "end_logit": -8.9765625,
            "text": "anthrax toxin synthesis",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 3.2734375,
            "text": "pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -9.265625,
            "end_logit": 3.2734375,
            "text": "toxin synthesis.",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -9.34375,
            "end_logit": 3.2734375,
            "text": "transactivator of anthrax toxin synthesis.",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -10.296875,
            "end_logit": 3.2734375,
            "text": "atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.40625,
            "end_logit": 3.2734375,
            "text": "of anthrax toxin synthesis.",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 3.2734375,
            "text": "O1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 3.2734375,
            "text": "ax toxin synthesis.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.984375,
            "end_logit": 3.2734375,
            "text": "encodes a transactivator of anthrax toxin synthesis.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 3.2734375,
            "text": "in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 3.2734375,
            "text": "another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -11.078125,
            "end_logit": 3.2734375,
            "text": "This CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 3.2734375,
            "text": "CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -4.296875,
            "text": "pXO1 gene, atxA, which encodes a transactivator of anthrax",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -4.296875,
            "text": "transactivator of anthrax",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_16": [
        {
            "start_logit": 6.5078125,
            "end_logit": 5.74609375,
            "text": "CO2",
            "probability": 1.0
        },
        {
            "start_logit": 6.5078125,
            "end_logit": -2.337890625,
            "text": "CO2 compared with cells grown in air.",
            "probability": 0.0003101825714111328
        },
        {
            "start_logit": -4.83203125,
            "end_logit": 5.74609375,
            "text": "5% CO2",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 6.5078125,
            "end_logit": -8.8828125,
            "text": "CO2 compared",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.6484375,
            "end_logit": 5.74609375,
            "text": "% CO2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.5078125,
            "end_logit": -9.5703125,
            "text": "CO2 compared with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.5078125,
            "end_logit": -9.65625,
            "text": "CO2 compared with cells grown in air",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.96875,
            "end_logit": 5.74609375,
            "text": "in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.015625,
            "end_logit": 5.74609375,
            "text": "appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1875,
            "end_logit": 5.74609375,
            "text": "atxA does not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.734375,
            "end_logit": 5.74609375,
            "text": "cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.828125,
            "end_logit": 5.74609375,
            "text": "not appear to differ in cells grown in 5% CO2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 5.74609375,
            "text": "grown in 5% CO2",
            "probability": 0.0
        },
        {
            "start_logit": -4.83203125,
            "end_logit": -2.337890625,
            "text": "5% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6484375,
            "end_logit": -2.337890625,
            "text": "% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": -2.337890625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -2.337890625,
            "text": "in 5% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -2.337890625,
            "text": "appear to differ in cells grown in 5% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -2.337890625,
            "text": "atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -2.337890625,
            "text": "in air.",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_17": [
        {
            "start_logit": 10.09375,
            "end_logit": 11.8828125,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 11.8828125,
            "text": "A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.09375,
            "end_logit": -4.98828125,
            "text": "acp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.09375,
            "end_logit": -7.5625,
            "text": "acpA,",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 11.8828125,
            "text": "and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.8828125,
            "text": "activated by both atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.8828125,
            "text": "atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.0703125,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.1015625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.5546875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.578125,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.734375,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.8125,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.9296875,
            "text": "acpA, and",
            "probability": 0.0
        },
        {
            "start_logit": 10.09375,
            "end_logit": -9.96875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -7.5625,
            "text": "A,",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -9.0703125,
            "text": "A, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -4.98828125,
            "text": "and acp",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -9.1015625,
            "text": "A, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -9.5546875,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_18": [
        {
            "start_logit": 7.55078125,
            "end_logit": 10.5546875,
            "text": "acpA",
            "probability": 1.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": 10.5546875,
            "text": "A",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.55078125,
            "end_logit": -6.2109375,
            "text": "acp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.55078125,
            "end_logit": -6.53515625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 10.5546875,
            "text": "and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.5546875,
            "text": "capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 10.5546875,
            "text": "initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 10.5546875,
            "text": "both atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 10.5546875,
            "text": ", upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 0.0
        },
        {
            "start_logit": 7.55078125,
            "end_logit": -9.015625,
            "text": "acpA,",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -6.53515625,
            "text": "A, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -9.015625,
            "text": "A,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -6.2109375,
            "text": "and acp",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -6.53515625,
            "text": "bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -6.53515625,
            "text": "and acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -6.2109375,
            "text": "capB. Transcription initiated from P1 and P2 was activated by both atxA and acp",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -6.53515625,
            "text": "capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -6.53515625,
            "text": "stimulated by bicarbonate.",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -6.2109375,
            "text": "initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acp",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -6.2109375,
            "text": "both atxA and acp",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_19": [
        {
            "start_logit": 2.779296875,
            "end_logit": 9.6328125,
            "text": "acpA",
            "probability": 0.998046875
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 2.201171875,
            "text": "bicarbonate.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "acpA, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": 2.779296875,
            "end_logit": 0.89697265625,
            "text": "bicarbonate",
            "probability": 0.00016057491302490234
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 9.6328125,
            "text": "A",
            "probability": 5.817413330078125e-05
        },
        {
            "start_logit": -10.125,
            "end_logit": 9.6328125,
            "text": "and acpA",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 9.6328125,
            "text": "activated by both atxA and acpA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -11.0,
            "end_logit": 9.6328125,
            "text": "atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.015625,
            "end_logit": 9.6328125,
            "text": "both atxA and acpA",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -11.0625,
            "end_logit": 9.6328125,
            "text": "Transcription initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 9.6328125,
            "text": "initiated from P1 and P2 was activated by both atxA and acpA",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -6.0078125,
            "text": "acpA,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -7.40625,
            "text": "acp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 2.201171875,
            "text": "A, and activation appeared to be stimulated by bicarbonate.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 2.201171875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 0.89697265625,
            "text": "A, and activation appeared to be stimulated by bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.375,
            "text": "acpA, and",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -9.421875,
            "text": "acpA, and activation appeared to be",
            "probability": 0.0
        },
        {
            "start_logit": 2.779296875,
            "end_logit": -10.1328125,
            "text": "acpA, and activation appeared",
            "probability": 0.0
        }
    ],
    "5710a592cf1c32585100002a_20": [
        {
            "start_logit": 7.609375,
            "end_logit": 7.55078125,
            "text": "CO2/bicarbonate",
            "probability": 1.0
        },
        {
            "start_logit": 7.609375,
            "end_logit": -1.2763671875,
            "text": "CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 7.55078125,
            "text": "bicarbonate",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.55078125,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.50390625,
            "text": "CO2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7421875,
            "end_logit": 7.55078125,
            "text": "not CO2/bicarbonate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 7.55078125,
            "text": "Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -8.453125,
            "text": "CO2/bicarbonate,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 7.55078125,
            "text": "/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.609375,
            "end_logit": -9.640625,
            "text": "CO2/bicarbonate, affects AtxA synthesis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 7.55078125,
            "text": "temperature, not CO2/bicarbonate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.609375,
            "end_logit": -9.8359375,
            "text": "CO2/bicarbonate, affects AtxA",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 7.55078125,
            "text": "anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 7.55078125,
            "text": "toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 7.55078125,
            "text": ", not CO2/bicarbonate",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": -1.2763671875,
            "text": "bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -1.2763671875,
            "text": "anthrax toxin activator gene (atxA) expression in Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7421875,
            "end_logit": -1.2763671875,
            "text": "not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -1.2763671875,
            "text": "Bacillus anthracis: temperature, not CO2/bicarbonate, affects AtxA synthesis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -1.2763671875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5a87ea1861bb38fb2400000d_1": [
        {
            "start_logit": 10.328125,
            "end_logit": 10.4921875,
            "text": "circularized oligodeoxynucleotides",
            "probability": 1.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -2.1875,
            "text": "circularized oligodeoxynucleotides (",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 10.328125,
            "end_logit": -4.1328125,
            "text": "circularized oligodeoxynucleotides (coligos)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 10.4921875,
            "text": "oligodeoxynucleotides",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 10.4921875,
            "text": "ized oligodeoxynucleotides",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.15234375,
            "text": "circular",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 10.4921875,
            "text": "otides",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -8.0546875,
            "text": "circularized oligodeoxynucle",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -9.359375,
            "text": "circularized",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -9.5703125,
            "text": "circularized oligodeoxynucleotides (coligos",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.296875,
            "text": "circularized oligodeoxynucleotides (coligo",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 10.4921875,
            "text": "ynucleotides",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.390625,
            "text": "circularized oligodeoxynucleotides (coli",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -2.1875,
            "text": "oligodeoxynucleotides (",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -2.1875,
            "text": "ized oligodeoxynucleotides (",
            "probability": 0.0
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -4.1328125,
            "text": "oligodeoxynucleotides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -2.1875,
            "text": "otides (",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": -4.1328125,
            "text": "ized oligodeoxynucleotides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -4.1328125,
            "text": "otides (coligos)",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -2.1875,
            "text": "ynucleotides (",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_1": [
        {
            "start_logit": 13.6875,
            "end_logit": 14.484375,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -1.8740234375,
            "text": "hypertrophic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.154296875,
            "end_logit": 14.484375,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 14.484375,
            "text": "The most common cause of death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 14.484375,
            "text": "death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.484375,
            "text": "was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -9.09375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.484375,
            "text": "most common cause of death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.484375,
            "text": "cause of death was hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -9.859375,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -9.8671875,
            "text": "hypertrophic cardiomyopathy (30 %)",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.0546875,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %).",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.21875,
            "text": "hypertrophic cardiomyopathy (30 %",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.2421875,
            "text": "hypertrophic cardiomyopathy (30 %),",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.2578125,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.2578125,
            "text": "hypertrophic cardiomyopathy (30 %), followed",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.2890625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.359375,
            "text": "hypertrophic cardiomyopathy (30",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.40625,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %)",
            "probability": 0.0
        },
        {
            "start_logit": 13.6875,
            "end_logit": -10.4609375,
            "text": "hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_2": [
        {
            "start_logit": 11.6953125,
            "end_logit": 12.0078125,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": 0.1397705078125,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -3.92578125,
            "text": "hypertrophic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.25,
            "end_logit": 12.0078125,
            "text": "cardiomyopathy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -5.2890625,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -7.09765625,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 12.0078125,
            "text": "The most common cause of this, hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 12.0078125,
            "text": ", hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -9.75,
            "text": "hypertrophic cardiomyopathy (HCM),",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -9.8125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -9.828125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -9.8515625,
            "text": "hypertrophic cardiomyopathy (HCM), is",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.0,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.109375,
            "text": "hypertrophic cardiomyopathy (HCM), is a",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.1328125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.3203125,
            "text": "hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 12.0078125,
            "text": "most common cause of this, hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": 0.1397705078125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 0.1397705078125,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 0.1397705078125,
            "text": "(HCM)",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_3": [
        {
            "start_logit": 11.4140625,
            "end_logit": 8.828125,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 0.94970703125
        },
        {
            "start_logit": 11.4140625,
            "end_logit": 5.89453125,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.05035400390625
        },
        {
            "start_logit": 11.4140625,
            "end_logit": 0.0166473388671875,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 0.00014030933380126953
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -4.7109375,
            "text": "Hypertrophic",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -7.4921875,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 8.828125,
            "text": "cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.28125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -9.953125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.3515625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including trained athletes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.359375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.421875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.4296875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.4921875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.5234375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD)",
            "probability": 0.0
        },
        {
            "start_logit": -5.48828125,
            "end_logit": 5.89453125,
            "text": "HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 5.89453125,
            "text": "(HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 5.89453125,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": 5.89453125,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -5.48828125,
            "end_logit": 0.0166473388671875,
            "text": "HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 0.0166473388671875,
            "text": "(HCM",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_4": [
        {
            "start_logit": 11.2734375,
            "end_logit": 9.4375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 0.96142578125
        },
        {
            "start_logit": 11.2734375,
            "end_logit": 6.2265625,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.038482666015625
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -1.267578125,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -4.8359375,
            "text": "Hypertrophic",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.99609375,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 9.4375,
            "text": "cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -9.9453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.4375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.484375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.4921875,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.515625,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.609375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.6484375,
            "text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 6.2265625,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 6.2265625,
            "text": "(HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 6.2265625,
            "text": "HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 6.2265625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -6.12890625,
            "end_logit": -1.267578125,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.3046875,
            "end_logit": -1.267578125,
            "text": "(HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -1.267578125,
            "text": "HCM",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_5": [
        {
            "start_logit": 11.1796875,
            "end_logit": 9.09375,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 0.75439453125
        },
        {
            "start_logit": 11.1796875,
            "end_logit": 7.97265625,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.2449951171875
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -0.71728515625,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 4.100799560546875e-05
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -4.83203125,
            "text": "Hypertrophic",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -7.11328125,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.09375,
            "text": "cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -5.96875,
            "end_logit": 7.97265625,
            "text": "HCM)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.203125,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 7.97265625,
            "text": "(HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 7.97265625,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.5,
            "end_logit": 7.97265625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.40625,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.578125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young",
            "probability": 0.0
        },
        {
            "start_logit": -5.96875,
            "end_logit": -0.71728515625,
            "text": "HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.2265625,
            "end_logit": -0.71728515625,
            "text": "(HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.23828125,
            "end_logit": -0.71728515625,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.2265625,
            "end_logit": -7.11328125,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -6.23828125,
            "end_logit": -7.11328125,
            "text": "cardiomyopathy (",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_6": [
        {
            "start_logit": 13.7578125,
            "end_logit": 14.265625,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -2.134765625,
            "text": "Hypertrophic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.55859375,
            "end_logit": 14.265625,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -9.9765625,
            "text": "Hypertrophic cardiomyopathy is regarded",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.1015625,
            "text": "Hypertrophic cardiomyopathy is",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.3125,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.3671875,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.4375,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.59375,
            "text": "Hypertrophic cardiomyopathy is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.6484375,
            "text": "Hypertrophic cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.65625,
            "text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -9.9765625,
            "text": "cardiomyopathy is regarded",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.1015625,
            "text": "cardiomyopathy is",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.3125,
            "text": "cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.3671875,
            "text": "cardiomyopathy is regarded as the most common",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.4375,
            "text": "cardiomyopathy is regarded as the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.59375,
            "text": "cardiomyopathy is regarded as the",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.6484375,
            "text": "cardiomyopathy is regarded as the most",
            "probability": 0.0
        },
        {
            "start_logit": -3.55859375,
            "end_logit": -10.65625,
            "text": "cardiomyopathy is regarded as the most common cause of sudden cardiac death in young",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -9.9765625,
            "text": "regarded",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_7": [
        {
            "start_logit": 13.9453125,
            "end_logit": 14.40625,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -1.7021484375,
            "text": "hypertrophic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.37890625,
            "end_logit": 14.40625,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.25,
            "end_logit": 14.40625,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 14.40625,
            "text": "is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 14.40625,
            "text": "most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.40625,
            "text": "athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.40625,
            "text": "sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.40625,
            "text": "death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -10.0703125,
            "text": "hypertrophic cardiomyopathy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 14.40625,
            "text": "cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.40625,
            "text": "common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.40625,
            "text": "cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.40625,
            "text": "in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.40625,
            "text": "of sudden cardiac death in athletes is hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": -1.7021484375,
            "text": "The most common cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": -1.7021484375,
            "text": "is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -1.7021484375,
            "text": "most common cause of sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -1.7021484375,
            "text": "athletes is hypertrophic",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -1.7021484375,
            "text": "sudden cardiac death in athletes is hypertrophic",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_8": [
        {
            "start_logit": 11.734375,
            "end_logit": 10.71875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 0.990234375
        },
        {
            "start_logit": 11.734375,
            "end_logit": 6.09375,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 0.00971221923828125
        },
        {
            "start_logit": 11.734375,
            "end_logit": -4.3046875,
            "text": "Hypertrophic",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.734375,
            "end_logit": -4.3828125,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.734375,
            "end_logit": -6.09765625,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 10.71875,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.734375,
            "end_logit": -9.2265625,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.21875,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.21875,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young athletes.",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.2734375,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.53125,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.546875,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.5625,
            "text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": 6.09375,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 6.09375,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 6.09375,
            "text": "(HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 6.09375,
            "text": "HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -4.3828125,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -4.3828125,
            "text": "(HCM",
            "probability": 0.0
        },
        {
            "start_logit": -5.5859375,
            "end_logit": -6.09765625,
            "text": "cardiomyopathy (",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_9": [
        {
            "start_logit": 11.484375,
            "end_logit": 11.46875,
            "text": "hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": 1.4921875,
            "text": "hypertrophic cardiomyopathy (HCM",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": 11.484375,
            "end_logit": -2.607421875,
            "text": "hypertrophic cardiomyopathy (HCM)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -3.8984375,
            "end_logit": 11.46875,
            "text": "disorder hypertrophic cardiomyopathy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.484375,
            "end_logit": -4.09765625,
            "text": "hypertrophic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.02734375,
            "end_logit": 11.46875,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.78125,
            "text": "hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 11.46875,
            "text": "The most common cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 11.46875,
            "text": "the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 11.46875,
            "text": "inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -10.3828125,
            "text": "hypertrophic cardiomyopathy (HCM).",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.46875,
            "text": "is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.46875,
            "text": "competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.46875,
            "text": "sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.46875,
            "text": "athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.46875,
            "text": "individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.46875,
            "text": "including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": -3.8984375,
            "end_logit": 1.4921875,
            "text": "disorder hypertrophic cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": 1.4921875,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 1.4921875,
            "text": "HCM",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_10": [
        {
            "start_logit": 12.0703125,
            "end_logit": 12.0546875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": 0.0219573974609375,
            "text": "Hypertrophic cardiomyopathy (HCM)",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -3.9921875,
            "text": "Hypertrophic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -4.02734375,
            "text": "Hypertrophic cardiomyopathy (HCM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.96484375,
            "end_logit": 12.0546875,
            "text": "cardiomyopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -7.76171875,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -9.9140625,
            "text": "Hypertrophic cardiomyopathy (HCM) is",
            "probability": 0.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -10.296875,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young",
            "probability": 0.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -10.375,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly in young competitive athletes.",
            "probability": 0.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -10.453125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly",
            "probability": 0.0
        },
        {
            "start_logit": 12.0703125,
            "end_logit": -10.6328125,
            "text": "Hypertrophic cardiomyopathy (HCM) is the most common",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": 0.0219573974609375,
            "text": "cardiomyopathy (HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 0.0219573974609375,
            "text": "HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 0.0219573974609375,
            "text": "(HCM)",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 0.0219573974609375,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -4.02734375,
            "text": "cardiomyopathy (HCM",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -4.02734375,
            "text": "HCM",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -4.02734375,
            "text": "(HCM",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -7.76171875,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -4.96484375,
            "end_logit": -9.9140625,
            "text": "cardiomyopathy (HCM) is",
            "probability": 0.0
        }
    ],
    "530cf4e0c8a0b4a00c000006_11": [
        {
            "start_logit": 13.609375,
            "end_logit": 13.921875,
            "text": "Hypertrophic cardiomyopathy",
            "probability": 1.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -2.58203125,
            "text": "Hypertrophic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.859375,
            "end_logit": 13.921875,
            "text": "cardiomyopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -6.08203125,
            "text": "Hypertrophic cardiomyopathy (HC)",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -6.9609375,
            "text": "Hypertrophic cardiomyopathy (HC",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -8.8984375,
            "text": "Hypertrophic cardiomyopathy (HC) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -8.9765625,
            "text": "Hypertrophic cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.09375,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.2109375,
            "text": "Hypertrophic cardiomyopathy (HC) is probably",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.3046875,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.375,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.5,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.5078125,
            "text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -6.08203125,
            "text": "cardiomyopathy (HC)",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -6.9609375,
            "text": "cardiomyopathy (HC",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -8.8984375,
            "text": "cardiomyopathy (HC) is",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -8.9765625,
            "text": "cardiomyopathy (",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -10.09375,
            "text": "cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -10.2109375,
            "text": "cardiomyopathy (HC) is probably",
            "probability": 0.0
        },
        {
            "start_logit": -3.859375,
            "end_logit": -10.3046875,
            "text": "cardiomyopathy (HC) is probably the most common cause",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_1": [
        {
            "start_logit": 14.453125,
            "end_logit": 15.046875,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": 15.046875,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.453125,
            "end_logit": -1.732421875,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.453125,
            "end_logit": -7.7109375,
            "text": "multiple sclerosis with a simplified three-lesion algorithm.",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -8.3125,
            "text": "multiple sclerosis with",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -8.5546875,
            "text": "multiple sclerosis with a simplified three-lesion algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 15.046875,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.34375,
            "text": "multiple sclerosis with a simplified three-lesion",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.515625,
            "text": "multiple sclerosis with a",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 15.046875,
            "text": "Diagnostic performance of central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.65625,
            "text": "multiple sclerosis with a simplified",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.7578125,
            "text": "multiple sclerosis with a simplified three",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.78125,
            "text": "multiple sclerosis with a simplified three-",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.046875,
            "text": "central vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 15.046875,
            "text": "vein sign for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -7.7109375,
            "text": "sclerosis with a simplified three-lesion algorithm.",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -8.3125,
            "text": "sclerosis with",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -8.5546875,
            "text": "sclerosis with a simplified three-lesion algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": -1.732421875,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -9.34375,
            "text": "sclerosis with a simplified three-lesion",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_2": [
        {
            "start_logit": 14.140625,
            "end_logit": 14.6953125,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.833984375,
            "end_logit": 14.6953125,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.140625,
            "end_logit": -2.45703125,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 14.6953125,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.734375,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.9296875,
            "text": "multiple sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.0546875,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.125,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.6953125,
            "text": ": Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.6953125,
            "text": "central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.6953125,
            "text": "FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.6953125,
            "text": "Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.6953125,
            "text": "highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.6953125,
            "text": "magnetic resonance imaging (MRI) is highly specific and sensitive for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -2.45703125,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.833984375,
            "end_logit": -8.734375,
            "text": "sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -2.833984375,
            "end_logit": -8.9296875,
            "text": "sclerosis (MS).",
            "probability": 0.0
        },
        {
            "start_logit": -2.833984375,
            "end_logit": -9.0546875,
            "text": "sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -2.833984375,
            "end_logit": -9.125,
            "text": "sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -2.45703125,
            "text": ": Detection of a \"central vein sign\" (CVS) on FLAIR* magnetic resonance imaging (MRI) is highly specific and sensitive for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_3": [
        {
            "start_logit": 14.0859375,
            "end_logit": 14.84375,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.5,
            "end_logit": 14.84375,
            "text": "Sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -2.54296875,
            "text": "Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 14.84375,
            "text": "Central vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -7.421875,
            "text": "Multiple Sclerosis from central nervous system inflammatory vasculopathies.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -7.55078125,
            "text": "Multiple Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.5859375,
            "text": "Multiple Sclerosis from",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.0234375,
            "text": "Multiple Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.84375,
            "text": "vein sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.84375,
            "text": "sign differentiates Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.84375,
            "text": "s Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": -2.54296875,
            "text": "Central vein sign differentiates Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.5,
            "end_logit": -7.421875,
            "text": "Sclerosis from central nervous system inflammatory vasculopathies.",
            "probability": 0.0
        },
        {
            "start_logit": -2.5,
            "end_logit": -7.55078125,
            "text": "Sclerosis from central nervous system inflammatory vasculopathies",
            "probability": 0.0
        },
        {
            "start_logit": -2.5,
            "end_logit": -8.5859375,
            "text": "Sclerosis from",
            "probability": 0.0
        },
        {
            "start_logit": -2.5,
            "end_logit": -9.0234375,
            "text": "Sclerosis from central nervous system inflammatory vascul",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -2.54296875,
            "text": "vein sign differentiates Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -2.54296875,
            "text": "sign differentiates Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": -7.421875,
            "text": "Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -2.54296875,
            "text": "s Multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_4": [
        {
            "start_logit": 10.5546875,
            "end_logit": 12.7109375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -3.767578125,
            "end_logit": 12.7109375,
            "text": "sclerosis",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 12.7109375,
            "text": "between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -6.92578125,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -6.97265625,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 12.7109375,
            "text": "central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 12.7109375,
            "text": "the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 12.7109375,
            "text": ": To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.7109375,
            "text": "OBJECTIVE: To assess the value of the central vein sign (CVS) on a clinical 3T scanner to distinguish between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.03125,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.1953125,
            "text": "multiple sclerosis (MS) and",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.3125,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOS",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.59375,
            "text": "multiple sclerosis (MS) and neuromyelitis optica",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.7578125,
            "text": "multiple sclerosis (MS) and neuromyelitis optic",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -9.828125,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -10.015625,
            "text": "multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).",
            "probability": 0.0
        },
        {
            "start_logit": 10.5546875,
            "end_logit": -10.109375,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.767578125,
            "end_logit": -6.97265625,
            "text": "sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD",
            "probability": 0.0
        },
        {
            "start_logit": -3.767578125,
            "end_logit": -9.03125,
            "text": "sclerosis (MS) and neuromyelitis optica spectrum disorder",
            "probability": 0.0
        },
        {
            "start_logit": -3.767578125,
            "end_logit": -9.1953125,
            "text": "sclerosis (MS) and",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_5": [
        {
            "start_logit": 14.1953125,
            "end_logit": 14.7265625,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -2.853515625,
            "end_logit": 14.7265625,
            "text": "Sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -2.328125,
            "text": "Multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -5.48828125,
            "text": "Multiple Sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": 14.7265625,
            "text": "in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.7265625,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.7265625,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.7265625,
            "text": "Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.7265625,
            "text": "Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.7265625,
            "text": "Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 14.7265625,
            "text": "of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 14.7265625,
            "text": "Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 14.7265625,
            "text": "a Diagnostic Imaging Biomarker in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.853515625,
            "end_logit": -5.48828125,
            "text": "Sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -2.328125,
            "text": "in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -2.328125,
            "text": "the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -5.48828125,
            "text": "in Multiple Sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -2.328125,
            "text": "Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -2.328125,
            "text": "Imaging Biomarker in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -2.328125,
            "text": "Vein Sign as a Diagnostic Imaging Biomarker in Multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_6": [
        {
            "start_logit": 13.90625,
            "end_logit": 14.40625,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": -3.08203125,
            "end_logit": 14.40625,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.005859375,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -7.8984375,
            "text": "multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.5390625,
            "text": "multiple sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.578125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.6015625,
            "text": "multiple sclerosis (MS) and not MS, mainly",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.671875,
            "text": "multiple sclerosis (MS) and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.40625,
            "text": "The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.40625,
            "text": "between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.84375,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.953125,
            "text": "multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI)",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.9609375,
            "text": "multiple sclerosis (MS) and not MS,",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -10.0234375,
            "text": "multiple sclerosis (MS) and not MS",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -10.0703125,
            "text": "multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.40625,
            "text": "Importance  The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.40625,
            "text": "central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -3.08203125,
            "end_logit": -7.8984375,
            "text": "sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": -3.08203125,
            "end_logit": -8.5390625,
            "text": "sclerosis (",
            "probability": 0.0
        },
        {
            "start_logit": -3.08203125,
            "end_logit": -9.578125,
            "text": "sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_7": [
        {
            "start_logit": 14.21875,
            "end_logit": 14.7734375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.234375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.8125,
            "end_logit": 14.7734375,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.21875,
            "end_logit": -7.9375,
            "text": "multiple sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 14.7734375,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 14.7734375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 14.7734375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.7734375,
            "text": "BACKGROUND AND PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.7734375,
            "text": "PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.7734375,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.7734375,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.7734375,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.7734375,
            "text": "AND PURPOSE  The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.7734375,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.7734375,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.7734375,
            "text": "a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -7.9375,
            "text": "sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -2.234375,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -2.234375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -2.234375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_8": [
        {
            "start_logit": 14.21875,
            "end_logit": 14.7734375,
            "text": "multiple sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.234375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.8125,
            "end_logit": 14.7734375,
            "text": "sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.21875,
            "end_logit": -7.9375,
            "text": "multiple sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 14.7734375,
            "text": "for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 14.7734375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 14.7734375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.7734375,
            "text": "BACKGROUND AND PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.7734375,
            "text": "PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.7734375,
            "text": "imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.7734375,
            "text": "MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.7734375,
            "text": "vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.7734375,
            "text": "AND PURPOSE The central vein sign is a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.7734375,
            "text": "diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.7734375,
            "text": "promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.7734375,
            "text": "a promising MR imaging diagnostic biomarker for multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -7.9375,
            "text": "sclerosis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -2.234375,
            "text": "for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -2.234375,
            "text": "The central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -2.234375,
            "text": "central vein sign is a promising MR imaging diagnostic biomarker for multiple",
            "probability": 0.0
        }
    ],
    "5e4601293f54159529000002_9": [
        {
            "start_logit": 14.2421875,
            "end_logit": 14.71875,
            "text": "Multiple Sclerosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -2.1796875,
            "text": "Multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.69921875,
            "end_logit": 14.71875,
            "text": "Sclerosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 14.71875,
            "text": "in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 14.71875,
            "text": "The Central Vein Sign in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.5625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.71875,
            "text": "Central Vein Sign in Multiple Sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.7421875,
            "text": "Multiple Sclerosis Lesions",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.8125,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.9296875,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -10.0234375,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -10.0625,
            "text": "Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -2.1796875,
            "text": "in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -2.1796875,
            "text": "The Central Vein Sign in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -9.5625,
            "text": "Sclerosis Lesions Is Present Irrespective",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -2.1796875,
            "text": "Central Vein Sign in Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -9.7421875,
            "text": "Sclerosis Lesions",
            "probability": 0.0
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -9.8125,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*-weighted magnetic resonance imaging (MRI",
            "probability": 0.0
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -9.9296875,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2",
            "probability": 0.0
        },
        {
            "start_logit": -2.69921875,
            "end_logit": -10.0234375,
            "text": "Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T. BACKGROUND AND PURPOSE Previous T2*",
            "probability": 0.0
        }
    ],
    "5c8fe7cb0101eac87000000c_1": [
        {
            "start_logit": 13.265625,
            "end_logit": 14.3828125,
            "text": "Runt related factor-2",
            "probability": 1.0
        },
        {
            "start_logit": -2.8359375,
            "end_logit": 14.3828125,
            "text": "2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.265625,
            "end_logit": -1.8271484375,
            "text": "Runt related factor-2 (Runx2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.265625,
            "end_logit": -4.328125,
            "text": "Run",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -6.54296875,
            "text": "Runt related factor-2 (",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 14.3828125,
            "text": "t related factor-2",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 14.3828125,
            "text": "related factor-2",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 14.3828125,
            "text": "factor-2",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -8.0234375,
            "text": "Runt related factor-2 (Runx2)",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.3828125,
            "text": "-2",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -9.0859375,
            "text": "Runt",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -9.5703125,
            "text": "Runt related factor",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -9.8359375,
            "text": "Runt related factor-",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -10.453125,
            "text": "Runt related",
            "probability": 0.0
        },
        {
            "start_logit": -2.8359375,
            "end_logit": -1.8271484375,
            "text": "2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -2.8359375,
            "end_logit": -6.54296875,
            "text": "2 (",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": -1.8271484375,
            "text": "t related factor-2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -1.8271484375,
            "text": "related factor-2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": -1.8271484375,
            "text": "factor-2 (Runx2",
            "probability": 0.0
        },
        {
            "start_logit": -2.8359375,
            "end_logit": -8.0234375,
            "text": "2 (Runx2)",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_1": [
        {
            "start_logit": 13.3984375,
            "end_logit": 14.515625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": 14.515625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -2.05859375,
            "text": "calcitonin gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -3.794921875,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 14.515625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 14.515625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 14.515625,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 14.515625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -7.64453125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -8.3203125,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.515625,
            "text": "In vivo quantification of calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -9.796875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -9.8984375,
            "text": "calcitonin gene-related peptide receptor occupancy",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -10.015625,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -10.109375,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -10.125,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -10.171875,
            "text": "calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and",
            "probability": 0.0
        },
        {
            "start_logit": 13.3984375,
            "end_logit": -10.1875,
            "text": "calcitonin gene-related peptide receptor occupancy by",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -2.05859375,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.05859375,
            "text": "gene-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_2": [
        {
            "start_logit": 11.5,
            "end_logit": 11.3046875,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -4.0546875,
            "text": "calcitonin gene-related peptide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 11.3046875,
            "text": "receptor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.5,
            "end_logit": -4.68359375,
            "text": "calcitonin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.015625,
            "end_logit": 11.3046875,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 11.3046875,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 11.3046875,
            "text": "novel calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.5234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.7109375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.7734375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 11.3046875,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 11.3046875,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.0078125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.0546875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.2734375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.3046875,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.3046875,
            "text": "CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.3046875,
            "text": "Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_3": [
        {
            "start_logit": 13.359375,
            "end_logit": 13.40625,
            "text": "CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -2.56640625,
            "text": "CGRP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.8359375,
            "end_logit": 13.40625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.0703125,
            "end_logit": 13.40625,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 13.40625,
            "text": "Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.40625,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -9.890625,
            "text": "CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.40625,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.40625,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.40625,
            "text": "(CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 13.40625,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.109375,
            "text": "CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.21875,
            "text": "CGRP) receptor antagonist being evaluated for acute migraine treatment.",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.3046875,
            "text": "CGRP) receptor antagonist being",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.4296875,
            "text": "CGRP) receptor antagonist being evaluated for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.40625,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 13.40625,
            "text": "a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.40625,
            "text": "pant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 13.40625,
            "text": "gepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 13.40625,
            "text": "cagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_4": [
        {
            "start_logit": 13.640625,
            "end_logit": 14.3125,
            "text": "Calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.87109375,
            "end_logit": 14.3125,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.640625,
            "end_logit": -3.033203125,
            "text": "Calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -5.890625,
            "text": "Calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 14.3125,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 14.3125,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 14.3125,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 14.3125,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -8.84375,
            "text": "Calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.21875,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -9.75,
            "text": "Calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.3125,
            "text": ": Calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.203125,
            "text": "Calcitonin gene-related peptide receptor antagonists, such",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.25,
            "text": "Calcitonin gene-related peptide receptor antagonists",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.375,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.4140625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine treatment in patients with cardiovascular disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.4140625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful for acute migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.640625,
            "end_logit": -10.4765625,
            "text": "Calcitonin gene-related peptide receptor antagonists, such as telcagepant, may be useful",
            "probability": 0.0
        },
        {
            "start_logit": -2.87109375,
            "end_logit": -9.21875,
            "text": "receptor antagonists, such as telcagepant, may",
            "probability": 0.0
        },
        {
            "start_logit": -2.87109375,
            "end_logit": -10.203125,
            "text": "receptor antagonists, such",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_5": [
        {
            "start_logit": 10.671875,
            "end_logit": 10.578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -3.23046875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 10.671875,
            "end_logit": -4.99609375,
            "text": "calcitonin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.9453125,
            "end_logit": 10.578125,
            "text": "receptor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.671875,
            "end_logit": -8.734375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -9.1171875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -9.5859375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -9.7890625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 10.578125,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 10.578125,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -10.171875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 10.578125,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.671875,
            "end_logit": -10.2265625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 10.578125,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -3.23046875,
            "text": "gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -3.23046875,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -3.23046875,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -4.9453125,
            "end_logit": -9.7890625,
            "text": "receptor antagonists",
            "probability": 0.0
        },
        {
            "start_logit": -4.9453125,
            "end_logit": -10.0390625,
            "text": "receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK",
            "probability": 0.0
        },
        {
            "start_logit": -4.9453125,
            "end_logit": -10.171875,
            "text": "receptor antagonists (gepants)-olcegepant (BIBN 4096 BS",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_6": [
        {
            "start_logit": 14.015625,
            "end_logit": 14.7421875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.240234375,
            "end_logit": 14.7421875,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.015625,
            "end_logit": -2.318359375,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 14.7421875,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 14.7421875,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 14.7421875,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.7421875,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.1953125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 14.7421875,
            "text": "Telcagepant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.40625,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.7421875,
            "text": "a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.9609375,
            "text": "calcitonin gene-related peptide receptor antagonist, is being developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.7421875,
            "text": "gepant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.7421875,
            "text": "cagepant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.7421875,
            "text": "pant, a calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.1640625,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.1953125,
            "text": "calcitonin gene-related peptide receptor antagonist, is being developed for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -2.240234375,
            "end_logit": -9.9609375,
            "text": "receptor antagonist, is being developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -2.240234375,
            "end_logit": -10.1640625,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.240234375,
            "end_logit": -10.1953125,
            "text": "receptor antagonist, is being developed for the acute treatment of migraine.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_7": [
        {
            "start_logit": 13.3125,
            "end_logit": 14.5390625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.74609375,
            "end_logit": 14.5390625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.3125,
            "end_logit": -3.490234375,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -5.24609375,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 14.5390625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 14.5390625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 14.5390625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 14.5390625,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -8.59375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -8.703125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 14.5390625,
            "text": "potent calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.5390625,
            "text": "The potent calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -9.3046875,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -9.3125,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -9.6171875,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -9.6328125,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -10.1484375,
            "text": "calcitonin gene-related peptide receptor antagonist,",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -10.1953125,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -10.234375,
            "text": "calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-",
            "probability": 0.0
        },
        {
            "start_logit": -2.74609375,
            "end_logit": -8.59375,
            "text": "receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_8": [
        {
            "start_logit": 7.83203125,
            "end_logit": 11.78125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": -4.12109375,
            "end_logit": 11.78125,
            "text": "receptor",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 11.78125,
            "text": "CGRP) receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.40625,
            "end_logit": 11.78125,
            "text": ") receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -5.49609375,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.78125,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.78125,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 11.78125,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.78125,
            "text": ": To assess the effect of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.78125,
            "text": "(CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.78125,
            "text": "the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.78125,
            "text": "To assess the effect of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.78125,
            "text": "the effect of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -7.578125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -8.5234375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -8.984375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -9.1875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG).",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -9.6640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -9.859375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG",
            "probability": 0.0
        },
        {
            "start_logit": 7.83203125,
            "end_logit": -9.9453125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_9": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.015625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.14453125,
            "end_logit": 15.015625,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -1.5986328125,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 15.015625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": 15.015625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 15.015625,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -7.84375,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 15.015625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.5703125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.2890625,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.015625,
            "text": "Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.015625,
            "text": ": Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.015625,
            "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.015625,
            "text": "gepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.015625,
            "text": "oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.203125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.2109375,
            "text": "calcitonin gene-related peptide receptor antagonist which is being evaluated for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.2265625,
            "text": "calcitonin gene-related peptide receptor antagonist which",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -1.5986328125,
            "text": "Telcagepant is an oral calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -1.5986328125,
            "text": ": Telcagepant is an oral calcitonin",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_10": [
        {
            "start_logit": 10.8828125,
            "end_logit": 9.640625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -4.40234375,
            "text": "calcitonin",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 9.640625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -6.46875,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -8.59375,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -8.9375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -9.4140625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -9.7265625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent drugs.",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -9.734375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -9.9609375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -10.1484375,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -10.2578125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant",
            "probability": 0.0
        },
        {
            "start_logit": 10.8828125,
            "end_logit": -10.3203125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 9.640625,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.640625,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.640625,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.640625,
            "text": ": The calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 9.640625,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 9.640625,
            "text": "The calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 9.640625,
            "text": "BACKGROUND: The calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_11": [
        {
            "start_logit": 9.125,
            "end_logit": 5.90234375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.92333984375
        },
        {
            "start_logit": 9.125,
            "end_logit": 3.423828125,
            "text": "Calcitonin gene-related peptide",
            "probability": 0.07696533203125
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.33203125,
            "text": "Calcitonin gene-related peptide (CGRP",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.4921875,
            "text": "Calcitonin",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.125,
            "end_logit": -9.15625,
            "text": "Calcitonin gene-related peptide (CGRP)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -9.3515625,
            "text": "Calcitonin gene-related peptide (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -9.40625,
            "text": "Calcitonin gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.15625,
            "text": "Calcitonin gene-related",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.2109375,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.2890625,
            "text": "Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 5.90234375,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5625,
            "end_logit": 5.90234375,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 5.90234375,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 5.90234375,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 5.90234375,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 5.90234375,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": 3.423828125,
            "text": "peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 3.423828125,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 3.423828125,
            "text": "gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 3.423828125,
            "text": "-related peptide",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_12": [
        {
            "start_logit": 12.6640625,
            "end_logit": 13.6328125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": -3.705078125,
            "end_logit": 13.6328125,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -3.2265625,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -6.296875,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 13.6328125,
            "text": "CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 13.6328125,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 13.6328125,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -8.78125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 13.6328125,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 13.6328125,
            "text": "- Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 13.6328125,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 13.6328125,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 13.6328125,
            "text": "Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 13.6328125,
            "text": "a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.6328125,
            "text": "Background.- Telcagepant is a calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.6328125,
            "text": "(CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -9.953125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -10.03125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -10.0390625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 12.6640625,
            "end_logit": -10.1015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_13": [
        {
            "start_logit": 13.5859375,
            "end_logit": 14.515625,
            "text": "calcitonin gene-related peptide",
            "probability": 1.0
        },
        {
            "start_logit": -3.072265625,
            "end_logit": 14.515625,
            "text": "peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -2.921875,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 14.515625,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 14.515625,
            "text": "gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -7.05078125,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 14.515625,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -7.4296875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.7421875,
            "text": "calcitonin gene-related peptide antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.515625,
            "text": "= 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.515625,
            "text": "the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.515625,
            "text": "n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.515625,
            "text": "(n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.515625,
            "text": "clinical trials (n = 1585) the calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -10.234375,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -10.3125,
            "text": "calcitonin gene-related peptide antagonist telcagepant 300 mg",
            "probability": 0.0
        },
        {
            "start_logit": -3.072265625,
            "end_logit": -9.7421875,
            "text": "peptide antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -3.072265625,
            "end_logit": -9.8828125,
            "text": "peptide antagonist telcagepant 300 mg orally had an incidence of adverse events similar to placebo when used in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -3.072265625,
            "end_logit": -10.234375,
            "text": "peptide antagonist telcagepant 300",
            "probability": 0.0
        },
        {
            "start_logit": -3.072265625,
            "end_logit": -10.3125,
            "text": "peptide antagonist telcagepant 300 mg",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_14": [
        {
            "start_logit": 12.9609375,
            "end_logit": 14.515625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.84765625,
            "end_logit": 14.515625,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -3.466796875,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 14.515625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 14.515625,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 14.515625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -6.9453125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": 14.515625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.515625,
            "text": "Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.515625,
            "text": ": Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.515625,
            "text": "BACKGROUND: Telcagepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -9.2109375,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.515625,
            "text": "gepant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.515625,
            "text": "pant is an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -9.4453125,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -10.2890625,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -10.40625,
            "text": "calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable to oral triptans",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -10.46875,
            "text": "calcitonin gene-related peptide receptor antagonist with acute antimigraine",
            "probability": 0.0
        },
        {
            "start_logit": 12.9609375,
            "end_logit": -10.5625,
            "text": "calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable",
            "probability": 0.0
        },
        {
            "start_logit": -2.84765625,
            "end_logit": -10.2890625,
            "text": "receptor antagonist",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_15": [
        {
            "start_logit": 10.203125,
            "end_logit": 12.8515625,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": -3.74609375,
            "end_logit": 12.8515625,
            "text": "receptor",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 10.203125,
            "end_logit": -4.45703125,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 12.8515625,
            "text": "CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 12.8515625,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 12.8515625,
            "text": ": This study evaluated the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 12.8515625,
            "text": "METHODS: This study evaluated the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 12.8515625,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.8515625,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 12.8515625,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.8515625,
            "text": "the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.8515625,
            "text": "(CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.8515625,
            "text": "This study evaluated the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -9.3671875,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -9.6875,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -9.984375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -10.2109375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -10.375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -10.390625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 10.203125,
            "end_logit": -10.515625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_16": [
        {
            "start_logit": 10.1484375,
            "end_logit": 5.8515625,
            "text": "calcitonin gene-related peptide",
            "probability": 0.7021484375
        },
        {
            "start_logit": 10.1484375,
            "end_logit": 4.98828125,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.29736328125
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -5.609375,
            "text": "calcitonin",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -6.51171875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -9.265625,
            "text": "calcitonin gene-related",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -9.5546875,
            "text": "calcitonin gene-related peptide (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -9.9375,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.0,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.015625,
            "text": "calcitonin gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.1015625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitriptan in the acute treatment of migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.40625,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitript",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zol",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.1484375,
            "end_logit": -10.421875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, and zolmitriptan in the acute treatment of migraine.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 5.8515625,
            "text": "peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 4.98828125,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 4.98828125,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 5.8515625,
            "text": "-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 5.8515625,
            "text": "gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 5.8515625,
            "text": "related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 4.98828125,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_17": [
        {
            "start_logit": 9.2890625,
            "end_logit": 10.4609375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 10.4609375,
            "text": "receptor",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -4.19921875,
            "text": "calcitonin gene-related peptide",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -5.2890625,
            "text": "calcitonin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.15234375,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.4609375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.42578125,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 10.4609375,
            "text": "CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 10.4609375,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -8.78125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 10.4609375,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 10.4609375,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 10.4609375,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -9.4609375,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -9.5078125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -9.5625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 10.4609375,
            "text": "(CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -9.78125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 10.4609375,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -9.8125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist telca",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_18": [
        {
            "start_logit": 13.8203125,
            "end_logit": 14.9921875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": 14.9921875,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -2.90625,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -5.58203125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 14.9921875,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 14.9921875,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 14.9921875,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 14.9921875,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -8.328125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -8.78125,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -8.984375,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.015625,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.515625,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.6015625,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.7109375,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.9921875,
            "text": "the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.9453125,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.9453125,
            "text": "calcitonin gene-related peptide receptor antagonist telcagepant (MK",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.96875,
            "text": "calcitonin gene-related peptide receptor antagonist tel",
            "probability": 0.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": -8.78125,
            "text": "receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_19": [
        {
            "start_logit": 13.6171875,
            "end_logit": 14.578125,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 14.578125,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.6171875,
            "end_logit": -2.953125,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 14.578125,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 14.578125,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 14.578125,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.6171875,
            "end_logit": -7.5546875,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 14.578125,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 14.578125,
            "text": "Telcagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.6171875,
            "end_logit": -8.734375,
            "text": "calcitonin gene-related peptide receptor blockers",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.578125,
            "text": "the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.6171875,
            "end_logit": -9.3359375,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.6171875,
            "end_logit": -9.703125,
            "text": "calcitonin gene-related peptide receptor blockers.",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.578125,
            "text": "pant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.578125,
            "text": "cagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.578125,
            "text": "gepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 14.578125,
            "text": "-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 14.578125,
            "text": "antimigraine drug-the calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -8.734375,
            "text": "receptor blockers",
            "probability": 0.0
        },
        {
            "start_logit": -2.564453125,
            "end_logit": -9.703125,
            "text": "receptor blockers.",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_20": [
        {
            "start_logit": 13.578125,
            "end_logit": 14.0390625,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -3.177734375,
            "end_logit": 14.0390625,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.578125,
            "end_logit": -2.939453125,
            "text": "calcitonin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.34375,
            "end_logit": 14.0390625,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 14.0390625,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -8.5390625,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 14.0390625,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.0390625,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 14.0390625,
            "text": "dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -9.734375,
            "text": "calcitonin gene-related peptide receptor antagonist, in adults.",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -9.7578125,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.0390625,
            "text": "oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.0390625,
            "text": "-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.0390625,
            "text": "tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.0390625,
            "text": "telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.0390625,
            "text": "- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.3125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.0390625,
            "text": "Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.0390625,
            "text": "multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.0390625,
            "text": "pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_21": [
        {
            "start_logit": 13.984375,
            "end_logit": 14.9296875,
            "text": "calcitonin gene-related peptide receptor",
            "probability": 1.0
        },
        {
            "start_logit": -2.265625,
            "end_logit": 14.9296875,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.984375,
            "end_logit": -2.63671875,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 14.9296875,
            "text": "-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 14.9296875,
            "text": "related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 14.9296875,
            "text": "gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": 14.9296875,
            "text": "peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -7.03125,
            "text": "calcitonin gene-related peptide",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.3359375,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.65625,
            "text": "calcitonin gene-related",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.9296875,
            "text": "selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.9296875,
            "text": "Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.9296875,
            "text": ", orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.9296875,
            "text": "and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.9296875,
            "text": ", and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 14.9296875,
            "text": "active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.9296875,
            "text": "novel, orally active, and selective calcitonin gene-related peptide receptor",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.0078125,
            "text": "calcitonin gene-related peptide receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.03125,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.2578125,
            "text": "calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_22": [
        {
            "start_logit": 0.93994140625,
            "end_logit": 10.234375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.81201171875
        },
        {
            "start_logit": -0.54052734375,
            "end_logit": 10.234375,
            "text": "CGRP) receptor",
            "probability": 0.1854248046875
        },
        {
            "start_logit": -5.05859375,
            "end_logit": 10.234375,
            "text": "receptor",
            "probability": 0.00202178955078125
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 10.234375,
            "text": ") receptor",
            "probability": 2.1517276763916016e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 10.234375,
            "text": "human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -10.5625,
            "end_logit": 10.234375,
            "text": "-related peptide (CGRP) receptor",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -10.59375,
            "end_logit": 10.234375,
            "text": "related peptide (CGRP) receptor",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 10.234375,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 10.234375,
            "text": "Studies were conducted in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -10.796875,
            "end_logit": 10.234375,
            "text": "isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 10.234375,
            "text": "vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 10.234375,
            "text": "coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 10.234375,
            "text": "in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 10.234375,
            "text": "the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -10.921875,
            "end_logit": 10.234375,
            "text": "were conducted in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 0.93994140625,
            "end_logit": -5.984375,
            "text": "calcitonin gene-related peptide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.93994140625,
            "end_logit": -8.0078125,
            "text": "calcitonin",
            "probability": 0.0
        },
        {
            "start_logit": 0.93994140625,
            "end_logit": -8.2890625,
            "text": "calcitonin gene-related peptide (CGRP)",
            "probability": 0.0
        },
        {
            "start_logit": 0.93994140625,
            "end_logit": -8.671875,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": -0.54052734375,
            "end_logit": -8.2890625,
            "text": "CGRP)",
            "probability": 0.0
        }
    ],
    "55032efde9bde69634000035_23": [
        {
            "start_logit": 12.3984375,
            "end_logit": 10.359375,
            "text": "calcitonin gene-related peptide (CGRP) receptor",
            "probability": 1.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -3.8515625,
            "text": "calcitonin",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -5.01171875,
            "text": "calcitonin gene-related peptide",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 10.359375,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.3203125,
            "text": "calcitonin gene-related peptide (CGRP",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.6328125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development.",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -9.9140625,
            "text": "calcitonin gene-related peptide (",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -10.1171875,
            "text": "calcitonin gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -10.171875,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development",
            "probability": 0.0
        },
        {
            "start_logit": 12.3984375,
            "end_logit": -10.1953125,
            "text": "calcitonin gene-related peptide (CGRP) receptor antagonist and",
            "probability": 0.0
        },
        {
            "start_logit": -8.765625,
            "end_logit": 10.359375,
            "text": "peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 10.359375,
            "text": "CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.359375,
            "text": "related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 10.359375,
            "text": "gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 10.359375,
            "text": "novel oral calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 10.359375,
            "text": "oral calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 10.359375,
            "text": "-related peptide (CGRP) receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 10.359375,
            "text": ") receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 10.359375,
            "text": "Telcagepant (MK-0974) is a novel oral calcitonin gene-related peptide (CGRP) receptor",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_1": [
        {
            "start_logit": 12.609375,
            "end_logit": 11.1484375,
            "text": "MATLAB environment",
            "probability": 0.71875
        },
        {
            "start_logit": 12.609375,
            "end_logit": 10.2109375,
            "text": "MATLAB",
            "probability": 0.281494140625
        },
        {
            "start_logit": 12.609375,
            "end_logit": -3.67578125,
            "text": "MATLAB environment,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.609375,
            "end_logit": -4.39453125,
            "text": "MAT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.03515625,
            "end_logit": 11.1484375,
            "text": "environment",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 11.1484375,
            "text": "LAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 11.1484375,
            "text": "the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.1640625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 10.2109375,
            "text": "LAB",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 10.2109375,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.4375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.46875,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.6328125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.71875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 12.609375,
            "end_logit": -9.8671875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 11.1484375,
            "text": "under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 11.1484375,
            "text": "total flexibility regarding network topology, kinetics and parameterization, as well as simulation options.Availability and implementation: SELANSI runs under the MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 10.2109375,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 10.2109375,
            "text": "total flexibility regarding network topology, kinetics and parameterization, as well as simulation options.Availability and implementation: SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -3.67578125,
            "text": "environment,",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_2": [
        {
            "start_logit": 13.8671875,
            "end_logit": 14.046875,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": 0.406005859375,
            "text": "MATLAB environment",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -2.529296875,
            "text": "MAT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.853515625,
            "end_logit": 14.046875,
            "text": "LAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -8.4140625,
            "text": "MATLAB environment,",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 14.046875,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.40625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.453125,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.5078125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.546875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.6796875,
            "text": "MATLAB environment, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.703125,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 14.046875,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.78125,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.921875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.9921875,
            "text": "MATLAB environment, and is available under GP",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.015625,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.046875,
            "text": "SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 14.046875,
            "text": "Availability and implementation SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.046875,
            "text": "implementation SELANSI runs under the MATLAB",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_3": [
        {
            "start_logit": 14.25,
            "end_logit": 14.3984375,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -1.7119140625,
            "text": "MAT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 14.3984375,
            "text": "LAB",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -4.2578125,
            "text": "MATLAB environment",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -8.6640625,
            "text": "MATLAB environment,",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 14.3984375,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.46875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.6484375,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.71875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.859375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.90625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.9140625,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.9375,
            "text": "MATLAB environment, and is available under GP",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.3984375,
            "text": "<br><b>Availability and implementation</b>: SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.3984375,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.3984375,
            "text": "<b>Availability and implementation</b>: SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": -3.43359375,
            "end_logit": -4.2578125,
            "text": "LAB environment",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -1.7119140625,
            "text": "the MAT",
            "probability": 0.0
        },
        {
            "start_logit": -3.43359375,
            "end_logit": -8.6640625,
            "text": "LAB environment,",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -1.7119140625,
            "text": "<br><b>Availability and implementation</b>: SELANSI runs under the MAT",
            "probability": 0.0
        }
    ],
    "5c6ab4c17c78d6947100001d_4": [
        {
            "start_logit": 13.65625,
            "end_logit": 13.984375,
            "text": "MATLAB",
            "probability": 1.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": 2.85546875,
            "text": "MATLAB environment",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 13.65625,
            "end_logit": -2.92578125,
            "text": "MAT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.947265625,
            "end_logit": 13.984375,
            "text": "LAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -7.91796875,
            "text": "MATLAB environment,",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 13.984375,
            "text": "the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.421875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi.",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 13.984375,
            "text": "SELANSI runs under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.4296875,
            "text": "MATLAB environment, and is available under GPLv3 licens",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.4609375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.5546875,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.6015625,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.609375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google.com/view/selansi",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.984375,
            "text": "under the MATLAB",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.6484375,
            "text": "MATLAB environment, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.75,
            "text": "MATLAB environment, and is available under GPLv3 license",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.859375,
            "text": "MATLAB environment, and is available under GPLv3 license at https://sites.google",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.921875,
            "text": "MATLAB environment, and is available under GP",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.9921875,
            "text": "MATLAB environment, and is available under GPLv",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 13.984375,
            "text": "ANSI runs under the MATLAB",
            "probability": 0.0
        }
    ],
    "5a992b371d1251d03b00000a_1": [
        {
            "start_logit": 10.21875,
            "end_logit": 14.1328125,
            "text": "Metagenomics of the Human Intestinal Tract",
            "probability": 1.0
        },
        {
            "start_logit": -3.482421875,
            "end_logit": 14.1328125,
            "text": "Tract",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.17578125,
            "end_logit": 14.1328125,
            "text": "Human Intestinal Tract",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 14.1328125,
            "text": "of the Human Intestinal Tract",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 14.1328125,
            "text": "Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": 14.1328125,
            "text": "the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 14.1328125,
            "text": "Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 14.1328125,
            "text": "omics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 14.1328125,
            "text": "The importance of microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -5.19140625,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 14.1328125,
            "text": "microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 14.1328125,
            "text": "and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 14.1328125,
            "text": "the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 14.1328125,
            "text": "of microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 14.1328125,
            "text": "Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -6.92578125,
            "text": "Metagenomics of the Human Intestinal Tract (",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -7.4921875,
            "text": "Metagen",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -7.91796875,
            "text": "Metagenomics",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -8.3359375,
            "text": "Metagenomics of the Human Intestinal Tract (MetaHIT) project",
            "probability": 0.0
        },
        {
            "start_logit": 10.21875,
            "end_logit": -8.40625,
            "text": "Metagenomics of the Human Intestinal",
            "probability": 0.0
        }
    ],
    "530c7f52970c65fa6b000010_1": [
        {
            "start_logit": -2.392578125,
            "end_logit": 8.296875,
            "text": "Oxantel disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.83203125
        },
        {
            "start_logit": -4.06640625,
            "end_logit": 8.296875,
            "text": "periodontal pathogens",
            "probability": 0.1556396484375
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 8.296875,
            "text": "pathogens",
            "probability": 0.01010894775390625
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 8.296875,
            "text": "ntel disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.0005011558532714844
        },
        {
            "start_logit": -9.8125,
            "end_logit": 8.296875,
            "text": "of periodontal pathogens",
            "probability": 0.0004973411560058594
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 8.296875,
            "text": "disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.00029468536376953125
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 8.296875,
            "text": "biofilm development of periodontal pathogens",
            "probability": 0.00021898746490478516
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 8.296875,
            "text": "polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.00021219253540039062
        },
        {
            "start_logit": -10.796875,
            "end_logit": 8.296875,
            "text": "el disrupts polymicrobial biofilm development of periodontal pathogens",
            "probability": 0.00018596649169921875
        },
        {
            "start_logit": -10.8125,
            "end_logit": 8.296875,
            "text": "robial biofilm development of periodontal pathogens",
            "probability": 0.00018310546875
        },
        {
            "start_logit": -10.8125,
            "end_logit": 8.296875,
            "text": "ial biofilm development of periodontal pathogens",
            "probability": 0.00018310546875
        },
        {
            "start_logit": -11.0,
            "end_logit": 8.296875,
            "text": "icrobial biofilm development of periodontal pathogens",
            "probability": 0.00015175342559814453
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 8.296875,
            "text": "development of periodontal pathogens",
            "probability": 0.0001436471939086914
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -7.5078125,
            "text": "Oxantel disrupts polymicrobial biofilm development of periodontal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -7.7734375,
            "text": "Oxantel disrupts polymicrobial biofilm development",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -8.609375,
            "text": "Oxantel disrupts polymicrobial biofilm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.06640625,
            "end_logit": -7.5078125,
            "text": "periodontal",
            "probability": 0.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -9.9453125,
            "text": "Oxantel disrupts polymicrobial biofilm development of",
            "probability": 0.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -10.3828125,
            "text": "Oxantel",
            "probability": 0.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -10.4921875,
            "text": "Oxant",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_1": [
        {
            "start_logit": 13.8671875,
            "end_logit": 15.0234375,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": 15.0234375,
            "text": "autophagy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -2.82421875,
            "text": "Chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -3.62890625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -6.03515625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -6.765625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 15.0234375,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -7.33984375,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -7.65625,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 15.0234375,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -8.8984375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.03125,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.6796875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.03125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.0859375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.1328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.21875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.2421875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting",
            "probability": 0.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": -3.62890625,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": -6.03515625,
            "text": "autophagy (CMA) is",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_2": [
        {
            "start_logit": 13.8671875,
            "end_logit": 15.0234375,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": 15.0234375,
            "text": "autophagy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -2.82421875,
            "text": "Chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -3.62890625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -6.03515625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -6.765625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 15.0234375,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -7.33984375,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -7.65625,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 15.0234375,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -8.8984375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.03125,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.6796875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.03125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.0859375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.1328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.21875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.2421875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting",
            "probability": 0.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": -3.62890625,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.9951171875,
            "end_logit": -6.03515625,
            "text": "autophagy (CMA) is",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_3": [
        {
            "start_logit": 13.9609375,
            "end_logit": 15.0234375,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -2.052734375,
            "end_logit": 15.0234375,
            "text": "autophagy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -2.548828125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -2.73046875,
            "text": "Chaperone",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 15.0234375,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.48046875,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.5234375,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.52734375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.890625,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.0234375,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.1171875,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.7890625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.90625,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.9140625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.015625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.1328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.171875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.234375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.234375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": -2.052734375,
            "end_logit": -2.548828125,
            "text": "autophagy (",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_4": [
        {
            "start_logit": 11.484375,
            "end_logit": 11.421875,
            "text": "chaperone-mediated autophagy",
            "probability": 0.990234375
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 11.421875,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 0.00955963134765625
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 7.56640625,
            "text": "Macroautophagy",
            "probability": 0.0002014636993408203
        },
        {
            "start_logit": 11.484375,
            "end_logit": -4.296875,
            "text": "chaperone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.96875,
            "end_logit": 11.421875,
            "text": "autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -5.890625,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -6.2109375,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": 11.421875,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.140625,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.44140625,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 11.421875,
            "text": "by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.421875,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.421875,
            "text": "y is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.421875,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 6.83984375,
            "end_logit": -4.296875,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.5625,
            "text": "chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.65625,
            "text": "chaperone-mediated autophagy (CMA), in",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 11.421875,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.78125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.8671875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_5": [
        {
            "start_logit": 11.484375,
            "end_logit": 11.421875,
            "text": "chaperone-mediated autophagy",
            "probability": 0.990234375
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 11.421875,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 0.00955963134765625
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 7.56640625,
            "text": "Macroautophagy",
            "probability": 0.0002014636993408203
        },
        {
            "start_logit": 11.484375,
            "end_logit": -4.296875,
            "text": "chaperone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.96875,
            "end_logit": 11.421875,
            "text": "autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -5.890625,
            "text": "chaperone-mediated autophagy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.484375,
            "end_logit": -6.2109375,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": 11.421875,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.140625,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -7.44140625,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 0.0
        },
        {
            "start_logit": -7.98046875,
            "end_logit": 11.421875,
            "text": "by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.421875,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.421875,
            "text": "y is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.421875,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 6.83984375,
            "end_logit": -4.296875,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.5625,
            "text": "chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.65625,
            "text": "chaperone-mediated autophagy (CMA), in",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 11.421875,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.78125,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc70",
            "probability": 0.0
        },
        {
            "start_logit": 11.484375,
            "end_logit": -9.8671875,
            "text": "chaperone-mediated autophagy (CMA), in which Hsc",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_6": [
        {
            "start_logit": 14.015625,
            "end_logit": 15.2265625,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -1.625,
            "end_logit": 15.2265625,
            "text": "autophagy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.015625,
            "end_logit": -2.525390625,
            "text": "Chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -4.8515625,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 15.2265625,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 15.2265625,
            "text": "AIMS: Chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.2265625,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -8.34375,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -8.4453125,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 15.2265625,
            "text": ": Chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.1328125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.140625,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.1796875,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.90625,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.0078125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.03125,
            "text": "Chaperone-mediated",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.1484375,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.203125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.2109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.2578125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_7": [
        {
            "start_logit": 13.203125,
            "end_logit": 14.46875,
            "text": "Chaperone-mediated autophagy",
            "probability": 1.0
        },
        {
            "start_logit": -3.068359375,
            "end_logit": 14.46875,
            "text": "autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.203125,
            "end_logit": -3.453125,
            "text": "Chaperone",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -3.45703125,
            "text": "Chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 14.46875,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.6875,
            "text": "Chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.9609375,
            "text": "Chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -7.97265625,
            "text": "Chaperone-mediated autophagy (CMA) is",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 14.46875,
            "text": "-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.3984375,
            "text": "Chaperone-",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.828125,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.9296875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.0,
            "text": "Chaperone-mediated autophagy (CMA) is a selective",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.0546875,
            "text": "Chaperone-mediated autophagy (CMA) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.0546875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.171875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.2109375,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.21875,
            "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble",
            "probability": 0.0
        },
        {
            "start_logit": -3.068359375,
            "end_logit": -3.45703125,
            "text": "autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -3.068359375,
            "end_logit": -7.6875,
            "text": "autophagy (CMA",
            "probability": 0.0
        }
    ],
    "5540fbce234c5a7c75000001_8": [
        {
            "start_logit": 10.9921875,
            "end_logit": 11.078125,
            "text": "chaperone-mediated autophagy",
            "probability": 0.8896484375
        },
        {
            "start_logit": 8.7265625,
            "end_logit": 11.078125,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy",
            "probability": 0.09375
        },
        {
            "start_logit": 8.7265625,
            "end_logit": 9.3671875,
            "text": "Macroautophagy",
            "probability": 0.0167999267578125
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -4.61328125,
            "text": "chaperone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 11.078125,
            "text": "autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 11.078125,
            "text": "autophagy is followed by chaperone-mediated autophagy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -5.93359375,
            "text": "chaperone-mediated autophagy (CMA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -6.37109375,
            "text": "chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -6.640625,
            "text": "chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -4.61328125,
            "text": "Macroautophagy is followed by chaperone",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": 11.078125,
            "text": "y is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 9.3671875,
            "text": "autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -7.73046875,
            "text": "chaperone-mediated autophagy (CMA),",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.078125,
            "text": "ophagy is followed by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 11.078125,
            "text": "mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 11.078125,
            "text": "by chaperone-mediated autophagy",
            "probability": 0.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -5.93359375,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA",
            "probability": 0.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.37109375,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.3671875,
            "text": "y",
            "probability": 0.0
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.640625,
            "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA)",
            "probability": 0.0
        }
    ],
    "5ac138aa95d0062724000001_1": [
        {
            "start_logit": 12.375,
            "end_logit": 14.1875,
            "text": "N-arginine dibasic convertase",
            "probability": 1.0
        },
        {
            "start_logit": -1.189453125,
            "end_logit": 14.1875,
            "text": "Nardilysin (N-arginine dibasic convertase",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -3.65625,
            "end_logit": 14.1875,
            "text": "ase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 14.1875,
            "text": "arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -4.796875,
            "text": "N",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -4.80078125,
            "text": "N-arginine dibasic convert",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 14.1875,
            "text": "-arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 14.1875,
            "text": "dilysin (N-arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 14.1875,
            "text": "dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -7.109375,
            "text": "N-arginine dibasic convertase; Nrdc) is",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.1875,
            "text": "convertase",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.1875,
            "text": "(N-arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -7.390625,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 14.1875,
            "text": "asic convertase",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 14.1875,
            "text": "in (N-arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 14.1875,
            "text": "lysin (N-arginine dibasic convertase",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -8.3203125,
            "text": "N-arginine dibasic convertase; Nrdc",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.46875,
            "text": "N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.703125,
            "text": "N-arginine dibasic convertase; Nrdc)",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.734375,
            "text": "N-arginine dibasic convertase; Nrdc) is a",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_1": [
        {
            "start_logit": 12.046875,
            "end_logit": 9.453125,
            "text": "Wnt",
            "probability": 1.0
        },
        {
            "start_logit": 12.046875,
            "end_logit": -9.3671875,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": 12.046875,
            "end_logit": -10.3203125,
            "text": "Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": 12.046875,
            "end_logit": -10.3828125,
            "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -9.3671875,
            "text": "cellular events and be regulated by the proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -9.625,
            "text": "Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -9.3671875,
            "text": "Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.3671875,
            "text": "proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.625,
            "text": "Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -9.625,
            "text": "cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -9.3671875,
            "text": "post-natal cellular events and be regulated by the proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -9.3671875,
            "text": "the proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -9.3671875,
            "text": "embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin.",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -9.9375,
            "text": "Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -9.9765625,
            "text": "Dishevelled is activated by Wnt and involved in signal transduction",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -9.625,
            "text": "Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.625,
            "text": "proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -9.625,
            "text": "post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.9375,
            "text": "Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -9.9765625,
            "text": "Wnt and involved in signal transduction",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_2": [
        {
            "start_logit": 11.828125,
            "end_logit": 10.5234375,
            "text": "Wnt",
            "probability": 1.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -8.5078125,
            "text": "Wnt signaling,",
            "probability": 0.0
        },
        {
            "start_logit": 11.828125,
            "end_logit": -9.28125,
            "text": "Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 10.5234375,
            "text": "Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.5234375,
            "text": "Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 10.5234375,
            "text": "Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.5234375,
            "text": "biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 10.5234375,
            "text": "dsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 10.5234375,
            "text": "cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.5234375,
            "text": "protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 10.5234375,
            "text": "evelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 10.5234375,
            "text": "within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 10.5234375,
            "text": "mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 10.5234375,
            "text": "diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -8.5078125,
            "text": "Xdsh) controls cell fate via canonical Wnt signaling,",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": -9.625,
            "text": "The Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -8.5078125,
            "text": "Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling,",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -8.5078125,
            "text": "Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling,",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": -9.828125,
            "text": "The Dishevelled protein mediates several diverse biological processes. Intriguingly",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -8.5078125,
            "text": "biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling,",
            "probability": 0.0
        }
    ],
    "5708a845cf1c32585100000f_3": [
        {
            "start_logit": 11.90625,
            "end_logit": 10.609375,
            "text": "Wnt",
            "probability": 1.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -8.0390625,
            "text": "Wnt signaling pathways.",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -9.3828125,
            "text": "Wnt signaling pathways",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -9.609375,
            "text": "Wnt signaling",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 10.609375,
            "text": "Dishevelled (DVL) proteins, three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 10.609375,
            "text": "humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 10.609375,
            "text": "al Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 10.609375,
            "text": "been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 10.609375,
            "text": "components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 10.609375,
            "text": "in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 10.609375,
            "text": "noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.609375,
            "text": "identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 10.609375,
            "text": "highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 10.609375,
            "text": "conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 10.609375,
            "text": "evelled (DVL) proteins, three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 10.609375,
            "text": "DVL) proteins, three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 10.609375,
            "text": "have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 10.609375,
            "text": "of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -8.0390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -8.0390625,
            "text": "humans, are highly conserved components of canonical and noncanonical Wnt signaling pathways.",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_1": [
        {
            "start_logit": 14.3203125,
            "end_logit": 15.0234375,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -0.58203125,
            "text": "ABCC1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.353515625,
            "end_logit": 15.0234375,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -2.560546875,
            "text": "ABC",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -8.2265625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian descent",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 15.0234375,
            "text": "C11",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.5859375,
            "text": "ABCC11 affects the cerumen VOC profiles of",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 15.0234375,
            "text": "in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.0234375,
            "text": "A single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.734375,
            "text": "ABCC11 affects the cerumen VOC profiles",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.9140625,
            "text": "ABCC11 affects",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.96875,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.0078125,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.0234375,
            "text": "SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.0625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.1015625,
            "text": "ABCC11 affects the cerumen VOC profiles of individuals from African, Caucasian",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.0234375,
            "text": "single nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.0234375,
            "text": "nucleotide polymorphism (SNP) in ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -0.58203125,
            "text": "C1",
            "probability": 0.0
        },
        {
            "start_logit": -2.353515625,
            "end_logit": -8.2265625,
            "text": "1 affects the cerumen VOC profiles of individuals from African, Caucasian, and Asian descent",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_2": [
        {
            "start_logit": 14.3125,
            "end_logit": 15.046875,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -1.392578125,
            "text": "ABCC1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.162109375,
            "end_logit": 15.046875,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3125,
            "end_logit": -2.4921875,
            "text": "ABC",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.046875,
            "text": "C11",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -8.4296875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen,",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.6171875,
            "text": "ABCC11 genotype",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.625,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.671875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.78125,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.84375,
            "text": "ABCC11 genotype alone",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.9140625,
            "text": "ABCC11 genotype alone does not predict",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.9140625,
            "text": "ABCC11 genotype alone does",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.921875,
            "text": "ABCC11 genotype alone does not predict the type and relative levels of volatiles found in human cerumen, and suggest",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.046875,
            "text": "Our findings also reveal that ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.046875,
            "text": "that ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -1.392578125,
            "text": "C1",
            "probability": 0.0
        },
        {
            "start_logit": -2.162109375,
            "end_logit": -8.4296875,
            "text": "1 genotype alone does not predict the type and relative levels of volatiles found in human cerumen,",
            "probability": 0.0
        },
        {
            "start_logit": -2.162109375,
            "end_logit": -9.6171875,
            "text": "1 genotype",
            "probability": 0.0
        },
        {
            "start_logit": -2.162109375,
            "end_logit": -9.625,
            "text": "1 genotype alone does not predict the type and relative levels of volatiles found in human cerumen",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_3": [
        {
            "start_logit": 14.3828125,
            "end_logit": 15.15625,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -1.0673828125,
            "text": "ABCC1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.046875,
            "end_logit": 15.15625,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -2.384765625,
            "text": "ABC",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.15625,
            "text": "C11",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.71875,
            "text": "ABCC11 encodes",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.1328125,
            "text": "ABCC11 encodes an ATP-driven efflux pump",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.3125,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.59375,
            "text": "ABCC11 encodes an ATP-driven efflux",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.7734375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.96875,
            "text": "ABCC11 encodes an",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -10.0390625,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -10.09375,
            "text": "ABCC11 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal and the secretion",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -1.0673828125,
            "text": "C1",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -8.71875,
            "text": "1 encodes",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -9.1328125,
            "text": "1 encodes an ATP-driven efflux pump",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -9.3125,
            "text": "1 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -9.59375,
            "text": "1 encodes an ATP-driven efflux",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -9.7734375,
            "text": "1 encodes an ATP-driven efflux pump protein that plays an important function in ceruminous apocrine glands of the auditory canal",
            "probability": 0.0
        },
        {
            "start_logit": -2.046875,
            "end_logit": -9.96875,
            "text": "1 encodes an",
            "probability": 0.0
        }
    ],
    "5acf74460340b9f058000013_4": [
        {
            "start_logit": 14.0859375,
            "end_logit": 14.796875,
            "text": "ABCC11",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": 0.1392822265625,
            "text": "ABCC1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -2.865234375,
            "end_logit": 14.796875,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -3.111328125,
            "text": "ABC",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 14.796875,
            "text": "(ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -6.5078125,
            "text": "ABCC11)",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 14.796875,
            "text": "C11",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 14.796875,
            "text": "the adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.796875,
            "text": "11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 14.796875,
            "text": "adenosine triphosphate (ATP) binding cassette, sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 14.796875,
            "text": "gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 14.796875,
            "text": "member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.5078125,
            "text": "ABCC11) to the production of different types of axillary odorants and cerumen",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.640625,
            "text": "ABCC11) to",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.7734375,
            "text": "ABCC11) to the production",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.8203125,
            "text": "ABCC11) to the",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.96875,
            "text": "ABCC11) to the production of different types of axillary odorants and cer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.796875,
            "text": "family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.796875,
            "text": ", sub-family C, member 11 gene (ABCC11",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 0.1392822265625,
            "text": "(ABCC1",
            "probability": 0.0
        }
    ],
    "62265b4a3a8413c653000083_1": [
        {
            "start_logit": 12.9765625,
            "end_logit": 14.9140625,
            "text": "Runt-related transcription factor 1",
            "probability": 1.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 14.9140625,
            "text": "1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -0.90771484375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.966796875,
            "end_logit": 14.9140625,
            "text": "transcription factor 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -4.48828125,
            "text": "Run",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -4.9609375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 14.9140625,
            "text": "factor 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 14.9140625,
            "text": "t-related transcription factor 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 14.9140625,
            "text": "related transcription factor 1",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -6.29296875,
            "text": "Runt-related transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -7.33203125,
            "text": "Runt-related transcription",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 14.9140625,
            "text": "-related transcription factor 1",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -7.4765625,
            "text": "Runt-related transcription factor 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -8.203125,
            "text": "Runt",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.2265625,
            "text": "Runt-related transcription factor 1 (RUNX1T1)",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.6328125,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.7734375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -9.8984375,
            "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -10.0859375,
            "text": "Runt-related transcription factor 1 (RUNX1",
            "probability": 0.0
        },
        {
            "start_logit": 12.9765625,
            "end_logit": -10.1875,
            "text": "Runt-related transcription factor 1 (RUN",
            "probability": 0.0
        }
    ],
    "54e8c7220fc566b149000002_1": [
        {
            "start_logit": -4.5390625,
            "end_logit": 12.8203125,
            "text": "in the nucleus",
            "probability": 0.68017578125
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 12.8203125,
            "text": "nucleus",
            "probability": 0.305419921875
        },
        {
            "start_logit": -9.28125,
            "end_logit": 12.8203125,
            "text": "the nucleus",
            "probability": 0.005931854248046875
        },
        {
            "start_logit": -9.65625,
            "end_logit": 12.8203125,
            "text": "S100A4 interacts with p53 in the nucleus",
            "probability": 0.004077911376953125
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.8203125,
            "text": "interacts with p53 in the nucleus",
            "probability": 0.0013875961303710938
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 12.8203125,
            "text": "4 interacts with p53 in the nucleus",
            "probability": 0.0010223388671875
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 12.8203125,
            "text": "with p53 in the nucleus",
            "probability": 0.0008482933044433594
        },
        {
            "start_logit": -11.3515625,
            "end_logit": 12.8203125,
            "text": "p53 in the nucleus",
            "probability": 0.0007481575012207031
        },
        {
            "start_logit": -4.5390625,
            "end_logit": -8.296875,
            "text": "in the",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -8.296875,
            "text": "the",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -8.296875,
            "text": "S100A4 interacts with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -8.296875,
            "text": "interacts with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -8.296875,
            "text": "4 interacts with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": -8.296875,
            "text": "with p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -9.984375,
            "text": "S100A4 interacts with p53",
            "probability": 0.0
        },
        {
            "start_logit": -11.3515625,
            "end_logit": -8.296875,
            "text": "p53 in the",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -9.984375,
            "text": "interacts with p53",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -9.984375,
            "text": "4 interacts with p53",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": -9.984375,
            "text": "with p53",
            "probability": 0.0
        },
        {
            "start_logit": -11.3515625,
            "end_logit": -9.984375,
            "text": "p53",
            "probability": 0.0
        }
    ],
    "54e8c7220fc566b149000002_2": [
        {
            "start_logit": -1.638671875,
            "end_logit": 13.4453125,
            "text": "nucleus",
            "probability": 0.9658203125
        },
        {
            "start_logit": -5.23046875,
            "end_logit": 13.4453125,
            "text": "cell nucleus",
            "probability": 0.026763916015625
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 13.4453125,
            "text": "in the cell nucleus",
            "probability": 0.004058837890625
        },
        {
            "start_logit": -8.4375,
            "end_logit": 13.4453125,
            "text": "the cell nucleus",
            "probability": 0.001079559326171875
        },
        {
            "start_logit": -9.265625,
            "end_logit": 13.4453125,
            "text": "proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 0.00047135353088378906
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 13.4453125,
            "text": "the interaction takes place in the cell nucleus",
            "probability": 0.0003478527069091797
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 13.4453125,
            "text": "interaction takes place in the cell nucleus",
            "probability": 0.0003116130828857422
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 13.4453125,
            "text": "place in the cell nucleus",
            "probability": 0.0002665519714355469
        },
        {
            "start_logit": -9.984375,
            "end_logit": 13.4453125,
            "text": "takes place in the cell nucleus",
            "probability": 0.00022971630096435547
        },
        {
            "start_logit": -10.046875,
            "end_logit": 13.4453125,
            "text": "that the interaction takes place in the cell nucleus",
            "probability": 0.00021588802337646484
        },
        {
            "start_logit": -10.5625,
            "end_logit": 13.4453125,
            "text": "using proximity ligation assay, we show that the interaction takes place in the cell nucleus",
            "probability": 0.00012886524200439453
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.4453125,
            "text": "we show that the interaction takes place in the cell nucleus",
            "probability": 0.00011026859283447266
        },
        {
            "start_logit": -11.078125,
            "end_logit": 13.4453125,
            "text": ", we show that the interaction takes place in the cell nucleus",
            "probability": 7.700920104980469e-05
        },
        {
            "start_logit": -1.638671875,
            "end_logit": -7.1640625,
            "text": "nucleus.",
            "probability": 0.0
        },
        {
            "start_logit": -5.23046875,
            "end_logit": -7.1640625,
            "text": "cell nucleus.",
            "probability": 0.0
        },
        {
            "start_logit": -5.23046875,
            "end_logit": -7.84375,
            "text": "cell",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -6.890625,
            "text": "in the",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.1640625,
            "text": "in the cell nucleus.",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -7.84375,
            "text": "in the cell",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -6.890625,
            "text": "the",
            "probability": 0.0
        }
    ],
    "58f0b0c070f9fc6f0f000006_1": [
        {
            "start_logit": 14.65625,
            "end_logit": 15.3515625,
            "text": "tardive dyskinesia",
            "probability": 1.0
        },
        {
            "start_logit": -1.4052734375,
            "end_logit": 15.3515625,
            "text": "dyskinesia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.65625,
            "end_logit": -1.400390625,
            "text": "tard",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.65625,
            "end_logit": -2.73046875,
            "text": "tardive",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 15.3515625,
            "text": "treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -5.19921875,
            "text": "tardive dyskinesia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 15.3515625,
            "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 15.3515625,
            "text": "ive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 15.3515625,
            "text": "drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 15.3515625,
            "text": "ed breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 15.3515625,
            "text": "granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 15.3515625,
            "text": "benazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 15.3515625,
            "text": "status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.3515625,
            "text": "breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 15.3515625,
            "text": "nazine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.3515625,
            "text": "zine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.3515625,
            "text": "ine granted breakthrough drug status for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.3515625,
            "text": "for treating tardive dyskinesia",
            "probability": 0.0
        },
        {
            "start_logit": -1.4052734375,
            "end_logit": -5.19921875,
            "text": "dyskinesia.",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -1.400390625,
            "text": "treating tard",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_1": [
        {
            "start_logit": 3.662109375,
            "end_logit": 3.060546875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.8291015625
        },
        {
            "start_logit": 3.662109375,
            "end_logit": 1.4765625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.17041015625
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -6.9375,
            "text": "Borderline oxacillin-resistant",
            "probability": 3.7670135498046875e-05
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 3.060546875,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 3.060546875,
            "text": "Staphylococcus aureus (",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 1.4765625,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.546875,
            "text": "Borderline oxacillin-",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.6015625,
            "text": "Borderline oxacillin",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.609375,
            "text": "Borderline oxacillin-resistant Staphylococcus",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.8671875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 3.060546875,
            "text": "cillin-resistant Staphylococcus aureus (",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -10.3828125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -10.4453125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 3.060546875,
            "text": "resistant Staphylococcus aureus (",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 3.060546875,
            "text": "(",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 1.4765625,
            "text": "Staphylococcus aureus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.703125,
            "end_logit": 3.060546875,
            "text": "aureus (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.71875,
            "end_logit": 3.060546875,
            "text": "-resistant Staphylococcus aureus (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 1.4765625,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -11.046875,
            "end_logit": 3.060546875,
            "text": "lin-resistant Staphylococcus aureus (",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5aae6499fcf456587200000c_2": [
        {
            "start_logit": 11.203125,
            "end_logit": 11.8984375,
            "text": "MRSA",
            "probability": 1.0
        },
        {
            "start_logit": -2.75,
            "end_logit": 11.8984375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -8.40625,
            "end_logit": 11.8984375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 11.8984375,
            "text": "methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 11.8984375,
            "text": "intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 11.8984375,
            "text": "misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 11.8984375,
            "text": "Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 11.8984375,
            "text": "resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.09375,
            "text": "MRSA) in the clinical laboratory.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 11.8984375,
            "text": "(MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 11.8984375,
            "text": "cillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 11.8984375,
            "text": "as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 11.8984375,
            "text": "Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.8984375,
            "text": "BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.8984375,
            "text": "resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.8984375,
            "text": "identified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.421875,
            "text": "MRSA)",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.4609375,
            "text": "MRSA) in the clinical laboratory",
            "probability": 0.0
        },
        {
            "start_logit": -2.75,
            "end_logit": -9.0546875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may",
            "probability": 0.0
        },
        {
            "start_logit": -2.75,
            "end_logit": -9.7265625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_3": [
        {
            "start_logit": 1.1455078125,
            "end_logit": -4.8984375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.8798828125
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -8.0625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.03717041015625
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -8.46875,
            "text": "borderline oxacillin-resistant",
            "probability": 0.0247650146484375
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -8.84375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0170135498046875
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -9.09375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 0.01325225830078125
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -9.78125,
            "text": "borderline oxacillin-resistant Staphylococcus",
            "probability": 0.00669097900390625
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -9.8203125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L",
            "probability": 0.00643157958984375
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -9.96875,
            "text": "borderline oxacillin-",
            "probability": 0.00554656982421875
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -10.1484375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L,",
            "probability": 0.004634857177734375
        },
        {
            "start_logit": 1.1455078125,
            "end_logit": -10.1640625,
            "text": "borderline oxacillin",
            "probability": 0.0045623779296875
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -4.8984375,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.0003986358642578125
        },
        {
            "start_logit": -9.078125,
            "end_logit": -4.8984375,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 3.2067298889160156e-05
        },
        {
            "start_logit": -9.1953125,
            "end_logit": -4.8984375,
            "text": "resistant Staphylococcus aureus",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": -9.40625,
            "end_logit": -4.8984375,
            "text": "Staphylococcus aureus",
            "probability": 2.3126602172851562e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.0625,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.46875,
            "text": "oxacillin-resistant",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -4.8984375,
            "text": "against borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -8.84375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -9.09375,
            "text": "oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": -9.78125,
            "text": "oxacillin-resistant Staphylococcus",
            "probability": 2.9802322387695312e-06
        }
    ],
    "5aae6499fcf456587200000c_4": [
        {
            "start_logit": 7.890625,
            "end_logit": 6.8828125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.9951171875
        },
        {
            "start_logit": 7.890625,
            "end_logit": 1.4541015625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.004360198974609375
        },
        {
            "start_logit": 7.890625,
            "end_logit": -2.728515625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance.",
            "probability": 6.681680679321289e-05
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 6.8828125,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 6.8828125,
            "text": "(",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.890625,
            "end_logit": -7.31640625,
            "text": "Borderline oxacillin-resistant",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.890625,
            "end_logit": -7.71875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.890625,
            "end_logit": -8.5078125,
            "text": "Borderline oxacillin-resistant Staphylococcus",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.890625,
            "end_logit": -8.578125,
            "text": "Borderline",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.890625,
            "end_logit": -9.390625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 6.8828125,
            "text": "Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.640625,
            "end_logit": 6.8828125,
            "text": "cillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -9.7578125,
            "text": "Borderline oxacillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -9.953125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -10.015625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -10.0859375,
            "text": "Borderline oxacillin-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.09375,
            "end_logit": 6.8828125,
            "text": "resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -10.1796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -10.25,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -10.2578125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite",
            "probability": 5.960464477539063e-08
        }
    ],
    "5aae6499fcf456587200000c_5": [
        {
            "start_logit": 6.97265625,
            "end_logit": -0.395751953125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.6171875
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -0.87451171875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.3818359375
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -8.234375,
            "text": "Borderline oxacillin-resistant",
            "probability": 0.0002429485321044922
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -8.7421875,
            "text": "Borderline oxacillin-resistant Staphylococcus",
            "probability": 0.00014674663543701172
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -8.7421875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1),",
            "probability": 0.00014674663543701172
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -9.0,
            "text": "Borderline",
            "probability": 0.00011259317398071289
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -9.375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1)",
            "probability": 7.742643356323242e-05
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -10.0078125,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin",
            "probability": 4.1425228118896484e-05
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -10.0234375,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(",
            "probability": 4.076957702636719e-05
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -10.15625,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of",
            "probability": 3.540515899658203e-05
        },
        {
            "start_logit": 6.97265625,
            "end_logit": -10.1796875,
            "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 3.4868717193603516e-05
        },
        {
            "start_logit": -6.359375,
            "end_logit": -0.395751953125,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.359375,
            "end_logit": -0.87451171875,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -8.859375,
            "end_logit": -0.395751953125,
            "text": "Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -0.395751953125,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.859375,
            "end_logit": -0.87451171875,
            "text": "Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3359375,
            "end_logit": -0.395751953125,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -0.87451171875,
            "text": "cillin-resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3359375,
            "end_logit": -0.87451171875,
            "text": "resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1875,
            "end_logit": -0.395751953125,
            "text": "-resistant Staphylococcus aureus",
            "probability": 5.960464477539063e-08
        }
    ],
    "5aae6499fcf456587200000c_6": [
        {
            "start_logit": 6.27734375,
            "end_logit": 7.328125,
            "text": "borderline oxacillin resistant Staphylococcus aureus (",
            "probability": 0.9990234375
        },
        {
            "start_logit": 6.27734375,
            "end_logit": 0.61767578125,
            "text": "borderline oxacillin resistant Staphylococcus aureus",
            "probability": 0.0012121200561523438
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -5.2109375,
            "text": "borderline oxacillin resistant",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 7.328125,
            "text": "oxacillin resistant Staphylococcus aureus (",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -7.94921875,
            "end_logit": 7.328125,
            "text": "(",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.015625,
            "end_logit": 7.328125,
            "text": "cillin resistant Staphylococcus aureus (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 7.328125,
            "text": "resistant Staphylococcus aureus (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.578125,
            "end_logit": 7.328125,
            "text": "Staphylococcus aureus (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -9.234375,
            "text": "borderline",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -9.3046875,
            "text": "borderline oxa",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.359375,
            "end_logit": 7.328125,
            "text": "lin resistant Staphylococcus aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.375,
            "end_logit": 7.328125,
            "text": "aureus (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -9.5234375,
            "text": "borderline oxacillin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -9.5859375,
            "text": "borderline oxacillin resistant Staphylococcus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -10.171875,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BORSA",
            "probability": 0.0
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -10.2421875,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BORSA)",
            "probability": 0.0
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -10.296875,
            "text": "borderline oxacillin resistant Staphylococcus aureus (BOR",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 0.61767578125,
            "text": "oxacillin resistant Staphylococcus aureus",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 0.61767578125,
            "text": "cillin resistant Staphylococcus aureus",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 0.61767578125,
            "text": "resistant Staphylococcus aureus",
            "probability": 0.0
        }
    ],
    "5aae6499fcf456587200000c_7": [
        {
            "start_logit": 3.662109375,
            "end_logit": 3.060546875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.8291015625
        },
        {
            "start_logit": 3.662109375,
            "end_logit": 1.4765625,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.17041015625
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -6.9375,
            "text": "borderline oxacillin-resistant",
            "probability": 3.7670135498046875e-05
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 3.060546875,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 3.060546875,
            "text": "Staphylococcus aureus (",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 1.4765625,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.546875,
            "text": "borderline oxacillin-",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.6015625,
            "text": "borderline oxacillin",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.609375,
            "text": "borderline oxacillin-resistant Staphylococcus",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -9.8671875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA)",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 3.060546875,
            "text": "cillin-resistant Staphylococcus aureus (",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -10.3828125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 3.662109375,
            "end_logit": -10.4453125,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 3.060546875,
            "text": "resistant Staphylococcus aureus (",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 3.060546875,
            "text": "(",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 1.4765625,
            "text": "Staphylococcus aureus",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.703125,
            "end_logit": 3.060546875,
            "text": "aureus (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.71875,
            "end_logit": 3.060546875,
            "text": "-resistant Staphylococcus aureus (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 1.4765625,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -11.046875,
            "end_logit": 3.060546875,
            "text": "lin-resistant Staphylococcus aureus (",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5aae6499fcf456587200000c_8": [
        {
            "start_logit": -0.54736328125,
            "end_logit": 2.599609375,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.93115234375
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -0.03338623046875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus",
            "probability": 0.06695556640625
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 2.599609375,
            "text": "oxacillin-resistant Staphylococcus aureus (",
            "probability": 0.001728057861328125
        },
        {
            "start_logit": -9.34375,
            "end_logit": 2.599609375,
            "text": "Staphylococcus aureus (",
            "probability": 0.00014066696166992188
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -0.03338623046875,
            "text": "oxacillin-resistant Staphylococcus aureus",
            "probability": 0.00012421607971191406
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -6.43359375,
            "text": "borderline oxacillin-resistant",
            "probability": 0.00011134147644042969
        },
        {
            "start_logit": -9.8125,
            "end_logit": 2.599609375,
            "text": "cillin-resistant Staphylococcus aureus (",
            "probability": 8.803606033325195e-05
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 2.599609375,
            "text": "resistant Staphylococcus aureus (",
            "probability": 6.914138793945312e-05
        },
        {
            "start_logit": -10.296875,
            "end_logit": 2.599609375,
            "text": "(",
            "probability": 5.424022674560547e-05
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 2.599609375,
            "text": "-resistant Staphylococcus aureus (",
            "probability": 2.9742717742919922e-05
        },
        {
            "start_logit": -9.34375,
            "end_logit": -0.03338623046875,
            "text": "Staphylococcus aureus",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -9.8125,
            "end_logit": -0.03338623046875,
            "text": "cillin-resistant Staphylococcus aureus",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -9.3828125,
            "text": "borderline oxacillin",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -9.4453125,
            "text": "borderline oxacillin-",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -0.03338623046875,
            "text": "resistant Staphylococcus aureus",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -9.546875,
            "text": "borderline oxacillin-resistant Staphylococcus",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -10.1875,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BOR",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -0.54736328125,
            "end_logit": -10.25,
            "text": "borderline oxacillin-resistant Staphylococcus aureus (BORSA",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -0.03338623046875,
            "text": "-resistant Staphylococcus aureus",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -6.43359375,
            "text": "oxacillin-resistant",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e46eb7a3f5415952900000d_1": [
        {
            "start_logit": 14.421875,
            "end_logit": 15.0625,
            "text": "Parkinson's Disease",
            "probability": 1.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -1.2880859375,
            "text": "Parkinson",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.931640625,
            "end_logit": 15.0625,
            "text": "Disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.421875,
            "end_logit": -2.23046875,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.953125,
            "end_logit": 15.0625,
            "text": "'s Disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -6.66015625,
            "text": "Parkinson'",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": 15.0625,
            "text": "s Disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.1171875,
            "text": "Parkinson's",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.640625,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.65625,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.7890625,
            "text": "Parkinson's Disease Rating",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.921875,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.9375,
            "text": "Parkinson's Disease Rating Scale,",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.9609375,
            "text": "Parkinson's Disease Rating Scale, and the Quality of Life for Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.0625,
            "text": "Unified Parkinson's Disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.0625,
            "text": "the Unified Parkinson's Disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.931640625,
            "end_logit": -2.23046875,
            "text": "Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -4.5390625,
            "end_logit": -2.23046875,
            "text": "Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": -2.23046875,
            "text": "'s Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -2.23046875,
            "text": "s Disease Rating Scale, and the Quality of Life for Essential Tremor",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_2": [
        {
            "start_logit": 13.9921875,
            "end_logit": 14.8984375,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": 14.8984375,
            "text": "tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -2.6328125,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 14.8984375,
            "text": "Tremor (FTM) has been used in large trials for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 14.8984375,
            "text": "for essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.4375,
            "text": "essential tremor (ET",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.4921875,
            "text": "essential tremor (",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.5,
            "text": "essential tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.6875,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.8984375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.9375,
            "text": "essential tremor (ET),",
            "probability": 0.0
        },
        {
            "start_logit": 13.9921875,
            "end_logit": -9.984375,
            "text": "essential tremor (ET), but its anchors for ratings from 0 to 4 of upper limb tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -2.6328125,
            "text": "Tremor (FTM) has been used in large trials for essential",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": -2.6328125,
            "text": "for essential",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.4375,
            "text": "tremor (ET",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.4921875,
            "text": "tremor (",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.5,
            "text": "tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.6875,
            "text": "tremor (ET), but its anchors for ratings from 0 to 4",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.8984375,
            "text": "tremor (ET), but its anchors for ratings from 0 to 4 of upper",
            "probability": 0.0
        },
        {
            "start_logit": -2.599609375,
            "end_logit": -9.9375,
            "text": "tremor (ET),",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_3": [
        {
            "start_logit": 12.515625,
            "end_logit": 13.84375,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": -3.8984375,
            "end_logit": 13.84375,
            "text": "Tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.515625,
            "end_logit": -4.69140625,
            "text": "Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.84375,
            "text": "Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.84375,
            "text": "the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 13.84375,
            "text": "Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.84375,
            "text": "Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.84375,
            "text": "Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.84375,
            "text": "and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 13.84375,
            "text": "the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -3.8984375,
            "end_logit": -9.578125,
            "text": "Tremor Rating Scale, and the Tremor Research Group Essential Tremor Rating Assessment Scale), one ADL/disability scale (the Bain and Findley Tremor ADL",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -6.671875,
            "text": "tremor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3359375,
            "end_logit": -6.9921875,
            "text": "tremor severity scales (the Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -4.69140625,
            "text": "Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -4.69140625,
            "text": "the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -4.69140625,
            "text": "Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -4.69140625,
            "text": "Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -4.69140625,
            "text": "Findley Clinical Tremor Rating Scale, the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -4.69140625,
            "text": "and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -4.69140625,
            "text": "the Bain and Findley Spirography Scale, the Washington Heights-Inwood Genetic Study of Essential",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_4": [
        {
            "start_logit": 13.5859375,
            "end_logit": 14.53125,
            "text": "essential tremor",
            "probability": 1.0
        },
        {
            "start_logit": -3.29296875,
            "end_logit": 14.53125,
            "text": "tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -3.568359375,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 14.53125,
            "text": "Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 14.53125,
            "text": "in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -8.0859375,
            "text": "essential tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -8.1640625,
            "text": "essential tremor (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.0703125,
            "text": "essential tremor (ET).",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.2578125,
            "text": "essential tremor (ET",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.53125,
            "text": "Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 14.53125,
            "text": "Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 14.53125,
            "text": "Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.234375,
            "end_logit": 14.53125,
            "text": "the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 14.53125,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.2578125,
            "end_logit": 14.53125,
            "text": "ter reliability of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -3.568359375,
            "text": "Tremor Rating Scale (TRS) in essential",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": -4.4765625,
            "text": "Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -3.568359375,
            "text": "in essential",
            "probability": 0.0
        },
        {
            "start_logit": -3.29296875,
            "end_logit": -8.0859375,
            "text": "tremor (ET)",
            "probability": 0.0
        },
        {
            "start_logit": -3.29296875,
            "end_logit": -8.1640625,
            "text": "tremor (",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_5": [
        {
            "start_logit": 10.7421875,
            "end_logit": 12.6328125,
            "text": "essential tremor",
            "probability": 0.8642578125
        },
        {
            "start_logit": 8.8359375,
            "end_logit": 12.6328125,
            "text": "Tremor Rating Scale in essential tremor",
            "probability": 0.1285400390625
        },
        {
            "start_logit": 8.8359375,
            "end_logit": 9.7265625,
            "text": "Tremor",
            "probability": 0.007022857666015625
        },
        {
            "start_logit": -4.61328125,
            "end_logit": 12.6328125,
            "text": "tremor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 12.6328125,
            "text": "in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -6.1953125,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -7.921875,
            "text": "essential tremor.",
            "probability": 0.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.1953125,
            "text": "Tremor Rating Scale in essential",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 12.6328125,
            "text": "Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.3125,
            "end_logit": 12.6328125,
            "text": "Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.359375,
            "end_logit": 12.6328125,
            "text": "Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.40625,
            "end_logit": 12.6328125,
            "text": "reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.4140625,
            "end_logit": 12.6328125,
            "text": "ter reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.4140625,
            "end_logit": 12.6328125,
            "text": "interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor",
            "probability": 0.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.921875,
            "text": "Tremor Rating Scale in essential tremor.",
            "probability": 0.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.9921875,
            "text": "Tremor Rating Scale in",
            "probability": 0.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -9.2578125,
            "text": "Tremor Rating",
            "probability": 0.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -9.5859375,
            "text": "Tremor Rating Scale",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 9.7265625,
            "text": "Tolosa-Marin Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.359375,
            "end_logit": 9.7265625,
            "text": "Fahn-Tolosa-Marin Tremor",
            "probability": 0.0
        }
    ],
    "5e46eb7a3f5415952900000d_6": [
        {
            "start_logit": 13.9609375,
            "end_logit": 14.78125,
            "text": "Essential Tremor",
            "probability": 1.0
        },
        {
            "start_logit": -2.763671875,
            "end_logit": 14.78125,
            "text": "Tremor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -2.841796875,
            "text": "Essential",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.1484375,
            "text": "Essential Tremor Rating",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.1875,
            "text": "Essential Tremor Rating Assessment",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.1015625,
            "text": "Essential Tremor Rating Assessment Scale",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.109375,
            "text": "Essential Tremor Rating Assessment Scale.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 14.78125,
            "text": "the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.78125,
            "text": "Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 14.78125,
            "text": "Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 14.78125,
            "text": "Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.21875,
            "end_logit": 14.78125,
            "text": "the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": 14.78125,
            "text": "Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -11.2734375,
            "end_logit": 14.78125,
            "text": "-Tolosa-Marin Clinical Rating Scale and the Essential Tremor",
            "probability": 0.0
        },
        {
            "start_logit": -2.763671875,
            "end_logit": -8.1484375,
            "text": "Tremor Rating",
            "probability": 0.0
        },
        {
            "start_logit": -2.763671875,
            "end_logit": -8.1875,
            "text": "Tremor Rating Assessment",
            "probability": 0.0
        },
        {
            "start_logit": -2.763671875,
            "end_logit": -9.1015625,
            "text": "Tremor Rating Assessment Scale",
            "probability": 0.0
        },
        {
            "start_logit": -2.763671875,
            "end_logit": -9.109375,
            "text": "Tremor Rating Assessment Scale.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -2.841796875,
            "text": "the Essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -2.841796875,
            "text": "Clinical Rating Scale and the Essential",
            "probability": 0.0
        }
    ],
    "58f4b1a170f9fc6f0f000010_1": [
        {
            "start_logit": -10.7265625,
            "end_logit": -0.35498046875,
            "text": "Amanita phalloides poisoning",
            "probability": 0.1552734375
        },
        {
            "start_logit": -10.8125,
            "end_logit": -0.35498046875,
            "text": "post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.1424560546875
        },
        {
            "start_logit": -10.96875,
            "end_logit": -0.35498046875,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.121826171875
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -0.35498046875,
            "text": "term post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.1190185546875
        },
        {
            "start_logit": -11.0,
            "end_logit": -0.35498046875,
            "text": "anita phalloides poisoning",
            "probability": 0.11810302734375
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -0.35498046875,
            "text": "' short-term post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.1171875
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -0.35498046875,
            "text": "patients' short-term post liver transplantation survival in Amanita phalloides poisoning",
            "probability": 0.113525390625
        },
        {
            "start_logit": -11.046875,
            "end_logit": -0.35498046875,
            "text": "in Amanita phalloides poisoning",
            "probability": 0.11273193359375
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -9.046875,
            "text": "Amanita phalloides",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": -10.8125,
            "end_logit": -9.046875,
            "text": "post liver transplantation survival in Amanita phalloides",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": -10.96875,
            "end_logit": -9.046875,
            "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -9.046875,
            "text": "term post liver transplantation survival in Amanita phalloides",
            "probability": 2.008676528930664e-05
        },
        {
            "start_logit": -11.0,
            "end_logit": -9.046875,
            "text": "anita phalloides",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -9.046875,
            "text": "' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -9.046875,
            "text": "patients' short-term post liver transplantation survival in Amanita phalloides",
            "probability": 1.8835067749023438e-05
        },
        {
            "start_logit": -11.046875,
            "end_logit": -9.046875,
            "text": "in Amanita phalloides",
            "probability": 1.8835067749023438e-05
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -9.765625,
            "text": "Amanita phallo",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": -10.8125,
            "end_logit": -9.765625,
            "text": "post liver transplantation survival in Amanita phallo",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": -10.8125,
            "end_logit": -9.8046875,
            "text": "post liver transplantation survival in",
            "probability": 1.1086463928222656e-05
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -9.9921875,
            "text": "Am",
            "probability": 1.0073184967041016e-05
        }
    ],
    "58aa0c6f396a458e50000008_1": [
        {
            "start_logit": 11.6875,
            "end_logit": 11.53125,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 11.53125,
            "text": "hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -9.203125,
            "text": "oxytocin (OXT) and its receptor (OXTR",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -9.3359375,
            "text": "oxytocin (OXT",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -9.859375,
            "text": "oxytocin (OXT)",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.53125,
            "text": "neurohypophysial hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.2265625,
            "text": "oxytocin (",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.34375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors,",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.4765625,
            "text": "oxytocin (OXT) and its receptor (OXTR)",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 11.53125,
            "text": "The neurohypophysial hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.5625,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.5703125,
            "text": "oxytocin (OXT) and its receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.5859375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.5859375,
            "text": "oxytocin (OXT) and",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -10.59375,
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.53125,
            "text": "ial hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.53125,
            "text": "ypophysial hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -9.203125,
            "text": "hormone oxytocin (OXT) and its receptor (OXTR",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -9.3359375,
            "text": "hormone oxytocin (OXT",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -9.859375,
            "text": "hormone oxytocin (OXT)",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_2": [
        {
            "start_logit": 11.5703125,
            "end_logit": 11.71875,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -6.26953125,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 11.71875,
            "text": "hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": 11.71875,
            "text": "Neuropeptide hormone oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -9.9921875,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.0,
            "text": "oxytocin has",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.3515625,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.375,
            "text": "oxytocin has roles in social bonding, energy metabolism",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.390625,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.40625,
            "text": "oxytocin has roles in",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.421875,
            "text": "oxytocin has roles in social bonding,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.4375,
            "text": "oxytocin has roles in social bonding, energy metabolism, and wound healing contributing",
            "probability": 0.0
        },
        {
            "start_logit": -7.10546875,
            "end_logit": -6.26953125,
            "text": "hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8984375,
            "end_logit": -6.26953125,
            "text": "Neuropeptide hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -6.26953125,
            "text": "social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -6.26953125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -6.26953125,
            "text": "wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -7.10546875,
            "end_logit": -9.59375,
            "text": "hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -6.26953125,
            "text": "energy metabolism, and wound healing contributing to good physical, mental and social health.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -6.26953125,
            "text": "social health.",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_3": [
        {
            "start_logit": 11.6953125,
            "end_logit": 11.578125,
            "text": "Oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -7.59765625,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.109375,
            "text": "Oxytocin is known as the 'love hormone'",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.328125,
            "text": "Oxytocin is known as the 'love hormone",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.4765625,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.5234375,
            "text": "Oxytocin is known as the 'love hormone' due its role in",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.5703125,
            "text": "Oxytocin is known as the 'love hormone' due",
            "probability": 0.0
        },
        {
            "start_logit": 11.6953125,
            "end_logit": -10.578125,
            "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -7.59765625,
            "text": "love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -7.59765625,
            "text": "mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -7.59765625,
            "text": "the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": -7.59765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": -7.59765625,
            "text": "promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -7.59765625,
            "text": "-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -7.59765625,
            "text": "'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -7.59765625,
            "text": "is known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -7.59765625,
            "text": "bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -7.59765625,
            "text": "known as the 'love hormone' due its role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -7.59765625,
            "text": "role in promoting mother-child and pair bonding.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -7.59765625,
            "text": "child and pair bonding.",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_4": [
        {
            "start_logit": 11.53125,
            "end_logit": 11.578125,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 11.578125,
            "text": "The oxytocin",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -8.8359375,
            "text": "oxytocin (OT",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -9.3671875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -9.6171875,
            "text": "oxytocin (",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -9.7890625,
            "text": "oxytocin (OT) hormone pathway",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.0390625,
            "text": "oxytocin (OT)",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.1484375,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR)",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.1640625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes,",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.296875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.3671875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.4140625,
            "text": "oxytocin (OT) hormone",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.453125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.4765625,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OX",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.4921875,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in",
            "probability": 0.0
        },
        {
            "start_logit": 11.53125,
            "end_logit": -10.5078125,
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -8.8359375,
            "text": "The oxytocin (OT",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -9.3671875,
            "text": "The oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -9.6171875,
            "text": "The oxytocin (",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -9.7890625,
            "text": "The oxytocin (OT) hormone pathway",
            "probability": 0.0
        }
    ],
    "58aa0c6f396a458e50000008_5": [
        {
            "start_logit": 10.9765625,
            "end_logit": 12.1640625,
            "text": "oxytocin",
            "probability": 1.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -7.0703125,
            "text": "oxytocin, a hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -8.453125,
            "text": "oxytocin,",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.421875,
            "text": "oxytocin, a hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.9609375,
            "text": "oxytocin, a",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.4609375,
            "text": "oxytocin, a hormone involved in",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -7.0703125,
            "text": "parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -7.0703125,
            "text": "-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -7.0703125,
            "text": "in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -7.0703125,
            "text": "bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -7.0703125,
            "text": "involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -7.0703125,
            "text": "hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -7.0703125,
            "text": "offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -7.0703125,
            "text": "a hormone involved in parent-offspring bonding",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -9.421875,
            "text": "parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -9.421875,
            "text": "-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.421875,
            "text": "in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -9.421875,
            "text": "involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -9.421875,
            "text": "hormone involved in parent-offspring",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -9.421875,
            "text": "offspring",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_1": [
        {
            "start_logit": -1.6767578125,
            "end_logit": 4.76171875,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.9853515625
        },
        {
            "start_logit": -6.0390625,
            "end_logit": 4.76171875,
            "text": ".",
            "probability": 0.01255035400390625
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 4.76171875,
            "text": ". SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00038504600524902344
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 4.76171875,
            "text": "conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.0003345012664794922
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 4.76171875,
            "text": "enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.0002574920654296875
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 4.76171875,
            "text": "ating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00024962425231933594
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 4.76171875,
            "text": "(Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00018262863159179688
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 4.76171875,
            "text": "-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00016880035400390625
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 4.76171875,
            "text": "important conjunction enzyme in the SUMO pathway.",
            "probability": 0.00014007091522216797
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -7.07421875,
            "text": "SUMO-conjugating enzyme",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -8.265625,
            "text": "SUMO-conjugating enzyme (Ubc9)",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -8.7578125,
            "text": "SUMO-conjugating enzyme (Ubc9) is",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -9.34375,
            "text": "SUMO-conjugating enzyme (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -2.6328125,
            "end_logit": -8.5859375,
            "text": "The small ubiquitin-like modifier (SUMO)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -9.65625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -9.6640625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -9.84375,
            "text": "SUMO-conjugating enzyme (Ub",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -2.6328125,
            "end_logit": -8.953125,
            "text": "The small ubiquitin-like modifier (SUMO) pathway in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -10.0625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -1.6767578125,
            "end_logit": -10.2265625,
            "text": "SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme",
            "probability": 2.980232238769531e-07
        }
    ],
    "58a5b1fe60087bc10a000024_2": [
        {
            "start_logit": 1.5869140625,
            "end_logit": 5.6875,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.91845703125
        },
        {
            "start_logit": 1.5869140625,
            "end_logit": 3.158203125,
            "text": "SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.0733642578125
        },
        {
            "start_logit": -3.80078125,
            "end_logit": 5.6875,
            "text": "enzyme",
            "probability": 0.00420379638671875
        },
        {
            "start_logit": -4.1484375,
            "end_logit": 5.6875,
            "text": "RAP80 interacts with the SUMO-conjugating enzyme",
            "probability": 0.0029697418212890625
        },
        {
            "start_logit": -3.80078125,
            "end_logit": 3.158203125,
            "text": "enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.000335693359375
        },
        {
            "start_logit": -4.1484375,
            "end_logit": 3.158203125,
            "text": "RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 0.00023627281188964844
        },
        {
            "start_logit": 1.5869140625,
            "end_logit": -3.08203125,
            "text": "SUMO-conjugating enzyme UBC9 and",
            "probability": 0.00014328956604003906
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 3.158203125,
            "text": ".",
            "probability": 6.0677528381347656e-05
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 5.6875,
            "text": "ating enzyme",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": -9.125,
            "end_logit": 5.6875,
            "text": "conjugating enzyme",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 5.6875,
            "text": "the SUMO-conjugating enzyme",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 5.6875,
            "text": "-conjugating enzyme",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 5.6875,
            "text": "80 interacts with the SUMO-conjugating enzyme",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 5.6875,
            "text": "with the SUMO-conjugating enzyme",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 3.158203125,
            "text": "ating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -9.125,
            "end_logit": 3.158203125,
            "text": "conjugating enzyme UBC9 and is a novel target for sumoylation.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 1.5869140625,
            "end_logit": -8.2265625,
            "text": "SUMO-conjugating enzyme UB",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 1.5869140625,
            "end_logit": -8.359375,
            "text": "SUMO-conjugating",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -9.953125,
            "end_logit": 3.158203125,
            "text": "sumoylation.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -3.80078125,
            "end_logit": -3.08203125,
            "text": "enzyme UBC9 and",
            "probability": 6.556510925292969e-07
        }
    ],
    "58a5b1fe60087bc10a000024_3": [
        {
            "start_logit": 1.01171875,
            "end_logit": 11.3203125,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.990234375
        },
        {
            "start_logit": -3.623046875,
            "end_logit": 11.3203125,
            "text": "enzyme",
            "probability": 0.00963592529296875
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 11.3203125,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.0001952648162841797
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 11.3203125,
            "text": "the E2 SUMO-conjugating enzyme",
            "probability": 0.00014281272888183594
        },
        {
            "start_logit": -9.34375,
            "end_logit": 11.3203125,
            "text": "ating enzyme",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 11.3203125,
            "text": "conjugating enzyme",
            "probability": 2.1517276763916016e-05
        },
        {
            "start_logit": -10.40625,
            "end_logit": 11.3203125,
            "text": "/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.3203125,
            "text": "-conjugating enzyme",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -8.296875,
            "text": "E2",
            "probability": 0.0
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -8.3359375,
            "text": "E2 SUMO-conjugating",
            "probability": 0.0
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -8.375,
            "text": "E2 SUMO-conjugating enzyme Ub",
            "probability": 0.0
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -9.40625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and",
            "probability": 0.0
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -9.65625,
            "text": "E2 SUMO-conjugating enzyme Ubc",
            "probability": 0.0
        },
        {
            "start_logit": 1.01171875,
            "end_logit": -9.6640625,
            "text": "E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can",
            "probability": 0.0
        },
        {
            "start_logit": -3.623046875,
            "end_logit": -8.375,
            "text": "enzyme Ub",
            "probability": 0.0
        },
        {
            "start_logit": -3.623046875,
            "end_logit": -9.40625,
            "text": "enzyme Ubc9 and",
            "probability": 0.0
        },
        {
            "start_logit": -3.623046875,
            "end_logit": -9.4453125,
            "text": "enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1",
            "probability": 0.0
        },
        {
            "start_logit": -3.623046875,
            "end_logit": -9.65625,
            "text": "enzyme Ubc",
            "probability": 0.0
        },
        {
            "start_logit": -3.623046875,
            "end_logit": -9.6640625,
            "text": "enzyme Ubc9 and a E3 SUMO ligase, PIASy, can",
            "probability": 0.0
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -8.3203125,
            "text": "Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R),",
            "probability": 0.0
        }
    ],
    "58a5b1fe60087bc10a000024_4": [
        {
            "start_logit": -3.9453125,
            "end_logit": 1.873046875,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.7939453125
        },
        {
            "start_logit": -5.8515625,
            "end_logit": 1.873046875,
            "text": "enzyme",
            "probability": 0.1180419921875
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 1.873046875,
            "text": "SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.0599365234375
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 1.873046875,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.014801025390625
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 1.873046875,
            "text": "blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.004367828369140625
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -4.0703125,
            "text": "E2 SUMO-conjugating enzyme Ub",
            "probability": 0.002079010009765625
        },
        {
            "start_logit": -10.046875,
            "end_logit": 1.873046875,
            "text": "conjugating enzyme",
            "probability": 0.00177764892578125
        },
        {
            "start_logit": -10.125,
            "end_logit": 1.873046875,
            "text": "of E2 SUMO-conjugating enzyme",
            "probability": 0.001644134521484375
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 1.873046875,
            "text": "ating enzyme",
            "probability": 0.0014848709106445312
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 1.873046875,
            "text": "ylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme",
            "probability": 0.0009150505065917969
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -4.0703125,
            "text": "enzyme Ub",
            "probability": 0.00030875205993652344
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -6.59375,
            "text": "E2",
            "probability": 0.0001666545867919922
        },
        {
            "start_logit": -6.52734375,
            "end_logit": -4.0703125,
            "text": "SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme Ub",
            "probability": 0.0001577138900756836
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -7.7890625,
            "text": "E2 SUMO-conjugating enzyme Ubc9, inhibits various physiological stimuli-induced p100 processing and ultimate activation of the alternative NF-kappaB pathway",
            "probability": 5.042552947998047e-05
        },
        {
            "start_logit": -7.9296875,
            "end_logit": -4.0703125,
            "text": "SUMO-conjugating enzyme Ub",
            "probability": 3.8683414459228516e-05
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -8.375,
            "text": "E2 SUMO-conjugating enzyme Ubc9, inhibits various physiological stimuli-induced p100 processing and ultimate activation of the alternative NF-kappaB",
            "probability": 2.8073787689208984e-05
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -8.59375,
            "text": "E2 SUMO-conjugating enzyme Ubc",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -3.9453125,
            "end_logit": -8.921875,
            "text": "E2 SUMO-conjugating",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -6.52734375,
            "end_logit": -6.59375,
            "text": "SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -9.1484375,
            "end_logit": -4.0703125,
            "text": "blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme Ub",
            "probability": 1.1444091796875e-05
        }
    ],
    "58a5b1fe60087bc10a000024_5": [
        {
            "start_logit": 4.73828125,
            "end_logit": 2.17578125,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.6943359375
        },
        {
            "start_logit": 4.73828125,
            "end_logit": 1.3486328125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 0.30322265625
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -3.541015625,
            "text": "SUMO-conjugating enzyme E2",
            "probability": 0.0022792816162109375
        },
        {
            "start_logit": -3.21875,
            "end_logit": 1.3486328125,
            "text": "E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 0.00010657310485839844
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -6.859375,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in",
            "probability": 8.302927017211914e-05
        },
        {
            "start_logit": -5.1796875,
            "end_logit": 2.17578125,
            "text": "enzyme",
            "probability": 3.409385681152344e-05
        },
        {
            "start_logit": -5.1796875,
            "end_logit": 1.3486328125,
            "text": "enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 1.4901161193847656e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -8.6171875,
            "text": "SUMO-conjugating",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.328125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.5234375,
            "text": "SUMO-conjugating enzyme E2 UB",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.5625,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.578125,
            "text": "SUMO-conjugating enzyme E2 UBC",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.7109375,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.71875,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.734375,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.7890625,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.8125,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -9.9375,
            "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 4.73828125,
            "end_logit": -10.015625,
            "text": "SUMO",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -7.09375,
            "end_logit": 1.3486328125,
            "text": "viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.",
            "probability": 2.205371856689453e-06
        }
    ],
    "58a5b1fe60087bc10a000024_6": [
        {
            "start_logit": -1.017578125,
            "end_logit": 10.859375,
            "text": "E2 SUMO-conjugating enzyme",
            "probability": 0.95166015625
        },
        {
            "start_logit": -5.08203125,
            "end_logit": 10.859375,
            "text": "enzyme",
            "probability": 0.0163116455078125
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 10.859375,
            "text": "unique E2 SUMO-conjugating enzyme",
            "probability": 0.01004791259765625
        },
        {
            "start_logit": -5.75,
            "end_logit": 10.859375,
            "text": "SUMO-conjugating enzyme",
            "probability": 0.00836181640625
        },
        {
            "start_logit": -6.0,
            "end_logit": 10.859375,
            "text": "Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.006511688232421875
        },
        {
            "start_logit": -6.19921875,
            "end_logit": 10.859375,
            "text": "Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.005336761474609375
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 10.859375,
            "text": "SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0004982948303222656
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 10.859375,
            "text": "conjugating enzyme",
            "probability": 0.0002353191375732422
        },
        {
            "start_logit": -9.421875,
            "end_logit": 10.859375,
            "text": "ating enzyme",
            "probability": 0.00021266937255859375
        },
        {
            "start_logit": -9.90625,
            "end_logit": 10.859375,
            "text": "the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 0.0001310110092163086
        },
        {
            "start_logit": -1.017578125,
            "end_logit": 1.841796875,
            "text": "E2 SUMO-conjugating enzyme.",
            "probability": 0.00011563301086425781
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 10.859375,
            "text": "-conjugating enzyme",
            "probability": 0.00011116266250610352
        },
        {
            "start_logit": -10.21875,
            "end_logit": 10.859375,
            "text": "of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 9.584426879882812e-05
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 10.859375,
            "text": "revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 9.21487808227539e-05
        },
        {
            "start_logit": -10.375,
            "end_logit": 10.859375,
            "text": "targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 8.195638656616211e-05
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.859375,
            "text": "ited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme",
            "probability": 8.0108642578125e-05
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 10.859375,
            "text": "the unique E2 SUMO-conjugating enzyme",
            "probability": 7.88569450378418e-05
        },
        {
            "start_logit": -5.08203125,
            "end_logit": 1.841796875,
            "text": "enzyme.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 1.841796875,
            "text": "unique E2 SUMO-conjugating enzyme.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.75,
            "end_logit": 1.841796875,
            "text": "SUMO-conjugating enzyme.",
            "probability": 1.0132789611816406e-06
        }
    ],
    "5c011057133db5eb78000025_1": [
        {
            "start_logit": 14.5625,
            "end_logit": 14.84375,
            "text": "phase II",
            "probability": 1.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.0029296875,
            "text": "phase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.9140625,
            "end_logit": 14.84375,
            "text": "II",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.84375,
            "text": "in phase II",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.875,
            "text": "phase II clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.9765625,
            "text": "phase II clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.25,
            "text": "phase II clinical",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.84375,
            "text": "been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 14.84375,
            "text": "-824, SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.84375,
            "text": ", SQ109 and sutezolid) have been evaluated in phase II",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -1.0029296875,
            "text": "in phase",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -1.0029296875,
            "text": "been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -1.0029296875,
            "text": "-824, SQ109 and sutezolid) have been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -1.0029296875,
            "text": ", SQ109 and sutezolid) have been evaluated in phase",
            "probability": 0.0
        },
        {
            "start_logit": -2.9140625,
            "end_logit": -9.875,
            "text": "II clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": -2.9140625,
            "end_logit": -9.9765625,
            "text": "II clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -2.9140625,
            "end_logit": -10.25,
            "text": "II clinical",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -9.875,
            "text": "in phase II clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -9.875,
            "text": "clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -9.9765625,
            "text": "in phase II clinical trials.",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_1": [
        {
            "start_logit": 13.40625,
            "end_logit": 14.2578125,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": -3.205078125,
            "end_logit": 14.2578125,
            "text": "y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.40625,
            "end_logit": -3.73828125,
            "text": "primary",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -6.2890625,
            "text": "primary microcephaly and define a novel laminopathy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 14.2578125,
            "text": "microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 14.2578125,
            "text": "ephaly",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.265625,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.5078125,
            "text": "primary microcephaly and",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.5625,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.6484375,
            "text": "primary microc",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -8.9453125,
            "text": "primary microcephaly and define a",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.2578125,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.3828125,
            "text": "primary microcephal",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.2578125,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.2578125,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.75,
            "text": "primary microcephaly and define a novel",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.0703125,
            "text": "primary microcephaly and define",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 14.2578125,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.2578125,
            "text": "lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 14.2578125,
            "text": "B2 variants cause primary microcephaly",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_2": [
        {
            "start_logit": 6.78125,
            "end_logit": 9.0703125,
            "text": "laminopathy",
            "probability": 1.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": 9.0703125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 5.8770179748535156e-05
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.0703125,
            "text": "opathy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.78125,
            "end_logit": -5.8203125,
            "text": "lamin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 9.0703125,
            "text": "microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 9.0703125,
            "text": "new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -5.8203125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of lamin",
            "probability": 0.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -6.94140625,
            "text": "primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -2.962890625,
            "end_logit": -10.0,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -3.525390625,
            "text": "helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -3.525390625,
            "text": "\u0251-helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -3.525390625,
            "text": "de novo in nine cases and shown to affect highly conserved residues within the lamin \u0251-helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -3.525390625,
            "text": "variants were established to be de novo in nine cases and shown to affect highly conserved residues within the lamin \u0251-helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -3.525390625,
            "text": "Recurrent variants were established to be de novo in nine cases and shown to affect highly conserved residues within the lamin \u0251-helical rod",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -5.8203125,
            "text": "microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of lamin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -5.8203125,
            "text": "new form of lamin",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -6.94140625,
            "text": "microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": -6.94140625,
            "text": "variants in LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -7.4140625,
            "text": "helical rod domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -7.4140625,
            "text": "\u0251-helical rod domain",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_3": [
        {
            "start_logit": 12.875,
            "end_logit": 13.8671875,
            "text": "primary microcephaly",
            "probability": 1.0
        },
        {
            "start_logit": -3.400390625,
            "end_logit": 13.8671875,
            "text": "y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.875,
            "end_logit": -4.42578125,
            "text": "primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": 13.8671875,
            "text": "microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 13.8671875,
            "text": "ephaly",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.28125,
            "text": "primary microcephaly and define a novel laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.8515625,
            "text": "primary microcephaly and",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -8.9453125,
            "text": "primary microc",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -9.0546875,
            "text": "primary microcephaly and define a novel lamin",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -9.1875,
            "text": "primary microcephal",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.8671875,
            "text": "cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -9.5546875,
            "text": "primary microcephaly and define a",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -9.6875,
            "text": "primary microcephaly and define a novel",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 13.8671875,
            "text": "variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.8671875,
            "text": "Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": 12.875,
            "end_logit": -10.0703125,
            "text": "primary microcephaly and define",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 13.8671875,
            "text": "lamin B1 and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 13.8671875,
            "text": "lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -11.234375,
            "end_logit": 13.8671875,
            "text": "B2 variants cause primary microcephaly",
            "probability": 0.0
        },
        {
            "start_logit": -11.3046875,
            "end_logit": 13.8671875,
            "text": "and lamin B2 variants cause primary microcephaly",
            "probability": 0.0
        }
    ],
    "601bfa531cb411341a000008_4": [
        {
            "start_logit": 6.578125,
            "end_logit": 7.85546875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 0.87841796875
        },
        {
            "start_logit": 4.59765625,
            "end_logit": 7.85546875,
            "text": "laminopathy",
            "probability": 0.1207275390625
        },
        {
            "start_logit": 6.578125,
            "end_logit": 1.40234375,
            "text": "primary microcephaly",
            "probability": 0.0013790130615234375
        },
        {
            "start_logit": 6.578125,
            "end_logit": -6.4296875,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of lamin",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.85546875,
            "text": "opathy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.421875,
            "end_logit": 7.85546875,
            "text": "microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.578125,
            "end_logit": -8.3359375,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.59765625,
            "end_logit": -6.4296875,
            "text": "lamin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.90625,
            "end_logit": 7.85546875,
            "text": "ephaly, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 7.85546875,
            "text": "new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 7.85546875,
            "text": "of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4375,
            "end_logit": 7.85546875,
            "text": "y, implicating a major structural component of the nuclear envelope in its etiology and defining a new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.85546875,
            "text": "a new form of laminopathy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 7.85546875,
            "text": "form of laminopathy",
            "probability": 0.0
        },
        {
            "start_logit": 6.578125,
            "end_logit": -9.6875,
            "text": "primary microcephaly,",
            "probability": 0.0
        },
        {
            "start_logit": 6.578125,
            "end_logit": -9.6953125,
            "text": "primary microcephaly, implicating a major structural component of the nuclear envelope",
            "probability": 0.0
        },
        {
            "start_logit": 6.578125,
            "end_logit": -9.78125,
            "text": "primary",
            "probability": 0.0
        },
        {
            "start_logit": 6.578125,
            "end_logit": -9.828125,
            "text": "primary microcephal",
            "probability": 0.0
        },
        {
            "start_logit": 4.59765625,
            "end_logit": -8.3359375,
            "text": "laminopathy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 1.40234375,
            "text": "LMNB1 and LMNB2 as a genetic cause of primary microcephaly",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_1": [
        {
            "start_logit": 11.2890625,
            "end_logit": 11.375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -9.7734375,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 11.375,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.375,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.375,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -10.3984375,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.375,
            "text": "A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.375,
            "text": "up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -10.515625,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine).",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.375,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -10.59375,
            "text": "malaria infection (CHMI",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.375,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -10.625,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.375,
            "text": "vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -10.6328125,
            "text": "malaria infection (CHMI) using homologous parasites (same P. falciparum strain",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -9.9375,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -9.7734375,
            "text": "human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -9.7734375,
            "text": "controlled human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -9.9375,
            "text": ": A live-attenuated Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -10.359375,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_2": [
        {
            "start_logit": 10.078125,
            "end_logit": 9.6640625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -10.015625,
            "text": "malaria infection (CHMI",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -10.0625,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 9.6640625,
            "text": "vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 9.6640625,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 9.6640625,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 9.6640625,
            "text": "homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 9.6640625,
            "text": "100% against homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 9.6640625,
            "text": "to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 9.6640625,
            "text": "subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 9.6640625,
            "text": "of 100% against homologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -5.1953125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -7.92578125,
            "text": "Plasmodium",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -9.34375,
            "text": "Plasmodium falciparum sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -10.0859375,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -10.1484375,
            "text": "Plasmodium falciparum sporozoite (PfSPZ) Vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -10.1875,
            "text": "Plasmodium falciparum sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic",
            "probability": 0.0
        },
        {
            "start_logit": 0.1861572265625,
            "end_logit": -10.21875,
            "text": "Plasmodium falciparum sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic, purified, cryopreserved PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -5.1953125,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -9.34375,
            "text": "falciparum sporozoite",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_3": [
        {
            "start_logit": 10.8984375,
            "end_logit": 11.546875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 11.546875,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.8984375,
            "end_logit": -9.4765625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 10.8984375,
            "end_logit": -9.7109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 11.546875,
            "text": ": A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.546875,
            "text": "(SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.546875,
            "text": ") sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.8984375,
            "end_logit": -10.2109375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6",
            "probability": 0.0
        },
        {
            "start_logit": 10.8984375,
            "end_logit": -10.25,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 0.0
        },
        {
            "start_logit": 10.8984375,
            "end_logit": -10.3828125,
            "text": "malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -9.4765625,
            "text": "in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.4765625,
            "text": "homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -10.0078125,
            "text": "human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to ass",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -9.4765625,
            "text": "protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -9.4765625,
            "text": "against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.7109375,
            "text": "homologous Pf",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -9.4765625,
            "text": "(100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -10.0078125,
            "text": "in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to ass",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -9.4765625,
            "text": "(same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -10.2109375,
            "text": "human malaria infection",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_4": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.578125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.0078125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.0625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -8.578125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -9.859375,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -9.96875,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -10.03125,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -10.0625,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -9.5546875,
            "text": "Plasmodium vivax",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -9.9453125,
            "text": "Plasmodium vivax sexual erythrocytic and mosquito stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -8.578125,
            "text": "at Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -9.7578125,
            "text": ", viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -9.9921875,
            "text": ", viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.0625,
            "text": ", viruses and bacteria, and protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.7578125,
            "text": "at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.7734375,
            "text": "at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.1328125,
            "text": ", viruses and bacteria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -9.609375,
            "text": "and PfSPZ-CVac), (3) prime boost",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.7578125,
            "text": ", and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_5": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.578125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.578125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.0078125,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.0625,
            "text": "malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -8.578125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -9.859375,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -9.96875,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -10.03125,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole",
            "probability": 0.0
        },
        {
            "start_logit": -1.5966796875,
            "end_logit": -10.0625,
            "text": "Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -9.5546875,
            "text": "Plasmodium vivax",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -9.9453125,
            "text": "Plasmodium vivax sexual erythrocytic and mosquito stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -8.578125,
            "text": "at Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -9.7578125,
            "text": ", viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -9.9921875,
            "text": ", viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.0625,
            "text": ", viruses and bacteria, and protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.7578125,
            "text": "at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.7734375,
            "text": "at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.1328125,
            "text": ", viruses and bacteria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -9.609375,
            "text": "and PfSPZ-CVac), (3) prime boost",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.7578125,
            "text": ", and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_6": [
        {
            "start_logit": 11.390625,
            "end_logit": 11.484375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -9.9609375,
            "text": "malaria vaccine, Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.1328125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.2578125,
            "text": "malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.390625,
            "text": "malaria vaccine, Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.4140625,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": 11.390625,
            "end_logit": -10.46875,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.484375,
            "text": "attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.484375,
            "text": "live-attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.484375,
            "text": "A live-attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -9.9609375,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -10.1328125,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -10.2109375,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -10.390625,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -10.4140625,
            "text": "Plasmodium falciparum sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -10.46875,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -10.1328125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -10.171875,
            "text": "Plasmodium falciparum (Pf) parasites homologous to the vaccine strain",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -10.203125,
            "text": "Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -10.203125,
            "text": "Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_7": [
        {
            "start_logit": 10.9765625,
            "end_logit": 11.7421875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 11.7421875,
            "text": "Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.7421875,
            "text": "Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.8515625,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.7421875,
            "text": "attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.7421875,
            "text": "against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.7421875,
            "text": "falciparum sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 11.7421875,
            "text": "PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.0625,
            "text": "malaria, but the features of the antibody response",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.7421875,
            "text": "been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.1015625,
            "text": "malaria, but the features of the antibody response induced",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 11.7421875,
            "text": "sporozoites (PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.7421875,
            "text": "protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.1875,
            "text": "malaria, but the features of the antibody response induced by this treatment remain unclear.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.7421875,
            "text": "PZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 11.7421875,
            "text": "(PfSPZs) has been shown to be protective against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.3671875,
            "text": "malaria, but the features of the antibody",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.375,
            "text": "malaria, but the features of the antibody response induced by this treatment remain",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.4453125,
            "text": "malaria, but the features of the antibody response induced by this treatment",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -9.1875,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_8": [
        {
            "start_logit": 11.5703125,
            "end_logit": 11.5859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -9.78125,
            "text": "malaria vaccines",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 11.5859375,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.078125,
            "text": "malaria vaccines,",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.1796875,
            "text": "malaria vaccines, which is",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.2421875,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.5859375,
            "text": "of the candidate human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.28125,
            "text": "malaria vaccines, which is based on human malaria sporozoites",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.3203125,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.3359375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.34375,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.34375,
            "text": "malaria vaccines, which",
            "probability": 0.0
        },
        {
            "start_logit": 11.5703125,
            "end_logit": -10.40625,
            "text": "malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -9.59375,
            "text": "human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -9.59375,
            "text": "which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -9.78125,
            "text": "human malaria vaccines",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -10.1875,
            "text": "human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -10.2421875,
            "text": "human malaria sporozoites and called PfSPZ Vaccine, has been shown",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.59375,
            "text": "called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -10.28125,
            "text": "human malaria sporozoites",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_9": [
        {
            "start_logit": 11.015625,
            "end_logit": 11.1875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 11.1875,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -8.03125,
            "text": "malaria infection (CHMI) using homologous parasites (sa",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.1875,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.3984375,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.1875,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.421875,
            "text": "malaria infection (CHMI",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.1875,
            "text": "falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.1875,
            "text": "up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.1875,
            "text": "A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.1875,
            "text": "attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.1875,
            "text": "(PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.1875,
            "text": "vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.1875,
            "text": "shown up to 100% protection against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -7.98828125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -10.15625,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -10.375,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -10.375,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -10.375,
            "text": "Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100%",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -10.390625,
            "text": "Plasmodium falciparum sporozoite",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_10": [
        {
            "start_logit": 10.796875,
            "end_logit": 11.09375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 11.09375,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.09375,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -9.9921875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We ass",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.0,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We asse",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.09375,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.2109375,
            "text": "malaria infection (CHMI) 3",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.3046875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.09375,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.09375,
            "text": ", is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.09375,
            "text": "Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.09375,
            "text": ", PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.09375,
            "text": ") sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.09375,
            "text": "PZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.4375,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.4375,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.09375,
            "text": "highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.09375,
            "text": "vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.09375,
            "text": "protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.796875,
            "end_logit": -10.4765625,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_11": [
        {
            "start_logit": 12.3828125,
            "end_logit": 13.1484375,
            "text": "Plasmodium falciparum",
            "probability": 0.998046875
        },
        {
            "start_logit": 12.3828125,
            "end_logit": 6.921875,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 0.001987457275390625
        },
        {
            "start_logit": 7.640625,
            "end_logit": 6.921875,
            "text": "malaria",
            "probability": 1.71661376953125e-05
        },
        {
            "start_logit": -4.375,
            "end_logit": 13.1484375,
            "text": "falciparum",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -4.57421875,
            "text": "Plasmodium",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.1484375,
            "text": ": Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -4.375,
            "end_logit": 6.921875,
            "text": "falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.9296875,
            "text": "Plasmodium falciparum sporozite",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -9.9921875,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -10.125,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria spor",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -10.1640625,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -10.1953125,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -10.2578125,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that",
            "probability": 0.0
        },
        {
            "start_logit": 12.3828125,
            "end_logit": -10.3203125,
            "text": "Plasmodium falciparum sporozite (PfSPZ)",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -5.671875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive ind",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.390625,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.4375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.8984375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.96875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -10.125,
            "text": "malaria spor",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_12": [
        {
            "start_logit": 10.96875,
            "end_logit": 11.796875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 11.796875,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -9.0,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -9.875,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.796875,
            "text": "Sterile protection against human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.015625,
            "text": "malaria by",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.1171875,
            "text": "malaria by chemoattenuated PfS",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 11.796875,
            "text": "against human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.296875,
            "text": "malaria by chemoattenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": 10.96875,
            "end_logit": -10.296875,
            "text": "malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -9.0,
            "text": "human malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -9.875,
            "text": "human malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -10.015625,
            "text": "human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -10.1171875,
            "text": "human malaria by chemoattenuated PfS",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -9.0,
            "text": "chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": -9.0,
            "text": "uated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -10.296875,
            "text": "human malaria by chemoattenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -10.296875,
            "text": "human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -9.0,
            "text": "tenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -9.0,
            "text": "PfSPZ vaccine",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_13": [
        {
            "start_logit": 10.4765625,
            "end_logit": 11.40625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 11.40625,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -8.546875,
            "text": "malaria. A cri",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 11.40625,
            "text": "direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 11.40625,
            "text": "falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.40625,
            "text": ", purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.40625,
            "text": ", cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.40625,
            "text": "venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.40625,
            "text": "administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.40625,
            "text": "cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.40625,
            "text": ", aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.40625,
            "text": "by direct venous inoculation (DVI) for maximal efficacy against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -9.9921875,
            "text": "malaria. A",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 11.40625,
            "text": "against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.4765625,
            "end_logit": -10.1640625,
            "text": "malaria.",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -7.671875,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -8.546875,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria. A cri",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -9.9921875,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria. A",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -10.0078125,
            "text": "Plasmodium falciparum sporozoites",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -10.0234375,
            "text": "Plasmodium falciparum sporozoites, is administered by direct venous inoculation",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_14": [
        {
            "start_logit": 11.015625,
            "end_logit": 11.578125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 11.578125,
            "text": "nfections. The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 11.578125,
            "text": "radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 11.578125,
            "text": "The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.578125,
            "text": "for malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.0859375,
            "text": "malaria vaccines because of its unparalleled",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.578125,
            "text": "been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.578125,
            "text": "considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.578125,
            "text": "ections. The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.578125,
            "text": "attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.3359375,
            "text": "malaria vaccines because",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.578125,
            "text": "gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.578125,
            "text": "the gold standard for malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.3515625,
            "text": "malaria vaccines because of its unpara",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.359375,
            "text": "malaria vaccines because of",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -10.421875,
            "text": "malaria vaccines",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -9.234375,
            "text": "nfections",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -9.7421875,
            "text": "nf",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -9.78125,
            "text": "nfections. The radiation attenuated sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -9.78125,
            "text": "radiation attenuated sporozoite",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_15": [
        {
            "start_logit": 10.9765625,
            "end_logit": 11.6015625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.421875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 11.6015625,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.8515625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.6015625,
            "text": "(SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -9.9921875,
            "text": "malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.6015625,
            "text": ": A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.6015625,
            "text": ") malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.2265625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.3203125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 0.0
        },
        {
            "start_logit": 10.9765625,
            "end_logit": -10.3515625,
            "text": "malaria vaccine, PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -9.421875,
            "text": "in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -9.421875,
            "text": "homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -9.421875,
            "text": "against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -9.421875,
            "text": ", protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -9.9921875,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.421875,
            "text": "(100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -9.421875,
            "text": "protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.421875,
            "text": "(same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.421875,
            "text": ") malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_16": [
        {
            "start_logit": 11.1875,
            "end_logit": 11.4921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -8.671875,
            "text": "malaria chemoprophylaxis. These advance",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -9.8125,
            "text": "malaria chemoprophylaxis",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 11.4921875,
            "text": "on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.4921875,
            "text": "exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -10.25,
            "text": "malaria chemoprophy",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -10.28125,
            "text": "malaria chemoprophylax",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -10.3359375,
            "text": "malaria chemo",
            "probability": 0.0
        },
        {
            "start_logit": 11.1875,
            "end_logit": -10.3671875,
            "text": "malaria chemoprop",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.4921875,
            "text": "to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.4921875,
            "text": "(IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.4921875,
            "text": "were exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.4921875,
            "text": "in those who were exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 11.4921875,
            "text": "live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.4921875,
            "text": "-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.4921875,
            "text": "PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.4921875,
            "text": "number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -8.671875,
            "text": "advance",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -8.671875,
            "text": "on malaria chemoprophylaxis. These advance",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -8.671875,
            "text": "exposed to live PfSPZ while on malaria chemoprophylaxis. These advance",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_17": [
        {
            "start_logit": 10.7109375,
            "end_logit": 10.8515625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.875,
            "text": "malaria (mAbs 580 and 66",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -9.9140625,
            "text": "malaria (mAbs 580 and 663).",
            "probability": 0.0
        },
        {
            "start_logit": 10.7109375,
            "end_logit": -10.0390625,
            "text": "malaria (mAbs 580 and 663). RTS,S",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 10.8515625,
            "text": "CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 10.8515625,
            "text": "; or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 10.8515625,
            "text": "; an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 10.8515625,
            "text": "individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 10.8515625,
            "text": "and MGG4); or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 10.8515625,
            "text": "irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 10.8515625,
            "text": "to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 10.8515625,
            "text": "exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 10.8515625,
            "text": "or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 10.8515625,
            "text": "an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -9.875,
            "text": "CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 66",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -9.9140625,
            "text": "CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 663).",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -9.875,
            "text": "; or individuals exposed to malaria (mAbs 580 and 66",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -9.9140625,
            "text": "; or individuals exposed to malaria (mAbs 580 and 663).",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -10.0390625,
            "text": "CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 663). RTS,S",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -9.6015625,
            "text": "pared in vitro and in vivo activities of six CSP-specific mAbs derived from human recipients of a recombinant CSP vaccine RTS,S/AS01",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_18": [
        {
            "start_logit": 11.515625,
            "end_logit": 11.6875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.15625,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.5,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.875,
            "text": "malaria by a simple chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.875,
            "text": "malaria by",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.9296875,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -9.96875,
            "text": "malaria by a simple chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.046875,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.078125,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.078125,
            "text": "malaria by a simple chemoattenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.1484375,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.15625,
            "text": "malaria by a simple chemoattenuated PfSPZ vaccine regimen in",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.1953125,
            "text": "malaria by a simple chemoattenuated PfS",
            "probability": 0.0
        },
        {
            "start_logit": 11.515625,
            "end_logit": -10.21875,
            "text": "malaria by a simple",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.6875,
            "text": "Heterologous protection against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.6875,
            "text": "protection against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -9.15625,
            "text": "chemoattenuated PfSPZ vaccine regimen",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -9.5,
            "text": "chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -9.875,
            "text": "chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -6.8515625,
            "end_logit": -9.9296875,
            "text": "chemoattenuated PfSPZ vaccine regimen in a randomized",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_19": [
        {
            "start_logit": 11.4453125,
            "end_logit": 11.6953125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.25,
            "text": "malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.609375,
            "text": "malaria at 1 year and immune correlates",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -9.6171875,
            "text": "malaria at 1 year",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.015625,
            "text": "malaria at 1 year and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.03125,
            "text": "malaria at 1 year and immune correlates following PfSPZ vaccination",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.109375,
            "text": "malaria at 1 year and immune correlates following PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.1875,
            "text": "malaria at 1 year and immune correlates following PfSP",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.2421875,
            "text": "malaria at 1 year and immune",
            "probability": 0.0
        },
        {
            "start_logit": 11.4453125,
            "end_logit": -10.2890625,
            "text": "malaria at 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.6953125,
            "text": "Protection against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 11.6953125,
            "text": "against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -9.25,
            "text": "PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -9.25,
            "text": "Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": -9.25,
            "text": "at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -9.25,
            "text": "1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -9.25,
            "text": "following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -11.125,
            "end_logit": -9.25,
            "text": "vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": -9.25,
            "text": "against malaria at 1 year and immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": -9.25,
            "text": "immune correlates following PfSPZ vaccination.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_20": [
        {
            "start_logit": 11.453125,
            "end_logit": 11.640625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.2890625,
            "text": "malaria infection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 11.640625,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.8359375,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 11.640625,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.640625,
            "text": "PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.640625,
            "text": "strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.640625,
            "text": "T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.640625,
            "text": "Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.640625,
            "text": "transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.640625,
            "text": "induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.640625,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.640625,
            "text": "-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.640625,
            "text": "durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.640625,
            "text": "protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.640625,
            "text": "ending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.640625,
            "text": "Z Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -9.2890625,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.2890625,
            "text": "human malaria infection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -9.8359375,
            "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_21": [
        {
            "start_logit": 11.328125,
            "end_logit": 11.859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -5.5625,
            "end_logit": 11.859375,
            "text": "Plasmodium falciparum malaria",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 11.859375,
            "text": "Protection against Plasmodium falciparum malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 11.859375,
            "text": "falciparum malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.578125,
            "text": "malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.0703125,
            "text": "malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.859375,
            "text": "against Plasmodium falciparum malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.34375,
            "text": "malaria by PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -5.5625,
            "end_logit": -9.3046875,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -5.5625,
            "end_logit": -9.578125,
            "text": "Plasmodium falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -5.5625,
            "end_logit": -10.0703125,
            "text": "Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -5.5625,
            "end_logit": -10.34375,
            "text": "Plasmodium falciparum malaria by PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -9.3046875,
            "text": "Protection against Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -9.3046875,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -9.578125,
            "text": "Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -9.703125,
            "text": "Protection",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -9.578125,
            "text": "falciparum malaria by PfSPZ Vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.0703125,
            "text": "Protection against Plasmodium falciparum malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.1875,
            "text": "Protection against",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -10.0703125,
            "text": "falciparum malaria by",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_22": [
        {
            "start_logit": 11.5,
            "end_logit": 11.71875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 11.71875,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.6640625,
            "text": "malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.90625,
            "text": "malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.9453125,
            "text": "malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.71875,
            "text": "Sterile protection against human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.015625,
            "text": "malaria by",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.1484375,
            "text": "malaria by chemoattenuated PfS",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.2265625,
            "text": "malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.2265625,
            "text": "malaria by chemoattenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.71875,
            "text": "protection against human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -9.6640625,
            "text": "human malaria by chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -9.90625,
            "text": "human malaria by chemoattenuated PfSPZ",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -9.9453125,
            "text": "human malaria by chemoattenuated PfSPZ vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -10.015625,
            "text": "human malaria by",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -10.1484375,
            "text": "human malaria by chemoattenuated PfS",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -10.2265625,
            "text": "human malaria by chemoattenuated",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -10.2265625,
            "text": "human malaria by chemoattenuated PfSP",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -9.6640625,
            "text": "chemoattenuated PfSPZ vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -9.6640625,
            "text": "uated PfSPZ vaccine.",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_23": [
        {
            "start_logit": 11.421875,
            "end_logit": 11.7421875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.8203125,
            "text": "malaria in",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.8359375,
            "text": "malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.8515625,
            "text": "malaria in infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.1953125,
            "text": "malaria in infants in",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.359375,
            "text": "malaria in infants in western Kenya: a",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.3984375,
            "text": "malaria in infants",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.7421875,
            "text": "PfSPZ Vaccine against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.7421875,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.484375,
            "text": "malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.7421875,
            "text": "against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.7421875,
            "text": "efficacy of PfSPZ Vaccine against malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.8359375,
            "text": "randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -9.8359375,
            "text": ", placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.8359375,
            "text": "infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.8515625,
            "text": "infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.8203125,
            "text": "PfSPZ Vaccine against malaria in",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.8359375,
            "text": "PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -9.8515625,
            "text": "PfSPZ Vaccine against malaria in infants in western Kenya",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -9.8203125,
            "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_24": [
        {
            "start_logit": 11.1484375,
            "end_logit": 11.2421875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -9.5859375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -9.953125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -9.9609375,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.0625,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.2421875,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.171875,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SP",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.1953125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DV",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.2109375,
            "text": "malaria infection (CHMI)",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.25,
            "text": "malaria infection (CHMI",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.2578125,
            "text": "malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) spor",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.2421875,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.5859375,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.6953125,
            "text": "Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.8046875,
            "text": "Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.953125,
            "text": "Plasmodium falciparum (Pf",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.9609375,
            "text": "Plasmodium falciparum (Pf) sporozoites (SPZ",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -10.15625,
            "text": "Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -10.171875,
            "text": "Plasmodium falciparum (Pf) sporozoites (SP",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -10.2578125,
            "text": "Plasmodium falciparum (Pf) spor",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_25": [
        {
            "start_logit": 10.9453125,
            "end_logit": 11.0859375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 11.0859375,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 11.0859375,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.0859375,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.234375,
            "text": "malaria infection (CHMI) 3",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.3984375,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.0859375,
            "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.4296875,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.4453125,
            "text": "malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.0859375,
            "text": "Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.0859375,
            "text": ", PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.0859375,
            "text": "PZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.5,
            "text": "malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.0859375,
            "text": ") sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.0859375,
            "text": ", is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.0859375,
            "text": "vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.0859375,
            "text": "PfSPZ Vaccine, is highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.0859375,
            "text": "highly protective against controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -10.25,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -10.34375,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_26": [
        {
            "start_logit": 11.453125,
            "end_logit": 11.6328125,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.265625,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 11.6328125,
            "text": "PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.8359375,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -9.90625,
            "text": "malaria through long-lived tissue-resident T cells and",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.6328125,
            "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.3046875,
            "text": "malaria through long-lived tissue-resident T cells and that",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.3671875,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.6328125,
            "text": "findings suggest that PfSPZ Vaccine conferred durable protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.390625,
            "text": "malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.6328125,
            "text": "durable protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.453125,
            "end_logit": -10.4296875,
            "text": "malaria through",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.6328125,
            "text": "protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.6328125,
            "text": "Vaccine conferred durable protection to malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -9.265625,
            "text": "tissue-resident T cells and that administration of higher doses may further enhance protection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -9.265625,
            "text": "PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -9.265625,
            "text": "higher doses may further enhance protection.",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -9.265625,
            "text": "long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -9.8359375,
            "text": "tissue-resident T cells and that administration of higher doses may",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -9.8359375,
            "text": "PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_27": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.40625,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.0703125,
            "text": "malaria vaccine, Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.203125,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.4375,
            "text": "malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.46875,
            "text": "malaria vaccine, Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.5234375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.5234375,
            "text": "malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.40625,
            "text": "live-attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.40625,
            "text": "attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.40625,
            "text": "A live-attenuated malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.0703125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.203125,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.265625,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.46875,
            "text": "Plasmodium falciparum spor",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.5234375,
            "text": "Plasmodium falciparum sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": -10.5234375,
            "text": "Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -10.203125,
            "text": "Plasmodium falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -10.21875,
            "text": "Plasmodium falciparum (Pf) parasites homologous to the vaccine strain",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -10.265625,
            "text": "Plasmodium falciparum (Pf",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -10.203125,
            "text": "human malaria infection (CHMI) with Plasmodium falciparum",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_28": [
        {
            "start_logit": 11.359375,
            "end_logit": 11.3984375,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 11.3984375,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.4765625,
            "text": "malaria season.FUNDING: US National In",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -9.7578125,
            "text": "malaria season",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 11.3984375,
            "text": "safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -10.015625,
            "text": "malaria season.FUNDING",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 11.3984375,
            "text": "well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 11.3984375,
            "text": "P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.3984375,
            "text": "PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.3984375,
            "text": ": PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.3984375,
            "text": "ON: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.359375,
            "end_logit": -10.4375,
            "text": "malaria season.FUNDING: US National",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.3984375,
            "text": "PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.3984375,
            "text": "significant protection in African adults against P falciparum infection throughout an entire malaria",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -9.4765625,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.FUNDING: US National In",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -9.7578125,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -10.015625,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.FUNDING",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -10.171875,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -10.203125,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": -10.265625,
            "text": "tolerated and safe. PfSPZ Vaccine showed significant protection in African",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_29": [
        {
            "start_logit": 11.09375,
            "end_logit": 11.5546875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.4453125,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 11.5546875,
            "text": "Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.5546875,
            "text": ": A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.0,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.5546875,
            "text": ") sporozoite (SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.5546875,
            "text": "(SPZ) malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.5546875,
            "text": ") malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.296875,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.375,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.3828125,
            "text": "malaria vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.625,
            "text": "malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": -9.4453125,
            "text": "in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.4453125,
            "text": "homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -9.4453125,
            "text": "protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -10.2265625,
            "text": "human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -9.4453125,
            "text": "against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.4453125,
            "text": "(100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.4453125,
            "text": "(same strain as in the vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.4453125,
            "text": "PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_30": [
        {
            "start_logit": 10.3046875,
            "end_logit": 10.984375,
            "text": "malaria",
            "probability": 0.9677734375
        },
        {
            "start_logit": 6.828125,
            "end_logit": 10.984375,
            "text": "Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 0.0301513671875
        },
        {
            "start_logit": 6.828125,
            "end_logit": 8.1015625,
            "text": "Plasmodium falciparum",
            "probability": 0.0016880035400390625
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 10.984375,
            "text": "falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -7.9296875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.1015625,
            "text": "falciparum",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -9.5078125,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 10.984375,
            "text": ": Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -9.8671875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -9.9296875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 10.984375,
            "text": "-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -10.0546875,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.984375,
            "text": ", whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 10.984375,
            "text": ", non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 10.984375,
            "text": "non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 10.984375,
            "text": "metabolically active, non-replicating, whole malaria",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -10.2421875,
            "text": "malaria spor",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -10.265625,
            "text": "malaria sporozoite",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -10.296875,
            "text": "malaria sporozoite vaccine that",
            "probability": 0.0
        },
        {
            "start_logit": 10.3046875,
            "end_logit": -10.3359375,
            "text": "malaria sporozoite vaccine that has been reported to be safe and protective against",
            "probability": 0.0
        }
    ],
    "61f7d745882a024a10000038_31": [
        {
            "start_logit": 11.4921875,
            "end_logit": 11.4921875,
            "text": "malaria",
            "probability": 1.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 11.4921875,
            "text": "tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.4921875,
            "end_logit": -9.9921875,
            "text": "malaria infection ten weeks after the last dose (group III).",
            "probability": 0.0
        },
        {
            "start_logit": 11.4921875,
            "end_logit": -10.0078125,
            "text": "malaria infection ten weeks after the last dose (group III",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.4921875,
            "text": "safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.4921875,
            "text": "human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.4921875,
            "text": "well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": 11.4921875,
            "end_logit": -10.3515625,
            "text": "malaria infection ten weeks after the last",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.4921875,
            "text": "infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.4921875,
            "text": "controlled human malaria",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.0234375,
            "text": "tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -10.0234375,
            "text": "PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -10.046875,
            "text": "PfSPZ Challenge",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.2421875,
            "text": "tolerated and safe, and prevented infection in 9 out of 9",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -10.2421875,
            "text": "PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.3515625,
            "text": "tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria infection ten weeks after the last",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.3671875,
            "text": "tolerated and safe, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.4453125,
            "text": "tolerated and safe, and prevented infection in 9",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -10.3671875,
            "text": "PfSPZ Challenge at 28-day intervals were well tolerated and safe, and",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -10.4765625,
            "text": "tolerated and safe,",
            "probability": 0.0
        }
    ],
    "622d1ed13a8413c6530000a3_1": [
        {
            "start_logit": -1.2275390625,
            "end_logit": 7.23828125,
            "text": "daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 0.720703125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -5.94921875,
            "text": "The daughterless (da)",
            "probability": 0.1396484375
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -7.234375,
            "text": "The",
            "probability": 0.03863525390625
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -7.890625,
            "text": "The daughterless (da) gene in",
            "probability": 0.020050048828125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -8.171875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination",
            "probability": 0.01512908935546875
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -8.390625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis",
            "probability": 0.0121612548828125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -8.671875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and",
            "probability": 0.00917816162109375
        },
        {
            "start_logit": -5.7109375,
            "end_logit": 7.23828125,
            "text": ".",
            "probability": 0.0081329345703125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.171875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the",
            "probability": 0.005565643310546875
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.4375,
            "text": "The daughterless (da) gene",
            "probability": 0.004268646240234375
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.4609375,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator",
            "probability": 0.004169464111328125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.703125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have",
            "probability": 0.0032711029052734375
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.71875,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly",
            "probability": 0.0032215118408203125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -9.8203125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose",
            "probability": 0.002910614013671875
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 7.23828125,
            "text": "sex determination and neurogenesis have been extensively examined.",
            "probability": 0.0027561187744140625
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -10.0703125,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific",
            "probability": 0.00226593017578125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -10.0703125,
            "text": "The daughterless (da) gene in Drosophila encodes",
            "probability": 0.00226593017578125
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -10.125,
            "text": "The daughterless (da) gene in Drosophila encodes a",
            "probability": 0.0021457672119140625
        },
        {
            "start_logit": 10.3203125,
            "end_logit": -10.140625,
            "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control",
            "probability": 0.00211334228515625
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.23828125,
            "text": "Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.",
            "probability": 0.0012969970703125
        }
    ],
    "56bc9268ac7ad1001900001b_1": [
        {
            "start_logit": 14.3359375,
            "end_logit": 15.4375,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": -1.0400390625,
            "end_logit": 15.4375,
            "text": "17",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -0.75830078125,
            "text": "interleukin-17 receptor A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -2.29296875,
            "text": "interleukin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -3.11328125,
            "text": "interleukin-17 receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -4.19921875,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 15.4375,
            "text": "-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.4375,
            "text": "clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.4375,
            "text": "Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.28125,
            "text": "interleukin-17 receptor A monoclonal",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.4375,
            "text": ": Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.4375,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.4375,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.4375,
            "text": "studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.4375,
            "text": "the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.4375,
            "text": "BACKGROUND: Early clinical studies suggested that the anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -9.734375,
            "text": "interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.125,
            "text": "interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.171875,
            "text": "interleukin-17 receptor A monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.234375,
            "text": "interleukin-17 receptor A monoclonal antibody brodalumab has efficacy",
            "probability": 0.0
        }
    ],
    "56bc9268ac7ad1001900001b_2": [
        {
            "start_logit": 14.421875,
            "end_logit": 15.453125,
            "text": "interleukin-17",
            "probability": 1.0
        },
        {
            "start_logit": -1.1171875,
            "end_logit": 15.453125,
            "text": "17",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.421875,
            "end_logit": -2.150390625,
            "text": "interleukin",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -4.09375,
            "text": "interleukin-",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -5.21484375,
            "text": "interleukin-17-receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -6.50390625,
            "text": "interleukin-17-receptor antibody for psoriasis",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -8.5546875,
            "text": "interleukin-17-",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 15.453125,
            "text": "anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.453125,
            "text": "-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.453125,
            "text": "-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.03125,
            "text": "interleukin-17-receptor antibody for psoriasis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.234375,
            "text": "interleukin-17-receptor antibody",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.453125,
            "text": "Brodalumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.453125,
            "text": "dalumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.453125,
            "text": "an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.453125,
            "text": "mab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 15.453125,
            "text": "lumab, an anti-interleukin-17",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -10.046875,
            "text": "interleukin-17-receptor antibody for",
            "probability": 0.0
        },
        {
            "start_logit": -1.1171875,
            "end_logit": -5.21484375,
            "text": "17-receptor",
            "probability": 0.0
        },
        {
            "start_logit": -1.1171875,
            "end_logit": -6.50390625,
            "text": "17-receptor antibody for psoriasis",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_1": [
        {
            "start_logit": 7.7109375,
            "end_logit": 11.7421875,
            "text": "essential hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": 11.7421875,
            "text": "hypertension",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.7421875,
            "text": "with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.7421875,
            "text": "; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.4140625,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -10.0078125,
            "text": "essential hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -10.0390625,
            "text": "essential hypertension (WHO classification I or II",
            "probability": 0.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": -10.0078125,
            "text": "hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": -10.0390625,
            "text": "hypertension (WHO classification I or II",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.34375,
            "text": "antihypertensive",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -7.4140625,
            "text": "with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": -7.4140625,
            "text": "; n = 30) administered for 3 years to patients with essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -9.9140625,
            "text": "antihypertensive treatment",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.09375,
            "text": "antihypertensive treatment with isradipine",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.109375,
            "text": "antihypertensive treatment with",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.140625,
            "text": "antihypertensive treatment with isradipine as monotherapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -9.359375,
            "text": "5 +/- 0.63 mg twice daily) in combination with bopindolol",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -9.359375,
            "text": "; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -9.4296875,
            "text": "; n = 11) or isradipine (7",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -9.4296875,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_2": [
        {
            "start_logit": 7.8515625,
            "end_logit": 13.046875,
            "text": "essential hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -3.1953125,
            "end_logit": 13.046875,
            "text": "hypertension",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 13.046875,
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -9.828125,
            "end_logit": 13.046875,
            "text": "antihypertensive drug in blacks with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.046875,
            "text": "blacks with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 13.046875,
            "text": "with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 13.046875,
            "text": "dipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 13.046875,
            "text": "an effective antihypertensive drug in blacks with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.91796875,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -7.921875,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.4765625,
            "text": "essential hypertension,",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.7734375,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.7890625,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.8203125,
            "text": "essential hypertension, resulting in",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.8671875,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.875,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass",
            "probability": 0.0
        },
        {
            "start_logit": 7.8515625,
            "end_logit": -9.953125,
            "text": "essential hypertension, resulting in regression of left ventricular wall thickness and mass and",
            "probability": 0.0
        },
        {
            "start_logit": -3.1953125,
            "end_logit": -7.921875,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.",
            "probability": 0.0
        },
        {
            "start_logit": -3.1953125,
            "end_logit": -9.4765625,
            "text": "hypertension,",
            "probability": 0.0
        },
        {
            "start_logit": -3.1953125,
            "end_logit": -9.7734375,
            "text": "hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_3": [
        {
            "start_logit": 7.7109375,
            "end_logit": 11.7421875,
            "text": "essential hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": 11.7421875,
            "text": "hypertension",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.7421875,
            "text": "with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.7421875,
            "text": "; n = 30) administered for 3 years to patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.4140625,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -10.0078125,
            "text": "essential hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -10.0390625,
            "text": "essential hypertension (WHO classification I or II",
            "probability": 0.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": -10.0078125,
            "text": "hypertension (WHO classification I or II).",
            "probability": 0.0
        },
        {
            "start_logit": -4.171875,
            "end_logit": -10.0390625,
            "text": "hypertension (WHO classification I or II",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -8.34375,
            "text": "antihypertensive",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -7.4140625,
            "text": "with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": -7.4140625,
            "text": "; n = 30) administered for 3 years to patients with essential",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -9.9140625,
            "text": "antihypertensive treatment",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.09375,
            "text": "antihypertensive treatment with isradipine",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.109375,
            "text": "antihypertensive treatment with",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.140625,
            "text": "antihypertensive treatment with isradipine as monotherapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -9.359375,
            "text": "5 +/- 0.63 mg twice daily) in combination with bopindolol",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -9.359375,
            "text": "; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -9.4296875,
            "text": "; n = 11) or isradipine (7",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -9.4296875,
            "text": ", 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_4": [
        {
            "start_logit": 6.32421875,
            "end_logit": 9.8515625,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 9.8515625,
            "text": "mild-to-moderate hypertension",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.15625,
            "end_logit": 9.8515625,
            "text": "to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 9.8515625,
            "text": "with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 9.8515625,
            "text": "isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.8515625,
            "text": "-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.328125,
            "end_logit": 9.8515625,
            "text": "The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.8515625,
            "text": "patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5625,
            "end_logit": 9.8515625,
            "text": "antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 9.8515625,
            "text": "moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 9.8515625,
            "text": "dipine was studied in 45 patients with mild-to-moderate hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -9.984375,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement.",
            "probability": 0.0
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -10.1953125,
            "text": "hypertension (mean age 59 years",
            "probability": 0.0
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -10.2734375,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -10.4375,
            "text": "hypertension (mean age 59 years)",
            "probability": 0.0
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -10.4453125,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement",
            "probability": 0.0
        },
        {
            "start_logit": 6.32421875,
            "end_logit": -10.46875,
            "text": "hypertension (mean age 59 years) using casual and ambulatory 24-h",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.984375,
            "text": "mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -10.1953125,
            "text": "mild-to-moderate hypertension (mean age 59 years",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -10.2734375,
            "text": "mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_5": [
        {
            "start_logit": 2.134765625,
            "end_logit": 8.734375,
            "text": "arterial hypertension",
            "probability": 0.755859375
        },
        {
            "start_logit": 2.134765625,
            "end_logit": 7.59765625,
            "text": "arterial hypertension and microvascular angina",
            "probability": 0.243408203125
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 8.734375,
            "text": "hypertension",
            "probability": 0.0005140304565429688
        },
        {
            "start_logit": -5.16015625,
            "end_logit": 7.59765625,
            "text": "hypertension and microvascular angina",
            "probability": 0.00016498565673828125
        },
        {
            "start_logit": -6.84375,
            "end_logit": 7.59765625,
            "text": "microvascular angina",
            "probability": 3.075599670410156e-05
        },
        {
            "start_logit": -8.03125,
            "end_logit": 8.734375,
            "text": "with arterial hypertension",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -7.75,
            "end_logit": 7.59765625,
            "text": "and microvascular angina",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": -7.9375,
            "end_logit": 7.59765625,
            "text": "angina",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -8.03125,
            "end_logit": 7.59765625,
            "text": "with arterial hypertension and microvascular angina",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -9.5625,
            "end_logit": 8.734375,
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 8.734375,
            "text": "antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -10.421875,
            "end_logit": 8.734375,
            "text": "coronary flow reserve in patients with arterial hypertension",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 8.734375,
            "text": "term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -10.5625,
            "end_logit": 8.734375,
            "text": "in patients with arterial hypertension",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 8.734375,
            "text": "Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -10.6875,
            "end_logit": 8.734375,
            "text": "patients with arterial hypertension",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -9.5625,
            "end_logit": 7.59765625,
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 8.734375,
            "text": "isradipine. Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -10.828125,
            "end_logit": 8.734375,
            "text": "Improvement of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 8.734375,
            "text": "of coronary flow reserve in patients with arterial hypertension",
            "probability": 1.7285346984863281e-06
        }
    ],
    "56c3184050c68dd416000003_6": [
        {
            "start_logit": 10.1875,
            "end_logit": 14.484375,
            "text": "arterial hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": 14.484375,
            "text": "hypertension",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -7.875,
            "end_logit": 14.484375,
            "text": "in arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 14.484375,
            "text": "[Isradipine in arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 14.484375,
            "text": "Isradipine in arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -4.96484375,
            "text": "arterial",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 14.484375,
            "text": "dipine in arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 14.484375,
            "text": "pine in arterial hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.6796875,
            "text": "arterial hypertension in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.796875,
            "text": "arterial hypertension in motor vehicle drivers",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -8.8671875,
            "text": "arterial hypertension in motor vehicle drivers].",
            "probability": 0.0
        },
        {
            "start_logit": 10.1875,
            "end_logit": -10.1015625,
            "text": "arterial hypertension in",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.6796875,
            "text": "hypertension in motor vehicle drivers]",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.796875,
            "text": "hypertension in motor vehicle drivers",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -8.8671875,
            "text": "hypertension in motor vehicle drivers].",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -10.1015625,
            "text": "hypertension in",
            "probability": 0.0
        },
        {
            "start_logit": -7.875,
            "end_logit": -4.96484375,
            "text": "in arterial",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -4.96484375,
            "text": "[Isradipine in arterial",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": -4.96484375,
            "text": "Isradipine in arterial",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -4.96484375,
            "text": "dipine in arterial",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_7": [
        {
            "start_logit": 11.265625,
            "end_logit": 13.7265625,
            "text": "essential hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -3.30078125,
            "end_logit": 13.7265625,
            "text": "hypertension",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 11.265625,
            "end_logit": -5.3203125,
            "text": "essential",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 13.7265625,
            "text": "elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 13.7265625,
            "text": "with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 13.7265625,
            "text": "patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.7265625,
            "text": "isradipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 13.7265625,
            "text": "safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.7265625,
            "text": "in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 13.7265625,
            "text": "dipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 13.7265625,
            "text": "the safety and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -11.234375,
            "end_logit": 13.7265625,
            "text": "of isradipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -11.3984375,
            "end_logit": 13.7265625,
            "text": "and efficacy of isradipine in elderly patients with essential hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.171875,
            "text": "essential hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -3.30078125,
            "end_logit": -9.171875,
            "text": "hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": -5.3203125,
            "text": "elderly patients with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -5.3203125,
            "text": "with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -5.3203125,
            "text": "patients with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -5.3203125,
            "text": "isradipine in elderly patients with essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -5.3203125,
            "text": "safety and efficacy of isradipine in elderly patients with essential",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_8": [
        {
            "start_logit": 5.296875,
            "end_logit": 9.6484375,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 9.6484375,
            "text": "treatment of hypertension",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 9.6484375,
            "text": "of hypertension",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.84375,
            "end_logit": 9.6484375,
            "text": "safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 9.6484375,
            "text": "isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.96875,
            "end_logit": 9.6484375,
            "text": "in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 9.6484375,
            "text": "dipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.6484375,
            "text": "multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.6484375,
            "text": "the safety and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.09375,
            "end_logit": 9.6484375,
            "text": "the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.1875,
            "end_logit": 9.6484375,
            "text": "and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 9.6484375,
            "text": "and efficacy of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 9.6484375,
            "text": "of isradipine and atenolol in the treatment of hypertension",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.296875,
            "end_logit": -9.1484375,
            "text": "hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -9.1484375,
            "text": "treatment of hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -10.03125,
            "text": "treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -9.1484375,
            "text": "of hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -10.3125,
            "text": "treatment",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -9.1484375,
            "text": "safety and efficacy of isradipine and atenolol in the treatment of hypertension.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": -9.1484375,
            "text": "isradipine and atenolol in the treatment of hypertension.",
            "probability": 0.0
        }
    ],
    "56c3184050c68dd416000003_9": [
        {
            "start_logit": 7.828125,
            "end_logit": 10.2421875,
            "text": "hypertension",
            "probability": 1.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 10.2421875,
            "text": "very careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 10.2421875,
            "text": "for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 10.2421875,
            "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.2421875,
            "text": "to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 10.2421875,
            "text": "therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.2421875,
            "text": "isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 10.2421875,
            "text": "be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 10.2421875,
            "text": "careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 10.2421875,
            "text": "in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 10.2421875,
            "text": "use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 10.2421875,
            "text": "is advisable to be very careful in the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 10.2421875,
            "text": "the use of isradipine as a therapy for hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 7.828125,
            "end_logit": -9.3203125,
            "text": "hypertension and other indications",
            "probability": 0.0
        },
        {
            "start_logit": 7.828125,
            "end_logit": -9.5078125,
            "text": "hypertension and other indications.",
            "probability": 0.0
        },
        {
            "start_logit": 7.828125,
            "end_logit": -9.796875,
            "text": "hypertension and other",
            "probability": 0.0
        },
        {
            "start_logit": 7.828125,
            "end_logit": -10.453125,
            "text": "hypertension and",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.3203125,
            "text": "very careful in the use of isradipine as a therapy for hypertension and other indications",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.3203125,
            "text": "for hypertension and other indications",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.5078125,
            "text": "very careful in the use of isradipine as a therapy for hypertension and other indications.",
            "probability": 0.0
        }
    ],
    "56ffd08bcf1c325851000009_1": [
        {
            "start_logit": 7.7734375,
            "end_logit": 8.21875,
            "text": "7SL RNA gene",
            "probability": 1.0
        },
        {
            "start_logit": -0.9267578125,
            "end_logit": 8.21875,
            "text": "the 7SL RNA gene",
            "probability": 0.00016605854034423828
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -2.52734375,
            "text": "7SL RNA",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -4.66796875,
            "text": "7SL RNA gene.",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.40625,
            "end_logit": 8.21875,
            "text": "Alu elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -6.00390625,
            "text": "7",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 8.21875,
            "text": "RNA gene",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.21875,
            "text": "L RNA gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 8.21875,
            "text": "from the 7SL RNA gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 8.21875,
            "text": "gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.859375,
            "end_logit": 8.21875,
            "text": "SL RNA gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -8.046875,
            "text": "7SL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -8.90625,
            "text": "7S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8125,
            "end_logit": 8.21875,
            "text": ", fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 8.21875,
            "text": "not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 8.21875,
            "text": "about 300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 8.21875,
            "text": "300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 8.21875,
            "text": "but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 8.21875,
            "text": "bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 8.21875,
            "text": "size about 300 bp, and originate from the 7SL RNA gene",
            "probability": 0.0
        }
    ],
    "58cf5c5a8acda34529000003_1": [
        {
            "start_logit": 3.96875,
            "end_logit": 9.53125,
            "text": "telomeric repeats",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.552734375,
            "end_logit": 10.3828125,
            "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.0012636184692382812
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 10.3828125,
            "text": "cil",
            "probability": 7.474422454833984e-05
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 9.53125,
            "text": "cil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 3.1888484954833984e-05
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 9.53125,
            "text": "in telomeric repeats",
            "probability": 2.4259090423583984e-05
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.53125,
            "text": "repeats",
            "probability": 1.7702579498291016e-05
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 10.3828125,
            "text": "hydroxymethyluracil",
            "probability": 1.5854835510253906e-05
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 10.3828125,
            "text": "osyl-hydroxymethyluracil",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -8.390625,
            "end_logit": 10.3828125,
            "text": "uracil",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 10.3828125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.53125,
            "text": "hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.53125,
            "text": "osyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -9.0,
            "end_logit": 10.3828125,
            "text": "glucosyl-hydroxymethyluracil",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -8.390625,
            "end_logit": 9.53125,
            "text": "uracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 9.53125,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 10.3828125,
            "text": "-hydroxymethyluracil",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.3828125,
            "text": "D-glucosyl-hydroxymethyluracil",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 10.3828125,
            "text": "-D-glucosyl-hydroxymethyluracil",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -9.0,
            "end_logit": 9.53125,
            "text": "glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 10.3828125,
            "text": "-glucosyl-hydroxymethyluracil",
            "probability": 1.6093254089355469e-06
        }
    ],
    "58cf5c5a8acda34529000003_2": [
        {
            "start_logit": 1.1455078125,
            "end_logit": 8.1875,
            "text": "telomeric repeats",
            "probability": 0.998046875
        },
        {
            "start_logit": -5.41015625,
            "end_logit": 8.1015625,
            "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 0.0012979507446289062
        },
        {
            "start_logit": -7.3125,
            "end_logit": 8.1875,
            "text": "in telomeric repeats",
            "probability": 0.00021123886108398438
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.1875,
            "text": "repeats",
            "probability": 0.0001531839370727539
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.1875,
            "text": "cil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 0.0001531839370727539
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.1015625,
            "text": "cil",
            "probability": 0.00013959407806396484
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 8.1875,
            "text": "hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": -8.90625,
            "end_logit": 8.1875,
            "text": "uracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 4.291534423828125e-05
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 8.1015625,
            "text": "hydroxymethyluracil",
            "probability": 4.225969314575195e-05
        },
        {
            "start_logit": -8.90625,
            "end_logit": 8.1015625,
            "text": "uracil",
            "probability": 3.93986701965332e-05
        },
        {
            "start_logit": -9.015625,
            "end_logit": 8.1875,
            "text": "osyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 3.844499588012695e-05
        },
        {
            "start_logit": -9.015625,
            "end_logit": 8.1015625,
            "text": "osyl-hydroxymethyluracil",
            "probability": 3.528594970703125e-05
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 8.1875,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 8.1015625,
            "text": "\u03b2-D-glucosyl-hydroxymethyluracil",
            "probability": 2.855062484741211e-05
        },
        {
            "start_logit": -9.46875,
            "end_logit": 8.1875,
            "text": "glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": -9.46875,
            "end_logit": 8.1015625,
            "text": "glucosyl-hydroxymethyluracil",
            "probability": 2.2411346435546875e-05
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 8.1875,
            "text": "D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 8.1875,
            "text": "-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats",
            "probability": 1.5854835510253906e-05
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 8.1015625,
            "text": "D-glucosyl-hydroxymethyluracil",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 8.1015625,
            "text": "-hydroxymethyluracil",
            "probability": 1.4603137969970703e-05
        }
    ],
    "61f86c03882a024a10000044_1": [
        {
            "start_logit": 8.984375,
            "end_logit": 13.7578125,
            "text": "recessive hereditary motor neuropathy",
            "probability": 0.96240234375
        },
        {
            "start_logit": 5.73828125,
            "end_logit": 13.7578125,
            "text": "hereditary motor neuropathy",
            "probability": 0.037322998046875
        },
        {
            "start_logit": -3.6875,
            "end_logit": 13.7578125,
            "text": "neuropathy",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 13.7578125,
            "text": "motor neuropathy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 13.7578125,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -3.4375,
            "text": "recessive",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 13.7578125,
            "text": "repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 13.7578125,
            "text": "causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.7578125,
            "text": "bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 13.7578125,
            "text": "ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.7578125,
            "text": "10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.7578125,
            "text": "VWA1 causes recessive hereditary motor neuropathy",
            "probability": 0.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.58203125,
            "text": "recessive hereditary motor neuropathy.",
            "probability": 0.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.1328125,
            "text": "recessive hereditary motor",
            "probability": 0.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -9.7265625,
            "text": "recessive hereditary",
            "probability": 0.0
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -6.58203125,
            "text": "hereditary motor neuropathy.",
            "probability": 0.0
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -7.1328125,
            "text": "hereditary motor",
            "probability": 0.0
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -9.7265625,
            "text": "hereditary",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": -3.4375,
            "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive",
            "probability": 0.0
        },
        {
            "start_logit": -3.6875,
            "end_logit": -6.58203125,
            "text": "neuropathy.",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_1": [
        {
            "start_logit": 14.3125,
            "end_logit": 14.6796875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -1.91015625,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.943359375,
            "end_logit": 14.6796875,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.0859375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 14.6796875,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.6484375,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.7265625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 14.6796875,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.03125,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.6796875,
            "text": ": Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.140625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.234375,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 14.6796875,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.6796875,
            "text": "BACKGROUND: Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.3828125,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.4140625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.6796875,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -1.91015625,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.943359375,
            "end_logit": -9.0859375,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -1.91015625,
            "text": "of cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_2": [
        {
            "start_logit": 14.1015625,
            "end_logit": 14.1796875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -2.412109375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.392578125,
            "end_logit": 14.1796875,
            "text": "fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -5.9921875,
            "text": "cystic fibrosis transmembrane conductance regulator",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.65625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.40625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride concentrations in subjects.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.546875,
            "text": "cystic fibrosis transmembrane conductance",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.765625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride concentrations in subjects",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.78125,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.859375,
            "text": "cystic fibrosis transmembrane conductance regulator)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.0390625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.046875,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.109375,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating sweat sodium and sweat chloride concentrations in",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.140625,
            "text": "cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the ST, as well as correlating",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.1796875,
            "text": "(cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.1796875,
            "text": ": To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.1796875,
            "text": "test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.1796875,
            "text": "the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.1796875,
            "text": "Objective: To conduct a descriptive analysis of the sweat test (ST), associating ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 14.1796875,
            "text": "ST results with epidemiological data, CFTR (cystic fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_3": [
        {
            "start_logit": 14.109375,
            "end_logit": 14.5078125,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -2.41796875,
            "text": "Cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.00390625,
            "end_logit": 14.5078125,
            "text": "Fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.625,
            "end_logit": 14.5078125,
            "text": "Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.4375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.703125,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.890625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.5078125,
            "text": "Metabolome of Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.09375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.5078125,
            "text": "Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.1875,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.265625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.28125,
            "text": "Cystic Fibrosis Infants",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.3359375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.375,
            "text": "Cystic Fibrosis Infants:",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.5078125,
            "text": "The Sweat Metabolome of Screen-Positive Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.3984375,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -10.40625,
            "text": "Cystic Fibrosis Infants: Revealing Mechanisms",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -2.41796875,
            "text": "Positive Cystic",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -9.4375,
            "text": "Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_4": [
        {
            "start_logit": 14.40625,
            "end_logit": 14.796875,
            "text": "Cystic Fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -1.7080078125,
            "text": "Cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.779296875,
            "end_logit": 14.796875,
            "text": "Fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.40625,
            "end_logit": -8.7421875,
            "text": "Cystic Fibrosis Patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 14.796875,
            "text": "of Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.5859375,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -10.1640625,
            "text": "Cystic Fibrosis Patients.The diagnosis is often delayed",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -10.1640625,
            "text": "Cystic Fibrosis Patients.",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -10.234375,
            "text": "Cystic Fibrosis Patients.The diagnosis is",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.796875,
            "text": "Clinical Features of Cystic Fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": -8.7421875,
            "text": "Fibrosis Patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -1.7080078125,
            "text": "of Cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": -9.5859375,
            "text": "Fibrosis Patients.The diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -1.7080078125,
            "text": "Clinical Features of Cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": -10.1640625,
            "text": "Fibrosis Patients.The diagnosis is often delayed",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": -10.1640625,
            "text": "Fibrosis Patients.",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": -10.234375,
            "text": "Fibrosis Patients.The diagnosis is",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -8.7421875,
            "text": "of Cystic Fibrosis Patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": -8.7421875,
            "text": "Patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -9.3125,
            "text": "of",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_5": [
        {
            "start_logit": 14.2265625,
            "end_logit": 14.546875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -2.23046875,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.07421875,
            "end_logit": 14.546875,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.41796875,
            "end_logit": 14.546875,
            "text": "In cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -7.37890625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -8.0625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -8.625,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.0546875,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.2890625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.4609375,
            "text": "cystic fibrosis (CF),",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.5,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.609375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.9453125,
            "text": "cystic fibrosis (CF), sweat chloride",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.9609375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -10.0234375,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -10.140625,
            "text": "cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -2.23046875,
            "text": "In cystic",
            "probability": 0.0
        },
        {
            "start_logit": -3.07421875,
            "end_logit": -7.37890625,
            "text": "fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": -6.359375,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": -3.07421875,
            "end_logit": -8.0625,
            "text": "fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR.",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_6": [
        {
            "start_logit": 14.28125,
            "end_logit": 14.640625,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -1.9755859375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.958984375,
            "end_logit": 14.640625,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.9921875,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.640625,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.6015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.640625,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.640625,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.7578125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.015625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.1328125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.2578125,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.359375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.640625,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.40625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.640625,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 14.640625,
            "text": "testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -1.9755859375,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -8.9921875,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -1.9755859375,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_7": [
        {
            "start_logit": 14.359375,
            "end_logit": 14.7109375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -1.908203125,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 14.7109375,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.5625,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 14.7109375,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.7109375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.7421875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.7890625,
            "text": "cystic fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.7109375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.7109375,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.7109375,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.7109375,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.7109375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.7109375,
            "text": "standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.7109375,
            "text": "is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": -1.908203125,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -8.5625,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -1.908203125,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.125,
            "text": "fibrosis (",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_8": [
        {
            "start_logit": 14.546875,
            "end_logit": 14.859375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -1.265625,
            "text": "cystic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.626953125,
            "end_logit": 14.859375,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 14.859375,
            "text": "The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -8.75,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 14.859375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.3828125,
            "text": "cystic fibrosis (CF) in support of universal newborn screening programs.",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.3828125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.796875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.859375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.0625,
            "text": "cystic fibrosis (CF) in support of universal newborn screening",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.859375,
            "text": "confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.2890625,
            "text": "cystic fibrosis (CF) in support of universal",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.859375,
            "text": "gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.859375,
            "text": "for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.859375,
            "text": "sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.859375,
            "text": "the gold standard for confirmatory diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -1.265625,
            "text": "The sweat chloride test remains the gold standard for confirmatory diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -1.265625,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.626953125,
            "end_logit": -8.75,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_9": [
        {
            "start_logit": 14.3671875,
            "end_logit": 14.7734375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -1.7177734375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.8046875,
            "end_logit": 14.7734375,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.2578125,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 14.7734375,
            "text": "Sweat chloride is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.765625,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.921875,
            "text": "cystic fibrosis,",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.7734375,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.03125,
            "text": "cystic fibrosis, electrolyte",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.0625,
            "text": "cystic fibrosis, electrolyte metabolism",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.125,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.125,
            "text": "cystic fibrosis, electrolyte metabolism disorders, electrolyte balance",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.7734375,
            "text": "chloride is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.7734375,
            "text": "of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.7734375,
            "text": "is of interest as a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.7734375,
            "text": "a biomarker for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.8046875,
            "end_logit": -8.2578125,
            "text": "fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -1.7177734375,
            "text": "Sweat chloride is of interest as a biomarker for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": -1.7177734375,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -1.7177734375,
            "text": "chloride is of interest as a biomarker for cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_10": [
        {
            "start_logit": 14.359375,
            "end_logit": 14.7109375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -1.908203125,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 14.7109375,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.5625,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 14.7109375,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.7109375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.7421875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.7890625,
            "text": "cystic fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.7109375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.7109375,
            "text": "Sweat chloride testing is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.7109375,
            "text": "the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.7109375,
            "text": "gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.7109375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.7109375,
            "text": "standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.7109375,
            "text": "is the gold standard for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": -1.908203125,
            "text": "OBJECTIVES Sweat chloride testing is the gold standard for diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -8.5625,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -1.908203125,
            "text": "of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.125,
            "text": "fibrosis (",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_11": [
        {
            "start_logit": 14.28125,
            "end_logit": 14.640625,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -1.9755859375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.958984375,
            "end_logit": 14.640625,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.9921875,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.640625,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.6015625,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.640625,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.640625,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.7578125,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.015625,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.1328125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.2578125,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.359375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.640625,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -10.40625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.640625,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 14.640625,
            "text": "testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -1.9755859375,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.958984375,
            "end_logit": -8.9921875,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -1.9755859375,
            "text": "BACKGROUND Sweat chloride testing for diagnosis of cystic",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_12": [
        {
            "start_logit": 14.4375,
            "end_logit": 14.7109375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -1.662109375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.900390625,
            "end_logit": 14.7109375,
            "text": "fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.4296875,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.640625,
            "text": "cystic fibrosis (CF) diagnosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.7890625,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.375,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 14.7109375,
            "text": "BACKGROUND Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 14.7109375,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -9.6328125,
            "text": "cystic fibrosis (CF) diagnosis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.7109375,
            "text": "Sweat chloride test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.7109375,
            "text": "the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.7109375,
            "text": "gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.7109375,
            "text": "standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.7109375,
            "text": "test is the gold standard test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.7109375,
            "text": "test for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -8.4296875,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -1.662109375,
            "text": "BACKGROUND Sweat chloride test is the gold standard test for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -1.662109375,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -8.640625,
            "text": "fibrosis (CF) diagnosis",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_13": [
        {
            "start_logit": 14.4296875,
            "end_logit": 14.8515625,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -1.7060546875,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.697265625,
            "end_logit": 14.8515625,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 14.8515625,
            "text": "the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -8.1953125,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.8515625,
            "text": "Sweat chloride test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.7421875,
            "text": "cystic fibrosis due",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.953125,
            "text": "cystic fibrosis due to the fact that electrolyte levels in sweat",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.8515625,
            "text": "for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -10.140625,
            "text": "cystic fibrosis due to the fact that electrolyte",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.8515625,
            "text": "known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -10.265625,
            "text": "cystic fibrosis due to the fact",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.8515625,
            "text": "test is known to be a screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.8515625,
            "text": "screening test for the cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.84765625,
            "end_logit": -1.7060546875,
            "text": "the cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -8.1953125,
            "text": "fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -1.7060546875,
            "text": "Sweat chloride test is known to be a screening test for the cystic",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -1.7060546875,
            "text": "for the cystic",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -1.7060546875,
            "text": "known to be a screening test for the cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.697265625,
            "end_logit": -9.7421875,
            "text": "fibrosis due",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_14": [
        {
            "start_logit": 14.4140625,
            "end_logit": 14.7421875,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -1.6943359375,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.83203125,
            "end_logit": 14.7421875,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 14.7421875,
            "text": "for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -7.88671875,
            "text": "cystic fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -8.2109375,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -8.875,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 14.7421875,
            "text": "OBJECTIVE Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.171875,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.7421875,
            "text": "diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.7421875,
            "text": "considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.7421875,
            "text": "a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.7421875,
            "text": "standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.7421875,
            "text": "tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.7421875,
            "text": "Sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 14.7421875,
            "text": "measurement is considered a standard diagnostic tool for cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -1.6943359375,
            "text": "for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.83203125,
            "end_logit": -7.88671875,
            "text": "fibrosis (CF).",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": -1.6943359375,
            "text": "OBJECTIVE Sweat chloride measurement is considered a standard diagnostic tool for cystic",
            "probability": 0.0
        },
        {
            "start_logit": -2.83203125,
            "end_logit": -8.2109375,
            "text": "fibrosis (CF",
            "probability": 0.0
        }
    ],
    "5c6e16eb7c78d6947100004e_15": [
        {
            "start_logit": 14.265625,
            "end_logit": 14.5859375,
            "text": "cystic fibrosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -1.9814453125,
            "text": "cystic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.05078125,
            "end_logit": 14.5859375,
            "text": "fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.6953125,
            "text": "cystic fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.7421875,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 14.5859375,
            "text": "diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.4140625,
            "text": "cystic fibrosis (",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 14.5859375,
            "text": "of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.828125,
            "text": "cystic fibrosis (CF)",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.5859375,
            "text": "Sweat chloride testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.078125,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.109375,
            "text": "cystic fibrosis (CF) involves",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.265625,
            "text": "cystic fibrosis (CF) involves sweat induction",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.3359375,
            "text": "cystic fibrosis (CF) involves sweat",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.5859375,
            "text": "for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.34375,
            "text": "cystic fibrosis (CF) involves sweat induction, collection and handling, and",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 14.5859375,
            "text": "testing for diagnosis of cystic fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -1.9814453125,
            "text": "diagnosis of cystic",
            "probability": 0.0
        },
        {
            "start_logit": -3.05078125,
            "end_logit": -8.6953125,
            "text": "fibrosis (CF",
            "probability": 0.0
        },
        {
            "start_logit": -3.05078125,
            "end_logit": -8.7421875,
            "text": "fibrosis (CF) involves sweat induction, collection and handling, and measurement in an analytical lab.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_1": [
        {
            "start_logit": 8.2734375,
            "end_logit": 10.359375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.0625,
            "end_logit": 10.359375,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 10.359375,
            "text": "bladder cancer",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.25,
            "end_logit": 10.359375,
            "text": "Calmette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 10.359375,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 10.359375,
            "text": "ette-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 10.359375,
            "text": "Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 10.359375,
            "text": "-Gu\u00e9rin immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 10.359375,
            "text": "immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -9.859375,
            "text": "cancer: a review of immunological aspects, clinical effects and BCG infections.",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.09375,
            "text": "cancer: a review",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.1328125,
            "text": "cancer: a",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.2109375,
            "text": "cancer: a review of immunological",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.3515625,
            "text": "cancer: a review of immunological aspects, clinical effects and BCG infections",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.3828125,
            "text": "cancer:",
            "probability": 0.0
        },
        {
            "start_logit": 8.2734375,
            "end_logit": -10.4453125,
            "text": "cancer: a review of immunological aspects",
            "probability": 0.0
        },
        {
            "start_logit": -2.0625,
            "end_logit": -9.1796875,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -2.0625,
            "end_logit": -9.859375,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.",
            "probability": 0.0
        },
        {
            "start_logit": -2.0625,
            "end_logit": -9.875,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder",
            "probability": 0.0
        },
        {
            "start_logit": -2.0625,
            "end_logit": -10.09375,
            "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_2": [
        {
            "start_logit": 10.34375,
            "end_logit": 10.0703125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": 10.0703125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 10.0703125,
            "text": "bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.34375,
            "end_logit": -10.078125,
            "text": "cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 10.0703125,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.34375,
            "end_logit": -10.375,
            "text": "cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 10.0703125,
            "text": "BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 10.0703125,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 10.0703125,
            "text": "ette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.0703125,
            "text": "Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 10.0703125,
            "text": "-Gu\u00e9rin (BCG) immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 10.0703125,
            "text": "immunotherapy for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": -9.6953125,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": -10.375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": -10.375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG)",
            "probability": 0.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": -10.4765625,
            "text": "Bacillus Calmette-Gu\u00e9rin (",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -10.078125,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published.",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -10.375,
            "text": "bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -9.6953125,
            "text": "Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.6953125,
            "text": "ette-Gu\u00e9rin",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_3": [
        {
            "start_logit": 9.5546875,
            "end_logit": 9.5859375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.5859375,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.44140625,
            "end_logit": 9.5859375,
            "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.5859375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9765625,
            "end_logit": 9.5859375,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 9.5859375,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 9.5859375,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 9.5859375,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 9.5859375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 9.5859375,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.5546875,
            "end_logit": -9.5859375,
            "text": "cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 9.5859375,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.5546875,
            "end_logit": -10.2265625,
            "text": "cancer (NMIBC) after transurethral resection.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 9.5859375,
            "text": "choice of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.08203125,
            "end_logit": -9.5859375,
            "text": "high-grade non-muscle invasive bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -6.44140625,
            "end_logit": -9.5859375,
            "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -6.44140625,
            "end_logit": -9.859375,
            "text": "BCG immunotherapy is the choice of care",
            "probability": 0.0
        },
        {
            "start_logit": -6.08203125,
            "end_logit": -10.2265625,
            "text": "high-grade non-muscle invasive bladder cancer (NMIBC) after transurethral resection.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -9.5859375,
            "text": "non-muscle invasive bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -6.44140625,
            "end_logit": -10.2265625,
            "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer (NMIBC) after transurethral resection.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_4": [
        {
            "start_logit": 11.5234375,
            "end_logit": 11.71875,
            "text": "Tuberculosis",
            "probability": 1.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": 11.71875,
            "text": "Renal Tuberculosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.5234375,
            "end_logit": -8.1953125,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5234375,
            "end_logit": -9.6328125,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": 11.5234375,
            "end_logit": -9.7578125,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.5234375,
            "end_logit": -10.15625,
            "text": "Tuberculosis Following",
            "probability": 0.0
        },
        {
            "start_logit": 11.5234375,
            "end_logit": -10.2265625,
            "text": "Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -8.1953125,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -9.6328125,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -9.7578125,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -9.84375,
            "text": "Renal",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -8.1953125,
            "text": "Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -10.15625,
            "text": "Renal Tuberculosis Following",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -8.1953125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -8.1953125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -10.2265625,
            "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -8.1953125,
            "text": "Treatment of Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -8.1953125,
            "text": "Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -8.1953125,
            "text": "Cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -8.1953125,
            "text": "of Bladder Cancer.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_5": [
        {
            "start_logit": 9.890625,
            "end_logit": 10.1328125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": 10.1328125,
            "text": "superficial bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 10.1328125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 10.1328125,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 10.1328125,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 10.1328125,
            "text": "treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 10.1328125,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 10.1328125,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 10.1328125,
            "text": "Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 10.1328125,
            "text": "is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 10.1328125,
            "text": "-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 10.1328125,
            "text": "ette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 10.1328125,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 10.1328125,
            "text": "BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 10.1328125,
            "text": "Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.890625,
            "end_logit": -10.6328125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -10.6328125,
            "text": "superficial bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.6875,
            "end_logit": -10.1015625,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -6.6875,
            "end_logit": -10.6328125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -10.6328125,
            "text": "bladder cancer.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_6": [
        {
            "start_logit": 7.81640625,
            "end_logit": 9.5546875,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": 9.5546875,
            "text": "bladder cancer",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 9.5546875,
            "text": "Prostatic urethral mucosal involvement with bladder cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 9.5546875,
            "text": "with bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 9.5546875,
            "text": "urethral mucosal involvement with bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 9.5546875,
            "text": "involvement with bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 9.5546875,
            "text": "mucosal involvement with bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -9.9609375,
            "text": "cancer can be effectively",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -10.125,
            "text": "cancer can",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -10.2578125,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates,",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -10.3515625,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -10.4296875,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction",
            "probability": 0.0
        },
        {
            "start_logit": 7.81640625,
            "end_logit": -10.4609375,
            "text": "cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -9.515625,
            "text": "bladder",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -9.9609375,
            "text": "bladder cancer can be effectively",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -10.125,
            "text": "bladder cancer can",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -10.2578125,
            "text": "bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates,",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -10.3515625,
            "text": "bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -10.4296875,
            "text": "bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction",
            "probability": 0.0
        },
        {
            "start_logit": -2.95703125,
            "end_logit": -10.4609375,
            "text": "bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_7": [
        {
            "start_logit": 11.265625,
            "end_logit": 10.90625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.609375,
            "end_logit": 10.90625,
            "text": "nonmuscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.265625,
            "end_logit": -9.34375,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 10.90625,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 10.90625,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 10.90625,
            "text": "uscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 10.90625,
            "text": "in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 10.90625,
            "text": "Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 10.90625,
            "text": "le invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 10.90625,
            "text": "Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 10.90625,
            "text": "immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 10.90625,
            "text": "bovis BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 10.90625,
            "text": "BCG for immunotherapy in nonmuscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.609375,
            "end_logit": -9.34375,
            "text": "nonmuscle invasive bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -9.34375,
            "text": "invasive bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -9.34375,
            "text": "bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -9.34375,
            "text": "uscle invasive bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -9.34375,
            "text": "in nonmuscle invasive bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -9.34375,
            "text": "Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -9.34375,
            "text": "le invasive bladder cancer.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_8": [
        {
            "start_logit": 0.1317138671875,
            "end_logit": 6.77734375,
            "text": "cancer",
            "probability": 0.4951171875
        },
        {
            "start_logit": 9.734375,
            "end_logit": -2.849609375,
            "text": "carcinoma in situ",
            "probability": 0.48193359375
        },
        {
            "start_logit": 9.734375,
            "end_logit": -5.95703125,
            "text": "carcinoma",
            "probability": 0.0215911865234375
        },
        {
            "start_logit": 9.734375,
            "end_logit": -10.109375,
            "text": "carcinoma in situ (CIS),",
            "probability": 0.000339508056640625
        },
        {
            "start_logit": 9.734375,
            "end_logit": -10.140625,
            "text": "carcinoma in situ (CIS",
            "probability": 0.0003292560577392578
        },
        {
            "start_logit": 9.734375,
            "end_logit": -10.2734375,
            "text": "carcinoma in situ (CIS)",
            "probability": 0.0002880096435546875
        },
        {
            "start_logit": 9.734375,
            "end_logit": -10.4609375,
            "text": "carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5",
            "probability": 0.00023877620697021484
        },
        {
            "start_logit": 9.734375,
            "end_logit": -10.5546875,
            "text": "carcinoma in situ (CIS), where complete response is increased from 50",
            "probability": 0.000217437744140625
        },
        {
            "start_logit": -8.890625,
            "end_logit": 6.77734375,
            "text": "superficial bladder cancer",
            "probability": 5.9723854064941406e-05
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 6.77734375,
            "text": "bladder cancer",
            "probability": 4.684925079345703e-05
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -2.849609375,
            "text": "cancer has been most apparent in patients with carcinoma in situ",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -10.171875,
            "end_logit": 6.77734375,
            "text": "intravesical chemotherapy in superficial bladder cancer",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -10.265625,
            "end_logit": 6.77734375,
            "text": "BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 6.77734375,
            "text": "in superficial bladder cancer",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -5.95703125,
            "text": "cancer has been most apparent in patients with carcinoma",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -10.109375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS),",
            "probability": 0.0
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -10.140625,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS",
            "probability": 0.0
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -10.2734375,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS)",
            "probability": 0.0
        },
        {
            "start_logit": 0.1317138671875,
            "end_logit": -10.5546875,
            "text": "cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": -2.849609375,
            "text": "in situ",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_9": [
        {
            "start_logit": 8.59375,
            "end_logit": 6.88671875,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": 8.59375,
            "end_logit": -9.875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 6.88671875,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 6.88671875,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.046875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.265625,
            "text": "cancer (NMIBC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.296875,
            "text": "cancer (NMIBC) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.359375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.4765625,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While most a",
            "probability": 0.0
        },
        {
            "start_logit": 8.59375,
            "end_logit": -10.484375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 6.88671875,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 6.88671875,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 6.88671875,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 6.88671875,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 6.88671875,
            "text": "dministration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 6.88671875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 6.88671875,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 6.88671875,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 6.88671875,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 6.88671875,
            "text": "become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_10": [
        {
            "start_logit": 7.0390625,
            "end_logit": 5.92578125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 5.92578125,
            "text": "bladder cancer",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 7.0390625,
            "end_logit": -9.4296875,
            "text": "cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 5.92578125,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 5.92578125,
            "text": "stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.328125,
            "end_logit": 5.92578125,
            "text": ") bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.0390625,
            "end_logit": -10.59375,
            "text": "cancer (BC), though",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 5.92578125,
            "text": "(T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 5.92578125,
            "text": "for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0,
            "end_logit": 5.92578125,
            "text": "grade 3 (T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.015625,
            "end_logit": 5.92578125,
            "text": "T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1875,
            "end_logit": 5.92578125,
            "text": "T1 grade 3 (T1G3) bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.34375,
            "end_logit": 5.92578125,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.9140625,
            "end_logit": -9.4296875,
            "text": "bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -5.9140625,
            "end_logit": -10.59375,
            "text": "bladder cancer (BC), though",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -9.4296875,
            "text": "stage T1 grade 3 (T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": -9.4296875,
            "text": ") bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -9.4296875,
            "text": "(T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -9.4296875,
            "text": "for stage T1 grade 3 (T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": -10.2109375,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_11": [
        {
            "start_logit": 9.109375,
            "end_logit": 8.6640625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 8.6640625,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -7.74609375,
            "end_logit": 8.6640625,
            "text": "muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.734375,
            "end_logit": 8.6640625,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.765625,
            "end_logit": 8.6640625,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -9.65625,
            "text": "cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 8.6640625,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -10.125,
            "text": "cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 8.6640625,
            "text": "with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -10.375,
            "text": "cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.6640625,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -10.5625,
            "text": "cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG),",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 8.6640625,
            "text": "patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 8.6640625,
            "text": "The standard of care for most patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 8.6640625,
            "text": "most patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 8.6640625,
            "text": "standard of care for most patients with non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -9.65625,
            "text": "non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -10.125,
            "text": "non-muscle-invasive bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -10.453125,
            "text": "non",
            "probability": 0.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": -10.5625,
            "text": "non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG),",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_12": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.6484375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": 9.6484375,
            "text": "superficial bladder cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.6484375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 9.6484375,
            "text": "bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.765625,
            "end_logit": 9.6484375,
            "text": "treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 9.6484375,
            "text": "nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 9.6484375,
            "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 9.6484375,
            "text": "since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 9.6484375,
            "text": "Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 9.6484375,
            "text": "is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 9.6484375,
            "text": "ette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 9.6484375,
            "text": "-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 9.6484375,
            "text": "40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 9.6484375,
            "text": "Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.6484375,
            "text": "BCG) was first used as an immunotherapy to treat superficial bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -10.5625,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -10.5625,
            "text": "superficial bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -10.0859375,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -10.5625,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": -10.5625,
            "text": "bladder cancer.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_13": [
        {
            "start_logit": 8.8828125,
            "end_logit": 9.4140625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": 9.4140625,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 9.4140625,
            "text": "muscle-invasive bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5625,
            "end_logit": 9.4140625,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 9.4140625,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 9.4140625,
            "text": "bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 9.4140625,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 9.4140625,
            "text": "Intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 9.4140625,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 9.4140625,
            "text": "for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 9.4140625,
            "text": "ille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -9.7109375,
            "text": "cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -9.8046875,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 9.4140625,
            "text": "Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.4140625,
            "text": "BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -10.2734375,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression",
            "probability": 0.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -10.2890625,
            "text": "cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC.",
            "probability": 0.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -10.3046875,
            "text": "cancer (NMIBC)",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -9.7109375,
            "text": "non-muscle-invasive bladder cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": -2.150390625,
            "end_logit": -9.8046875,
            "text": "non-muscle-invasive bladder cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_14": [
        {
            "start_logit": 2.236328125,
            "end_logit": 8.2734375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 8.2734375,
            "text": "bladder cancer",
            "probability": 4.57763671875e-05
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 8.2734375,
            "text": "muscle invasive bladder cancer",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 8.2734375,
            "text": "invasive bladder cancer",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 8.2734375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -9.4375,
            "end_logit": 8.2734375,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 8.2734375,
            "text": "-muscle invasive bladder cancer",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -10.09375,
            "end_logit": 8.2734375,
            "text": "for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -10.140625,
            "end_logit": 8.2734375,
            "text": "approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -10.15625,
            "end_logit": 8.2734375,
            "text": "high-risk non-muscle invasive bladder cancer",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 8.2734375,
            "text": "to high-risk non-muscle invasive bladder cancer",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 2.236328125,
            "end_logit": -10.5078125,
            "text": "cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        },
        {
            "start_logit": 2.236328125,
            "end_logit": -10.5625,
            "text": "cancer, its long-term efficacy is still arguable",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -10.5078125,
            "text": "bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        },
        {
            "start_logit": -7.7578125,
            "end_logit": -10.5625,
            "text": "bladder cancer, its long-term efficacy is still arguable",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -9.5625,
            "text": "Bacille-Calmette-Guerin",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -10.5078125,
            "text": "muscle invasive bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": -10.5625,
            "text": "muscle invasive bladder cancer, its long-term efficacy is still arguable",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.5625,
            "text": "intravesical instillation of Bacille-Calmette-Guerin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": -10.5078125,
            "text": "invasive bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40%",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_15": [
        {
            "start_logit": 9.3828125,
            "end_logit": 8.0234375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -9.453125,
            "text": "cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": 8.0234375,
            "text": "bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -10.328125,
            "text": "cancer and urothelial CIS",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 8.0234375,
            "text": "high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 8.0234375,
            "text": "treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 8.0234375,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 8.0234375,
            "text": "muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 8.0234375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 8.0234375,
            "text": "risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 8.0234375,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 8.0234375,
            "text": "Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 8.0234375,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 8.0234375,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -9.515625,
            "text": "bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -10.265625,
            "text": "bacillus Calmette-Gu\u00e9rin (BCG",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -10.328125,
            "text": "bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer and urothelial CIS",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -9.453125,
            "text": "bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -9.453125,
            "text": "invasive bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": -10.328125,
            "text": "high-risk non-muscle-invasive bladder cancer and urothelial CIS",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_16": [
        {
            "start_logit": 11.1328125,
            "end_logit": 10.7578125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 10.7578125,
            "text": "high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -9.46875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": 10.7578125,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 10.7578125,
            "text": "treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 10.7578125,
            "text": "risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 10.7578125,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 10.7578125,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 10.7578125,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -10.296875,
            "text": "cancer and urothelial carcinoma in situ",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -10.375,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some",
            "probability": 0.0
        },
        {
            "start_logit": 11.1328125,
            "end_logit": -10.421875,
            "text": "cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 10.7578125,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.7578125,
            "text": "BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 10.7578125,
            "text": "intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -10.296875,
            "text": "high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -10.375,
            "text": "high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": -10.421875,
            "text": "high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -9.46875,
            "text": "urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -10.296875,
            "text": "muscle invasive bladder cancer and urothelial carcinoma in situ",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_17": [
        {
            "start_logit": 8.8671875,
            "end_logit": 7.27734375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.27734375,
            "text": "bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.171875,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.203125,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.28125,
            "text": "cancer and summarizes the mechanisms of action of BCG,",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.3046875,
            "text": "cancer and",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.390625,
            "text": "cancer and summarizes the mechanisms of action",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.4140625,
            "text": "cancer and summarizes the mechanisms of action of BCG, and the important role",
            "probability": 0.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -10.5078125,
            "text": "cancer and summarizes the mechanisms of action of BCG, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 7.27734375,
            "text": "intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 7.27734375,
            "text": "therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 7.27734375,
            "text": "recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 7.27734375,
            "text": "This comprehensive review highlights recent developments in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 7.27734375,
            "text": "of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 7.27734375,
            "text": "in intravesical therapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -10.171875,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -10.203125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -10.28125,
            "text": "bladder cancer and summarizes the mechanisms of action of BCG,",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -10.3046875,
            "text": "bladder cancer and",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": -10.390625,
            "text": "bladder cancer and summarizes the mechanisms of action",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_18": [
        {
            "start_logit": 2.509765625,
            "end_logit": 3.1171875,
            "text": "cancer",
            "probability": 0.86181640625
        },
        {
            "start_logit": 0.66259765625,
            "end_logit": 3.1171875,
            "text": "cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 0.1361083984375
        },
        {
            "start_logit": 0.66259765625,
            "end_logit": -1.6572265625,
            "text": "cancer",
            "probability": 0.001148223876953125
        },
        {
            "start_logit": -5.28125,
            "end_logit": 3.1171875,
            "text": "bladder cancer",
            "probability": 0.00035691261291503906
        },
        {
            "start_logit": -10.125,
            "end_logit": 3.1171875,
            "text": "modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 3.1171875,
            "text": "in bladder cancer",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 2.509765625,
            "end_logit": -9.8203125,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 3.1171875,
            "text": "BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 3.1171875,
            "text": "current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 2.509765625,
            "end_logit": -10.0078125,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 3.1171875,
            "text": "This review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 3.1171875,
            "text": "ises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 2.509765625,
            "end_logit": -10.125,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -10.75,
            "end_logit": 3.1171875,
            "text": "the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 3.1171875,
            "text": "ises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 3.1171875,
            "text": "immunotherapy in bladder cancer",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 3.1171875,
            "text": "BCG immunotherapy in bladder cancer",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 3.1171875,
            "text": "and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 2.509765625,
            "end_logit": -10.203125,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 2.509765625,
            "end_logit": -10.2734375,
            "text": "cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility",
            "probability": 1.3113021850585938e-06
        }
    ],
    "60292d191cb411341a00010e_19": [
        {
            "start_logit": 4.1015625,
            "end_logit": 9.2890625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 9.2890625,
            "text": "superficial bladder cancer",
            "probability": 0.00010722875595092773
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 9.2890625,
            "text": "bladder cancer",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 9.2890625,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -9.46875,
            "end_logit": 9.2890625,
            "text": "recurrence of superficial bladder cancer",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -9.484375,
            "end_logit": 9.2890625,
            "text": "Immunotherapy by intravesicular delivery of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -9.6875,
            "end_logit": 9.2890625,
            "text": "of superficial bladder cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -10.0,
            "end_logit": 9.2890625,
            "text": "treat and prevent the recurrence of superficial bladder cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 9.2890625,
            "text": "prevent the recurrence of superficial bladder cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.2890625,
            "text": "the recurrence of superficial bladder cancer",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.2890625,
            "text": "BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 9.2890625,
            "text": "and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 9.2890625,
            "text": "Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.578125,
            "end_logit": 9.2890625,
            "text": "Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.625,
            "end_logit": 9.2890625,
            "text": "of Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 9.2890625,
            "text": "ette-Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.1015625,
            "end_logit": -9.703125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -9.703125,
            "text": "superficial bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.01171875,
            "end_logit": -9.703125,
            "text": "bladder cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": -9.3828125,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_20": [
        {
            "start_logit": 11.1171875,
            "end_logit": 10.8359375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -4.75390625,
            "end_logit": 10.8359375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 10.8359375,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 10.8359375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 10.8359375,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 10.8359375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -10.0390625,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 10.8359375,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 10.8359375,
            "text": "Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 10.8359375,
            "text": "currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 10.8359375,
            "text": "BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 10.8359375,
            "text": "of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -10.53125,
            "text": "cancer and one of the most successful applications of immunotherapy to the treatment of cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1171875,
            "end_logit": -10.59375,
            "text": "cancer and one of the most successful",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 10.8359375,
            "text": "the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 10.8359375,
            "text": "Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 10.8359375,
            "text": "treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 10.8359375,
            "text": "ette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 10.8359375,
            "text": "immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -4.75390625,
            "end_logit": -10.09375,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_21": [
        {
            "start_logit": 8.8203125,
            "end_logit": 7.2109375,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 7.2109375,
            "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.109375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.2265625,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 7.2109375,
            "text": "high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.3515625,
            "text": "cancer (NMIBC",
            "probability": 0.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.546875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression.",
            "probability": 0.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.546875,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms",
            "probability": 0.0
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -10.609375,
            "text": "cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 7.2109375,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 7.2109375,
            "text": "grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 7.2109375,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 7.2109375,
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 7.2109375,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 7.2109375,
            "text": ": The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 7.2109375,
            "text": "for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 7.2109375,
            "text": "The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 7.2109375,
            "text": "-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 7.2109375,
            "text": "-grade non-muscle invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -9.203125,
            "text": "Bacillus Calmette-Gu\u00e9rin",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_22": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.28125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 8.28125,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 8.28125,
            "text": "muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 8.28125,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 8.28125,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 8.28125,
            "text": "T1 high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 8.28125,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 8.28125,
            "text": "high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -10.4921875,
            "text": "cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 8.28125,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 8.28125,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 8.28125,
            "text": "-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": -10.4921875,
            "text": "bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": -10.4921875,
            "text": "muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -10.4921875,
            "text": "invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -10.4921875,
            "text": "grade non-muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": -10.4921875,
            "text": "T1 high-grade non-muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -10.4921875,
            "text": "non-muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": -10.4921875,
            "text": "high-grade non-muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.5703125,
            "text": "not likely to work; this meets the new definition of a \"BCG unresponsive\" disease",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_23": [
        {
            "start_logit": 11.1484375,
            "end_logit": 10.7421875,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 10.7421875,
            "text": "muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 10.7421875,
            "text": "invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 10.7421875,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 10.7421875,
            "text": "grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 10.7421875,
            "text": "high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 10.7421875,
            "text": "primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 10.7421875,
            "text": "non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -10.4140625,
            "text": "cancer treated with BCG immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 10.7421875,
            "text": "PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 10.7421875,
            "text": "-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 10.7421875,
            "text": "treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 10.7421875,
            "text": "-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 10.7421875,
            "text": "-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 10.7421875,
            "text": "with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 10.7421875,
            "text": "patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 10.7421875,
            "text": "post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": -10.4140625,
            "text": "muscle-invasive bladder cancer treated with BCG immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -10.4140625,
            "text": "invasive bladder cancer treated with BCG immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -10.4140625,
            "text": "bladder cancer treated with BCG immunotherapy.",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_24": [
        {
            "start_logit": 11.234375,
            "end_logit": 11.0078125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 11.0078125,
            "text": "bladder cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.15625,
            "end_logit": 11.0078125,
            "text": "treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 11.0078125,
            "text": "intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.171875,
            "text": "cancer and it still remains at the forefront of immunotherapy for cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.2265625,
            "text": "cancer and it still remains at the forefront",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 11.0078125,
            "text": "Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.4140625,
            "text": "cancer and it still remains at the foref",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 11.0078125,
            "text": "BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.0078125,
            "text": "bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.5078125,
            "text": "cancer and",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 11.0078125,
            "text": "ille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.0078125,
            "text": "of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.0078125,
            "text": "the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.0078125,
            "text": "instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.0078125,
            "text": ", intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 11.0078125,
            "text": "In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.6328125,
            "text": "cancer and it still",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 11.0078125,
            "text": "Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.0078125,
            "text": "bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_25": [
        {
            "start_logit": 0.34033203125,
            "end_logit": 3.4765625,
            "text": "cancer",
            "probability": 0.9970703125
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 3.4765625,
            "text": "muscle invasive bladder cancer",
            "probability": 0.0019550323486328125
        },
        {
            "start_logit": -7.921875,
            "end_logit": 3.4765625,
            "text": "bladder cancer",
            "probability": 0.00025653839111328125
        },
        {
            "start_logit": -8.0859375,
            "end_logit": 3.4765625,
            "text": "BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 0.00021946430206298828
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 3.4765625,
            "text": "invasive bladder cancer",
            "probability": 0.00011199712753295898
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 3.4765625,
            "text": "into muscle invasive bladder cancer",
            "probability": 4.5299530029296875e-05
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 3.4765625,
            "text": "progression into muscle invasive bladder cancer",
            "probability": 3.5822391510009766e-05
        },
        {
            "start_logit": -10.0625,
            "end_logit": 3.4765625,
            "text": "reduce progression into muscle invasive bladder cancer",
            "probability": 3.0159950256347656e-05
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 3.4765625,
            "text": "represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": -10.40625,
            "end_logit": 3.4765625,
            "text": "-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 2.1398067474365234e-05
        },
        {
            "start_logit": -10.4375,
            "end_logit": 3.4765625,
            "text": "intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 2.0742416381835938e-05
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 3.4765625,
            "text": "for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -10.671875,
            "end_logit": 3.4765625,
            "text": "therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -9.7109375,
            "text": "cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.25,
            "text": "cancer,",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.25,
            "text": "cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.3984375,
            "text": "cancer, BCG is ineffective in",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.4140625,
            "text": "cancer, BCG is ineffective in approximately 30-40",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.421875,
            "text": "cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 0.34033203125,
            "end_logit": -10.453125,
            "text": "cancer, BCG is ineffective in approximately 30-40 % of cases",
            "probability": 8.940696716308594e-07
        }
    ],
    "60292d191cb411341a00010e_26": [
        {
            "start_logit": 11.046875,
            "end_logit": 10.53125,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 10.53125,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.046875,
            "end_logit": -10.328125,
            "text": "cancer immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 10.53125,
            "text": "mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 10.53125,
            "text": "been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 10.53125,
            "text": "for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 10.53125,
            "text": "more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 10.53125,
            "text": "toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 10.53125,
            "text": "the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.53125,
            "text": "less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.53125,
            "text": "therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 10.53125,
            "text": "these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 10.53125,
            "text": "the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 10.53125,
            "text": "genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": -10.328125,
            "text": "bladder cancer immunotherapy.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.5,
            "text": "mycobacteria has been appealing in the search",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.5,
            "text": "been appealing in the search",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.5,
            "text": "BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -9.5,
            "text": "the genetic manipulation of these mycobacteria has been appealing in the search",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -9.5,
            "text": "that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search",
            "probability": 0.0
        }
    ],
    "60292d191cb411341a00010e_27": [
        {
            "start_logit": 11.421875,
            "end_logit": 11.0390625,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 11.0390625,
            "text": "bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 11.0390625,
            "text": "BCG immunotherapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -9.7421875,
            "text": "cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.0546875,
            "text": "cancer: inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.1953125,
            "text": "cancer: inhibition of tumor recurrence and associated immune responses",
            "probability": 0.0
        },
        {
            "start_logit": 11.421875,
            "end_logit": -10.296875,
            "text": "cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.0390625,
            "text": "of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.0390625,
            "text": "immunotherapy of bladder cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -9.7421875,
            "text": "bladder cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -10.0546875,
            "text": "bladder cancer: inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -10.1953125,
            "text": "bladder cancer: inhibition of tumor recurrence and associated immune responses",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -10.296875,
            "text": "bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -9.7421875,
            "text": "BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -10.0546875,
            "text": "BCG immunotherapy of bladder cancer: inhibition of tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -10.1953125,
            "text": "BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -10.296875,
            "text": "BCG immunotherapy of bladder cancer:",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -9.7421875,
            "text": "tumor recurrence and associated immune responses.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -10.0546875,
            "text": "tumor recurrence",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.7421875,
            "text": "of bladder cancer: inhibition of tumor recurrence and associated immune responses.",
            "probability": 0.0
        }
    ],
    "5e776db8835f4e4777000011_1": [
        {
            "start_logit": 9.46875,
            "end_logit": 11.984375,
            "text": "Sanofi",
            "probability": 0.8125
        },
        {
            "start_logit": 6.92578125,
            "end_logit": 13.0546875,
            "text": "MannKind Corporation",
            "probability": 0.1871337890625
        },
        {
            "start_logit": -4.9921875,
            "end_logit": 13.0546875,
            "text": "tion",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -3.96875,
            "end_logit": 11.984375,
            "text": "i",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.1484375,
            "end_logit": 13.0546875,
            "text": "Corporation",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 13.0546875,
            "text": "d Corporation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 11.984375,
            "text": "by Sanofi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 11.984375,
            "text": "ofi",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 13.0546875,
            "text": "Kind Corporation",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 13.0546875,
            "text": "In contrary, MannKind Corporation",
            "probability": 0.0
        },
        {
            "start_logit": 6.92578125,
            "end_logit": -4.37890625,
            "text": "MannKind Corpora",
            "probability": 0.0
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.01171875,
            "text": "Sanof",
            "probability": 0.0
        },
        {
            "start_logit": 9.46875,
            "end_logit": -7.47265625,
            "text": "San",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.984375,
            "text": "Exubera was not successful. Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.984375,
            "text": "not successful. Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.984375,
            "text": "Afrezza has been marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.984375,
            "text": "marketed since February, 2015 by Sanofi",
            "probability": 0.0
        },
        {
            "start_logit": 9.46875,
            "end_logit": -9.4765625,
            "text": "Sanofi after getting FDA approval in June 2014.",
            "probability": 0.0
        },
        {
            "start_logit": 6.92578125,
            "end_logit": -8.0234375,
            "text": "MannKind Corporation started developing its ultra-rapid-acting insulin Afrezza in a bold bid",
            "probability": 0.0
        },
        {
            "start_logit": 6.92578125,
            "end_logit": -8.5,
            "text": "Mann",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_1": [
        {
            "start_logit": 14.5703125,
            "end_logit": 14.5859375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -0.97216796875,
            "text": "Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -3.02734375,
            "text": "Nox1 oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.283203125,
            "end_logit": 14.5859375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.5,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.234375,
            "text": "Nox1 oxidase,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.265625,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.34375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.359375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.734375,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.75,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.7578125,
            "text": "Nox1 oxidase, functions as either a canonical or hybrid system using Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 14.5859375,
            "text": ", Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.5859375,
            "text": "A unique member of this family, Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.5859375,
            "text": "family, Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -3.283203125,
            "end_logit": -3.02734375,
            "text": "1 oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -0.97216796875,
            "text": ", Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -0.97216796875,
            "text": "A unique member of this family, Nox",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -3.02734375,
            "text": "oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.283203125,
            "end_logit": -8.5,
            "text": "1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_2": [
        {
            "start_logit": 13.4140625,
            "end_logit": 12.15625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 13.4140625,
            "end_logit": 0.1282958984375,
            "text": "Nox1.",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 13.4140625,
            "end_logit": -2.732421875,
            "text": "Nox",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 12.15625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 12.15625,
            "text": "Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 12.15625,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 12.15625,
            "text": "producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 12.15625,
            "text": "threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 12.15625,
            "text": "superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 12.15625,
            "text": "with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 12.15625,
            "text": "Phosphorylation of Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 12.15625,
            "text": "Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 0.1282958984375,
            "text": "1.",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 0.1282958984375,
            "text": "Noxa1 and the superoxide-producing activity of Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 0.1282958984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -2.732421875,
            "text": "Noxa1 and the superoxide-producing activity of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 0.1282958984375,
            "text": "of Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 0.1282958984375,
            "text": "producing activity of Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 0.1282958984375,
            "text": "threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 0.1282958984375,
            "text": "superoxide-producing activity of Nox1.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_3": [
        {
            "start_logit": 14.5546875,
            "end_logit": 14.5546875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.1435546875,
            "text": "Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.318359375,
            "end_logit": 14.5546875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -6.97265625,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -7.09765625,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.1015625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.1328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.2109375,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.2734375,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.609375,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.609375,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.5546875,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.5546875,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -6.97265625,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -7.09765625,
            "text": "1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -1.1435546875,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -1.1435546875,
            "text": "by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.1015625,
            "text": "1, a member of the Nox family NAPDH oxidases,",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.1328125,
            "text": "1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.2109375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_4": [
        {
            "start_logit": 14.2734375,
            "end_logit": 13.5234375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -1.2998046875,
            "text": "Nox",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -0.7958984375,
            "end_logit": 13.5234375,
            "text": "Noxa1, an interaction that participates in Nox1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.3984375,
            "end_logit": 13.5234375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.2890625,
            "text": "Nox1 activation",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 13.5234375,
            "text": "Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.6953125,
            "text": "Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 13.5234375,
            "text": "a1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 13.5234375,
            "text": "in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 13.5234375,
            "text": "sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.5234375,
            "text": "Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 13.5234375,
            "text": "interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 13.5234375,
            "text": "Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 13.5234375,
            "text": "interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 13.5234375,
            "text": "to sufficiently interact with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.5234375,
            "text": "with Noxa1, an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.5234375,
            "text": "an interaction that participates in Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -0.7958984375,
            "end_logit": -1.2998046875,
            "text": "Noxa1, an interaction that participates in Nox",
            "probability": 0.0
        },
        {
            "start_logit": -0.7958984375,
            "end_logit": -5.04296875,
            "text": "Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": -0.7958984375,
            "end_logit": -5.96875,
            "text": "Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_5": [
        {
            "start_logit": 14.15625,
            "end_logit": 13.46875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -1.369140625,
            "text": "Nox",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.8203125,
            "end_logit": 13.46875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -7.703125,
            "text": "Nox1 activity in different manners.",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.3828125,
            "text": "Nox1 activity in different",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.640625,
            "text": "Nox1 activity in",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.7421875,
            "text": "Nox1 activity in different manners",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.7578125,
            "text": "Nox1 activity",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.9765625,
            "text": "Nox1 activity in different manner",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.46875,
            "text": "Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 13.46875,
            "text": "at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 13.46875,
            "text": "phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.46875,
            "text": "appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 13.46875,
            "text": "Noxo1 at Thr341 and at Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 13.46875,
            "text": "Ser154 appears to regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 13.46875,
            "text": "regulate Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -1.369140625,
            "text": "Thr341 and at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -1.369140625,
            "text": "at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -1.369140625,
            "text": "phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -1.369140625,
            "text": "appears to regulate Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_6": [
        {
            "start_logit": 9.0859375,
            "end_logit": 7.79296875,
            "text": "gp91(phox)/Nox2 and Nox1",
            "probability": 0.5439453125
        },
        {
            "start_logit": 8.625,
            "end_logit": 7.79296875,
            "text": "Nox1",
            "probability": 0.345703125
        },
        {
            "start_logit": 9.0859375,
            "end_logit": 6.11328125,
            "text": "gp91(phox)",
            "probability": 0.1021728515625
        },
        {
            "start_logit": 4.84375,
            "end_logit": 7.79296875,
            "text": "Nox2 and Nox1",
            "probability": 0.00788116455078125
        },
        {
            "start_logit": 9.0859375,
            "end_logit": 0.348388671875,
            "text": "gp91(phox)/Nox2",
            "probability": 0.00032019615173339844
        },
        {
            "start_logit": 4.84375,
            "end_logit": 0.348388671875,
            "text": "Nox2",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -4.15625,
            "text": "gp91(phox)/Nox2 and Nox",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 8.625,
            "end_logit": -4.15625,
            "text": "Nox",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -5.12109375,
            "text": "gp91",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.48828125,
            "text": "gp",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.62890625,
            "text": "gp91(phox)/Nox",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.375,
            "text": "gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.40234375,
            "text": "gp91(phox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.625,
            "end_logit": -7.375,
            "text": "Nox1 is known to absolutely require both an organizer protein (p47(phox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 7.79296875,
            "text": "(phox)/Nox2 and Nox1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -8.0859375,
            "text": "gp91(phox)/Nox2 and Nox1 is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.84375,
            "end_logit": -4.15625,
            "text": "Nox2 and Nox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.625,
            "end_logit": -8.0859375,
            "text": "Nox1 is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -8.9453125,
            "text": "gp91(phox)/Nox2 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 7.79296875,
            "text": "and Nox1",
            "probability": 5.960464477539063e-08
        }
    ],
    "58a5a51060087bc10a000021_7": [
        {
            "start_logit": 14.515625,
            "end_logit": 14.1640625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -0.9404296875,
            "text": "NOX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.888671875,
            "end_logit": 14.1640625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.3046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.421875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.5078125,
            "text": "NOX1 was",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.6171875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.703125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.8984375,
            "text": "NOX1 was absolutely",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.984375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.03125,
            "text": "NOX1 was absolutely required for activation with NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 14.1640625,
            "text": "of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 14.1640625,
            "text": "terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.1640625,
            "text": "the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.1640625,
            "text": "co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.1640625,
            "text": "cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.1640625,
            "text": "C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.1640625,
            "text": "factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.1640625,
            "text": "cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -0.9404296875,
            "text": "of NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_8": [
        {
            "start_logit": 13.515625,
            "end_logit": 12.1953125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -2.1328125,
            "text": "Nox",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 13.515625,
            "end_logit": -5.359375,
            "text": "Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 12.1953125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 12.1953125,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 12.1953125,
            "text": "Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 12.1953125,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.1953125,
            "text": ", NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 12.1953125,
            "text": "binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 12.1953125,
            "text": "r 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 12.1953125,
            "text": "1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 12.1953125,
            "text": "shown to interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 12.1953125,
            "text": "-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.1953125,
            "text": "interact with the NADPH-binding region of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -2.1328125,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -5.74609375,
            "end_logit": -5.359375,
            "text": "1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -2.1328125,
            "text": "Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -7.0078125,
            "end_logit": -5.359375,
            "text": "NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -2.1328125,
            "text": "of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -2.1328125,
            "text": ", NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_9": [
        {
            "start_logit": 14.65625,
            "end_logit": 14.609375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -0.6259765625,
            "text": "Nox",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.197265625,
            "end_logit": 14.609375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -7.7109375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1.",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -8.9375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.265625,
            "text": "Nox1, complexed with p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 14.609375,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.5390625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.6875,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.75,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.7578125,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.8359375,
            "text": "Nox1, complexed with p22",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.890625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.8984375,
            "text": "Nox1, complexed with p22(phox) at the membrane,",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 14.609375,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.609375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.609375,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.609375,
            "text": "phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -0.6259765625,
            "text": "oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -3.197265625,
            "end_logit": -7.7109375,
            "text": "1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_10": [
        {
            "start_logit": 13.6640625,
            "end_logit": 11.9296875,
            "text": "NADPH oxidase 1",
            "probability": 1.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -0.75341796875,
            "text": "NADPH oxidase",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -2.720703125,
            "text": "NADPH oxidase 1 assembly and activation.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -3.203125,
            "text": "NADPH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.71484375,
            "end_logit": 11.9296875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 11.9296875,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 11.9296875,
            "text": "oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.921875,
            "text": "NADPH oxidase 1 assembly and activation",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -10.1328125,
            "text": "NADPH oxidase 1 assembly and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.9296875,
            "text": "optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.9296875,
            "text": "critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.9296875,
            "text": "for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.9296875,
            "text": "on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 11.9296875,
            "text": "phosphorylation on serine 154 is critical for optimal NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -2.720703125,
            "text": "1 assembly and activation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": -0.75341796875,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -0.75341796875,
            "text": "oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": -2.720703125,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1 assembly and activation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": -3.203125,
            "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -2.720703125,
            "text": "oxidase 1 assembly and activation.",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_11": [
        {
            "start_logit": 14.6171875,
            "end_logit": 14.4609375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -0.68603515625,
            "text": "Nox",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.48828125,
            "end_logit": 14.4609375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -5.65234375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1.",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -8.1484375,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.15625,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.171875,
            "text": "Nox1 requires",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 14.4609375,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.671875,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.6796875,
            "text": "Nox1 requires both the organizer protein Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.8046875,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.8203125,
            "text": "Nox1 requires both",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.828125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 14.4609375,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.4609375,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.4609375,
            "text": "the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.4609375,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 14.4609375,
            "text": "-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -3.48828125,
            "end_logit": -5.65234375,
            "text": "1 requires both the organizer protein Noxo1 and the activator protein Noxa1.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -0.68603515625,
            "text": "oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_12": [
        {
            "start_logit": 14.640625,
            "end_logit": 14.7109375,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -0.93408203125,
            "text": "NOX",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.03515625,
            "end_logit": 14.7109375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -8.15625,
            "text": "NOX1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -8.640625,
            "text": "NOX1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.5078125,
            "text": "NOX1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.53125,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.78125,
            "text": "NOX1, an NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.8203125,
            "text": "NOX1, an NADPH oxidase homologue that",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.890625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.9140625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.9375,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -8.15625,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -8.640625,
            "text": "1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.5078125,
            "text": "1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.53125,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.78125,
            "text": "1, an NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.8203125,
            "text": "1, an NADPH oxidase homologue that",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.890625,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.9140625,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_13": [
        {
            "start_logit": 14.609375,
            "end_logit": 14.4453125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -0.91650390625,
            "text": "Nox",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.546875,
            "end_logit": 14.4453125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -7.53125,
            "text": "Nox1, an oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -7.8984375,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -8.8984375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.21875,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.2734375,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p4",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 14.4453125,
            "text": "Activation of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.7109375,
            "text": "Nox1, an oxidase that is likely involved in host defence",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.796875,
            "text": "Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.4453125,
            "text": "of Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": -0.91650390625,
            "text": "Activation of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -0.91650390625,
            "text": "of Nox",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -7.53125,
            "text": "1, an oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -7.8984375,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -8.8984375,
            "text": "1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -9.21875,
            "text": "1, an oxidase that is likely involved in host defence at the colon, requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -9.2734375,
            "text": "1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p4",
            "probability": 0.0
        },
        {
            "start_logit": -3.546875,
            "end_logit": -9.5546875,
            "text": "1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox,",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_14": [
        {
            "start_logit": 8.90625,
            "end_logit": 5.63671875,
            "text": "NADPH oxidase 1",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.90625,
            "end_logit": 0.1351318359375,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.004039764404296875
        },
        {
            "start_logit": 8.90625,
            "end_logit": -2.677734375,
            "text": "NADPH oxidase 1 with betaPix",
            "probability": 0.00024259090423583984
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.1328125,
            "text": "NADPH oxidase",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.77734375,
            "text": "NADPH",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.375,
            "text": "NADPH oxidase 1 with betaPix and",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.6015625,
            "text": "NADPH oxidase 1 with",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.984375,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -8.984375,
            "text": "NADPH oxidase 1 with betaPix and Nox",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -9.140625,
            "text": "NADPH oxidase 1 with betaPix and Nox Organizer 1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -10.125,
            "text": "NADPH oxidase 1 with betaPi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 5.63671875,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 5.63671875,
            "text": "oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 5.63671875,
            "text": "Molecular interaction of NADPH oxidase 1",
            "probability": 0.0
        },
        {
            "start_logit": -5.08203125,
            "end_logit": 0.1351318359375,
            "text": "betaPix and Nox Organizer 1.",
            "probability": 0.0
        },
        {
            "start_logit": -5.08203125,
            "end_logit": -2.677734375,
            "text": "betaPix",
            "probability": 0.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 0.1351318359375,
            "text": "1 with betaPix and Nox Organizer 1.",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 0.1351318359375,
            "text": "oxidase 1 with betaPix and Nox Organizer 1.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 0.1351318359375,
            "text": "Pix and Nox Organizer 1.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 0.1351318359375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_15": [
        {
            "start_logit": 14.03125,
            "end_logit": 13.4296875,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -1.62109375,
            "text": "NOX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.82421875,
            "end_logit": 13.4296875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": 13.4296875,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -7.78125,
            "text": "NOX1)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.1953125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.328125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.375,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.3828125,
            "text": "NOX1),",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.4453125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.5703125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.609375,
            "text": "NOX1), which",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.6953125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 13.4296875,
            "text": "(NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 13.4296875,
            "text": "oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 13.4296875,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 13.4296875,
            "text": "oxygen species (ROS) production by NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -1.62109375,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -1.62109375,
            "text": "(NOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -1.62109375,
            "text": "oxidase 1 (NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_16": [
        {
            "start_logit": 14.5625,
            "end_logit": 14.5703125,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.0830078125,
            "text": "NOX",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.310546875,
            "end_logit": 14.5703125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -8.1484375,
            "text": "NOX1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -8.8046875,
            "text": "NOX1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.4296875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.4921875,
            "text": "NOX1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.734375,
            "text": "NOX1, an NADPH oxidase homologue that",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.828125,
            "text": "NOX1, an NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.8671875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.875,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.9140625,
            "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -8.1484375,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -8.8046875,
            "text": "1, an NADPH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.4296875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.4921875,
            "text": "1, an NADPH oxidase homologue",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.734375,
            "text": "1, an NADPH oxidase homologue that",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.828125,
            "text": "1, an NADPH",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.8671875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.310546875,
            "end_logit": -9.875,
            "text": "1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_17": [
        {
            "start_logit": 13.984375,
            "end_logit": 13.328125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -1.7119140625,
            "text": "Nox",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.95703125,
            "end_logit": 13.328125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -7.39453125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.3203125,
            "text": "Nox1 requires",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.4453125,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator protein Nox",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.75,
            "text": "Nox1 requires both",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.765625,
            "text": "Nox1 requires both the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8359375,
            "text": "Nox1 requires both the organizer protein Noxo1 and",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8828125,
            "text": "Nox1 requires both the organizer protein Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.9765625,
            "text": "Nox1 requires both the organizer protein Noxo1 and the activator",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.03125,
            "text": "Nox1 requires both the organize",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 13.328125,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 13.328125,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.328125,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.328125,
            "text": "the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.328125,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 13.328125,
            "text": "of the superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -1.7119140625,
            "text": "oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -1.7119140625,
            "text": "Activation of the superoxide-producing NADPH oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_18": [
        {
            "start_logit": 14.6171875,
            "end_logit": 14.53125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -0.6865234375,
            "text": "Nox",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.333984375,
            "end_logit": 14.53125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -7.97265625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -8.9140625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.1171875,
            "text": "Nox1, complexed with p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.59375,
            "text": "Nox1, complexed with p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.609375,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.7265625,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.7421875,
            "text": "Nox1, complexed with p22",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 14.53125,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.859375,
            "text": "Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.9140625,
            "text": "Nox1, complexed with p22(phox) at the membrane,",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.53125,
            "text": "NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.53125,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.53125,
            "text": "producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.53125,
            "text": "phagocytic superoxide-producing NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -0.6865234375,
            "text": "oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -0.6865234375,
            "text": "NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -0.6865234375,
            "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_19": [
        {
            "start_logit": 14.3984375,
            "end_logit": 13.7265625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -1.2744140625,
            "text": "Nox",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": 13.7265625,
            "text": "NADPH oxidase 1 (Nox1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.546875,
            "end_logit": 13.7265625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -7.62890625,
            "text": "Nox1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 13.7265625,
            "text": "oxidase 1 (Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -7.95703125,
            "text": "Nox1) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.1875,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.40625,
            "text": "Nox1) is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.578125,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 13.7265625,
            "text": "(Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.6015625,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.6640625,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.6875,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.7890625,
            "text": "Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.84375,
            "text": "Nox1) is a multicomponent enzyme consisting",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.875,
            "text": "Nox1) is a multicomponent",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 13.7265625,
            "text": "1 (Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": -1.2744140625,
            "text": "NADPH oxidase 1 (Nox",
            "probability": 0.0
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": -6.1171875,
            "text": "NADPH oxidase 1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_20": [
        {
            "start_logit": 14.578125,
            "end_logit": 14.640625,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -1.0859375,
            "text": "Nox",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.177734375,
            "end_logit": 14.640625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -6.91796875,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -7.16796875,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.0390625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases,",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.1796875,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.3046875,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.5703125,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 14.640625,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.75,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 14.640625,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.640625,
            "text": ": Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.640625,
            "text": "UNLABELLED: Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -3.177734375,
            "end_logit": -6.91796875,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.177734375,
            "end_logit": -7.16796875,
            "text": "1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -1.0859375,
            "text": "by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -1.0859375,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -1.0859375,
            "text": ": Superoxide production by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -1.0859375,
            "text": "UNLABELLED: Superoxide production by Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_21": [
        {
            "start_logit": 13.875,
            "end_logit": 12.7890625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -1.490234375,
            "text": "NOX",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.3203125,
            "end_logit": 12.7890625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -7.44140625,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 12.7890625,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.3359375,
            "text": "NOX1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 12.7890625,
            "text": "(NOX1",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.8828125,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS)",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.890625,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.984375,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.984375,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.9921875,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -10.0390625,
            "text": "NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 12.7890625,
            "text": "activation of NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 12.7890625,
            "text": "The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 12.7890625,
            "text": "oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 12.7890625,
            "text": "of NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.7890625,
            "text": "organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 12.7890625,
            "text": "dependent activation of NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 12.7890625,
            "text": "1 (NOX1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_22": [
        {
            "start_logit": 14.515625,
            "end_logit": 14.1640625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -0.9404296875,
            "text": "NOX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.888671875,
            "end_logit": 14.1640625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.3046875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.421875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.5078125,
            "text": "NOX1 was",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.6171875,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.703125,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.8984375,
            "text": "NOX1 was absolutely",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.984375,
            "text": "NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.03125,
            "text": "NOX1 was absolutely required for activation with NOXO1",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 14.1640625,
            "text": "of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 14.1640625,
            "text": "terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.1640625,
            "text": "the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.1640625,
            "text": "co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.1640625,
            "text": "cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.1640625,
            "text": "C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.1640625,
            "text": "factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.1640625,
            "text": "cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -0.9404296875,
            "text": "of NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_23": [
        {
            "start_logit": 13.265625,
            "end_logit": 12.078125,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -2.46484375,
            "text": "Nox",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.265625,
            "end_logit": -4.54296875,
            "text": "Nox1.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 12.078125,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 12.078125,
            "text": "reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.078125,
            "text": "organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.078125,
            "text": "regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 12.078125,
            "text": "oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 12.078125,
            "text": "oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 12.078125,
            "text": "with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -5.9765625,
            "end_logit": -4.54296875,
            "text": "1.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -2.46484375,
            "text": "reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -2.46484375,
            "text": "(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -2.46484375,
            "text": "organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -2.46484375,
            "text": "regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -2.46484375,
            "text": "oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -5.98828125,
            "end_logit": -7.27734375,
            "text": "p67(phox",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -2.46484375,
            "text": "oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -2.46484375,
            "text": "with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": -6.6640625,
            "text": "NoxA1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_24": [
        {
            "start_logit": 14.5703125,
            "end_logit": 14.5,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -0.96533203125,
            "text": "Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.41015625,
            "end_logit": 14.5,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.6875,
            "text": "Nox1 is highly expressed in the colon,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.7578125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.8046875,
            "text": "Nox1 is highly expressed in the colon, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.421875,
            "text": "Nox1 is",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.5703125,
            "text": "Nox1 is highly expressed in the colon, and requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.578125,
            "text": "Nox1 is highly expressed in the colon",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.640625,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.7734375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.8125,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.859375,
            "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -8.6875,
            "text": "1 is highly expressed in the colon,",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -8.7578125,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -8.8046875,
            "text": "1 is highly expressed in the colon, and",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -9.421875,
            "text": "1 is",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -9.5703125,
            "text": "1 is highly expressed in the colon, and requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -9.578125,
            "text": "1 is highly expressed in the colon",
            "probability": 0.0
        },
        {
            "start_logit": -3.41015625,
            "end_logit": -9.640625,
            "text": "1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit Nox",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_25": [
        {
            "start_logit": 14.625,
            "end_logit": 14.5859375,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -0.89892578125,
            "text": "Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.26953125,
            "end_logit": 14.5859375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.0703125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.1015625,
            "text": "Nox1 is highly expressed in the colon,",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.4609375,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.5078125,
            "text": "Nox1 is highly expressed in the colon, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.546875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.5546875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.6015625,
            "text": "Nox1 is highly expressed in the colon",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.6640625,
            "text": "Nox1 is",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.796875,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.828125,
            "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well",
            "probability": 0.0
        },
        {
            "start_logit": 14.625,
            "end_logit": -9.9375,
            "text": "Nox1 is highly expressed in the colon, and it requires two",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.0703125,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.1015625,
            "text": "1 is highly expressed in the colon,",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.4609375,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.5078125,
            "text": "1 is highly expressed in the colon, and",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.546875,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and Nox",
            "probability": 0.0
        },
        {
            "start_logit": -3.26953125,
            "end_logit": -9.5546875,
            "text": "1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_26": [
        {
            "start_logit": 14.1484375,
            "end_logit": 13.5625,
            "text": "NOX1",
            "probability": 1.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -1.484375,
            "text": "NOX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.6875,
            "end_logit": 13.5625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -5.11328125,
            "end_logit": 13.5625,
            "text": "NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.30078125,
            "text": "NOX1)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.1328125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.2734375,
            "text": "NOX1),",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.328125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.4375,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.4453125,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.5390625,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": 13.5625,
            "text": "(NOX1",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.6484375,
            "text": "NOX1), which is mainly expressed in colon epithelial cells, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.65625,
            "text": "NOX1), which",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 13.5625,
            "text": "oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 13.5625,
            "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.5625,
            "text": "1 (NOX1",
            "probability": 0.0
        },
        {
            "start_logit": -5.11328125,
            "end_logit": -1.484375,
            "text": "NADPH oxidase 1 (NOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -1.484375,
            "text": "(NOX",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": -1.484375,
            "text": "oxidase 1 (NOX",
            "probability": 0.0
        }
    ],
    "58a5a51060087bc10a000021_27": [
        {
            "start_logit": 14.5546875,
            "end_logit": 14.5546875,
            "text": "Nox1",
            "probability": 1.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.1435546875,
            "text": "Nox",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.318359375,
            "end_logit": 14.5546875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -6.97265625,
            "text": "Nox1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -7.09765625,
            "text": "Nox1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.1015625,
            "text": "Nox1, a member of the Nox family NAPDH oxidases,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.1328125,
            "text": "Nox1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.2109375,
            "text": "Nox1, a member of the Nox family",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.2734375,
            "text": "Nox1, a member of the Nox family NAPDH oxidase",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.609375,
            "text": "Nox1, a member of the Nox family NAPDH oxidases",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.609375,
            "text": "Nox1, a member of the Nox family NAP",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.5546875,
            "text": "Superoxide production by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.5546875,
            "text": "by Nox1",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -6.97265625,
            "text": "1,",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -7.09765625,
            "text": "1, a member of the Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -1.1435546875,
            "text": "Superoxide production by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -1.1435546875,
            "text": "by Nox",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.1015625,
            "text": "1, a member of the Nox family NAPDH oxidases,",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.1328125,
            "text": "1, a member of the Nox family NAPDH oxidases, requires",
            "probability": 0.0
        },
        {
            "start_logit": -3.318359375,
            "end_logit": -9.2109375,
            "text": "1, a member of the Nox family",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_1": [
        {
            "start_logit": 14.8203125,
            "end_logit": 15.15625,
            "text": "IFN signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": 0.208251953125,
            "text": "IFN",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.96875,
            "end_logit": 15.15625,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.15625,
            "text": "type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 15.15625,
            "text": "I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 15.15625,
            "text": "A five gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 15.15625,
            "text": "gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.65625,
            "text": "IFN signature was",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.78125,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.8203125,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.90625,
            "text": "IFN signature was assessed in these subjects to identify subpopulations",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -10.0546875,
            "text": "IFN signature was assessed",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -10.0625,
            "text": "IFN signature was assessed in these",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -10.1953125,
            "text": "IFN signature was assessed in",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -10.2734375,
            "text": "IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.15625,
            "text": "five gene type I IFN signature",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 0.208251953125,
            "text": "type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 0.208251953125,
            "text": "I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 0.208251953125,
            "text": "A five gene type I IFN",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 0.208251953125,
            "text": "gene type I IFN",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_2": [
        {
            "start_logit": 14.7578125,
            "end_logit": 15.15625,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -0.1490478515625,
            "text": "interferon",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.9052734375,
            "end_logit": 15.15625,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 15.15625,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.3203125,
            "text": "interferon signature similar to but less intense than that seen in patients with lupus",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.15625,
            "text": "an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.65625,
            "text": "interferon signature similar",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.75,
            "text": "interferon signature similar to but less intense than that seen in patients with lupus.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 15.15625,
            "text": "multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 15.15625,
            "text": "patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.15625,
            "text": "rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.15625,
            "text": "peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.25,
            "text": "interferon signature similar to but less intense than that seen",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.4453125,
            "text": "interferon signature similar to but less intense",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.5234375,
            "text": "interferon signature similar to but less intense than that seen in",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -0.1490478515625,
            "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -0.1490478515625,
            "text": "an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -0.1490478515625,
            "text": "multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -0.1490478515625,
            "text": "patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -0.1490478515625,
            "text": "rheumatoid arthritis and multiple sclerosis demonstrate an interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_3": [
        {
            "start_logit": 14.7265625,
            "end_logit": 15.109375,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -0.23095703125,
            "text": "interferon",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.107421875,
            "end_logit": 15.109375,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 15.109375,
            "text": "the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 15.109375,
            "text": "interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -9.296875,
            "text": "interferon signature.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.109375,
            "text": "of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.109375,
            "text": "patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.109375,
            "text": "termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.109375,
            "text": "a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.109375,
            "text": "in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 15.109375,
            "text": ", psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 15.109375,
            "text": "a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.109375,
            "text": ", and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -6.96484375,
            "end_logit": -0.23095703125,
            "text": "the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": -0.23095703125,
            "text": "interferon-dependent genes in their leukocytes, termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -0.23095703125,
            "text": "of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -0.23095703125,
            "text": "patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -0.23095703125,
            "text": "termed the interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -0.23095703125,
            "text": "dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_4": [
        {
            "start_logit": 14.7265625,
            "end_logit": 15.2109375,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -0.07891845703125,
            "text": "interferon",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": 15.2109375,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -5.265625,
            "text": "interferon signature in lupus",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -9.125,
            "text": "interferon signature in",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -9.2265625,
            "text": "interferon signature in lupus).",
            "probability": 0.0
        },
        {
            "start_logit": 14.7265625,
            "end_logit": -9.34375,
            "text": "interferon signature in lupus)",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 15.2109375,
            "text": "autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 15.2109375,
            "text": ". interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 15.2109375,
            "text": "gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.2109375,
            "text": "e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.2109375,
            "text": "in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.2109375,
            "text": "patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -1.8115234375,
            "end_logit": -5.265625,
            "text": "signature in lupus",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -0.07891845703125,
            "text": "autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -0.07891845703125,
            "text": ". interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -0.07891845703125,
            "text": "gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -0.07891845703125,
            "text": "e.g. interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -0.07891845703125,
            "text": "in these diseases (e.g. interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -0.07891845703125,
            "text": "patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_5": [
        {
            "start_logit": 14.6875,
            "end_logit": 15.078125,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -0.218994140625,
            "text": "interferon",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.2109375,
            "end_logit": 15.078125,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 15.078125,
            "text": "type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 15.078125,
            "text": "I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -8.9140625,
            "text": "interferon signature and",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": 15.078125,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.265625,
            "text": "interferon signature and the response to rituximab in rheumatoid arthritis patients.",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.734375,
            "text": "interferon signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.7421875,
            "text": "interferon signature and the response to rituximab in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.8984375,
            "text": "interferon signature and the response to rituximab in",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -10.1328125,
            "text": "interferon signature and the response to rituximab in rheumatoid",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -10.1640625,
            "text": "interferon signature and the response to rituximab in rheumatoid arthritis patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -0.218994140625,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -0.218994140625,
            "text": "I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -0.218994140625,
            "text": "the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -8.9140625,
            "text": "signature and",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -9.265625,
            "text": "signature and the response to rituximab in rheumatoid arthritis patients.",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -9.734375,
            "text": "signature and the response to rituximab",
            "probability": 0.0
        },
        {
            "start_logit": -2.2109375,
            "end_logit": -9.7421875,
            "text": "signature and the response to rituximab in rheumatoid arthritis",
            "probability": 0.0
        }
    ],
    "58e7902b3e8b6dc87c000007_6": [
        {
            "start_logit": 14.8203125,
            "end_logit": 15.1328125,
            "text": "interferon signature",
            "probability": 1.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": 0.270263671875,
            "text": "interferon",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.041015625,
            "end_logit": 15.1328125,
            "text": "signature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -6.76953125,
            "text": "interferon signature in",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 15.1328125,
            "text": "type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 15.1328125,
            "text": "the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 15.1328125,
            "text": "I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.1875,
            "text": "interferon signature in rheumatoid arthritis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.1328125,
            "text": "to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.8203125,
            "end_logit": -9.78125,
            "text": "interferon signature in rheumatoid arthritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 15.1328125,
            "text": "application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.1328125,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon signature",
            "probability": 0.0
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 0.270263671875,
            "text": "type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 0.270263671875,
            "text": "the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 0.270263671875,
            "text": "I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -6.76953125,
            "text": "signature in",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 0.270263671875,
            "text": "to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 0.270263671875,
            "text": "application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 0.270263671875,
            "text": "Importance of correlation between gene expression levels: application to the type I interferon",
            "probability": 0.0
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -9.1875,
            "text": "signature in rheumatoid arthritis.",
            "probability": 0.0
        }
    ],
    "517170c48ed59a060a00000d_1": [
        {
            "start_logit": 11.5859375,
            "end_logit": 11.484375,
            "text": "25",
            "probability": 1.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": 11.484375,
            "text": "The human selenoproteome consists of 25",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -6.96484375,
            "text": "25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 11.484375,
            "text": "selenoproteome consists of 25",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 11.484375,
            "text": "human selenoproteome consists of 25",
            "probability": 0.0
        },
        {
            "start_logit": 11.5859375,
            "end_logit": -9.7109375,
            "text": "25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.484375,
            "text": "of 25",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.484375,
            "text": "oproteome consists of 25",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": 11.484375,
            "text": "consists of 25",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -6.96484375,
            "text": "The human selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -9.390625,
            "text": "The",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -9.7109375,
            "text": "The human selenoproteome consists of 25 selenoproteins",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -9.75,
            "text": "The human selenoproteome consists",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -9.875,
            "text": "The human selenoproteome",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": -6.96484375,
            "text": "selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -5.671875,
            "end_logit": -10.125,
            "text": "The human selenoprote",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -6.96484375,
            "text": "human selenoproteome consists of 25 selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -6.96484375,
            "text": "selenoproteins.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -6.96484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -6.96484375,
            "text": "of 25 selenoproteins.",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_1": [
        {
            "start_logit": 12.21875,
            "end_logit": 12.3828125,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -3.4375,
            "text": "XX",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 12.3828125,
            "text": "Y",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 12.3828125,
            "text": "Klinefelter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.21875,
            "end_logit": -9.59375,
            "text": "XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 12.3828125,
            "text": "(XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 12.3828125,
            "text": "lter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 12.3828125,
            "text": "felter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 12.3828125,
            "text": "inefelter syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 12.3828125,
            "text": "er syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.2578125,
            "end_logit": 12.3828125,
            "text": "syndrome (XXY",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -3.4375,
            "text": "Klinefelter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -3.4375,
            "text": "(XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -3.4375,
            "text": "lter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": -3.4375,
            "text": "felter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -3.4375,
            "text": "inefelter syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -3.4375,
            "text": "er syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.2578125,
            "end_logit": -3.4375,
            "text": "syndrome (XX",
            "probability": 0.0
        },
        {
            "start_logit": -5.51953125,
            "end_logit": -9.59375,
            "text": "Y)",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -9.59375,
            "text": "Klinefelter syndrome (XXY)",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_2": [
        {
            "start_logit": 11.171875,
            "end_logit": 11.984375,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 11.984375,
            "text": "extra X",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 11.984375,
            "text": "an extra X",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -8.625,
            "text": "X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 11.984375,
            "text": "About 1 in 650 boys are born with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.1484375,
            "text": "X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 11.984375,
            "text": "1 in 650 boys are born with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 11.984375,
            "text": "in 650 boys are born with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.5546875,
            "text": "X chromosome (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.984375,
            "text": "boys are born with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.71875,
            "text": "X chromosome (47,XXY or Klinefelter syndrome). 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.984375,
            "text": "born with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.984375,
            "text": "with an extra X",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -9.9609375,
            "text": "X chromosome (",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -10.0078125,
            "text": "X chromosome (47,XXY or Klinefelter syndrome). 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -10.140625,
            "text": "X chromosome (47",
            "probability": 0.0
        },
        {
            "start_logit": 11.171875,
            "end_logit": -10.1484375,
            "text": "X chromosome (47,XXY or Klinefelter syndrome). 47",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -8.625,
            "text": "extra X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -9.1484375,
            "text": "extra X chromosome (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -6.6015625,
            "end_logit": -9.5546875,
            "text": "extra X chromosome (47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_3": [
        {
            "start_logit": 7.390625,
            "end_logit": 13.84375,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": 13.84375,
            "text": "an additional X",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": -5.21484375,
            "end_logit": 13.84375,
            "text": "additional X",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.84375,
            "text": "On the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 13.84375,
            "text": "by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 13.84375,
            "text": "the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 13.84375,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.84375,
            "text": "other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -8.03125,
            "text": "X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -8.1015625,
            "text": "X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -9.2734375,
            "text": "X chromosome in males (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -9.53125,
            "text": "X chromosome in",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -9.9765625,
            "text": "X chromosome in males (47,XXY),",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -10.078125,
            "text": "X chromosome in males (47,XXY), and",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -10.109375,
            "text": "X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity of external genitalia, testicular dysfunction.",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -10.1640625,
            "text": "X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -10.203125,
            "text": "X chromosome in males (47",
            "probability": 0.0
        },
        {
            "start_logit": 7.390625,
            "end_logit": -10.21875,
            "text": "X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature, immaturity",
            "probability": 0.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -8.03125,
            "text": "an additional X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -2.392578125,
            "end_logit": -8.1015625,
            "text": "an additional X chromosome in males (47,XXY",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_4": [
        {
            "start_logit": 7.92578125,
            "end_logit": 11.5859375,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 11.5859375,
            "text": "Y",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 11.5859375,
            "text": "47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -5.2734375,
            "text": "XX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 11.5859375,
            "text": ", XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.140625,
            "end_logit": 11.5859375,
            "text": "The formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 11.5859375,
            "text": "formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -6.76171875,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -9.0078125,
            "text": "XXY; the extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -9.171875,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 0.0
        },
        {
            "start_logit": 7.92578125,
            "end_logit": -10.203125,
            "text": "XXY;",
            "probability": 0.0
        },
        {
            "start_logit": -3.490234375,
            "end_logit": -6.76171875,
            "text": "extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -3.490234375,
            "end_logit": -9.0078125,
            "text": "extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": -3.490234375,
            "end_logit": -9.171875,
            "text": "extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 0.0
        },
        {
            "start_logit": -7.8515625,
            "end_logit": -5.2734375,
            "text": "47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -6.41015625,
            "end_logit": -6.76171875,
            "text": "the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -6.53515625,
            "end_logit": -6.76171875,
            "text": "Y; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -6.76171875,
            "text": "nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -5.2734375,
            "text": ", XX",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -5.2734375,
            "text": "The formal cytogenetic designation for Klinefelter syndrome is 47, XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_5": [
        {
            "start_logit": 7.68359375,
            "end_logit": 13.546875,
            "text": "X",
            "probability": 1.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": 13.546875,
            "text": "additional X",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": -4.89453125,
            "end_logit": 13.546875,
            "text": "an additional X",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 13.546875,
            "text": "Klinefelter syndrome (KS) is characterized by an additional X",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 13.546875,
            "text": "by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.546875,
            "text": "inefelter syndrome (KS) is characterized by an additional X",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -8.6875,
            "text": "X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -8.8203125,
            "text": "X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -9.203125,
            "text": "X chromosome in",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -9.78125,
            "text": "X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -9.8046875,
            "text": "X chromosome in males leading to a karyotype of 47,XXY.",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -10.2109375,
            "text": "X chromosome in males leading to a karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 7.68359375,
            "end_logit": -10.265625,
            "text": "X chromosome in males leading to a karyotype of 47",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -8.6875,
            "text": "additional X chromosome in males leading to a karyotype of 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -8.8203125,
            "text": "additional X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -9.203125,
            "text": "additional X chromosome in",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -9.78125,
            "text": "additional X chromosome in males leading to a karyotype of 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -9.8046875,
            "text": "additional X chromosome in males leading to a karyotype of 47,XXY.",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -10.0703125,
            "text": "additional",
            "probability": 0.0
        },
        {
            "start_logit": -1.7587890625,
            "end_logit": -10.2109375,
            "text": "additional X chromosome in males leading to a karyotype",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_6": [
        {
            "start_logit": 7.09375,
            "end_logit": 9.5,
            "text": "a 47,XXY",
            "probability": 1.0
        },
        {
            "start_logit": -2.93359375,
            "end_logit": 9.5,
            "text": "47,XXY",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": -3.638671875,
            "end_logit": 9.5,
            "text": "XXY",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -3.712890625,
            "end_logit": 9.5,
            "text": "Klinefelter syndrome (KS), a 47,XXY",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.5,
            "text": ",XXY",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 9.5,
            "text": "Y",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -5.0625,
            "text": "a 47,XX",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -5.21484375,
            "text": "a 47",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.10546875,
            "text": "a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.5,
            "text": "inefelter syndrome (KS), a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 9.5,
            "text": "lter syndrome (KS), a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 9.5,
            "text": "felter syndrome (KS), a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 9.5,
            "text": "er syndrome (KS), a 47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.5234375,
            "text": "a 47,XXY chromosomal abnormality",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.71875,
            "text": "a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias to date",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.796875,
            "text": "a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies,",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.828125,
            "text": "a 47,XXY chromosomal abnormality,",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.8515625,
            "text": "a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -9.96875,
            "text": "a 47,XXY chromosomal abnormality, has been shown to be associated with a number",
            "probability": 0.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -10.0,
            "text": "a 47,XXY chromosomal abnormality, has been shown to be associated with a number of malignancies, but has not been linked to acute leukemias",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_7": [
        {
            "start_logit": 7.69921875,
            "end_logit": 11.9765625,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 11.9765625,
            "text": "47, XXY",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 11.9765625,
            "text": "Y",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -8.140625,
            "end_logit": 11.9765625,
            "text": "formal cytogenetic designation for Klinefelter syndrome is 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.8125,
            "end_logit": 11.9765625,
            "text": ", XXY",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.4140625,
            "text": "XX",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 11.9765625,
            "text": "designation for Klinefelter syndrome is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.9765625,
            "text": "is 47, XXY",
            "probability": 0.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -7.5234375,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -9.2265625,
            "text": "XXY; the extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -9.3984375,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction. In",
            "probability": 0.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -9.515625,
            "text": "XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 0.0
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -10.2109375,
            "text": "XXY;",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -5.4140625,
            "text": "47, XX",
            "probability": 0.0
        },
        {
            "start_logit": -3.97265625,
            "end_logit": -7.5234375,
            "text": "extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -7.5234375,
            "text": "47, XXY; the extra sex chromosome is due to meiotic chromosomal nondisjunction",
            "probability": 0.0
        },
        {
            "start_logit": -3.97265625,
            "end_logit": -9.2265625,
            "text": "extra sex chromosome is",
            "probability": 0.0
        },
        {
            "start_logit": -3.97265625,
            "end_logit": -9.3984375,
            "text": "extra sex chromosome is due to meiotic chromosomal nondisjunction. In",
            "probability": 0.0
        },
        {
            "start_logit": -3.97265625,
            "end_logit": -9.515625,
            "text": "extra sex chromosome is due to meiotic chromosomal nondisjunction.",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -5.4140625,
            "text": "formal cytogenetic designation for Klinefelter syndrome is 47, XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_8": [
        {
            "start_logit": 12.375,
            "end_logit": 13.421875,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -3.091796875,
            "text": "XX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.69140625,
            "end_logit": 13.421875,
            "text": "Y",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.59375,
            "end_logit": 13.421875,
            "text": "the XXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.1953125,
            "text": "XXY chromosomal abnormality",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.3203125,
            "text": "XXY chromosomal abnormality may be more than coincidental.",
            "probability": 0.0
        },
        {
            "start_logit": 12.375,
            "end_logit": -9.5,
            "text": "XXY chromosomal abnormality may",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.421875,
            "text": "the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 13.421875,
            "text": "teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 13.421875,
            "text": "development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.421875,
            "text": "mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 13.421875,
            "text": "is reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 13.421875,
            "text": "reported suggesting that the association of a gonadotropin-secreting tumor with the XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -3.091796875,
            "text": "the XX",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -9.1953125,
            "text": "Y chromosomal abnormality",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -3.091796875,
            "text": "the association of a gonadotropin-secreting tumor with the XX",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -3.091796875,
            "text": "teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XX",
            "probability": 0.0
        },
        {
            "start_logit": -4.69140625,
            "end_logit": -9.3203125,
            "text": "Y chromosomal abnormality may be more than coincidental.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -3.091796875,
            "text": "development of a mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XX",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -3.091796875,
            "text": "mediastinal teratocarcinoma is reported suggesting that the association of a gonadotropin-secreting tumor with the XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_9": [
        {
            "start_logit": 5.0859375,
            "end_logit": 13.921875,
            "text": "47, XXY",
            "probability": 0.9111328125
        },
        {
            "start_logit": 2.708984375,
            "end_logit": 13.921875,
            "text": "a 47, XXY",
            "probability": 0.084716796875
        },
        {
            "start_logit": -0.3935546875,
            "end_logit": 13.921875,
            "text": "XXY",
            "probability": 0.0038394927978515625
        },
        {
            "start_logit": -4.24609375,
            "end_logit": 13.921875,
            "text": "Y",
            "probability": 8.094310760498047e-05
        },
        {
            "start_logit": -5.68359375,
            "end_logit": 13.921875,
            "text": "Klinefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -6.40625,
            "end_logit": 13.921875,
            "text": ", XXY",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.921875,
            "text": "chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 13.921875,
            "text": "by a 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.921875,
            "text": "inefelter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.921875,
            "end_logit": 13.921875,
            "text": "lter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.921875,
            "text": "felter syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.921875,
            "text": "er syndrome (KS) is a chromosomal abnormality characterised by a 47, XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.0859375,
            "end_logit": -5.7890625,
            "text": "47",
            "probability": 0.0
        },
        {
            "start_logit": 5.0859375,
            "end_logit": -6.796875,
            "text": "47, XX",
            "probability": 0.0
        },
        {
            "start_logit": 5.0859375,
            "end_logit": -7.453125,
            "text": "47, XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 2.708984375,
            "end_logit": -5.7890625,
            "text": "a 47",
            "probability": 0.0
        },
        {
            "start_logit": 2.708984375,
            "end_logit": -6.796875,
            "text": "a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": 2.708984375,
            "end_logit": -7.453125,
            "text": "a 47, XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 5.0859375,
            "end_logit": -9.9765625,
            "text": "47, XXY karyotype associated with hypogonadism and infertility.",
            "probability": 0.0
        },
        {
            "start_logit": 5.0859375,
            "end_logit": -10.2734375,
            "text": "47, XXY karyotype associated with hypogonadism and infertility",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_10": [
        {
            "start_logit": 6.6328125,
            "end_logit": 12.421875,
            "text": "Y chromosome microdeletions",
            "probability": 1.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 12.421875,
            "text": "ions",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 12.421875,
            "text": "microdeletions",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 12.421875,
            "text": "and Y chromosome microdeletions",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -8.046875,
            "end_logit": 12.421875,
            "text": "chromosome microdeletions",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.234375,
            "end_logit": 12.421875,
            "text": "including Klinefelter syndrome (47,XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 12.421875,
            "text": "eletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.421875,
            "end_logit": 12.421875,
            "text": "(47,XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 12.421875,
            "text": ",XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.421875,
            "text": "47,XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.421875,
            "text": "XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6875,
            "end_logit": 12.421875,
            "text": "Klinefelter syndrome (47,XXY) and Y chromosome microdeletions",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -5.1640625,
            "text": "Y",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -7.6328125,
            "text": "Y chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -8.3125,
            "text": "Y chromosome microdelet",
            "probability": 0.0
        },
        {
            "start_logit": 6.6328125,
            "end_logit": -8.8125,
            "text": "Y chromosome microdeletions.",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": -5.1640625,
            "text": "and Y",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -8.3125,
            "text": "microdelet",
            "probability": 0.0
        },
        {
            "start_logit": -5.09765625,
            "end_logit": -8.8125,
            "text": "ions.",
            "probability": 0.0
        },
        {
            "start_logit": -5.13671875,
            "end_logit": -8.8125,
            "text": "microdeletions.",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_11": [
        {
            "start_logit": 3.4453125,
            "end_logit": 13.9609375,
            "text": "X",
            "probability": 0.9921875
        },
        {
            "start_logit": -1.509765625,
            "end_logit": 13.9609375,
            "text": "an additional X",
            "probability": 0.007007598876953125
        },
        {
            "start_logit": -4.24609375,
            "end_logit": 13.9609375,
            "text": "additional X",
            "probability": 0.00045490264892578125
        },
        {
            "start_logit": -9.84375,
            "end_logit": 13.9609375,
            "text": "the other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 13.9609375,
            "text": "by an additional X",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.9609375,
            "text": "other hand, Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.9609375,
            "text": "Klinefelter syndrome is well recognized chromosomal abnormality caused by an additional X",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -5.88671875,
            "text": "X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -6.703125,
            "text": "X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -9.046875,
            "text": "X chromosome in males (47,XX",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -9.203125,
            "text": "X chromosome in",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -9.359375,
            "text": "X chromosome in males (47",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -10.078125,
            "text": "X chromosome in males (47,XXY), and",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -10.1328125,
            "text": "X chromosome in males (47,XXY),",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -10.1484375,
            "text": "X chromosome in males (47,XXY), and the characteristic clinical findings include tall stature",
            "probability": 0.0
        },
        {
            "start_logit": 3.4453125,
            "end_logit": -10.171875,
            "text": "X chromosome in males (47,XXY)",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -5.88671875,
            "text": "an additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -6.703125,
            "text": "an additional X chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.24609375,
            "end_logit": -5.88671875,
            "text": "additional X chromosome in males (47,XXY",
            "probability": 0.0
        },
        {
            "start_logit": -1.509765625,
            "end_logit": -9.046875,
            "text": "an additional X chromosome in males (47,XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_12": [
        {
            "start_logit": -6.42578125,
            "end_logit": -2.64453125,
            "text": "XXY",
            "probability": 0.39697265625
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -2.64453125,
            "text": "Klinefelter's syndrome (47, XXY",
            "probability": 0.235107421875
        },
        {
            "start_logit": -7.3515625,
            "end_logit": -2.64453125,
            "text": "47, XXY",
            "probability": 0.15673828125
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -2.64453125,
            "text": ", XXY",
            "probability": 0.032318115234375
        },
        {
            "start_logit": -6.42578125,
            "end_logit": -5.2109375,
            "text": "XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.0303802490234375
        },
        {
            "start_logit": -9.09375,
            "end_logit": -2.64453125,
            "text": "(47, XXY",
            "probability": 0.0276336669921875
        },
        {
            "start_logit": -9.421875,
            "end_logit": -2.64453125,
            "text": "(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0199127197265625
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -5.2109375,
            "text": "Klinefelter's syndrome (47, XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.01812744140625
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -2.64453125,
            "text": ", 39(10.9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0162506103515625
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -2.64453125,
            "text": "chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0132598876953125
        },
        {
            "start_logit": -7.3515625,
            "end_logit": -5.2109375,
            "text": "47, XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.0120849609375
        },
        {
            "start_logit": -10.09375,
            "end_logit": -2.64453125,
            "text": "9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.0101776123046875
        },
        {
            "start_logit": -10.328125,
            "end_logit": -2.64453125,
            "text": "Y",
            "probability": 0.00804901123046875
        },
        {
            "start_logit": -10.4375,
            "end_logit": -2.64453125,
            "text": ".9%) were found to have chromosomal abnormalities in which Klinefelter's syndrome (47, XXY",
            "probability": 0.007213592529296875
        },
        {
            "start_logit": -10.546875,
            "end_logit": -2.64453125,
            "text": "inefelter's syndrome (47, XXY",
            "probability": 0.0064697265625
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -5.2109375,
            "text": ", XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.0024929046630859375
        },
        {
            "start_logit": -9.09375,
            "end_logit": -5.2109375,
            "text": "(47, XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.0021152496337890625
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -5.2109375,
            "text": "The incidenc",
            "probability": 0.0018520355224609375
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -5.2109375,
            "text": "incidenc",
            "probability": 0.0018520355224609375
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -5.2109375,
            "text": "chromosomal abnormalities in which Klinefelter's syndrome (47, XXY) was the most common chromosomal aberration. The incidenc",
            "probability": 0.0010223388671875
        }
    ],
    "5e669e0e1af46fc130000019_13": [
        {
            "start_logit": 4.21875,
            "end_logit": 13.7265625,
            "text": "a 47, XXY",
            "probability": 0.63671875
        },
        {
            "start_logit": 3.638671875,
            "end_logit": 13.7265625,
            "text": "47, XXY",
            "probability": 0.357177734375
        },
        {
            "start_logit": -0.62451171875,
            "end_logit": 13.7265625,
            "text": "XXY",
            "probability": 0.00505828857421875
        },
        {
            "start_logit": -3.01953125,
            "end_logit": 13.7265625,
            "text": "Klinefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 0.00045943260192871094
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 13.7265625,
            "text": "Y",
            "probability": 0.00011795759201049805
        },
        {
            "start_logit": -6.421875,
            "end_logit": 13.7265625,
            "text": ", XXY",
            "probability": 1.537799835205078e-05
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.7265625,
            "text": "chromosome abnormality characterized by a 47, XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.7265625,
            "text": "by a 47, XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.7265625,
            "text": "inefelter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.7265625,
            "text": "lter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.828125,
            "end_logit": 13.7265625,
            "text": "felter syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 13.7265625,
            "text": "er syndrome (KS) is a chromosome abnormality characterized by a 47, XXY",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.7265625,
            "text": "abnormality characterized by a 47, XXY",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.21875,
            "end_logit": -5.85546875,
            "text": "a 47",
            "probability": 0.0
        },
        {
            "start_logit": 3.638671875,
            "end_logit": -5.85546875,
            "text": "47",
            "probability": 0.0
        },
        {
            "start_logit": 4.21875,
            "end_logit": -6.6484375,
            "text": "a 47, XX",
            "probability": 0.0
        },
        {
            "start_logit": 3.638671875,
            "end_logit": -6.6484375,
            "text": "47, XX",
            "probability": 0.0
        },
        {
            "start_logit": 4.21875,
            "end_logit": -7.65625,
            "text": "a 47, XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 3.638671875,
            "end_logit": -7.65625,
            "text": "47, XXY karyotype",
            "probability": 0.0
        },
        {
            "start_logit": 4.21875,
            "end_logit": -8.6640625,
            "text": "a",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_14": [
        {
            "start_logit": 12.6484375,
            "end_logit": 12.734375,
            "text": "XXY",
            "probability": 1.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -3.921875,
            "text": "XX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 12.734375,
            "text": "Y",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 12.734375,
            "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -8.9609375,
            "text": "XXY, XXYY, XXXY and XXXXY.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 12.734375,
            "text": "sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -9.65625,
            "text": "XXY, XXYY, XXXY and XXXXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -10.0390625,
            "text": "XXY, XXYY, XXXY",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -10.125,
            "text": "XXY, XXYY, XX",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -10.1796875,
            "text": "XXY, XXYY, XXXY and XX",
            "probability": 0.0
        },
        {
            "start_logit": 12.6484375,
            "end_logit": -10.2421875,
            "text": "XXY, XXYY, XXXY and XXX",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 12.734375,
            "text": "chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.734375,
            "text": "including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 12.734375,
            "text": "felter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 12.734375,
            "text": "inefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 12.734375,
            "text": "lter's syndrome may be associated with a variety of different sex chromosome anomalies including XXY",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -3.921875,
            "text": "Klinefelter's syndrome may be associated with a variety of different sex chromosome anomalies including XX",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -3.921875,
            "text": "sex chromosome anomalies including XX",
            "probability": 0.0
        },
        {
            "start_logit": -5.2890625,
            "end_logit": -8.9609375,
            "text": "Y, XXYY, XXXY and XXXXY.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -3.921875,
            "text": "chromosome anomalies including XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_15": [
        {
            "start_logit": 4.86328125,
            "end_logit": 12.7578125,
            "text": "a 47,XXY",
            "probability": 0.9921875
        },
        {
            "start_logit": -0.286376953125,
            "end_logit": 12.7578125,
            "text": "47,XXY",
            "probability": 0.005718231201171875
        },
        {
            "start_logit": -1.12890625,
            "end_logit": 12.7578125,
            "text": "XXY",
            "probability": 0.002460479736328125
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 12.7578125,
            "text": "Y",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 12.7578125,
            "text": ",XXY",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -9.078125,
            "end_logit": 12.7578125,
            "text": "Klinefelter's syndrome, characterised by a 47,XXY",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -9.609375,
            "end_logit": 12.7578125,
            "text": "by a 47,XXY",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -11.0,
            "end_logit": 12.7578125,
            "text": "felter's syndrome, characterised by a 47,XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 12.7578125,
            "text": "lter's syndrome, characterised by a 47,XXY",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -4.46484375,
            "text": "a 47",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -7.1328125,
            "text": "a 47,XX",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -7.9765625,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -9.09375,
            "text": "a 47,XXY chromosomal pattern, has largely been associated with physical abnormalities.",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -9.3203125,
            "text": "a 47,XXY chromosomal pattern",
            "probability": 0.0
        },
        {
            "start_logit": -0.286376953125,
            "end_logit": -4.46484375,
            "text": "47",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -10.1484375,
            "text": "a 47,XXY chromosomal pattern,",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -10.3046875,
            "text": "a 47,XXY chromosomal pattern, has largely",
            "probability": 0.0
        },
        {
            "start_logit": 4.86328125,
            "end_logit": -10.34375,
            "text": "a 47,XXY chromosomal pattern, has largely been associated with physical abnormalities",
            "probability": 0.0
        },
        {
            "start_logit": -0.286376953125,
            "end_logit": -7.1328125,
            "text": "47,XX",
            "probability": 0.0
        },
        {
            "start_logit": -1.12890625,
            "end_logit": -7.1328125,
            "text": "XX",
            "probability": 0.0
        }
    ],
    "5e669e0e1af46fc130000019_16": [
        {
            "start_logit": 10.71875,
            "end_logit": 12.734375,
            "text": "t(13q;14q)",
            "probability": 1.0
        },
        {
            "start_logit": 10.71875,
            "end_logit": 0.53271484375,
            "text": "t(13q;14q",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": -4.54296875,
            "end_logit": 12.734375,
            "text": ")",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 12.734375,
            "text": "(13q;14q)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.5625,
            "end_logit": 12.734375,
            "text": ",t(13q;14q)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 12.734375,
            "text": ";14q)",
            "probability": 0.0
        },
        {
            "start_logit": 10.71875,
            "end_logit": -5.60546875,
            "text": "t",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 12.734375,
            "text": "13/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -7.87890625,
            "end_logit": 12.734375,
            "text": "13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 12.734375,
            "text": "with 13/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 12.734375,
            "text": "Klinefelter syndrome associated with 13/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 12.734375,
            "text": "XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 12.734375,
            "text": "translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 12.734375,
            "text": ",XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 12.734375,
            "text": "14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": 10.71875,
            "end_logit": -7.57421875,
            "text": "t(13q",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 12.734375,
            "text": "14q)",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 12.734375,
            "text": "/14 translocation abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        },
        {
            "start_logit": 10.71875,
            "end_logit": -8.453125,
            "text": "t(13q;14",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 12.734375,
            "text": "abnormality 46,XXY,t(13q;14q)",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_1": [
        {
            "start_logit": 14.125,
            "end_logit": 15.1875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": 15.1875,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.125,
            "end_logit": -2.984375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -4.17578125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -4.8828125,
            "text": "GBshape:",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 15.1875,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.5703125,
            "text": "GBshape: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.5703125,
            "text": "GBshape: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.6875,
            "text": "GBshape: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.7265625,
            "text": "GBshape: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.890625,
            "text": "GBshape: a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -10.1015625,
            "text": "GBshape: a genome browser database for DNA shape",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -10.1328125,
            "text": "GBshape: a genome browse",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -4.8828125,
            "text": "e:",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.5703125,
            "text": "e: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.5703125,
            "text": "e: a genome browser database for DNA shape annotations.",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.6875,
            "text": "e: a genome browser database",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.7265625,
            "text": "e: a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -9.890625,
            "text": "e: a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -10.1015625,
            "text": "e: a genome browser database for DNA shape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_2": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.328125,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.3349609375,
            "end_logit": 15.328125,
            "text": "e",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.330078125,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.8515625,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -7.68359375,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -7.7734375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 15.328125,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 15.328125,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 15.328125,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.71875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.0234375,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.34375,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.328125,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.5859375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.71875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": -1.3349609375,
            "end_logit": -7.68359375,
            "text": "e;",
            "probability": 0.0
        },
        {
            "start_logit": -1.3349609375,
            "end_logit": -7.7734375,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.3349609375,
            "end_logit": -8.71875,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.3349609375,
            "end_logit": -9.0234375,
            "text": "e; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_3": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.2109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": 15.2109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.703125,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -3.63671875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.2109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.5390625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5234375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6171875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.703125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -8.5390625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.296875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5234375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5390625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6171875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6953125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.703125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -3.63671875,
            "text": "hap",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_4": [
        {
            "start_logit": 14.140625,
            "end_logit": 15.1875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": 15.1875,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.140625,
            "end_logit": -2.8984375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -4.8203125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -7.2421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 15.1875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.1875,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.0390625,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.40625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 15.1875,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.5625,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.171875,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.25,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.3984375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.4609375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -7.2421875,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.0390625,
            "text": "e;",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.40625,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.5625,
            "text": "e; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -9.171875,
            "text": "e; freely available at http://ro",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_5": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.2109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": 15.2109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.703125,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -3.63671875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.2109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.5390625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5234375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6171875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.703125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -8.5390625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.296875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5234375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5390625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6171875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6953125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.703125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -3.63671875,
            "text": "hap",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_6": [
        {
            "start_logit": 14.2265625,
            "end_logit": 15.2109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": 15.2109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -2.71875,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -4.13671875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 15.2109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.09375,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.34375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.546875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.7265625,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.75,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.8515625,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.859375,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.890625,
            "text": "GBshape can be used to",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.90625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.09375,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.34375,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.546875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.7265625,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.75,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.7265625,
            "end_logit": -9.8515625,
            "text": "e can be used",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_7": [
        {
            "start_logit": 13.2265625,
            "end_logit": 14.96875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": 14.96875,
            "text": "e",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -3.935546875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -4.41015625,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -6.18359375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 14.96875,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 14.96875,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -7.94921875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -8.2265625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.96875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.015625,
            "text": "GBshape; freely available at http",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.046875,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.171875,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.28125,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.5546875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.5546875,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.578125,
            "text": "GBshape; freely available at http://rohs",
            "probability": 0.0
        },
        {
            "start_logit": 13.2265625,
            "end_logit": -9.640625,
            "text": "GBshape; freely available at http:",
            "probability": 0.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -6.18359375,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -7.94921875,
            "text": "e; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_8": [
        {
            "start_logit": 14.125,
            "end_logit": 15.1484375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.5498046875,
            "end_logit": 15.1484375,
            "text": "e",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.125,
            "end_logit": -2.765625,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -2.82421875,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": 15.1484375,
            "text": "the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 15.1484375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -8.3828125,
            "text": "GBshape framework. GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 15.1484375,
            "text": "Additional genomes can easily be added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 15.1484375,
            "text": "genomes can easily be added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.46875,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.484375,
            "text": "GBshape framework",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.5078125,
            "text": "GBshape framework.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.1484375,
            "text": "using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.1484375,
            "text": "added using the GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.8984375,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.8984375,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.90625,
            "text": "GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.9140625,
            "text": "GBshape framework. GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.125,
            "end_logit": -9.9375,
            "text": "GBshape framework. GBs",
            "probability": 0.0
        },
        {
            "start_logit": -1.5498046875,
            "end_logit": -8.3828125,
            "text": "e framework. GBshape",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_9": [
        {
            "start_logit": 14.2734375,
            "end_logit": 15.265625,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": 15.265625,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -2.58984375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -4.3359375,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 15.265625,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -7.46875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -8.015625,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.265625,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 15.265625,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -8.5234375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -8.7421875,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.28125,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.3671875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.4609375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.4765625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 15.265625,
            "text": "Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": -7.46875,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": -8.015625,
            "text": "e;",
            "probability": 0.0
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": -8.5234375,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": -8.7421875,
            "text": "e; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_10": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.2109375,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": 15.2109375,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.703125,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -3.63671875,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 15.2109375,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.5390625,
            "text": "GBshape can",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.296875,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5234375,
            "text": "GBshape can be",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.5390625,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6171875,
            "text": "GBshape can be used",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.6953125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.703125,
            "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -8.5390625,
            "text": "e can",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.296875,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5234375,
            "text": "e can be",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.5390625,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser track format,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6171875,
            "text": "e can be used",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.6953125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome browser",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -9.703125,
            "text": "e can be used to visualize DNA shape annotations qualitatively in a genome",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -3.63671875,
            "text": "hap",
            "probability": 0.0
        }
    ],
    "56c8f4615795f9a73e00001a_11": [
        {
            "start_logit": 14.140625,
            "end_logit": 15.1875,
            "text": "GBshape",
            "probability": 1.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": 15.1875,
            "text": "e",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.140625,
            "end_logit": -2.8984375,
            "text": "GBs",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -4.8203125,
            "text": "GBshap",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -7.2421875,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 15.1875,
            "text": "Our Genome Browser for DNA shape annotations (GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.1875,
            "text": "hape",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.0390625,
            "text": "GBshape;",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.40625,
            "text": "GBshape; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 15.1875,
            "text": "(GBshape",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.5625,
            "text": "GBshape; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.171875,
            "text": "GBshape; freely available at http://ro",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.25,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.3984375,
            "text": "GBshape; freely available at http://rohslab.cmb",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.4609375,
            "text": "GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -7.2421875,
            "text": "e; freely available at http://rohslab.cmb.usc.edu",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.0390625,
            "text": "e;",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.40625,
            "text": "e; freely available at http://rohslab.cmb.usc",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -8.5625,
            "text": "e; freely available at http://rohslab.cmb.us",
            "probability": 0.0
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": -9.171875,
            "text": "e; freely available at http://ro",
            "probability": 0.0
        }
    ],
    "5e36cf8eb5b409ea53000007_1": [
        {
            "start_logit": 5.73828125,
            "end_logit": 1.7236328125,
            "text": "melanocyte",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -6.31640625,
            "text": "melan",
            "probability": 0.0003223419189453125
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -7.66796875,
            "text": "melanocyte umbrella",
            "probability": 8.344650268554688e-05
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -7.79296875,
            "text": "melanocyte umb",
            "probability": 7.361173629760742e-05
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -8.2109375,
            "text": "melanocyte umbrel",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -8.4453125,
            "text": "melanocyte umbrella above",
            "probability": 3.814697265625e-05
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -9.765625,
            "text": "melanocyte umbrella above the kidney marrow",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -9.84375,
            "text": "melanocyte umbrella above the kidney marrow protects HSPCs against ultraviolet light in",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -9.859375,
            "text": "melanocyte umbrella above the kidney",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -8.0,
            "end_logit": 1.7236328125,
            "text": "a melanocyte",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 1.7236328125,
            "text": "ocyte",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 1.7236328125,
            "text": "in the kidney marrow in teleost fish. Here we show that a melanocyte",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.828125,
            "end_logit": 1.7236328125,
            "text": "the kidney marrow in teleost fish. Here we show that a melanocyte",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.212890625,
            "end_logit": -9.765625,
            "text": "melanocytes above the haematopoietic niche",
            "probability": 0.0
        },
        {
            "start_logit": -3.212890625,
            "end_logit": -9.765625,
            "text": "melanocytes above",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -6.31640625,
            "text": "a melan",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": -6.16015625,
            "text": "the cortical bone around the marrow",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -7.66796875,
            "text": "a melanocyte umbrella",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -6.16015625,
            "text": "into the bone marrow, which is protected from ultraviolet light by the cortical bone around the marrow",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -6.31640625,
            "text": "in the kidney marrow in teleost fish. Here we show that a melan",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_1": [
        {
            "start_logit": 11.625,
            "end_logit": 13.9921875,
            "text": "SPINK5",
            "probability": 1.0
        },
        {
            "start_logit": -2.466796875,
            "end_logit": 13.9921875,
            "text": "5",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 11.625,
            "end_logit": -3.94140625,
            "text": "SPINK",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -5.33203125,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5)",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -6.12890625,
            "text": "SPIN",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 13.9921875,
            "text": "mutations in the gene SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.9921875,
            "text": "gene SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 13.9921875,
            "text": "K5",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -8.2109375,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.9921875,
            "text": "Netherton syndrome (NS) is a serious inherited skin disorder caused by mutations in the gene SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -8.390625,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.9921875,
            "text": "skin disorder caused by mutations in the gene SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 13.9921875,
            "text": "in the gene SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.546875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.71875,
            "text": "SPINK5 (",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.765625,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.9921875,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -10.0,
            "text": "SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI (lymphoepithelial Kazal type",
            "probability": 0.0
        },
        {
            "start_logit": -2.466796875,
            "end_logit": -5.33203125,
            "text": "5 (serine protease inhibitor Kazal type 5)",
            "probability": 0.0
        },
        {
            "start_logit": -2.466796875,
            "end_logit": -8.2109375,
            "text": "5 (serine protease inhibitor Kazal type 5) which",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_2": [
        {
            "start_logit": 12.8203125,
            "end_logit": 14.7265625,
            "text": "SPINK5",
            "probability": 1.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": 14.7265625,
            "text": "5",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -2.05078125,
            "text": "SPINK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -2.8984375,
            "text": "SPINK5)",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -4.94140625,
            "text": "SPIN",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": 14.7265625,
            "text": "Mutations in the serine protease inhibitor Kazal type 5 (SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 14.7265625,
            "text": "(SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -7.3359375,
            "text": "SPINK5) gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.7265625,
            "text": "K5",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.7265625,
            "text": "type 5 (SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.7265625,
            "text": "al type 5 (SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.75,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.8984375,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency cause NS.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.984375,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency cause NS",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.3046875,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.3046875,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI)",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.578125,
            "text": "SPINK5) gene leading",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.84375,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.96875,
            "text": "SPINK5) gene leading to lymphoepithelial Kazal-type-related inhibitor (LEKTI) deficiency cause",
            "probability": 0.0
        },
        {
            "start_logit": -1.6201171875,
            "end_logit": -2.8984375,
            "text": "5)",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_3": [
        {
            "start_logit": 12.0625,
            "end_logit": 14.3984375,
            "text": "SPINK5",
            "probability": 1.0
        },
        {
            "start_logit": -2.490234375,
            "end_logit": 14.3984375,
            "text": "5",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.0625,
            "end_logit": -4.36328125,
            "text": "SPINK",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -5.35546875,
            "text": "SPIN",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -5.44140625,
            "text": "SPINK5 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.3984375,
            "text": "the SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 14.3984375,
            "text": "K5",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.3984375,
            "text": "loss-of-function mutations in the SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.3984375,
            "text": "NS is due to loss-of-function mutations in the SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.3984375,
            "text": "mutations in the SPINK5",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -8.7734375,
            "text": "SPINK5 gene and",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -8.984375,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI in the skin and all stratified epithelial tissues.",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -9.6171875,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -10.0390625,
            "text": "SPINK5 gene and to the consequent lack of expression of its encoded",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -10.140625,
            "text": "SPINK5 gene and to the consequent lack of expression of its",
            "probability": 0.0
        },
        {
            "start_logit": 12.0625,
            "end_logit": -10.140625,
            "text": "SPINK5 gene and to the consequent lack of expression of",
            "probability": 0.0
        },
        {
            "start_logit": -2.490234375,
            "end_logit": -5.44140625,
            "text": "5 gene",
            "probability": 0.0
        },
        {
            "start_logit": -2.490234375,
            "end_logit": -8.7734375,
            "text": "5 gene and",
            "probability": 0.0
        },
        {
            "start_logit": -2.490234375,
            "end_logit": -8.984375,
            "text": "5 gene and to the consequent lack of expression of its encoded protein LEKTI in the skin and all stratified epithelial tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -2.490234375,
            "end_logit": -9.6171875,
            "text": "5 gene and to the consequent lack of expression of its encoded protein LEKTI",
            "probability": 0.0
        }
    ],
    "54ff45966ad7dcbc12000010_4": [
        {
            "start_logit": 5.98828125,
            "end_logit": 10.5078125,
            "text": "LEKTI)",
            "probability": 0.79541015625
        },
        {
            "start_logit": 5.98828125,
            "end_logit": 9.1015625,
            "text": "LEKTI",
            "probability": 0.195068359375
        },
        {
            "start_logit": 0.92041015625,
            "end_logit": 10.5078125,
            "text": "(LEKTI)",
            "probability": 0.00499725341796875
        },
        {
            "start_logit": 0.17333984375,
            "end_logit": 10.5078125,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LEKTI)",
            "probability": 0.0023593902587890625
        },
        {
            "start_logit": 0.92041015625,
            "end_logit": 9.1015625,
            "text": "(LEKTI",
            "probability": 0.001224517822265625
        },
        {
            "start_logit": 0.17333984375,
            "end_logit": 9.1015625,
            "text": "Lympho-epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 0.0005784034729003906
        },
        {
            "start_logit": -6.125,
            "end_logit": 10.5078125,
            "text": "inhibitor (LEKTI)",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 10.5078125,
            "text": ")",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 10.5078125,
            "text": "I)",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.1015625,
            "text": "inhibitor (LEKTI",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 10.5078125,
            "text": "epithelial Kazal-type-related inhibitor (LEKTI)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 9.1015625,
            "text": "I",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -8.8125,
            "end_logit": 10.5078125,
            "text": "Kazal-type-related inhibitor (LEKTI)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 10.5078125,
            "text": "-epithelial Kazal-type-related inhibitor (LEKTI)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.83984375,
            "end_logit": 9.1015625,
            "text": "epithelial Kazal-type-related inhibitor (LEKTI",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.40625,
            "end_logit": 10.5078125,
            "text": "type-related inhibitor (LEKTI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 10.5078125,
            "text": "KTI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.875,
            "end_logit": 10.5078125,
            "text": "related inhibitor (LEKTI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 10.5078125,
            "text": "al-type-related inhibitor (LEKTI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 10.5078125,
            "text": "zal-type-related inhibitor (LEKTI)",
            "probability": 1.1920928955078125e-07
        }
    ],
    "54ff45966ad7dcbc12000010_5": [
        {
            "start_logit": 12.671875,
            "end_logit": 12.9296875,
            "text": "LEKTI",
            "probability": 1.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": 12.9296875,
            "text": "I",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -5.203125,
            "text": "LEKT",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -5.484375,
            "text": "LE",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -6.66796875,
            "text": "LEKTI is",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 12.9296875,
            "text": "Deficiency in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -7.8515625,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and chronic inflammation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 12.9296875,
            "text": "inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -9.6015625,
            "text": "LEKTI is the etiological origin of Netherton syndrome,",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -9.640625,
            "text": "LEKTI is the etiological origin",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 12.9296875,
            "text": "KTI",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -9.75,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -10.0625,
            "text": "LEKTI is the etiological origin of",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -10.0703125,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and chronic inflammation",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -10.1328125,
            "text": "LEKTI is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.9296875,
            "text": "in the serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 12.9296875,
            "text": "protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 12.9296875,
            "text": "serine protease inhibitor LEKTI",
            "probability": 0.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -6.66796875,
            "text": "I is",
            "probability": 0.0
        },
        {
            "start_logit": -5.0390625,
            "end_logit": -7.8515625,
            "text": "I is the etiological origin of Netherton syndrome, which causes detachment of the stratum corneum and chronic inflammation.",
            "probability": 0.0
        }
    ],
    "53175e9fb166e2b80600000a_1": [
        {
            "start_logit": 8.1640625,
            "end_logit": 6.22265625,
            "text": "Wnt-signaling pathway",
            "probability": 1.0
        },
        {
            "start_logit": -1.94921875,
            "end_logit": 6.22265625,
            "text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -5.265625,
            "text": "Wnt",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.671875,
            "text": "Wnt-signaling",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -4.890625,
            "end_logit": 6.22265625,
            "text": "LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.46875,
            "text": "Wnt-",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -8.703125,
            "text": "Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -9.1328125,
            "text": "Wnt-signaling pathway and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -9.8671875,
            "text": "Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 6.22265625,
            "text": "the Wnt-signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.53125,
            "end_logit": 6.22265625,
            "text": "controlling the Wnt-signaling pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.96875,
            "end_logit": 6.22265625,
            "text": "pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 6.22265625,
            "text": "that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 6.22265625,
            "text": "-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 6.22265625,
            "text": "pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 6.22265625,
            "text": "signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 6.22265625,
            "text": "a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 6.22265625,
            "text": "role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 6.22265625,
            "text": "functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 6.22265625,
            "text": "plays a physiological role in controlling the Wnt-signaling pathway",
            "probability": 0.0
        }
    ],
    "5a9d31711d1251d03b00001c_1": [
        {
            "start_logit": 14.09375,
            "end_logit": 15.171875,
            "text": "100 nm",
            "probability": 1.0
        },
        {
            "start_logit": -1.8271484375,
            "end_logit": 15.171875,
            "text": "nm",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.09375,
            "end_logit": -1.056640625,
            "text": "100",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.09375,
            "end_logit": -6.2578125,
            "text": "100 nm.",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 15.171875,
            "text": "of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 15.171875,
            "text": "diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 15.171875,
            "text": "maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 15.171875,
            "text": "attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 15.171875,
            "text": "vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.171875,
            "text": "the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 15.171875,
            "text": "their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.171875,
            "text": "tere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.171875,
            "text": "relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.171875,
            "text": "This number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.171875,
            "text": "they attained their maximum diamtere of 100 nm",
            "probability": 0.0
        },
        {
            "start_logit": -1.8271484375,
            "end_logit": -6.2578125,
            "text": "nm.",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": -1.056640625,
            "text": "of 100",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": -1.056640625,
            "text": "diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -1.056640625,
            "text": "maximum diamtere of 100",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -1.056640625,
            "text": "attained their maximum diamtere of 100",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_1": [
        {
            "start_logit": 13.265625,
            "end_logit": 14.8359375,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": 14.8359375,
            "text": "abuse",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.265625,
            "end_logit": -3.77734375,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 14.8359375,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": 14.8359375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -6.5859375,
            "text": "intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -6.7265625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.8359375,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.8359375,
            "text": "of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.8359375,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.8359375,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 14.8359375,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.8359375,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.8359375,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -6.5859375,
            "text": "abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -3.77734375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -6.5859375,
            "text": "drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -6.7265625,
            "text": "drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.5859375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.7265625,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_2": [
        {
            "start_logit": 13.359375,
            "end_logit": 14.8828125,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.23046875,
            "end_logit": 14.8828125,
            "text": "abuse",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.359375,
            "end_logit": -3.767578125,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 14.8828125,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -6.0625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 14.8828125,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 14.8828125,
            "text": ": Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 14.8828125,
            "text": "of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -8.75,
            "text": "intravenous drug abuse,",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.8828125,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.8828125,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.8828125,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.8828125,
            "text": "BACKGROUND: Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.8828125,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.0234375,
            "text": "intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.40625,
            "text": "intravenous drug abuse, which has no current available treatment",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.4765625,
            "text": "intravenous drug abuse, which",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.515625,
            "text": "intravenous drug abuse, which has no",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.546875,
            "text": "intravenous drug abuse, which has no current available",
            "probability": 0.0
        },
        {
            "start_logit": -2.23046875,
            "end_logit": -8.75,
            "text": "abuse,",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_3": [
        {
            "start_logit": 13.375,
            "end_logit": 14.7421875,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.375,
            "end_logit": 14.7421875,
            "text": "abuse",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.734375,
            "end_logit": 14.7421875,
            "text": "Puffy hand syndrome is a complication of intravenous drug abuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.375,
            "end_logit": -3.7734375,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 14.7421875,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -5.9140625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -7.92578125,
            "text": "intravenous drug abuse, which has no current available treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.7421875,
            "text": "y hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 14.7421875,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.7421875,
            "text": "of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.7421875,
            "text": "hand syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -9.4453125,
            "text": "intravenous drug abuse, which",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -9.46875,
            "text": "intravenous drug abuse,",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.7421875,
            "text": "syndrome is a complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.3671875,
            "text": "intravenous drug abuse, which has",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.3828125,
            "text": "intravenous drug abuse, which has no current available treatment",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.4375,
            "text": "intravenous drug abuse, which has no",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.46875,
            "text": "intravenous drug abuse, which has no current available",
            "probability": 0.0
        },
        {
            "start_logit": -3.734375,
            "end_logit": -3.7734375,
            "text": "Puffy hand syndrome is a complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -3.734375,
            "end_logit": -5.9140625,
            "text": "Puffy hand syndrome is a complication of intravenous drug",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_4": [
        {
            "start_logit": 13.265625,
            "end_logit": 14.8359375,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": 14.8359375,
            "text": "abuse",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.265625,
            "end_logit": -3.77734375,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 14.8359375,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": 14.8359375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -6.5859375,
            "text": "intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": 13.265625,
            "end_logit": -6.7265625,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.8359375,
            "text": "y hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.8359375,
            "text": "of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.8359375,
            "text": "hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.8359375,
            "text": "complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 14.8359375,
            "text": "unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.8359375,
            "text": "an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.8359375,
            "text": "syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -6.5859375,
            "text": "abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -3.77734375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -6.5859375,
            "text": "drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -6.7265625,
            "text": "drug",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.5859375,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -6.7265625,
            "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_5": [
        {
            "start_logit": 13.1640625,
            "end_logit": 14.703125,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.65625,
            "end_logit": 14.703125,
            "text": "abuse",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.1640625,
            "end_logit": -3.681640625,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 14.703125,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.1640625,
            "end_logit": -5.921875,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 14.703125,
            "text": "puffy hand syndrome is an unrecognized complication of intravenous drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 13.1640625,
            "end_logit": -9.6796875,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction",
            "probability": 0.0
        },
        {
            "start_logit": 13.1640625,
            "end_logit": -9.890625,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may",
            "probability": 0.0
        },
        {
            "start_logit": 13.1640625,
            "end_logit": -10.09375,
            "text": "intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearm",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -5.921875,
            "text": "drug",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -3.681640625,
            "text": "puffy hand syndrome is an unrecognized complication of intravenous",
            "probability": 0.0
        },
        {
            "start_logit": -2.65625,
            "end_logit": -9.6796875,
            "text": "abuse this painless syndrome appears during or after a long period of drug addiction",
            "probability": 0.0
        },
        {
            "start_logit": -2.65625,
            "end_logit": -9.890625,
            "text": "abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may",
            "probability": 0.0
        },
        {
            "start_logit": -2.65625,
            "end_logit": -10.09375,
            "text": "abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearm",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": -5.921875,
            "text": "puffy hand syndrome is an unrecognized complication of intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -9.6796875,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -9.890625,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -10.09375,
            "text": "drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearm",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -6.765625,
            "text": "bandage and elastic garment usually used in lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -6.765625,
            "text": "stretch bandage and elastic garment usually used in lymphedema",
            "probability": 0.0
        }
    ],
    "5a7346662dc08e987e00001a_6": [
        {
            "start_logit": 11.6640625,
            "end_logit": 13.9453125,
            "text": "intravenous drug abuse",
            "probability": 1.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": 13.9453125,
            "text": "abuse",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 13.9453125,
            "text": "drug abuse",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -5.3984375,
            "text": "intravenous drug",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -5.40234375,
            "text": "intravenous",
            "probability": 0.0
        },
        {
            "start_logit": 11.6640625,
            "end_logit": -9.84375,
            "text": "intravenous drug abuse which has no current available treatment arm and forearm edema",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -5.3984375,
            "text": "drug",
            "probability": 0.0
        },
        {
            "start_logit": -2.873046875,
            "end_logit": -9.84375,
            "text": "abuse which has no current available treatment arm and forearm edema",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -7.203125,
            "text": "venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -9.84375,
            "text": "drug abuse which has no current available treatment arm and forearm edema",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -8.2265625,
            "text": "venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -9.4453125,
            "text": "hand",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -9.53125,
            "text": "hand circumference",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -9.4453125,
            "text": "truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -9.8203125,
            "text": "arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -9.84375,
            "text": "arm and forearm edema",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -9.8203125,
            "text": "voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -9.53125,
            "text": "truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -9.4453125,
            "text": "a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -9.578125,
            "text": "truncated cone",
            "probability": 0.0
        }
    ],
    "56cf236f3975bb303a000002_1": [
        {
            "start_logit": 13.0703125,
            "end_logit": 13.9921875,
            "text": "T-type calcium channels",
            "probability": 1.0
        },
        {
            "start_logit": -3.49609375,
            "end_logit": 13.9921875,
            "text": "channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.80078125,
            "end_logit": 13.9921875,
            "text": "type calcium channels",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -3.83984375,
            "text": "T",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -4.37890625,
            "text": "T-type calcium",
            "probability": 0.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 13.9921875,
            "text": "calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -8.109375,
            "text": "T-type",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 13.9921875,
            "text": "block T-type calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -8.5625,
            "text": "T-",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.078125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.4140625,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 13.9921875,
            "text": "-type calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 13.9921875,
            "text": "to block T-type calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 13.9921875,
            "text": "Given evidence that chemotherapy-induced neuropathic pain is blocked by ethosuximide, known to block T-type calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 13.9921875,
            "text": "ethosuximide, known to block T-type calcium channels",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -10.1953125,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -10.21875,
            "text": "T-type calcium channels, we examined if more selective T-type calcium channel",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -10.3828125,
            "text": "T-type calcium channels, we examined",
            "probability": 0.0
        },
        {
            "start_logit": -3.80078125,
            "end_logit": -4.37890625,
            "text": "type calcium",
            "probability": 0.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -4.37890625,
            "text": "calcium",
            "probability": 0.0
        }
    ],
    "6026ed981cb411341a0000d2_1": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.359375,
            "text": "erenumab",
            "probability": 1.0
        },
        {
            "start_logit": -0.87109375,
            "end_logit": 15.359375,
            "text": "umab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.048828125,
            "text": "er",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -4.48046875,
            "text": "eren",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.2578125,
            "text": "erenumab), LY2951742 (galcanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.359375,
            "text": "(erenumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.359375,
            "text": "enumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.625,
            "text": "erenumab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.359375,
            "text": "eptinezumab), AMG334 (erenumab",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.8515625,
            "text": "erenumab), LY2951742 (galcanez",
            "probability": 0.0
        },
        {
            "start_logit": -0.87109375,
            "end_logit": -8.2578125,
            "text": "umab), LY2951742 (galcanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -0.87109375,
            "end_logit": -9.625,
            "text": "umab), LY2951742 (galcanezumab) and TEV48125 (fremanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -0.87109375,
            "end_logit": -9.8515625,
            "text": "umab), LY2951742 (galcanez",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -2.048828125,
            "text": "(er",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -2.048828125,
            "text": "eptinezumab), AMG334 (er",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -4.48046875,
            "text": "(eren",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -4.48046875,
            "text": "en",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -4.48046875,
            "text": "eptinezumab), AMG334 (eren",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -8.2578125,
            "text": "(erenumab), LY2951742 (galcanezumab",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -8.2578125,
            "text": "enumab), LY2951742 (galcanezumab",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_1": [
        {
            "start_logit": 14.078125,
            "end_logit": 15.109375,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": 15.109375,
            "text": "per",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.078125,
            "end_logit": -2.98046875,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -4.80078125,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 15.109375,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -8.84375,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.4921875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.75,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.953125,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -10.0390625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -10.1640625,
            "text": "CisMapper: predicting regulatory interactions",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -8.84375,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -9.4921875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -9.75,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -9.953125,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -10.0390625,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -10.1640625,
            "text": "per: predicting regulatory interactions",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -4.80078125,
            "text": "Map",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -8.84375,
            "text": "Mapper:",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": -9.4921875,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_2": [
        {
            "start_logit": 14.3984375,
            "end_logit": 15.4140625,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": 15.4140625,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.32421875,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -3.826171875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -4.4453125,
            "text": "CisMapper,",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 15.4140625,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 15.4140625,
            "text": "present CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.875,
            "text": "CisMapper, which predicts the regulatory targets of a",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.8984375,
            "text": "CisMapper, which predicts the regulatory targets of a TF",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.15625,
            "text": "CisMapper, which",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.5703125,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.4140625,
            "text": "We present CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.921875,
            "text": "CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.953125,
            "text": "CisMapper, which predicts",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -4.4453125,
            "text": "per,",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -8.875,
            "text": "per, which predicts the regulatory targets of a",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -8.8984375,
            "text": "per, which predicts the regulatory targets of a TF",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -9.15625,
            "text": "per, which",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -9.5703125,
            "text": "per, which predicts the regulatory targets of a TF using the correlation",
            "probability": 0.0
        },
        {
            "start_logit": -1.4248046875,
            "end_logit": -9.734375,
            "text": "per, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_3": [
        {
            "start_logit": 14.2421875,
            "end_logit": 15.2890625,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": 15.2890625,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -2.693359375,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -4.62109375,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 15.2890625,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.671875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -8.7578125,
            "text": "CisMapper is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.2890625,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.15625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.1875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.2109375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.328125,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.5078125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.53125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.6328125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous",
            "probability": 0.0
        },
        {
            "start_logit": 14.2421875,
            "end_logit": -9.75,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.2890625,
            "text": "chromatin conformation capture and differential expression data, we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -8.671875,
            "text": "per is more accurate at predicting the target genes of a TF",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -8.7578125,
            "text": "per is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -9.15625,
            "text": "per is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_4": [
        {
            "start_logit": 14.3046875,
            "end_logit": 15.390625,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.443359375,
            "end_logit": 15.390625,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -2.580078125,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -3.654296875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -6.98046875,
            "text": "CisMapper also",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.390625,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.1015625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.6328125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.2421875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.28125,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.421875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.4296875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.4375,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods,",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.6015625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.6015625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.6171875,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.6640625,
            "text": "CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMap",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.6640625,
            "text": "CisMapper also predicts",
            "probability": 0.0
        },
        {
            "start_logit": -1.443359375,
            "end_logit": -6.98046875,
            "text": "per also",
            "probability": 0.0
        },
        {
            "start_logit": -1.443359375,
            "end_logit": -8.1015625,
            "text": "per also predicts which TF binding sites regulate a given gene more accurately than using genomic distance.",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_5": [
        {
            "start_logit": 14.390625,
            "end_logit": 15.328125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": 15.328125,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.369140625,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -4.17578125,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 15.328125,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.4921875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.734375,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.640625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.96875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.9765625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.0234375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -8.4921875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -8.734375,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.640625,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.96875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.9765625,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -10.0234375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -4.17578125,
            "text": "Map",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.4921875,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.734375,
            "text": "Mapper:",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_6": [
        {
            "start_logit": 14.390625,
            "end_logit": 15.328125,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": 15.328125,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.369140625,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -4.17578125,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 15.328125,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.4921875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -8.734375,
            "text": "CisMapper:",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.640625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.96875,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -9.9765625,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -10.0234375,
            "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -8.4921875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -8.734375,
            "text": "per:",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.640625,
            "text": "per: predicting regulatory interactions from transcription factor",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.96875,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -9.9765625,
            "text": "per: predicting regulatory interactions from transcription factor ChIP-seq data",
            "probability": 0.0
        },
        {
            "start_logit": -1.697265625,
            "end_logit": -10.0234375,
            "text": "per: predicting regulatory interactions from transcription factor ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -4.17578125,
            "text": "Map",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.4921875,
            "text": "Mapper: predicting regulatory interactions from transcription factor ChIP-seq data.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.734375,
            "text": "Mapper:",
            "probability": 0.0
        }
    ],
    "587e0116ae05ffb474000002_7": [
        {
            "start_logit": 14.25,
            "end_logit": 15.3046875,
            "text": "CisMapper",
            "probability": 1.0
        },
        {
            "start_logit": -1.7255859375,
            "end_logit": 15.3046875,
            "text": "per",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.25,
            "end_logit": -2.693359375,
            "text": "Cis",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -4.66796875,
            "text": "CisMap",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 15.3046875,
            "text": "Mapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -8.734375,
            "text": "CisMapper is more accurate at predicting the target genes of a TF",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -8.7578125,
            "text": "CisMapper is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 15.3046875,
            "text": "that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.1171875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.21875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.2265625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used,",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.3828125,
            "text": "CisMapper is",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.5078125,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.5546875,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.640625,
            "text": "CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 15.3046875,
            "text": "chromatin conformation capture and differential expression data, we show that CisMapper",
            "probability": 0.0
        },
        {
            "start_logit": -1.7255859375,
            "end_logit": -8.734375,
            "text": "per is more accurate at predicting the target genes of a TF",
            "probability": 0.0
        },
        {
            "start_logit": -1.7255859375,
            "end_logit": -8.7578125,
            "text": "per is more accurate at predicting the target genes of a",
            "probability": 0.0
        },
        {
            "start_logit": -1.7255859375,
            "end_logit": -9.1171875,
            "text": "per is more accurate at predicting the target genes of a TF than the distance-based approaches currently used",
            "probability": 0.0
        },
        {
            "start_logit": -1.7255859375,
            "end_logit": -9.21875,
            "text": "per is more accurate at predicting the target genes of a TF than",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_1": [
        {
            "start_logit": 10.265625,
            "end_logit": 11.0234375,
            "text": "inflammation of the aorta",
            "probability": 1.0
        },
        {
            "start_logit": -1.8173828125,
            "end_logit": 11.0234375,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 10.265625,
            "end_logit": -1.42578125,
            "text": "inflammation of the aorta due to various causes.",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -3.810546875,
            "end_logit": 11.0234375,
            "text": "aorta",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 10.265625,
            "end_logit": -7.26953125,
            "text": "inflammation",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -7.96875,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 11.0234375,
            "text": "of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 11.0234375,
            "text": "the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -8.6640625,
            "text": "inflammation of the aorta due to various causes",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 11.0234375,
            "text": "the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -9.5078125,
            "text": "inflammation of the aorta due to",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -9.5625,
            "text": "inflammation of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -10.0859375,
            "text": "inflammation of the aorta due to various",
            "probability": 0.0
        },
        {
            "start_logit": 10.265625,
            "end_logit": -10.2890625,
            "text": "inflammation of",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 11.0234375,
            "text": "itis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -1.8173828125,
            "end_logit": -1.42578125,
            "text": "Aortitis is the inflammation of the aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -3.810546875,
            "end_logit": -1.42578125,
            "text": "aorta due to various causes.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8173828125,
            "end_logit": -7.26953125,
            "text": "Aortitis is the inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -1.8173828125,
            "end_logit": -7.96875,
            "text": "Aortitis is the inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -1.42578125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_2": [
        {
            "start_logit": 9.4375,
            "end_logit": 11.921875,
            "text": "inflammation of the aorta",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.4375,
            "end_logit": 4.53125,
            "text": "inflammation of the aorta due",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": -5.10546875,
            "end_logit": 11.921875,
            "text": "aorta",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 11.921875,
            "text": "the inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 11.921875,
            "text": "of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 11.921875,
            "text": "Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 11.921875,
            "text": "the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 9.4375,
            "end_logit": -7.6640625,
            "text": "inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.921875,
            "text": ": Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.921875,
            "text": "PURPOSE OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.921875,
            "text": "OF REVIEW: Aortitis is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 11.921875,
            "text": "is the inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": 9.4375,
            "end_logit": -9.296875,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -5.10546875,
            "end_logit": 4.53125,
            "text": "aorta due",
            "probability": 0.0
        },
        {
            "start_logit": 9.4375,
            "end_logit": -10.5625,
            "text": "inflammation of",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 4.53125,
            "text": "the inflammation of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 4.53125,
            "text": "of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 4.53125,
            "text": "Aortitis is the inflammation of the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 4.53125,
            "text": "the aorta due",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 4.53125,
            "text": "due",
            "probability": 0.0
        }
    ],
    "60314c361cb411341a00012e_3": [
        {
            "start_logit": 11.4609375,
            "end_logit": 12.515625,
            "text": "inflammation of the aorta",
            "probability": 0.60009765625
        },
        {
            "start_logit": 11.4609375,
            "end_logit": 12.1015625,
            "text": "inflammation of the aorta.",
            "probability": 0.399658203125
        },
        {
            "start_logit": 1.544921875,
            "end_logit": 12.515625,
            "text": "Aortitis is the all-encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 2.9921531677246094e-05
        },
        {
            "start_logit": 1.544921875,
            "end_logit": 12.1015625,
            "text": "Aortitis is the all-encompassing pathological term ascribed to inflammation of the aorta.",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": -3.310546875,
            "end_logit": 12.515625,
            "text": "aorta",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.310546875,
            "end_logit": 12.1015625,
            "text": "aorta.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.4921875,
            "end_logit": 12.1015625,
            "text": ".",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 12.515625,
            "text": "to inflammation of the aorta",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 12.1015625,
            "text": "to inflammation of the aorta.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -6.05859375,
            "text": "inflammation",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 12.515625,
            "text": "of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 12.1015625,
            "text": "of the aorta.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -7.1796875,
            "text": "inflammation of the",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 12.515625,
            "text": "encompassing pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 12.515625,
            "text": "ascribed to inflammation of the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 12.1015625,
            "text": "encompassing pathological term ascribed to inflammation of the aorta.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.515625,
            "text": "the aorta",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 12.1015625,
            "text": "ascribed to inflammation of the aorta.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.1015625,
            "text": "the aorta.",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 12.515625,
            "text": "pathological term ascribed to inflammation of the aorta",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_1": [
        {
            "start_logit": 13.3671875,
            "end_logit": 13.8203125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -2.611328125,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.25,
            "end_logit": 13.8203125,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -7.28125,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.40625,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.4375,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.765625,
            "text": "INCA: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.8359375,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.9296875,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.0546875,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.0703125,
            "text": "INCA: synonymous",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.1171875,
            "text": "INCA: synonymous codon",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -7.28125,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.40625,
            "text": "A:",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.4375,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.765625,
            "text": "A: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.8359375,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.9296875,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -10.0546875,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -10.0703125,
            "text": "A: synonymous",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_2": [
        {
            "start_logit": 12.421875,
            "end_logit": 13.5,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": 13.5,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.421875,
            "end_logit": -3.568359375,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.421875,
            "end_logit": -7.0390625,
            "text": "INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 13.5,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 13.5,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.5,
            "text": "Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.7109375,
            "text": "INCA) provides",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.9609375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.984375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -7.0390625,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -3.568359375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -3.568359375,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -3.568359375,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -9.7109375,
            "text": "A) provides",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -9.9609375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -9.984375,
            "text": "A) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -7.0390625,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -7.0390625,
            "text": "(INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -7.0390625,
            "text": "Codon usage Analysis (INCA)",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_3": [
        {
            "start_logit": 3.103515625,
            "end_logit": 7.98828125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -4.8125,
            "end_logit": 7.98828125,
            "text": "(INCA",
            "probability": 0.00036406517028808594
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.98828125,
            "text": "A",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 7.98828125,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INCA",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -4.453125,
            "text": "INCA)",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 7.98828125,
            "text": ": INteractive Codon usage Analysis (INCA",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 7.98828125,
            "text": "Codon usage Analysis (INCA",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 7.98828125,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -7.125,
            "text": "INC",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -7.625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -8.6953125,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -9.3984375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -9.90625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole",
            "probability": 0.0
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -10.0859375,
            "text": "INCA) provides an array",
            "probability": 0.0
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -10.09375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 3.103515625,
            "end_logit": -10.2421875,
            "text": "INCA) provides an array of",
            "probability": 0.0
        },
        {
            "start_logit": -4.8125,
            "end_logit": -4.453125,
            "text": "(INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -4.8125,
            "end_logit": -6.109375,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -4.453125,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -4.8125,
            "end_logit": -7.125,
            "text": "(INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_4": [
        {
            "start_logit": 12.0,
            "end_logit": 12.859375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -4.1328125,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.046875,
            "end_logit": 12.859375,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.0,
            "end_logit": -7.71484375,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.546875,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.78125,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.8046875,
            "text": "INCA: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -9.9453125,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -10.0,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -10.0390625,
            "text": "INCA: synonymous",
            "probability": 0.0
        },
        {
            "start_logit": 12.0,
            "end_logit": -10.0859375,
            "text": "INCA: synonymous codon",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -7.71484375,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -9.546875,
            "text": "A:",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -9.78125,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -9.8046875,
            "text": "A: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -9.9453125,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -10.0,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -10.0390625,
            "text": "A: synonymous",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -10.0859375,
            "text": "A: synonymous codon",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -7.71484375,
            "text": "organizing map",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_5": [
        {
            "start_logit": 3.8828125,
            "end_logit": 8.0625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 8.0625,
            "text": "A",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 8.0625,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -9.0,
            "end_logit": 8.0625,
            "text": "(INCA",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 8.0625,
            "text": "Codon usage Analysis (INCA",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -6.37109375,
            "text": "INC",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -6.7109375,
            "text": "INCA)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -7.7890625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -8.3359375,
            "text": "INCA) provides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -9.828125,
            "text": "INCA) provides an array",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -9.90625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -10.0625,
            "text": "INCA) provides an array of",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -10.0703125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -10.0859375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -10.1171875,
            "text": "INCA) provides an array of features useful in",
            "probability": 0.0
        },
        {
            "start_logit": 3.8828125,
            "end_logit": -10.1875,
            "text": "INCA) provides an",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -6.0234375,
            "text": "INteractive Codon usage Analysis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -6.37109375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -6.89453125,
            "end_logit": -6.7109375,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -6.7109375,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_6": [
        {
            "start_logit": 8.0234375,
            "end_logit": 10.296875,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -5.265625,
            "end_logit": 10.296875,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 10.296875,
            "text": "A",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 10.296875,
            "text": "(INCA",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -5.515625,
            "text": "INC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -5.61328125,
            "text": "INCA)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -5.7734375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.09375,
            "end_logit": 10.296875,
            "text": "Codon usage Analysis (INCA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -8.6484375,
            "text": "INCA) provides",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -9.3828125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -9.8046875,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -9.9609375,
            "text": "INCA) provides an array",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -10.0078125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -10.015625,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -10.1171875,
            "text": "INCA) provides an array of",
            "probability": 0.0
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -10.1171875,
            "text": "INCA) provides an array of features useful in",
            "probability": 0.0
        },
        {
            "start_logit": -5.265625,
            "end_logit": -3.845703125,
            "text": "INteractive Codon usage Analysis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": -3.845703125,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -5.265625,
            "end_logit": -5.515625,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -5.265625,
            "end_logit": -5.61328125,
            "text": "INteractive Codon usage Analysis (INCA)",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_7": [
        {
            "start_logit": 13.1015625,
            "end_logit": 14.1484375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -3.697265625,
            "end_logit": 14.1484375,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -2.86328125,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -7.5390625,
            "text": "INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.1484375,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.1484375,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.1484375,
            "text": ": INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.1484375,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -9.8828125,
            "text": "INCA) provides",
            "probability": 0.0
        },
        {
            "start_logit": -3.697265625,
            "end_logit": -7.5390625,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -5.4296875,
            "end_logit": -6.640625,
            "text": "Win32",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -2.86328125,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -2.86328125,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -2.86328125,
            "text": ": INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -2.86328125,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -3.697265625,
            "end_logit": -9.8828125,
            "text": "A) provides",
            "probability": 0.0
        },
        {
            "start_logit": -5.4296875,
            "end_logit": -8.1875,
            "text": "Win32 platform",
            "probability": 0.0
        },
        {
            "start_logit": -5.4296875,
            "end_logit": -9.1484375,
            "text": "Win",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -6.5625,
            "text": "effective Nc",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -6.640625,
            "text": "the Win32",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_8": [
        {
            "start_logit": 12.2265625,
            "end_logit": 13.109375,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -3.84375,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.78125,
            "end_logit": 13.109375,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -6.296875,
            "text": "INCA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 13.109375,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": 13.109375,
            "text": "(INCA",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 13.109375,
            "text": ": INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -9.40625,
            "text": "INCA) provides",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 13.109375,
            "text": "Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 13.109375,
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.0
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -9.8203125,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage",
            "probability": 0.0
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -9.9375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.",
            "probability": 0.0
        },
        {
            "start_logit": 12.2265625,
            "end_logit": -10.109375,
            "text": "INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition",
            "probability": 0.0
        },
        {
            "start_logit": -4.78125,
            "end_logit": -6.296875,
            "text": "A)",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -3.84375,
            "text": "UNLABELLED: INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -9.640625,
            "end_logit": -3.84375,
            "text": "(INC",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": -3.84375,
            "text": ": INteractive Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -4.78125,
            "end_logit": -9.40625,
            "text": "A) provides",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -3.84375,
            "text": "Codon usage Analysis (INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -3.84375,
            "text": "INteractive Codon usage Analysis (INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_9": [
        {
            "start_logit": 14.0,
            "end_logit": 14.5,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -1.705078125,
            "text": "INC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.486328125,
            "end_logit": 14.5,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 14.5,
            "text": "effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 14.5,
            "text": "of INCA",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.5,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.7578125,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.8984375,
            "text": "INCA has",
            "probability": 0.0
        },
        {
            "start_logit": 14.0,
            "end_logit": -9.9765625,
            "text": "INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.5,
            "text": "the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.5,
            "text": ", effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.5,
            "text": "strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.5,
            "text": "'codon bias', effective Nc and CAI, the primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.5,
            "text": "primary strength of INCA",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -1.705078125,
            "text": "effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -1.705078125,
            "text": "of INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -1.705078125,
            "text": "the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -1.705078125,
            "text": ", effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -1.705078125,
            "text": "strength of INC",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -1.705078125,
            "text": "'codon bias', effective Nc and CAI, the primary strength of INC",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_10": [
        {
            "start_logit": 13.4921875,
            "end_logit": 14.40625,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 14.40625,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -2.7265625,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.609375,
            "end_logit": 14.40625,
            "text": ", INCA",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -8.828125,
            "text": "INCA includes",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.5703125,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.59375,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.609375,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map,",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.7109375,
            "text": "INCA includes a specific unsupervised neural network algorithm",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.796875,
            "text": "INCA includes a",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.8359375,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.90625,
            "text": "INCA includes a specific",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.921875,
            "text": "INCA includes a specific unsupervised neural network algorithm, the self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": -2.7265625,
            "text": ", INC",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -8.828125,
            "text": "A includes",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -9.5703125,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -9.59375,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -9.609375,
            "text": "A includes a specific unsupervised neural network algorithm, the self-organizing map,",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -9.7109375,
            "text": "A includes a specific unsupervised neural network algorithm",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": -9.796875,
            "text": "A includes a",
            "probability": 0.0
        }
    ],
    "5891c90949702f2e01000001_11": [
        {
            "start_logit": 13.3671875,
            "end_logit": 13.8203125,
            "text": "INCA",
            "probability": 1.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -2.611328125,
            "text": "INC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.25,
            "end_logit": 13.8203125,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -7.28125,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.40625,
            "text": "INCA:",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.4375,
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.765625,
            "text": "INCA: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.8359375,
            "text": "INCA: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.9296875,
            "text": "INCA: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.0546875,
            "text": "INCA: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.0703125,
            "text": "INCA: synonymous",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.1171875,
            "text": "INCA: synonymous codon",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -7.28125,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.40625,
            "text": "A:",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.4375,
            "text": "A: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.765625,
            "text": "A: synonymous codon usage",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.8359375,
            "text": "A: synonymous codon usage analysis and clustering",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -9.9296875,
            "text": "A: synonymous codon usage analysis and clustering by means",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -10.0546875,
            "text": "A: synonymous codon usage analysis",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": -10.0703125,
            "text": "A: synonymous",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_1": [
        {
            "start_logit": -3.875,
            "end_logit": -4.57421875,
            "text": "NSAIDs",
            "probability": 0.7607421875
        },
        {
            "start_logit": -6.671875,
            "end_logit": -3.259765625,
            "text": "acetaminophen",
            "probability": 0.1737060546875
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -3.259765625,
            "text": "use substitutes such as acetaminophen",
            "probability": 0.0115509033203125
        },
        {
            "start_logit": -9.5234375,
            "end_logit": -3.259765625,
            "text": "recommended to use substitutes such as acetaminophen",
            "probability": 0.01003265380859375
        },
        {
            "start_logit": -3.875,
            "end_logit": -9.21875,
            "text": "NSAIDs have been effective in treating respiratory infections",
            "probability": 0.007343292236328125
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -3.259765625,
            "text": "to use substitutes such as acetaminophen",
            "probability": 0.00452423095703125
        },
        {
            "start_logit": -3.875,
            "end_logit": -9.7421875,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhin",
            "probability": 0.0043487548828125
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -3.259765625,
            "text": "as acetaminophen",
            "probability": 0.003635406494140625
        },
        {
            "start_logit": -3.875,
            "end_logit": -10.0,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COV",
            "probability": 0.003360748291015625
        },
        {
            "start_logit": -3.875,
            "end_logit": -10.0,
            "text": "NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus",
            "probability": 0.003360748291015625
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -3.259765625,
            "text": "substitutes such as acetaminophen",
            "probability": 0.0033092498779296875
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -3.259765625,
            "text": "it is recommended to use substitutes such as acetaminophen",
            "probability": 0.00296783447265625
        },
        {
            "start_logit": -10.8125,
            "end_logit": -3.259765625,
            "text": "is recommended to use substitutes such as acetaminophen",
            "probability": 0.002765655517578125
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -3.259765625,
            "text": "clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen",
            "probability": 0.0027446746826171875
        },
        {
            "start_logit": -10.828125,
            "end_logit": -3.259765625,
            "text": "such as acetaminophen",
            "probability": 0.0027217864990234375
        },
        {
            "start_logit": -10.609375,
            "end_logit": -4.57421875,
            "text": "existing evidence, NSAIDs",
            "probability": 0.0009045600891113281
        },
        {
            "start_logit": -6.671875,
            "end_logit": -8.828125,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs",
            "probability": 0.0006618499755859375
        },
        {
            "start_logit": -6.671875,
            "end_logit": -9.296875,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management",
            "probability": 0.0004143714904785156
        },
        {
            "start_logit": -6.671875,
            "end_logit": -9.8671875,
            "text": "acetaminophen for controlling fever and inflammation and be cautious",
            "probability": 0.00023603439331054688
        },
        {
            "start_logit": -6.671875,
            "end_logit": -9.9609375,
            "text": "acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COV",
            "probability": 0.0002149343490600586
        }
    ],
    "6277e4ee56bf9aee6f000008_2": [
        {
            "start_logit": -3.1171875,
            "end_logit": -5.796875,
            "text": "pain",
            "probability": 0.84814453125
        },
        {
            "start_logit": -3.1171875,
            "end_logit": -8.6953125,
            "text": "pain management",
            "probability": 0.0467529296875
        },
        {
            "start_logit": -3.1171875,
            "end_logit": -8.7109375,
            "text": "pain management in children with COVID-19.",
            "probability": 0.0460205078125
        },
        {
            "start_logit": -3.1171875,
            "end_logit": -10.1328125,
            "text": "pain management in children",
            "probability": 0.0111083984375
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -3.509765625,
            "text": "per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.00594329833984375
        },
        {
            "start_logit": -10.515625,
            "end_logit": -3.509765625,
            "text": "and ibuprofen",
            "probability": 0.005123138427734375
        },
        {
            "start_logit": -10.546875,
            "end_logit": -3.509765625,
            "text": "strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.00496673583984375
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -3.509765625,
            "text": "acetaminophen and ibuprofen",
            "probability": 0.004627227783203125
        },
        {
            "start_logit": -10.625,
            "end_logit": -3.509765625,
            "text": ", spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.0045928955078125
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -3.509765625,
            "text": "-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.00428009033203125
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -3.509765625,
            "text": ", NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.004150390625
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -3.509765625,
            "text": "current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.004024505615234375
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -3.509765625,
            "text": "the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.003719329833984375
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -3.509765625,
            "text": "pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen",
            "probability": 0.0036640167236328125
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -5.796875,
            "text": "per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0006070137023925781
        },
        {
            "start_logit": -10.515625,
            "end_logit": -5.796875,
            "text": "and ibuprofen can be safely administered for pain",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": -10.546875,
            "end_logit": -5.796875,
            "text": "strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0005030632019042969
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -5.796875,
            "text": "acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0004730224609375
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -5.796875,
            "text": "for pain",
            "probability": 0.00044417381286621094
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -5.796875,
            "text": "-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain",
            "probability": 0.0004303455352783203
        }
    ],
    "6277e4ee56bf9aee6f000008_3": [
        {
            "start_logit": -5.32421875,
            "end_logit": -2.64453125,
            "text": "NSAIDs",
            "probability": 0.446044921875
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -3.923828125,
            "text": "NSAIDs",
            "probability": 0.39990234375
        },
        {
            "start_logit": -5.32421875,
            "end_logit": -3.923828125,
            "text": "NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.123779296875
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -2.64453125,
            "text": "to NSAIDs",
            "probability": 0.007099151611328125
        },
        {
            "start_logit": -9.671875,
            "end_logit": -2.64453125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.00579071044921875
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -2.64453125,
            "text": "(acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.0023403167724609375
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -2.64453125,
            "text": "acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.0022335052490234375
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -2.64453125,
            "text": "alternative to NSAIDs",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -3.923828125,
            "text": "to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0019855499267578125
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -9.53125,
            "text": "NSAIDs should",
            "probability": 0.00146484375
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -9.6640625,
            "text": "NSAIDs should not be used",
            "probability": 0.0012922286987304688
        },
        {
            "start_logit": -10.234375,
            "end_logit": -3.923828125,
            "text": "high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0009160041809082031
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -3.923828125,
            "text": "liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0007424354553222656
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -3.923828125,
            "text": "issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0007190704345703125
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -10.3046875,
            "text": "NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh",
            "probability": 0.0006809234619140625
        },
        {
            "start_logit": -4.15234375,
            "end_logit": -10.3203125,
            "text": "NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all",
            "probability": 0.0006704330444335938
        },
        {
            "start_logit": -10.609375,
            "end_logit": -3.923828125,
            "text": "with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0006299018859863281
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -3.923828125,
            "text": "COVID-19 cases where NSAIDs",
            "probability": 0.0005965232849121094
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -3.923828125,
            "text": "at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0005869865417480469
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -3.923828125,
            "text": "alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs",
            "probability": 0.0005779266357421875
        }
    ],
    "6277e4ee56bf9aee6f000008_4": [
        {
            "start_logit": 0.91259765625,
            "end_logit": 2.349609375,
            "text": "NSAIDs",
            "probability": 1.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 2.349609375,
            "text": "then NSAIDs",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.09375,
            "text": "NSAIDs can also be reliably",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -10.53125,
            "end_logit": 2.349609375,
            "text": "in these patients, and then NSAIDs",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 2.349609375,
            "text": "first option in these patients, and then NSAIDs",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.1640625,
            "text": "NSAIDs can also",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -10.78125,
            "end_logit": 2.349609375,
            "text": "provide analgesia, paracetamol can be listed as the first option in these patients, and then NSAIDs",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -10.84375,
            "end_logit": 2.349609375,
            "text": "paracetamol can be listed as the first option in these patients, and then NSAIDs",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 2.349609375,
            "text": "the first option in these patients, and then NSAIDs",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.5078125,
            "text": "NSAIDs can also be reliably used for pain management",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.53125,
            "text": "NSAIDs can also be reliably used for pain",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -10.984375,
            "end_logit": 2.349609375,
            "text": "as the first option in these patients, and then NSAIDs",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -11.0,
            "end_logit": 2.349609375,
            "text": "listed as the first option in these patients, and then NSAIDs",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.6015625,
            "text": "NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure or gastric bleeding.",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.796875,
            "text": "NSAIDs can",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 0.91259765625,
            "end_logit": -9.8828125,
            "text": "NSAIDs can also be reliably used for pain management in",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": -9.2578125,
            "end_logit": -9.5078125,
            "text": "pain management",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": -9.53125,
            "text": "pain",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": -9.6015625,
            "text": "pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure or gastric bleeding.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": -9.8828125,
            "text": "pain management in",
            "probability": 0.0
        }
    ],
    "6277e4ee56bf9aee6f000008_5": [
        {
            "start_logit": -5.15625,
            "end_logit": 1.02734375,
            "text": "NSAIDs",
            "probability": 0.75
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 1.02734375,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.194091796875
        },
        {
            "start_logit": -8.0,
            "end_logit": 1.02734375,
            "text": "to NSAIDs",
            "probability": 0.043670654296875
        },
        {
            "start_logit": -10.515625,
            "end_logit": 1.02734375,
            "text": "alternative to NSAIDs",
            "probability": 0.0035419464111328125
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 1.02734375,
            "text": "(acetaminophen) has been proposed as an alternative to NSAIDs",
            "probability": 0.003276824951171875
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 1.02734375,
            "text": "been proposed as an alternative to NSAIDs",
            "probability": 0.002803802490234375
        },
        {
            "start_logit": -10.8125,
            "end_logit": 1.02734375,
            "text": "as an alternative to NSAIDs",
            "probability": 0.00263214111328125
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -6.6484375,
            "text": "Paracetamol",
            "probability": 8.976459503173828e-05
        },
        {
            "start_logit": -5.15625,
            "end_logit": -9.765625,
            "text": "NSAIDs but",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -5.15625,
            "end_logit": -10.28125,
            "text": "NSAIDs but there are issues with liver toxicity at high doses",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -9.765625,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -10.2265625,
            "text": "Paracetamol (acetaminophen) has been proposed",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -10.25,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -10.28125,
            "text": "Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -8.0,
            "end_logit": -9.765625,
            "text": "to NSAIDs but",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.25,
            "text": "to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.0,
            "end_logit": -10.28125,
            "text": "to NSAIDs but there are issues with liver toxicity at high doses",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": -9.765625,
            "text": "alternative to NSAIDs but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -9.765625,
            "text": "(acetaminophen) has been proposed as an alternative to NSAIDs but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.765625,
            "text": "been proposed as an alternative to NSAIDs but",
            "probability": 5.960464477539063e-08
        }
    ],
    "589a247078275d0c4a000035_1": [
        {
            "start_logit": 3.72265625,
            "end_logit": 9.3359375,
            "text": "neuroblastoma",
            "probability": 0.8759765625
        },
        {
            "start_logit": 1.775390625,
            "end_logit": 9.3359375,
            "text": "high-risk neuroblastoma",
            "probability": 0.124267578125
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 9.3359375,
            "text": "risk neuroblastoma",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": -9.09375,
            "end_logit": 9.3359375,
            "text": "-risk neuroblastoma",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -9.15625,
            "end_logit": 9.3359375,
            "text": "for high-risk neuroblastoma",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -10.015625,
            "end_logit": 9.3359375,
            "text": "post-consolidation therapy for high-risk neuroblastoma",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 9.3359375,
            "text": "ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.234375,
            "end_logit": 9.3359375,
            "text": "against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 9.3359375,
            "text": "disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 9.3359375,
            "text": "survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.4375,
            "end_logit": 9.3359375,
            "text": "monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.3359375,
            "text": "oganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.3359375,
            "text": "ialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.3359375,
            "text": "anglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.775390625,
            "end_logit": -7.96484375,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": 3.72265625,
            "end_logit": -10.046875,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": 1.775390625,
            "end_logit": -10.046875,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": 1.775390625,
            "end_logit": -10.125,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -7.96484375,
            "text": "; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high",
            "probability": 0.0
        },
        {
            "start_logit": -6.57421875,
            "end_logit": -10.046875,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_2": [
        {
            "start_logit": 9.21875,
            "end_logit": 12.78125,
            "text": "High-Risk Neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 1.3046875,
            "end_logit": 12.78125,
            "text": "Neuroblastoma",
            "probability": 0.0003654956817626953
        },
        {
            "start_logit": -5.7734375,
            "end_logit": 12.78125,
            "text": "Risk Neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 12.78125,
            "text": "in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -5.71875,
            "text": "High",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 12.78125,
            "text": "-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 12.78125,
            "text": "Dinutuximab: A Review in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.78125,
            "text": "utuximab: A Review in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 12.78125,
            "text": ": A Review in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 12.78125,
            "text": "A Review in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 12.78125,
            "text": "Review in High-Risk Neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -8.6171875,
            "text": "High-Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -9.3671875,
            "text": "High-Risk",
            "probability": 0.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -10.296875,
            "text": "High-",
            "probability": 0.0
        },
        {
            "start_logit": 1.3046875,
            "end_logit": -8.6171875,
            "text": "Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6171875,
            "end_logit": -5.71875,
            "text": "in High",
            "probability": 0.0
        },
        {
            "start_logit": -5.7734375,
            "end_logit": -8.6171875,
            "text": "Risk Neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -5.7734375,
            "end_logit": -9.3671875,
            "text": "Risk",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -5.71875,
            "text": "Dinutuximab: A Review in High",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -5.71875,
            "text": "utuximab: A Review in High",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_3": [
        {
            "start_logit": 7.2578125,
            "end_logit": 9.4296875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 9.4296875,
            "text": "antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.109375,
            "end_logit": 9.4296875,
            "text": "highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 9.4296875,
            "text": "expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 9.4296875,
            "text": "disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 9.4296875,
            "text": "on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 9.4296875,
            "text": "oganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 9.4296875,
            "text": "ialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -9.9375,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.1796875,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.1875,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.1953125,
            "text": "neuroblastoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.203125,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.2578125,
            "text": "neuroblastoma cells. This intravenous",
            "probability": 0.0
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -10.265625,
            "text": "neuroblastoma cells. This intravenous drug is approved in the EU and USA",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -7.4296875,
            "text": "high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": -7.4296875,
            "text": "treatment of patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -9.7421875,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.4609375,
            "end_logit": -9.8359375,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -7.4296875,
            "text": "with high-risk neuroblastoma",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_4": [
        {
            "start_logit": 5.140625,
            "end_logit": 9.7109375,
            "text": "neuroblastoma",
            "probability": 0.9853515625
        },
        {
            "start_logit": 0.9365234375,
            "end_logit": 9.7109375,
            "text": "high-risk neuroblastoma",
            "probability": 0.01473236083984375
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.7109375,
            "text": "risk neuroblastoma",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 9.7109375,
            "text": "-risk neuroblastoma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.890625,
            "end_logit": 9.7109375,
            "text": "with high-risk neuroblastoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 9.7109375,
            "text": "treatment of patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 9.7109375,
            "text": "isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.90625,
            "end_logit": 9.7109375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.140625,
            "end_logit": -10.140625,
            "text": "neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.",
            "probability": 0.0
        },
        {
            "start_logit": 5.140625,
            "end_logit": -10.1953125,
            "text": "neuroblastoma,",
            "probability": 0.0
        },
        {
            "start_logit": 0.9365234375,
            "end_logit": -8.0703125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": 0.9365234375,
            "end_logit": -10.140625,
            "text": "high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.",
            "probability": 0.0
        },
        {
            "start_logit": 0.9365234375,
            "end_logit": -10.1953125,
            "text": "high-risk neuroblastoma,",
            "probability": 0.0
        },
        {
            "start_logit": 0.9365234375,
            "end_logit": -10.25,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -10.140625,
            "text": "risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -10.1953125,
            "text": "risk neuroblastoma,",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -10.25,
            "text": "risk",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -8.0703125,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -8.0703125,
            "text": "treatment of patients with high",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -8.0703125,
            "text": "isotretinoin represents an important advance in the postconsolidation treatment of patients with high",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_5": [
        {
            "start_logit": 7.60546875,
            "end_logit": 10.4609375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": 10.4609375,
            "text": "high-risk neuroblastoma",
            "probability": 0.00020194053649902344
        },
        {
            "start_logit": -6.796875,
            "end_logit": 10.4609375,
            "text": "risk neuroblastoma",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.234375,
            "end_logit": 10.4609375,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.4609375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 10.4609375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 10.4609375,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 10.4609375,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 10.4609375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 10.4609375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 10.4609375,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.4609375,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.60546875,
            "end_logit": -9.0625,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -9.046875,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -9.0625,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -10.234375,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -9.0625,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -10.234375,
            "text": "risk",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -9.046875,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -9.0625,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_6": [
        {
            "start_logit": 0.86474609375,
            "end_logit": 7.01953125,
            "text": "high-risk neuroblastoma",
            "probability": 0.80419921875
        },
        {
            "start_logit": -0.552734375,
            "end_logit": 7.01953125,
            "text": "neuroblastoma",
            "probability": 0.195556640625
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.01953125,
            "text": "risk neuroblastoma",
            "probability": 0.0001913309097290039
        },
        {
            "start_logit": -8.96875,
            "end_logit": 7.01953125,
            "text": "-risk neuroblastoma",
            "probability": 4.3392181396484375e-05
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 7.01953125,
            "text": "with high-risk neuroblastoma",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -10.171875,
            "end_logit": 7.01953125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.3053417205810547e-05
        },
        {
            "start_logit": -10.34375,
            "end_logit": 7.01953125,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -10.5,
            "end_logit": 7.01953125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 7.01953125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": 0.86474609375,
            "end_logit": -9.15625,
            "text": "high",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.86474609375,
            "end_logit": -10.203125,
            "text": "high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.86474609375,
            "end_logit": -10.3359375,
            "text": "high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -0.552734375,
            "end_logit": -10.203125,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -0.552734375,
            "end_logit": -10.3359375,
            "text": "neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -10.203125,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -10.3359375,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -9.15625,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -10.203125,
            "text": "-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -10.3359375,
            "text": "-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -9.15625,
            "text": "of pediatric patients with high",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_7": [
        {
            "start_logit": 1.59765625,
            "end_logit": 5.84375,
            "text": "neuroblastoma",
            "probability": 0.9208984375
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": 5.84375,
            "text": "high-risk neuroblastoma",
            "probability": 0.07891845703125
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 5.84375,
            "text": "risk neuroblastoma",
            "probability": 4.965066909790039e-05
        },
        {
            "start_logit": -9.5,
            "end_logit": 5.84375,
            "text": "-risk neuroblastoma",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 5.84375,
            "text": "with high-risk neuroblastoma",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 5.84375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 5.84375,
            "text": "[RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -10.34375,
            "end_logit": 5.84375,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -10.421875,
            "end_logit": 5.84375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 5.84375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 5.84375,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -10.5625,
            "end_logit": 5.84375,
            "text": ", and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 1.59765625,
            "end_logit": -10.1796875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.59765625,
            "end_logit": -10.1953125,
            "text": "neuroblastoma who",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -9.28125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -10.1796875,
            "text": "high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -10.1953125,
            "text": "high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -8.1953125,
            "text": "[RA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -10.1796875,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -10.1953125,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_8": [
        {
            "start_logit": 2.056640625,
            "end_logit": 7.0,
            "text": "neuroblastoma",
            "probability": 0.994140625
        },
        {
            "start_logit": -3.052734375,
            "end_logit": 7.0,
            "text": "high-risk neuroblastoma",
            "probability": 0.00600433349609375
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.0,
            "text": "risk neuroblastoma",
            "probability": 6.121397018432617e-05
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 7.0,
            "text": "with high-risk neuroblastoma",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -9.671875,
            "end_logit": 7.0,
            "text": "-risk neuroblastoma",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 7.0,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -10.171875,
            "end_logit": 7.0,
            "text": "/b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 2.056640625,
            "end_logit": -10.234375,
            "text": "neuroblastoma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.056640625,
            "end_logit": -10.3515625,
            "text": "neuroblastoma.<br",
            "probability": 0.0
        },
        {
            "start_logit": -3.052734375,
            "end_logit": -10.1953125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -3.052734375,
            "end_logit": -10.234375,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -3.052734375,
            "end_logit": -10.3515625,
            "text": "high-risk neuroblastoma.<br",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -10.234375,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -10.3515625,
            "text": "risk neuroblastoma.<br",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.2890625,
            "text": "5 mg/m<br><b>CONCLUSION</b",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.296875,
            "text": "5 mg/m<br><b>CONCLUSION</b>",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.515625,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.53125,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.546875,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -10.6796875,
            "text": "5 mg/m<br><b>CONCLUSION</b>: Dinutuximab",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_9": [
        {
            "start_logit": 6.93359375,
            "end_logit": 9.7109375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": 9.7109375,
            "text": "high-risk neuroblastoma",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 9.7109375,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 9.7109375,
            "text": "pediatric high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 9.7109375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1875,
            "end_logit": 9.7109375,
            "text": "or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.296875,
            "end_logit": 9.7109375,
            "text": "of pediatric high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.7109375,
            "text": "therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 9.7109375,
            "text": "treatment of pediatric high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 9.7109375,
            "text": "dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 9.7109375,
            "text": "utuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 6.93359375,
            "end_logit": -9.859375,
            "text": "neuroblastoma and",
            "probability": 0.0
        },
        {
            "start_logit": 6.93359375,
            "end_logit": -9.890625,
            "text": "neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": 6.93359375,
            "end_logit": -10.4296875,
            "text": "neuroblastoma and is now considered part of standard of care",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -9.859375,
            "text": "high-risk neuroblastoma and",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -9.890625,
            "text": "high-risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -10.21875,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -10.4296875,
            "text": "high-risk neuroblastoma and is now considered part of standard of care",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -9.859375,
            "text": "risk neuroblastoma and",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -9.890625,
            "text": "risk neuroblastoma and is now considered part of standard of care in this patient population.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_10": [
        {
            "start_logit": 4.44921875,
            "end_logit": 8.078125,
            "text": "neuroblastoma",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.341796875,
            "end_logit": 8.078125,
            "text": "high-risk pediatric neuroblastoma",
            "probability": 0.0011167526245117188
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 8.078125,
            "text": "risk pediatric neuroblastoma",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 8.078125,
            "text": "pediatric neuroblastoma",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.078125,
            "end_logit": 8.078125,
            "text": "of high-risk pediatric neuroblastoma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.09375,
            "end_logit": 8.078125,
            "text": "treatment of high-risk pediatric neuroblastoma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 8.078125,
            "text": "-risk pediatric neuroblastoma",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -9.734375,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -9.828125,
            "text": "neuroblastoma are",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -10.109375,
            "text": "neuroblastoma are reviewed.<br",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -10.140625,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -10.1796875,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unitux",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -10.21875,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin",
            "probability": 0.0
        },
        {
            "start_logit": 4.44921875,
            "end_logit": -10.3046875,
            "text": "neuroblastoma are reviewed.<br><b>SUMMARY</b",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -9.734375,
            "text": "high-risk pediatric neuroblastoma are reviewed.<br><b>SUMMARY",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -9.828125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -9.828125,
            "text": "high-risk pediatric neuroblastoma are",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -10.109375,
            "text": "high-risk pediatric neuroblastoma are reviewed.<br",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -10.140625,
            "text": "high-risk pediatric neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": -2.341796875,
            "end_logit": -10.1796875,
            "text": "high-risk pediatric neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unitux",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_11": [
        {
            "start_logit": 3.970703125,
            "end_logit": 8.0703125,
            "text": "neuroblastoma",
            "probability": 0.9990234375
        },
        {
            "start_logit": -3.529296875,
            "end_logit": 8.0703125,
            "text": "high-risk neuroblastoma",
            "probability": 0.0005526542663574219
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 8.0703125,
            "text": "risk neuroblastoma",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 8.0703125,
            "text": "-risk neuroblastoma",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 8.0703125,
            "text": "with high-risk neuroblastoma",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 8.0703125,
            "text": "of paediatric patients with high-risk neuroblastoma",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -10.328125,
            "end_logit": 8.0703125,
            "text": "treatment of paediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.515625,
            "end_logit": 8.0703125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 3.970703125,
            "end_logit": -10.2578125,
            "text": "neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": 3.970703125,
            "end_logit": -10.5390625,
            "text": "neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -3.529296875,
            "end_logit": -10.2578125,
            "text": "high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": -3.529296875,
            "end_logit": -10.328125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -3.529296875,
            "end_logit": -10.5390625,
            "text": "high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -10.2578125,
            "text": "risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -10.5390625,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.2578125,
            "text": "-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.2578125,
            "text": "with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.328125,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": -10.2578125,
            "text": "of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.5390625,
            "text": "-risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_12": [
        {
            "start_logit": 9.90625,
            "end_logit": 11.265625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": 11.265625,
            "text": "high-risk neuroblastoma",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 11.265625,
            "text": "risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 11.265625,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 11.265625,
            "text": "of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 11.265625,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 11.265625,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 11.265625,
            "text": "-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 11.265625,
            "text": "approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.265625,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 11.265625,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.265625,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 11.265625,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.265625,
            "text": "US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -9.6328125,
            "text": "neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -9.6328125,
            "text": "high-risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -10.1640625,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -10.5,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -9.6328125,
            "text": "risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -10.5,
            "text": "risk",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_13": [
        {
            "start_logit": 7.83984375,
            "end_logit": 9.5078125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.5078125,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 9.5078125,
            "text": "of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 9.5078125,
            "text": "treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 9.5078125,
            "text": "ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 9.5078125,
            "text": "GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 9.5078125,
            "text": "monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 9.5078125,
            "text": "antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 9.5078125,
            "text": "targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.5078125,
            "text": "for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.5078125,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.5078125,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.83984375,
            "end_logit": -8.96875,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 9.5078125,
            "text": "dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.96875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -9.9296875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.1875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3046875,
            "text": "; ch14.18), a monoclonal antibody targeting GD",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3359375,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3828125,
            "text": "; ch14.18),",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_14": [
        {
            "start_logit": 7.14453125,
            "end_logit": 9.453125,
            "text": "neuroblastoma",
            "probability": 0.98828125
        },
        {
            "start_logit": 2.681640625,
            "end_logit": 9.453125,
            "text": "high-risk neuroblastoma",
            "probability": 0.01141357421875
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.453125,
            "text": "risk neuroblastoma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 9.453125,
            "text": "Immunotherapy of high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 9.453125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 9.453125,
            "text": ": Immunotherapy of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 9.453125,
            "text": "of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -9.359375,
            "text": "neuroblastoma using the anti-GD2",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -9.6015625,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -9.8046875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -9.875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -9.890625,
            "text": "neuroblastoma using",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.1015625,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADC",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.1796875,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.28125,
            "text": "neuroblastoma using the anti-GD2 antibody din",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.328125,
            "text": "neuroblastoma using the anti-GD",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.34375,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.3515625,
            "text": "neuroblastoma using the anti-GD2 antibody",
            "probability": 0.0
        },
        {
            "start_logit": 7.14453125,
            "end_logit": -10.4140625,
            "text": "neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC)",
            "probability": 0.0
        },
        {
            "start_logit": 2.681640625,
            "end_logit": -7.1875,
            "text": "high",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_15": [
        {
            "start_logit": 1.59765625,
            "end_logit": 5.84375,
            "text": "neuroblastoma",
            "probability": 0.9208984375
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": 5.84375,
            "text": "high-risk neuroblastoma",
            "probability": 0.07891845703125
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 5.84375,
            "text": "risk neuroblastoma",
            "probability": 4.965066909790039e-05
        },
        {
            "start_logit": -9.5,
            "end_logit": 5.84375,
            "text": "-risk neuroblastoma",
            "probability": 1.4007091522216797e-05
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 5.84375,
            "text": "with high-risk neuroblastoma",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 5.84375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 5.84375,
            "text": "[RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": -10.34375,
            "end_logit": 5.84375,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -10.421875,
            "end_logit": 5.84375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 5.84375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 5.84375,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -10.5625,
            "end_logit": 5.84375,
            "text": ", and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 1.59765625,
            "end_logit": -10.1796875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.59765625,
            "end_logit": -10.1953125,
            "text": "neuroblastoma who",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -9.28125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -10.1796875,
            "text": "high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -0.8583984375,
            "end_logit": -10.1953125,
            "text": "high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -8.1953125,
            "text": "[RA",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -10.1796875,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -10.1953125,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_16": [
        {
            "start_logit": 4.9453125,
            "end_logit": 7.7109375,
            "text": "neuroblastoma",
            "probability": 0.9990234375
        },
        {
            "start_logit": -2.677734375,
            "end_logit": 7.7109375,
            "text": "high-risk neuroblastoma",
            "probability": 0.0004875659942626953
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 7.7109375,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 7.7109375,
            "text": "-risk neuroblastoma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.1875,
            "end_logit": 7.7109375,
            "text": "with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.328125,
            "end_logit": 7.7109375,
            "text": "maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 7.7109375,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.4375,
            "end_logit": 7.7109375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.484375,
            "end_logit": 7.7109375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.53125,
            "end_logit": 7.7109375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 7.7109375,
            "text": "approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.9453125,
            "end_logit": -10.1953125,
            "text": "neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": 4.9453125,
            "end_logit": -10.21875,
            "text": "neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -2.677734375,
            "end_logit": -9.7265625,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -2.677734375,
            "end_logit": -10.1953125,
            "text": "high-risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -2.677734375,
            "end_logit": -10.21875,
            "text": "high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -10.1953125,
            "text": "risk neuroblastoma who",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -10.21875,
            "text": "risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -10.0859375,
            "text": "CONCLUSIONS Dinutuximab is the first anti-GD2",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -10.1640625,
            "text": "CONCLUSIONS Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_17": [
        {
            "start_logit": 7.83984375,
            "end_logit": 9.5078125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.5078125,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 9.5078125,
            "text": "of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 9.5078125,
            "text": "treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 9.5078125,
            "text": "ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 9.5078125,
            "text": "GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 9.5078125,
            "text": "monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 9.5078125,
            "text": "antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 9.5078125,
            "text": "targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.5078125,
            "text": "for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 9.5078125,
            "text": "Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.5078125,
            "text": "developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.83984375,
            "end_logit": -8.96875,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 9.5078125,
            "text": "dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -8.96875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -9.9296875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.1875,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3046875,
            "text": "; ch14.18), a monoclonal antibody targeting GD",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3359375,
            "text": "; ch14.18), a monoclonal antibody targeting GD2, for",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -10.3828125,
            "text": "; ch14.18),",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_18": [
        {
            "start_logit": 2.421875,
            "end_logit": 6.45703125,
            "text": "neuroblastoma",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.8515625,
            "end_logit": 6.45703125,
            "text": "high-risk neuroblastoma",
            "probability": 0.0018892288208007812
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 6.45703125,
            "text": "risk neuroblastoma",
            "probability": 3.612041473388672e-05
        },
        {
            "start_logit": -9.4375,
            "end_logit": 6.45703125,
            "text": "-risk neuroblastoma",
            "probability": 7.092952728271484e-06
        },
        {
            "start_logit": -9.53125,
            "end_logit": 6.45703125,
            "text": "with high-risk neuroblastoma",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -10.125,
            "end_logit": 6.45703125,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -10.125,
            "end_logit": 6.45703125,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -10.265625,
            "end_logit": 6.45703125,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": 6.45703125,
            "text": "patients with high-risk neuroblastoma",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 6.45703125,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 2.421875,
            "end_logit": -9.640625,
            "text": "neuroblastoma.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.8515625,
            "end_logit": -9.640625,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -3.8515625,
            "end_logit": -10.078125,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -9.640625,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -9.640625,
            "text": "-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.640625,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -10.078125,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -9.640625,
            "text": "treatment of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -9.640625,
            "text": "of pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -9.640625,
            "text": "pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_19": [
        {
            "start_logit": 7.328125,
            "end_logit": 10.0390625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": 10.0390625,
            "text": "high-risk neuroblastoma",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 10.0390625,
            "text": "risk neuroblastoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 10.0390625,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 10.0390625,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.890625,
            "end_logit": 10.0390625,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 10.0390625,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 10.0390625,
            "text": "CONCLUSION Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 10.0390625,
            "text": "novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.0390625,
            "text": "utuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.0390625,
            "text": "patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.0390625,
            "text": "in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 10.0390625,
            "text": "combination immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 10.0390625,
            "text": "immunotherapy in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.328125,
            "end_logit": -9.359375,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": -9.359375,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -4.07421875,
            "end_logit": -10.359375,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -9.359375,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -9.359375,
            "text": "Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": -9.359375,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_20": [
        {
            "start_logit": 5.71875,
            "end_logit": 8.1875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": 8.1875,
            "text": "high-risk neuroblastoma",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -8.484375,
            "end_logit": 8.1875,
            "text": "risk neuroblastoma",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 8.1875,
            "text": "with high-risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 8.1875,
            "text": "-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.15625,
            "end_logit": 8.1875,
            "text": "disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 8.1875,
            "text": "anglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 8.1875,
            "text": "monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5,
            "end_logit": 8.1875,
            "text": "oganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 8.1875,
            "text": "ialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 8.1875,
            "text": "patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.640625,
            "end_logit": 8.1875,
            "text": "improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.65625,
            "end_logit": 8.1875,
            "text": "antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.71875,
            "end_logit": -9.390625,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3984375,
            "end_logit": -9.390625,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": -9.390625,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -9.8984375,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -10.203125,
            "text": "called ch14.18), a",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -10.21875,
            "text": "called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2,",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": -10.25,
            "text": "called ch14.18)",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_21": [
        {
            "start_logit": 7.1875,
            "end_logit": 9.4921875,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 7.1875,
            "end_logit": -7.1171875,
            "text": "neuroblastoma cells.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 9.4921875,
            "text": "antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 9.4921875,
            "text": "disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.296875,
            "end_logit": 9.4921875,
            "text": "oganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 9.4921875,
            "text": "ialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 9.4921875,
            "text": "highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.4921875,
            "text": "anglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.4921875,
            "text": "expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 9.4921875,
            "text": "of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 9.4921875,
            "text": "the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.1875,
            "end_logit": -9.6875,
            "text": "neuroblastoma cells",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -8.828125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -9.7578125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside,",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.0234375,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.0859375,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.328125,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.328125,
            "text": "; Unituxin",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.3359375,
            "text": "; Unituxin\u2122) is",
            "probability": 0.0
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -10.390625,
            "text": "; Unituxin\u2122) is a chimeric human-mouse monoclonal",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_22": [
        {
            "start_logit": 9.90625,
            "end_logit": 11.265625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": 11.265625,
            "text": "high-risk neuroblastoma",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 11.265625,
            "text": "risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 11.265625,
            "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 11.265625,
            "text": "of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 11.265625,
            "text": "treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 11.265625,
            "text": "FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 11.265625,
            "text": "-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 11.265625,
            "text": "approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.265625,
            "text": "dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 11.265625,
            "text": "the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 11.265625,
            "text": "use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 11.265625,
            "text": "recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.265625,
            "text": "US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.90625,
            "end_logit": -9.6328125,
            "text": "neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -9.6328125,
            "text": "high-risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -10.1640625,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": -10.5,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -9.6328125,
            "text": "risk neuroblastoma in paediatric patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -10.5,
            "text": "risk",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_23": [
        {
            "start_logit": 7.60546875,
            "end_logit": 10.4609375,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": 10.4609375,
            "text": "high-risk neuroblastoma",
            "probability": 0.00020194053649902344
        },
        {
            "start_logit": -6.796875,
            "end_logit": 10.4609375,
            "text": "risk neuroblastoma",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.234375,
            "end_logit": 10.4609375,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.4609375,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 10.4609375,
            "text": "treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 10.4609375,
            "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 10.4609375,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 10.4609375,
            "text": "patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 10.4609375,
            "text": "of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 10.4609375,
            "text": "utuximab for the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 10.4609375,
            "text": "the treatment of pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.60546875,
            "end_logit": -9.0625,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -9.046875,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -9.0625,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": -10.234375,
            "text": "high-risk",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -9.0625,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -6.796875,
            "end_logit": -10.234375,
            "text": "risk",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -9.046875,
            "text": "with high",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -9.0625,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_24": [
        {
            "start_logit": 9.9453125,
            "end_logit": 11.7890625,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 11.7890625,
            "text": "high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 11.7890625,
            "text": "risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 11.7890625,
            "text": "with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.7890625,
            "text": "pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.7890625,
            "text": "-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 11.7890625,
            "text": "Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.7890625,
            "text": "dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.7890625,
            "text": "patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.7890625,
            "text": "myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -10.3125,
            "text": "neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9453125,
            "end_logit": -10.453125,
            "text": "neuroblastoma: A case series",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": -10.3125,
            "text": "high-risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": -10.453125,
            "text": "high-risk neuroblastoma: A case series",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -10.3125,
            "text": "risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -10.453125,
            "text": "risk neuroblastoma: A case series",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -10.3125,
            "text": "with high-risk neuroblastoma: A case series.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -9.875,
            "text": "Transverse myelitis",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -10.453125,
            "text": "with high-risk neuroblastoma: A case series",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.875,
            "text": "myelitis",
            "probability": 0.0
        }
    ],
    "589a247078275d0c4a000035_25": [
        {
            "start_logit": 7.65625,
            "end_logit": 9.453125,
            "text": "neuroblastoma",
            "probability": 1.0
        },
        {
            "start_logit": -3.451171875,
            "end_logit": 9.453125,
            "text": "high-risk neuroblastoma",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 9.453125,
            "text": "risk neuroblastoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.53125,
            "end_logit": 9.453125,
            "text": "with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 9.453125,
            "text": "treatment of children with high-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.671875,
            "end_logit": 9.453125,
            "text": "-risk neuroblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 9.453125,
            "text": "approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 9.453125,
            "text": "children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 9.453125,
            "text": "dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 9.453125,
            "text": "of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 9.453125,
            "text": "phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 9.453125,
            "text": "the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 9.453125,
            "text": "the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 9.453125,
            "text": "ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma",
            "probability": 0.0
        },
        {
            "start_logit": 7.65625,
            "end_logit": -9.6875,
            "text": "neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -3.451171875,
            "end_logit": -9.6875,
            "text": "high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -3.451171875,
            "end_logit": -10.2890625,
            "text": "high",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -9.6875,
            "text": "risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.6875,
            "text": "with high-risk neuroblastoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -9.6875,
            "text": "treatment of children with high-risk neuroblastoma.",
            "probability": 0.0
        }
    ],
    "5c8cd26a0101eac870000003_1": [
        {
            "start_logit": -2.052734375,
            "end_logit": 10.1015625,
            "text": "secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.76708984375
        },
        {
            "start_logit": -3.46875,
            "end_logit": 10.1015625,
            "text": "protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.1865234375
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 10.1015625,
            "text": ".",
            "probability": 0.042449951171875
        },
        {
            "start_logit": -2.052734375,
            "end_logit": 3.232421875,
            "text": "secreted protein content",
            "probability": 0.0007987022399902344
        },
        {
            "start_logit": -9.171875,
            "end_logit": 10.1015625,
            "text": "enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.0006222724914550781
        },
        {
            "start_logit": -9.734375,
            "end_logit": 10.1015625,
            "text": "many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00035452842712402344
        },
        {
            "start_logit": -9.78125,
            "end_logit": 10.1015625,
            "text": "regulated by VdSec22 or VdSso1.",
            "probability": 0.0003383159637451172
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 10.1015625,
            "text": "exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.0003254413604736328
        },
        {
            "start_logit": -10.15625,
            "end_logit": 10.1015625,
            "text": "carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00023245811462402344
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 10.1015625,
            "text": "content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00022351741790771484
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 10.1015625,
            "text": "involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00020682811737060547
        },
        {
            "start_logit": -3.46875,
            "end_logit": 3.232421875,
            "text": "protein content",
            "probability": 0.00019419193267822266
        },
        {
            "start_logit": -10.34375,
            "end_logit": 10.1015625,
            "text": "the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by VdSec22 or VdSso1.",
            "probability": 0.00019276142120361328
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 10.1015625,
            "text": "VdSso1.",
            "probability": 0.00014662742614746094
        },
        {
            "start_logit": -2.052734375,
            "end_logit": 0.58203125,
            "text": "secreted protein content (exoproteome) revealed",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 3.232421875,
            "text": "Comparative analyses of the secreted protein content",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -3.46875,
            "end_logit": 0.58203125,
            "text": "protein content (exoproteome) revealed",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 0.58203125,
            "text": "Comparative analyses of the secreted protein content (exoproteome) revealed",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 3.232421875,
            "text": "content",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.34375,
            "end_logit": 3.232421875,
            "text": "the secreted protein content",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5cb0e4a6ecadf2e73f00005b_1": [
        {
            "start_logit": -2.09375,
            "end_logit": -2.662109375,
            "text": "surfaceome",
            "probability": 0.63818359375
        },
        {
            "start_logit": -2.09375,
            "end_logit": -3.466796875,
            "text": "surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.",
            "probability": 0.28564453125
        },
        {
            "start_logit": -2.09375,
            "end_logit": -6.06640625,
            "text": "surfaceome, we developed the surfaceome predictor SURFY,",
            "probability": 0.021331787109375
        },
        {
            "start_logit": -5.49609375,
            "end_logit": -2.662109375,
            "text": "human surfaceome",
            "probability": 0.021331787109375
        },
        {
            "start_logit": -2.09375,
            "end_logit": -6.8515625,
            "text": "surfaceome,",
            "probability": 0.0096893310546875
        },
        {
            "start_logit": -5.49609375,
            "end_logit": -3.466796875,
            "text": "human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.",
            "probability": 0.00954437255859375
        },
        {
            "start_logit": -7.640625,
            "end_logit": -2.662109375,
            "text": "the human surfaceome",
            "probability": 0.002490997314453125
        },
        {
            "start_logit": -6.8671875,
            "end_logit": -3.466796875,
            "text": "surfaceome predictor SURFY, based on machine learning.",
            "probability": 0.0024127960205078125
        },
        {
            "start_logit": -2.09375,
            "end_logit": -8.3671875,
            "text": "surfaceome, we developed the surfaceome",
            "probability": 0.0021305084228515625
        },
        {
            "start_logit": -7.640625,
            "end_logit": -3.466796875,
            "text": "the human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.",
            "probability": 0.0011138916015625
        },
        {
            "start_logit": -2.09375,
            "end_logit": -9.125,
            "text": "surfaceome, we",
            "probability": 0.0009975433349609375
        },
        {
            "start_logit": -8.703125,
            "end_logit": -2.662109375,
            "text": "o enable analysis of the human surfaceome",
            "probability": 0.0008602142333984375
        },
        {
            "start_logit": -2.09375,
            "end_logit": -9.296875,
            "text": "surfaceome, we developed the surfaceome predictor",
            "probability": 0.0008401870727539062
        },
        {
            "start_logit": -5.49609375,
            "end_logit": -6.06640625,
            "text": "human surfaceome, we developed the surfaceome predictor SURFY,",
            "probability": 0.0007076263427734375
        },
        {
            "start_logit": -2.09375,
            "end_logit": -9.703125,
            "text": "surfaceome, we developed the surfaceome predictor SURFY",
            "probability": 0.0005598068237304688
        },
        {
            "start_logit": -9.21875,
            "end_logit": -2.662109375,
            "text": "analysis of the human surfaceome",
            "probability": 0.0005140304565429688
        },
        {
            "start_logit": -2.09375,
            "end_logit": -9.9453125,
            "text": "surface",
            "probability": 0.00043964385986328125
        },
        {
            "start_logit": -2.09375,
            "end_logit": -10.046875,
            "text": "surfaceome, we developed the surfaceome predictor SURFY, based on machine learning",
            "probability": 0.00039696693420410156
        },
        {
            "start_logit": -8.703125,
            "end_logit": -3.466796875,
            "text": "o enable analysis of the human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.",
            "probability": 0.0003848075866699219
        },
        {
            "start_logit": -2.09375,
            "end_logit": -10.0859375,
            "text": "surfaceome, we developed the surfaceome predictor SURFY, based",
            "probability": 0.00038170814514160156
        }
    ],
    "550618f58e1671127b000007_1": [
        {
            "start_logit": 0.9853515625,
            "end_logit": 0.72607421875,
            "text": "(PPI-1)",
            "probability": 0.984375
        },
        {
            "start_logit": 0.9853515625,
            "end_logit": -3.646484375,
            "text": "(PPI-1",
            "probability": 0.01244354248046875
        },
        {
            "start_logit": 0.9853515625,
            "end_logit": -5.73046875,
            "text": "(PPI",
            "probability": 0.0015459060668945312
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 0.72607421875,
            "text": ", protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 0.0009670257568359375
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 0.72607421875,
            "text": "protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 8.684396743774414e-05
        },
        {
            "start_logit": 0.9853515625,
            "end_logit": -8.703125,
            "text": "(PPI-",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": 0.9853515625,
            "end_logit": -9.2890625,
            "text": "(",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": -9.328125,
            "end_logit": 0.72607421875,
            "text": "heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 0.72607421875,
            "text": "inhibitor-1 (PPI-1)",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -3.646484375,
            "text": ", protein phosphatase inhibitor-1 (PPI-1",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -10.515625,
            "end_logit": 0.72607421875,
            "text": "1 (PPI-1)",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 0.72607421875,
            "text": "-1 (PPI-1)",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 0.72607421875,
            "text": "its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 0.72607421875,
            "text": "endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -10.890625,
            "end_logit": 0.72607421875,
            "text": "inhibitor, protein phosphatase inhibitor-1 (PPI-1)",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -5.73046875,
            "text": ", protein phosphatase inhibitor-1 (PPI",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -3.646484375,
            "text": "protein phosphatase inhibitor-1 (PPI-1",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.94140625,
            "end_logit": -6.09375,
            "text": ", protein phosphatase inhibitor-1",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -9.328125,
            "end_logit": -3.646484375,
            "text": "heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -3.646484375,
            "text": "inhibitor-1 (PPI-1",
            "probability": 2.980232238769531e-07
        }
    ],
    "550618f58e1671127b000007_2": [
        {
            "start_logit": 13.6640625,
            "end_logit": 13.3046875,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": 4.09765625,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.00010073184967041016
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -3.671875,
            "text": "Inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.99609375,
            "end_logit": 13.3046875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -5.484375,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -6.56640625,
            "text": "Inhibitor 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -8.8046875,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -8.921875,
            "text": "Inhibitor 1 (I-1",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.640625,
            "text": "Inhibitor 1 (I",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.6953125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.7578125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.765625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 13.6640625,
            "end_logit": -9.765625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": 4.09765625,
            "text": "1 (I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -5.875,
            "end_logit": 4.09765625,
            "text": "(I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 4.09765625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 4.09765625,
            "text": "1)",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 4.09765625,
            "text": "I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 4.09765625,
            "text": "-1)",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.484375,
            "text": "1 (I-1) is",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_3": [
        {
            "start_logit": 11.203125,
            "end_logit": 12.1640625,
            "text": "inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -3.470703125,
            "text": "inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 12.1640625,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.203125,
            "end_logit": -5.79296875,
            "text": "inhibitor 1 is",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -6.20703125,
            "text": "inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 12.1640625,
            "text": "Ser67-phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 12.1640625,
            "text": "phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -8.6796875,
            "text": "inhibitor 1 is a potent",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.21875,
            "text": "inhibitor 1 is a",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 12.1640625,
            "text": "-phosphorylated inhibitor 1",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.6640625,
            "text": "inhibitor 1 is a potent protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.875,
            "text": "inhibitor 1 is a potent protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.109375,
            "text": "inhibitor 1 is a potent protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.1484375,
            "text": "inhibitor 1 is a potent protein phosphatase 1 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -5.67578125,
            "end_logit": -3.470703125,
            "text": "1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 0.0
        },
        {
            "start_logit": -5.67578125,
            "end_logit": -5.79296875,
            "text": "1 is",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -3.470703125,
            "text": "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -3.470703125,
            "text": "phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -3.470703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -3.470703125,
            "text": "-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor.",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_4": [
        {
            "start_logit": 13.46875,
            "end_logit": 12.6015625,
            "text": "Inhibitor 1",
            "probability": 0.85205078125
        },
        {
            "start_logit": 13.46875,
            "end_logit": 10.8359375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.1480712890625
        },
        {
            "start_logit": 13.46875,
            "end_logit": -3.908203125,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -4.015625,
            "text": "Inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.75,
            "end_logit": 12.6015625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -6.78125,
            "text": "Inhibitor 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -7.796875,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 0.0
        },
        {
            "start_logit": -5.75,
            "end_logit": 10.8359375,
            "text": "1 (I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 10.8359375,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -8.7421875,
            "text": "Inhibitor 1 (I",
            "probability": 0.0
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 10.8359375,
            "text": "(I-1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.3125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predom",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.5546875,
            "text": "Inhibitor 1 (I-1",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.640625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.65625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.7421875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.765625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.8671875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.9296875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_5": [
        {
            "start_logit": 13.59375,
            "end_logit": 13.4296875,
            "text": "Inhibitor 1",
            "probability": 1.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": 4.234375,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.00010073184967041016
        },
        {
            "start_logit": 13.59375,
            "end_logit": -3.798828125,
            "text": "Inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.59375,
            "end_logit": -4.35546875,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 13.4296875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -6.1484375,
            "text": "Inhibitor 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.015625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase.",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.296875,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.8125,
            "text": "Inhibitor 1 (I",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.5078125,
            "text": "Inhibitor 1 (I-1",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.8125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.8203125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.828125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.828125,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1),",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.90625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a major eukaryotic Ser/Thr phosphatase",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.96875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), a",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -10.046875,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 4.234375,
            "text": "1 (I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 4.234375,
            "text": "(I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 4.234375,
            "text": ")",
            "probability": 0.0
        }
    ],
    "550618f58e1671127b000007_6": [
        {
            "start_logit": 13.4765625,
            "end_logit": 14.1796875,
            "text": "Inhibitor 1 (I-1)",
            "probability": 0.89892578125
        },
        {
            "start_logit": 13.4765625,
            "end_logit": 11.9921875,
            "text": "Inhibitor 1",
            "probability": 0.100830078125
        },
        {
            "start_logit": -2.9375,
            "end_logit": 14.1796875,
            "text": ")",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -3.734375,
            "text": "Inhibitor 1 (I-1) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -3.93359375,
            "text": "Inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 14.1796875,
            "text": "1 (I-1)",
            "probability": 0.0
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 14.1796875,
            "text": "(I-1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -6.546875,
            "text": "Inhibitor 1 (",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 11.9921875,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -7.890625,
            "text": "Inhibitor 1 (I-1) is a",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -8.0390625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -8.640625,
            "text": "Inhibitor 1 (I",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 14.1796875,
            "text": "1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -9.3515625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predom",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -9.5859375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -9.6015625,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -9.609375,
            "text": "Inhibitor 1 (I-1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.1796875,
            "text": "-1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4765625,
            "end_logit": -9.6484375,
            "text": "Inhibitor 1 (I-1) is a protein inhibitor of protein phosphatase 1 (PP1), the predominating Ser/Thr phosphatase in the",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.1796875,
            "text": "I-1)",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_1": [
        {
            "start_logit": 6.0390625,
            "end_logit": 11.1015625,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": 11.1015625,
            "text": "neurons",
            "probability": 4.267692565917969e-05
        },
        {
            "start_logit": 6.0390625,
            "end_logit": -6.11328125,
            "text": "Parasympathetic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.0390625,
            "end_logit": -7.04296875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": 6.0390625,
            "end_logit": -7.94140625,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 6.0390625,
            "end_logit": -9.84375,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -7.04296875,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -7.94140625,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": -9.84375,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -7.04296875,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -7.04296875,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -7.04296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -7.04296875,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -7.04296875,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -7.04296875,
            "text": "glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": -7.04296875,
            "text": "-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -9.84375,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -9.84375,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -9.84375,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -9.84375,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_2": [
        {
            "start_logit": 8.1328125,
            "end_logit": 12.7578125,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": 12.7578125,
            "text": "neurons",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 12.7578125,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.7578125,
            "text": ". Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -6.56640625,
            "text": "Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -6.7578125,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -8.203125,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -9.84375,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -6.7578125,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -8.203125,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -9.84375,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -6.7578125,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.56640625,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -6.7578125,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -6.56640625,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.7578125,
            "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -6.7578125,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -6.7578125,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -6.7578125,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -6.7578125,
            "text": "glial progenitors.",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_3": [
        {
            "start_logit": 3.681640625,
            "end_logit": 9.7265625,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": 9.7265625,
            "text": "neurons",
            "probability": 0.0002269744873046875
        },
        {
            "start_logit": 3.681640625,
            "end_logit": -7.36328125,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.681640625,
            "end_logit": -7.62890625,
            "text": "Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": 3.681640625,
            "end_logit": -7.64453125,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 3.681640625,
            "end_logit": -10.4296875,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -7.36328125,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -7.64453125,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -10.4296875,
            "text": "neurons originate from nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -7.36328125,
            "text": "from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -7.36328125,
            "text": "nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -7.36328125,
            "text": "peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -7.36328125,
            "text": "associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": -7.36328125,
            "text": "glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": -7.36328125,
            "text": "-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -10.4296875,
            "text": "from nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -10.4296875,
            "text": "nerve-associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -10.4296875,
            "text": "peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -10.4296875,
            "text": "associated peripheral glial",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": -10.4296875,
            "text": "glial",
            "probability": 0.0
        }
    ],
    "5881f9b65bf093691f000001_4": [
        {
            "start_logit": 8.1328125,
            "end_logit": 12.7578125,
            "text": "Parasympathetic neurons",
            "probability": 1.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": 12.7578125,
            "text": "neurons",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 12.7578125,
            "text": "Neurodevelopment. Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.7578125,
            "text": ". Parasympathetic neurons",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -6.56640625,
            "text": "Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -6.7578125,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -8.203125,
            "text": "Parasympathetic neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": 8.1328125,
            "end_logit": -9.84375,
            "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -6.7578125,
            "text": "neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -8.203125,
            "text": "neurons originate",
            "probability": 0.0
        },
        {
            "start_logit": -3.322265625,
            "end_logit": -9.84375,
            "text": "neurons originate from nerve-associated peripheral glial progenitors",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -6.7578125,
            "text": "from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.56640625,
            "text": "Neurodevelopment. Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -6.7578125,
            "text": "nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -6.56640625,
            "text": ". Parasympathetic",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.7578125,
            "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -6.7578125,
            "text": ". Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -6.7578125,
            "text": "associated peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -6.7578125,
            "text": "peripheral glial progenitors.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": -6.7578125,
            "text": "glial progenitors.",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_1": [
        {
            "start_logit": 14.5078125,
            "end_logit": 15.2109375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": 15.2109375,
            "text": "difficile",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -1.197265625,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.453125,
            "end_logit": 15.2109375,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 15.2109375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.265625,
            "text": "Clostridium difficile,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.7265625,
            "text": "Clostridium difficile, a common hospital-acquired infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.2109375,
            "text": "highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.2109375,
            "text": "patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.2109375,
            "text": "intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.2109375,
            "text": "microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.2109375,
            "text": "from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 15.2109375,
            "text": "effective intervention for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.2109375,
            "text": "for patients suffering from recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -10.328125,
            "text": "Clostridium difficile, a common",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -9.265625,
            "text": "difficile,",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": -1.197265625,
            "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -9.7265625,
            "text": "difficile, a common hospital-acquired infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -1.197265625,
            "text": "recurrent Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -10.328125,
            "text": "difficile, a common",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_2": [
        {
            "start_logit": 14.828125,
            "end_logit": 15.546875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -0.287109375,
            "end_logit": 15.546875,
            "text": "difficile",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.828125,
            "end_logit": -0.30419921875,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.828125,
            "end_logit": -5.6171875,
            "text": "Clostridium difficile Proctitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -6.4609375,
            "text": "Clostridium difficile Proct",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -8.28125,
            "text": "Clostridium difficile Proctitis Following Total Colectomy.",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 15.546875,
            "text": "of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 15.546875,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 15.546875,
            "text": "Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 15.546875,
            "text": "Mini-Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.546875,
            "text": "-Fecal Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -9.9140625,
            "text": "Clostridium difficile Proctitis Following",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.546875,
            "text": "for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.828125,
            "end_logit": -9.9453125,
            "text": "Clostridium difficile Proctitis Following Total Colectomy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.546875,
            "text": "Microbiota Transplantation for Treatment of Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -0.287109375,
            "end_logit": -5.6171875,
            "text": "difficile Proctitis",
            "probability": 0.0
        },
        {
            "start_logit": -0.287109375,
            "end_logit": -6.4609375,
            "text": "difficile Proct",
            "probability": 0.0
        },
        {
            "start_logit": -0.287109375,
            "end_logit": -8.28125,
            "text": "difficile Proctitis Following Total Colectomy.",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -0.30419921875,
            "text": "of Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": -0.30419921875,
            "text": "Fecal Microbiota Transplantation for Treatment of Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_3": [
        {
            "start_logit": 14.6875,
            "end_logit": 15.328125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": 15.328125,
            "text": "difficile",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.6875,
            "end_logit": -0.87060546875,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.6875,
            "end_logit": -8.9375,
            "text": "Clostridium difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.3828125,
            "text": "Clostridium difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.75,
            "text": "Clostridium difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.8203125,
            "text": "Clostridium difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.9140625,
            "text": "Clostridium difficile carriage rates following",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -10.21875,
            "text": "Clostridium difficile carriage rates following fecal",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.328125,
            "text": "the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.328125,
            "text": "asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 15.328125,
            "text": "We aimed to assess the asymptomatic Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -8.9375,
            "text": "difficile carriage rates following fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -9.3828125,
            "text": "difficile carriage",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -9.75,
            "text": "difficile carriage rates following fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -9.8203125,
            "text": "difficile carriage rates",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -9.9140625,
            "text": "difficile carriage rates following",
            "probability": 0.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": -10.21875,
            "text": "difficile carriage rates following fecal",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -0.87060546875,
            "text": "the asymptomatic Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": -0.87060546875,
            "text": "asymptomatic Clostridium",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_4": [
        {
            "start_logit": 14.78125,
            "end_logit": 15.3984375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.052734375,
            "end_logit": 15.3984375,
            "text": "difficile",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.78125,
            "end_logit": -0.52685546875,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.78125,
            "end_logit": -7.53125,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 15.3984375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 15.3984375,
            "text": "donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 15.3984375,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.4765625,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.6328125,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.640625,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 15.3984375,
            "text": "intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.3984375,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.8671875,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.3984375,
            "text": "into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.3984375,
            "text": "recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.3984375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.9609375,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.3984375,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.3984375,
            "text": "feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -10.046875,
            "text": "Clostridium difficile infection, and",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_5": [
        {
            "start_logit": 14.4609375,
            "end_logit": 13.0234375,
            "text": "Clostridium difficile",
            "probability": 0.7578125
        },
        {
            "start_logit": 14.4609375,
            "end_logit": 11.890625,
            "text": "Clostridium difficile Infection",
            "probability": 0.2421875
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -1.6279296875,
            "text": "Clostridium",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 13.0234375,
            "text": "difficile",
            "probability": 0.0
        },
        {
            "start_logit": -4.54296875,
            "end_logit": 11.890625,
            "text": "Infection",
            "probability": 0.0
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 11.890625,
            "text": "difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.9765625,
            "text": "Clostridium difficile Infection in",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.25,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.328125,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.3359375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FM",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.3515625,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.4609375,
            "text": "Clostridium difficile Infection in Two English Hospitals: A Review.Fecal microbiota transplant (FMT) has emerged as a highly efficacious",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 13.0234375,
            "text": "Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.0234375,
            "text": "Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 13.0234375,
            "text": "Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.0234375,
            "text": "Treat Patients with Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 11.890625,
            "text": "Recurrent Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.890625,
            "text": "Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.890625,
            "text": "Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.890625,
            "text": "Treat Patients with Recurrent Clostridium difficile Infection",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_6": [
        {
            "start_logit": 14.3984375,
            "end_logit": 14.6640625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": 5.45703125,
            "text": "Clostridium difficile Infection",
            "probability": 0.00010073184967041016
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -1.431640625,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.6015625,
            "end_logit": 14.6640625,
            "text": "difficile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.40625,
            "text": "Clostridium difficile Infection following Fecal Microbiota Transplantation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.6640625,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.6640625,
            "text": "Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 14.6640625,
            "text": "Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -10.109375,
            "text": "Clostridium difficile Infection following Fecal Microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -10.1953125,
            "text": "Clostridium difficile Infection following",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -10.2578125,
            "text": "Clostridium difficile Infection following Fecal Microbiota Transplantation",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.6640625,
            "text": "Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.6640625,
            "text": "Not Essential for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.6640625,
            "text": "for Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.6640625,
            "text": "Recovery from Recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -2.6015625,
            "end_logit": 5.45703125,
            "text": "difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 5.45703125,
            "text": "Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 5.45703125,
            "text": "Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 5.45703125,
            "text": "Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 5.45703125,
            "text": "Recurrent Clostridium difficile Infection",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_7": [
        {
            "start_logit": 14.78125,
            "end_logit": 15.3984375,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.052734375,
            "end_logit": 15.3984375,
            "text": "difficile",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.78125,
            "end_logit": -0.52685546875,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.78125,
            "end_logit": -7.53125,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 15.3984375,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 15.3984375,
            "text": "donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 15.3984375,
            "text": "Fecal transplantation, the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.4765625,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.6328125,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.640625,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 15.3984375,
            "text": "intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.3984375,
            "text": "treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.8671875,
            "text": "Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.3984375,
            "text": "into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.3984375,
            "text": "recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.3984375,
            "text": "the infusion of donor feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -9.9609375,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.3984375,
            "text": "used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.3984375,
            "text": "feces into a recipient's intestinal tract, has been used for decades to treat recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.78125,
            "end_logit": -10.046875,
            "text": "Clostridium difficile infection, and",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_8": [
        {
            "start_logit": 14.203125,
            "end_logit": 14.0703125,
            "text": "Clostridium difficile infection",
            "probability": 0.9951171875
        },
        {
            "start_logit": 14.203125,
            "end_logit": 8.7890625,
            "text": "Clostridium difficile",
            "probability": 0.005062103271484375
        },
        {
            "start_logit": 14.203125,
            "end_logit": -2.2109375,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.826171875,
            "end_logit": 14.0703125,
            "text": "infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.046875,
            "end_logit": 14.0703125,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 14.0703125,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -8.90625,
            "text": "Clostridium difficile infection, with near 90% of success.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 14.0703125,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -9.8984375,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -10.015625,
            "text": "Clostridium difficile infection, with near 90% of success",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 14.0703125,
            "text": "treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -10.15625,
            "text": "Clostridium difficile infection, with near 90",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -10.25,
            "text": "Clostridium difficile infection, with near 90%",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -10.2578125,
            "text": "Clostridium difficile infection, with near",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.0703125,
            "text": "an incomparable efficacy to treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.0703125,
            "text": "incomparable efficacy to treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.0703125,
            "text": "microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.0703125,
            "text": "arable efficacy to treat recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": 8.7890625,
            "text": "difficile",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 8.7890625,
            "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_9": [
        {
            "start_logit": 14.6484375,
            "end_logit": 15.203125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": 15.203125,
            "text": "difficile",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -0.89501953125,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -4.515625,
            "text": "Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 15.203125,
            "text": "Fecal microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -8.0546875,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization.",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 15.203125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -9.0546875,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 15.203125,
            "text": "highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -9.3671875,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolonization",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.203125,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -9.9453125,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial dec",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -9.96875,
            "text": "Clostridium difficile infection, has emerged as a promising",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 15.203125,
            "text": "effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -10.015625,
            "text": "Clostridium difficile infection, has emerged as a promising therapy for intestinal MDR bacterial decolon",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.203125,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.6484375,
            "end_logit": -10.1015625,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.203125,
            "text": "microbiota transplantation (FMT), a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.203125,
            "text": "a highly effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -4.515625,
            "text": "difficile infection",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_10": [
        {
            "start_logit": 14.4140625,
            "end_logit": 15.21875,
            "text": "Clostridium difficile infection",
            "probability": 1.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": 0.396240234375,
            "text": "Clostridium difficile",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -1.5849609375,
            "end_logit": 15.21875,
            "text": "infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -2.048828125,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.75,
            "end_logit": 15.21875,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.21875,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.21875,
            "text": "OBJECTIVES Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 15.21875,
            "text": "Fecal microbiota transplantation (FMT) is increasingly being used for treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.21875,
            "text": "treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 15.21875,
            "text": "being used for treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.21875,
            "text": "of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.21875,
            "text": "increasingly being used for treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.0546875,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.1328125,
            "text": "Clostridium difficile infection (R-CDI) that cannot be cured with antibiotics alone",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.21875,
            "text": "used for treatment of recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.1796875,
            "text": "Clostridium difficile infection (R-CDI",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.234375,
            "text": "Clostridium difficile infection (R-CDI) that",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.328125,
            "text": "Clostridium difficile infection (R-CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -10.328125,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 0.396240234375,
            "text": "difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_11": [
        {
            "start_logit": 14.21875,
            "end_logit": 14.78125,
            "text": "Clostridium difficile infection",
            "probability": 1.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": 3.423828125,
            "text": "Clostridium difficile",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -2.220703125,
            "end_logit": 14.78125,
            "text": "infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.45703125,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.234375,
            "end_logit": 14.78125,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -8.921875,
            "text": "Clostridium difficile infection (CDI).",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 14.78125,
            "text": "Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.4765625,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.6015625,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.78125,
            "text": "with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.78125,
            "text": "treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.0546875,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.78125,
            "text": "BACKGROUND Fecal microbiota transplantation (FMT) restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.78125,
            "text": "a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.78125,
            "text": "bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 14.78125,
            "text": "restores a diverse bacterial profile to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 14.78125,
            "text": "patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.78125,
            "text": "to the gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 14.78125,
            "text": "gastrointestinal tract and may effectively treat patients with Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.234375,
            "end_logit": 3.423828125,
            "text": "difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_12": [
        {
            "start_logit": 14.3515625,
            "end_logit": 15.2421875,
            "text": "Clostridium difficile infection",
            "probability": 1.0
        },
        {
            "start_logit": -1.3466796875,
            "end_logit": 15.2421875,
            "text": "infection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -1.279296875,
            "text": "Clostridium difficile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -2.146484375,
            "text": "Clostridium",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 15.2421875,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.2421875,
            "text": "Bacterial communities from subjects treated for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 15.2421875,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.6171875,
            "text": "Clostridium difficile infection (",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.9765625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.2421875,
            "text": "for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.984375,
            "text": "Clostridium difficile infection (rCDI)",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 15.2421875,
            "text": "subjects treated for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.078125,
            "text": "Clostridium difficile infection (rC",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 15.2421875,
            "text": "communities from subjects treated for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.140625,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.171875,
            "text": "Clostridium difficile infection (rCDI",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.1875,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.2109375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.234375,
            "text": "Clostridium difficile infection (rCDI) by",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.234375,
            "text": "Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_13": [
        {
            "start_logit": 14.65625,
            "end_logit": 15.21875,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": -1.1796875,
            "end_logit": 15.21875,
            "text": "difficile",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.65625,
            "end_logit": -0.8330078125,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 15.21875,
            "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -7.35546875,
            "text": "Clostridium difficile infections",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -7.703125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 15.21875,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -8.8046875,
            "text": "Clostridium difficile infections,",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 15.21875,
            "text": "compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 15.21875,
            "text": "microbiota transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.7109375,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.7890625,
            "text": "Clostridium difficile infections, with potential applications against other diseases",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.8828125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -9.890625,
            "text": "Clostridium difficile infections, with potential applications against other",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.21875,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.21875,
            "text": "treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -10.1328125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated with",
            "probability": 0.0
        },
        {
            "start_logit": 14.65625,
            "end_logit": -10.1328125,
            "text": "Clostridium difficile infections, with potential applications against other diseases associated",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.21875,
            "text": "transplantation is a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.21875,
            "text": "a compelling treatment for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_14": [
        {
            "start_logit": 14.2734375,
            "end_logit": 15.0625,
            "text": "Clostridium difficile infection",
            "probability": 1.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": 2.673828125,
            "text": "Clostridium difficile",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -1.814453125,
            "end_logit": 15.0625,
            "text": "infection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -2.1875,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 15.0625,
            "text": "Fecal microbiota transplantation (FMT) holds considerable promise as a therapy for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 15.0625,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 15.0625,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.0625,
            "text": "for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.0625,
            "text": "considerable promise as a therapy for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.7421875,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are stilt required.",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.0625,
            "text": "therapy for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.0625,
            "text": "promise as a therapy for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.2890625,
            "text": "Clostridium difficile infection,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.4453125,
            "text": "Clostridium difficile infection, but well-designed, randomized-controlled trials and Long-term follow-up registries are",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 2.673828125,
            "text": "Fecal microbiota transplantation (FMT) holds considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 2.673828125,
            "text": "difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 2.673828125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 2.673828125,
            "text": "for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 2.673828125,
            "text": "considerable promise as a therapy for recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 2.673828125,
            "text": "therapy for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_15": [
        {
            "start_logit": 14.0546875,
            "end_logit": 14.53125,
            "text": "Clostridium difficile infection",
            "probability": 1.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": 3.80859375,
            "text": "Clostridium difficile",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -2.244140625,
            "end_logit": 14.53125,
            "text": "infection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -2.623046875,
            "text": "Clostridium",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 14.53125,
            "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -7.41796875,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases.",
            "probability": 0.0
        },
        {
            "start_logit": -8.375,
            "end_logit": 14.53125,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 14.53125,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -8.703125,
            "text": "Clostridium difficile infection (CDI)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -9.6796875,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.53125,
            "text": "for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -9.8671875,
            "text": "Clostridium difficile infection (CDI",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 14.53125,
            "text": "treatment for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -10.046875,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -10.09375,
            "text": "Clostridium difficile infection (CDI) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.0546875,
            "end_logit": -10.2265625,
            "text": "Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI)",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.53125,
            "text": "an effective treatment for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.53125,
            "text": "microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 14.53125,
            "text": "effective treatment for recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 3.80859375,
            "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_16": [
        {
            "start_logit": 14.609375,
            "end_logit": 14.953125,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": 1.4296875,
            "text": "Clostridium difficile infection",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 14.609375,
            "end_logit": -1.09765625,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.041015625,
            "end_logit": 14.953125,
            "text": "difficile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 14.953125,
            "text": "tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -8.765625,
            "end_logit": 14.953125,
            "text": "Fecal microbiota transplantation is relatively simple to perform, well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.4921875,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 14.953125,
            "text": "well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.953125,
            "text": "safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -9.7421875,
            "text": "Clostridium difficile infection with ulcerative pancolitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.953125,
            "text": "-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.953125,
            "text": ", well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.953125,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.0,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.953125,
            "text": "in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.1015625,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 14.953125,
            "text": "to perform, well-tolerated, safe and effective in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.109375,
            "text": "Clostridium difficile infection with ulcerative pancolitis, as an alternative",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.234375,
            "text": "Clostridium difficile infection with",
            "probability": 0.0
        },
        {
            "start_logit": 14.609375,
            "end_logit": -10.2578125,
            "text": "Clostridium difficile infection with ulcerative pancoli",
            "probability": 0.0
        }
    ],
    "5c71d6d27c78d6947100006a_17": [
        {
            "start_logit": 14.5546875,
            "end_logit": 14.9765625,
            "text": "Clostridium difficile",
            "probability": 1.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": 2.533203125,
            "text": "Clostridium difficile infection",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.240234375,
            "text": "Clostridium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.6962890625,
            "end_logit": 14.9765625,
            "text": "difficile",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.078125,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 14.9765625,
            "text": "fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 14.9765625,
            "text": "recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.9765625,
            "text": "The use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.84375,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease remains unclear",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -10.046875,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -10.0625,
            "text": "Clostridium difficile infection and coexistent inflammatory bowel",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -10.09375,
            "text": "Clostridium difficile infection and",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.9765625,
            "text": "use of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -10.34375,
            "text": "Clostridium difficile infection and coexist",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 14.9765625,
            "text": "microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.9765625,
            "text": "of fecal microbiota transplantation in recurrent Clostridium difficile",
            "probability": 0.0
        },
        {
            "start_logit": -1.6962890625,
            "end_logit": 2.533203125,
            "text": "difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 2.533203125,
            "text": "infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 2.533203125,
            "text": "fecal microbiota transplantation in recurrent Clostridium difficile infection",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 2.533203125,
            "text": "recurrent Clostridium difficile infection",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_1": [
        {
            "start_logit": 2.685546875,
            "end_logit": 2.27734375,
            "text": "Panobinostat",
            "probability": 0.9990234375
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 2.27734375,
            "text": "histone deacetylase (HDAC) inhibitors (Panobinostat",
            "probability": 0.0004153251647949219
        },
        {
            "start_logit": 2.685546875,
            "end_logit": -8.03125,
            "text": "Panobinost",
            "probability": 3.343820571899414e-05
        },
        {
            "start_logit": 2.685546875,
            "end_logit": -8.65625,
            "text": "Pan",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": -8.796875,
            "end_logit": 2.27734375,
            "text": "at",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 2.27734375,
            "text": "nostat",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": 2.685546875,
            "end_logit": -9.609375,
            "text": "Panobinostat).",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 2.685546875,
            "end_logit": -9.96875,
            "text": "Panobi",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 2.685546875,
            "end_logit": -10.109375,
            "text": "Panobino",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 2.27734375,
            "text": "stat",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -10.109375,
            "end_logit": 2.27734375,
            "text": "obinostat",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 2.27734375,
            "text": ", histone deacetylase (HDAC) inhibitors (Panobinostat",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 2.27734375,
            "text": "(Panobinostat",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -6.90234375,
            "text": "histone deacetylase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.03125,
            "text": "histone deacetylase (HDAC) inhibitors (Panobinost",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.65625,
            "text": "histone deacetylase (HDAC) inhibitors (Pan",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -8.8515625,
            "text": "histone deacetylase (HDAC",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -9.609375,
            "text": "histone deacetylase (HDAC) inhibitors (Panobinostat).",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -9.96875,
            "text": "histone deacetylase (HDAC) inhibitors (Panobi",
            "probability": 0.0
        },
        {
            "start_logit": -5.1015625,
            "end_logit": -10.0390625,
            "text": "histone deacetylase (HDAC) inhibitors",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_2": [
        {
            "start_logit": 9.9296875,
            "end_logit": 11.8125,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 11.8125,
            "text": "generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 11.8125,
            "text": "second-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.8125,
            "text": "the second-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.8125,
            "text": "-MLN2238), the second-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.8125,
            "text": "-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.8125,
            "text": "(MLN9708-MLN2238), the second-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 11.8125,
            "text": "Ixazomib (MLN9708-MLN2238), the second-generation proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -9.7890625,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -10.265625,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I",
            "probability": 0.0
        },
        {
            "start_logit": 9.9296875,
            "end_logit": -10.3671875,
            "text": "proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -9.7890625,
            "text": "generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -10.265625,
            "text": "generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -10.3671875,
            "text": "generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -9.7890625,
            "text": "second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -9.7890625,
            "text": "the second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.7890625,
            "text": "-MLN2238), the second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -9.7890625,
            "text": "bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -9.7890625,
            "text": "of bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -10.265625,
            "text": "second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_3": [
        {
            "start_logit": 10.2890625,
            "end_logit": 12.6796875,
            "text": "CD38",
            "probability": 1.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 12.6796875,
            "text": "target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 12.6796875,
            "text": "; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 12.6796875,
            "text": "multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.6796875,
            "text": "for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 12.6796875,
            "text": "the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 12.6796875,
            "text": "daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 12.6796875,
            "text": "first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 12.6796875,
            "text": "oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 12.6796875,
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -9.265625,
            "text": "CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -9.46875,
            "text": "CD38 and SLAMF7",
            "probability": 0.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -9.5078125,
            "text": "CD38 and SLAMF7, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": 10.2890625,
            "end_logit": -10.078125,
            "text": "CD38 and SLA",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -9.265625,
            "text": "target CD38 and SLAMF7, respectively",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -9.46875,
            "text": "target CD38 and SLAMF7",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -9.5078125,
            "text": "target CD38 and SLAMF7, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -8.8984375,
            "text": "FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -8.8984375,
            "text": "the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": -10.078125,
            "text": "target CD38 and SLA",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_4": [
        {
            "start_logit": 7.59375,
            "end_logit": 10.4296875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 10.4296875,
            "text": "Ixazomib, the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 10.4296875,
            "text": "the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 10.4296875,
            "text": "oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 10.4296875,
            "text": "azomib, the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 10.4296875,
            "text": ", the first oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -9.8828125,
            "text": "proteasome inhibitor to be",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -9.9453125,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.0234375,
            "text": "proteasome inhibitor to be evaluated",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.2890625,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.296875,
            "text": "proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.3125,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.375,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.3984375,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory",
            "probability": 0.0
        },
        {
            "start_logit": 7.59375,
            "end_logit": -10.3984375,
            "text": "proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -9.8828125,
            "text": "Ixazomib, the first oral proteasome inhibitor to be",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -9.9453125,
            "text": "Ixazomib, the first oral proteasome inhibitor to be evaluated in multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -10.0234375,
            "text": "Ixazomib, the first oral proteasome inhibitor to be evaluated",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -9.8828125,
            "text": "the first oral proteasome inhibitor to be",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -10.2890625,
            "text": "Ixazomib, the first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_5": [
        {
            "start_logit": 0.55322265625,
            "end_logit": 5.109375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 5.109375,
            "text": "introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 5.109375,
            "text": "the introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 5.109375,
            "text": "Since the introduction of bortezomib in 2003, several next-generation proteasome",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -11.109375,
            "end_logit": 5.109375,
            "text": "2003, several next-generation proteasome",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 5.109375,
            "text": "-generation proteasome",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -8.328125,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -9.8125,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -9.921875,
            "text": "proteasome inhibitors have also",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -9.953125,
            "text": "proteasome inhibitors have",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.0078125,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.0078125,
            "text": "proteasome inhibitors have also been used clinically,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.09375,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanz",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.09375,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.1640625,
            "text": "proteasome inhibitors have also been used clinically, including carfilzomib, op",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.55322265625,
            "end_logit": -10.234375,
            "text": "proteasome inhibitors have also been used clinically, including carfil",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.328125,
            "text": "delanzomib.",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -8.328125,
            "text": ", ixazomib, and delanzomib.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -8.328125,
            "text": ", and delanzomib.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -8.328125,
            "text": "been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib.",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_6": [
        {
            "start_logit": 9.15625,
            "end_logit": 11.8671875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.8671875,
            "text": ": The aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.8671875,
            "text": "The aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.8671875,
            "text": "the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.8671875,
            "text": "the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.8671875,
            "text": "of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.8671875,
            "text": "AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 11.8671875,
            "text": "oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.8671875,
            "text": "the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.8671875,
            "text": "to characterize the pharmacokinetics of the oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -9.859375,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.125,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.2734375,
            "text": "proteasome inhibitor, ixazomib, in",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.3125,
            "text": "proteasome inhibitor, ixazomib",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.3515625,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment,",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.359375,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.375,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.390625,
            "text": "proteasome inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.4375,
            "text": "proteasome inhibitor, ixazo",
            "probability": 0.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -10.4453125,
            "text": "proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_7": [
        {
            "start_logit": 9.8984375,
            "end_logit": 11.7421875,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 11.7421875,
            "text": "oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.7421875,
            "text": "ixazomib, an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.7421875,
            "text": "an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 11.7421875,
            "text": "of ixazomib, an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.7421875,
            "text": "azomib, an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.7421875,
            "text": ", an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.359375,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -10.1015625,
            "text": "proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -10.1796875,
            "text": "proteasome inhibitor, in solid tumour",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -10.3125,
            "text": "proteasome inhibitor, in",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -9.359375,
            "text": "hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.359375,
            "text": "oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -9.359375,
            "text": "solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -9.359375,
            "text": "severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -9.359375,
            "text": "or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -9.359375,
            "text": "ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -9.359375,
            "text": "with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -9.359375,
            "text": "patients with moderate or severe hepatic impairment",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.359375,
            "text": "an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_8": [
        {
            "start_logit": 6.12890625,
            "end_logit": 8.90625,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 8.90625,
            "text": ", proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.671875,
            "end_logit": 8.90625,
            "text": "Ixazomib is the first oral, proteasome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 8.90625,
            "text": "the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 8.90625,
            "text": "azomib is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.78125,
            "end_logit": 8.90625,
            "text": "mib is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 8.90625,
            "text": "first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.875,
            "end_logit": 8.90625,
            "text": "is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.90625,
            "end_logit": 8.90625,
            "text": "oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0625,
            "end_logit": 8.90625,
            "text": "b is the first oral, proteasome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -9.6796875,
            "text": "proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -10.2109375,
            "text": "proteasome inhibitor to reach phase III",
            "probability": 0.0
        },
        {
            "start_logit": 6.12890625,
            "end_logit": -10.34375,
            "text": "proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -9.6796875,
            "text": ", proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -9.6796875,
            "text": "Ixazomib is the first oral, proteasome inhibitor to reach phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.2109375,
            "text": ", proteasome inhibitor to reach phase III",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -10.2109375,
            "text": "Ixazomib is the first oral, proteasome inhibitor to reach phase III",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -10.34375,
            "text": ", proteasome inhibitor to",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -9.6796875,
            "text": "phase III trials.",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -10.34375,
            "text": "Ixazomib is the first oral, proteasome inhibitor to",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_9": [
        {
            "start_logit": 7.82421875,
            "end_logit": 11.4609375,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 11.4609375,
            "text": "oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.4609375,
            "text": "MLN2238 (ixazomib), an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.4609375,
            "text": "(ixazomib), an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.4609375,
            "text": "ixazomib), an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 11.4609375,
            "text": ", an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 11.4609375,
            "text": "mib), an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.4609375,
            "text": "N2238 (ixazomib), an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.4609375,
            "text": "an oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -8.9609375,
            "text": "proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -9.2421875,
            "text": "proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": 7.82421875,
            "end_logit": -10.1640625,
            "text": "proteasome inhibitor, has improved pharmacotherapeutic",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -8.9609375,
            "text": "oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -8.9609375,
            "text": "bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -8.9609375,
            "text": "MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -9.2421875,
            "text": "oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -8.9609375,
            "text": "(ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -8.9609375,
            "text": "to bortezomib",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.2421875,
            "text": "bortezomib.",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -8.9609375,
            "text": "compared to bortezomib",
            "probability": 0.0
        }
    ],
    "589630f378275d0c4a000007_10": [
        {
            "start_logit": 9.125,
            "end_logit": 11.75,
            "text": "proteasome",
            "probability": 1.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.75,
            "text": "oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.75,
            "text": "population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.75,
            "text": "the investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.75,
            "text": "This population pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.75,
            "text": "pharmacokinetic analysis of the investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.75,
            "text": "of the investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.75,
            "text": "investigational oral proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -9.9921875,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.2109375,
            "text": "proteasome inhibitor ixazomib assessed the feasibility",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.4140625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.4140625,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.4453125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.453125,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area",
            "probability": 0.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -10.46875,
            "text": "proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -9.9921875,
            "text": "body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.9921875,
            "text": "the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.9921875,
            "text": "dosing, and the impact of baseline covariates",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -10.2421875,
            "text": "body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -10.25,
            "text": "body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_1": [
        {
            "start_logit": 14.59375,
            "end_logit": 14.8046875,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -0.25,
            "text": "55",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.17578125,
            "end_logit": 14.8046875,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.59375,
            "end_logit": -7.16796875,
            "text": "55 S, consisting of 39 S large and 28 S small subunits.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 14.8046875,
            "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 14.8046875,
            "text": "mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 14.8046875,
            "text": "of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.21875,
            "text": "55 S, consisting of 39 S large and 28 S small subunits",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.625,
            "text": "55 S, consisting",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.8515625,
            "text": "55 S, consisting of 39 S large and 28",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.859375,
            "text": "55 S,",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.0390625,
            "text": "55 S, consisting of 39",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.8046875,
            "text": "ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.1640625,
            "text": "55 S, consisting of 39 S large and 28 S small",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.8046875,
            "text": "small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.8046875,
            "text": "sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.8046875,
            "text": "a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.8046875,
            "text": "mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.8046875,
            "text": "protein-rich composition with a small sedimentation coefficient of 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -0.25,
            "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_2": [
        {
            "start_logit": 14.6640625,
            "end_logit": 14.8203125,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": 14.8203125,
            "text": "The 55 S",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -0.3798828125,
            "text": "55",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 14.8203125,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -6.58203125,
            "text": "55 S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -7.76953125,
            "text": "55 S mammalian mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -7.91796875,
            "text": "55 S mammalian mitochondrial ribosome (",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.1875,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.265625,
            "text": "55 S mammalian",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.28125,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\")",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.6015625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich,",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.7265625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich",
            "probability": 0.0
        },
        {
            "start_logit": 14.6640625,
            "end_logit": -9.890625,
            "text": "55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -0.3798828125,
            "text": "The 55",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -3.373046875,
            "text": "The",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -6.58203125,
            "text": "The 55 S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -7.76953125,
            "text": "The 55 S mammalian mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -7.91796875,
            "text": "The 55 S mammalian mitochondrial ribosome (",
            "probability": 0.0
        },
        {
            "start_logit": -2.23828125,
            "end_logit": -6.58203125,
            "text": "S mammalian mitochondrial ribosome",
            "probability": 0.0
        },
        {
            "start_logit": 0.06982421875,
            "end_logit": -9.1875,
            "text": "The 55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is",
            "probability": 0.0
        }
    ],
    "55201a316b348bb82c000019_3": [
        {
            "start_logit": 14.5859375,
            "end_logit": 14.9765625,
            "text": "55 S",
            "probability": 1.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -0.61865234375,
            "text": "55",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.48046875,
            "end_logit": 14.9765625,
            "text": "about 55 S",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.30859375,
            "end_logit": 14.9765625,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -6.95703125,
            "text": "55 S.",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 14.9765625,
            "text": "The sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 14.9765625,
            "text": "monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 14.9765625,
            "text": "the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.9765625,
            "text": "intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.9765625,
            "text": "was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.9765625,
            "text": "sedimentation coefficient of the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.9765625,
            "text": "of the intact monosome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 14.9765625,
            "text": "ome was about 55 S",
            "probability": 0.0
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -0.61865234375,
            "text": "about 55",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -0.61865234375,
            "text": "The sedimentation coefficient of the intact monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -6.95703125,
            "text": "about 55 S.",
            "probability": 0.0
        },
        {
            "start_logit": -2.30859375,
            "end_logit": -6.95703125,
            "text": "S.",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -0.61865234375,
            "text": "monosome was about 55",
            "probability": 0.0
        },
        {
            "start_logit": -1.48046875,
            "end_logit": -8.78125,
            "text": "about",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -0.61865234375,
            "text": "the intact monosome was about 55",
            "probability": 0.0
        }
    ],
    "5e2a1096aa19d7443100000e_1": [
        {
            "start_logit": 10.4296875,
            "end_logit": 7.91796875,
            "text": "vascular endothelial growth factor A",
            "probability": 0.97314453125
        },
        {
            "start_logit": 10.4296875,
            "end_logit": 4.01953125,
            "text": "vascular endothelial growth factor A (VEGF-A",
            "probability": 0.0198822021484375
        },
        {
            "start_logit": 10.4296875,
            "end_logit": 2.94140625,
            "text": "vascular endothelial growth factor A (VEGF-A)",
            "probability": 0.00676727294921875
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -2.822265625,
            "text": "vascular endothelial growth factor A (VEGF-A), in vivo.",
            "probability": 2.1159648895263672e-05
        },
        {
            "start_logit": -2.654296875,
            "end_logit": 7.91796875,
            "text": "AZD8601, a modified mRNA encoding vascular endothelial growth factor A",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -6.32421875,
            "text": "vascular",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.31640625,
            "end_logit": 7.91796875,
            "text": "modified mRNA encoding vascular endothelial growth factor A",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.44921875,
            "end_logit": 7.91796875,
            "text": "mRNA encoding vascular endothelial growth factor A",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.109375,
            "end_logit": 7.91796875,
            "text": "encoding vascular endothelial growth factor A",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -7.6796875,
            "text": "vascular endothelial growth factor A (VEGF-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.65625,
            "end_logit": 4.01953125,
            "text": "VEGF-A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -8.21875,
            "text": "vascular endothelial growth factor A (VEGF-A),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 7.91796875,
            "text": "a modified mRNA encoding vascular endothelial growth factor A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.4375,
            "end_logit": 7.91796875,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -8.9765625,
            "text": "vascular endothelial growth factor A (VEGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.654296875,
            "end_logit": 4.01953125,
            "text": "AZD8601, a modified mRNA encoding vascular endothelial growth factor A (VEGF-A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.65625,
            "end_logit": 2.94140625,
            "text": "VEGF-A)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.6953125,
            "text": "vascular endothelial growth factor A (",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.8125,
            "text": "vascular endothelial growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.859375,
            "text": "vascular endothelial growth factor A (VEGF-A), in vivo",
            "probability": 0.0
        }
    ],
    "5caa0247ecadf2e73f000055_1": [
        {
            "start_logit": 12.6875,
            "end_logit": 13.609375,
            "text": "moesin",
            "probability": 1.0
        },
        {
            "start_logit": 12.6875,
            "end_logit": -2.91015625,
            "text": "mo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.078125,
            "end_logit": 13.609375,
            "text": "esin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6875,
            "end_logit": -7.625,
            "text": "moesin (Moe).",
            "probability": 0.0
        },
        {
            "start_logit": 12.6875,
            "end_logit": -8.3359375,
            "text": "moesin (Moe",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 13.609375,
            "text": "actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 13.609375,
            "text": "of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 13.609375,
            "text": "which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 13.609375,
            "text": "we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 13.609375,
            "text": "tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 13.609375,
            "text": "cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 13.609375,
            "text": "omyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 13.609375,
            "text": "an actomyosin complex, which we propose is mediated by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.609375,
            "text": "by Crb recruitment of moesin",
            "probability": 0.0
        },
        {
            "start_logit": 12.6875,
            "end_logit": -9.890625,
            "text": "moesin (Mo",
            "probability": 0.0
        },
        {
            "start_logit": 12.6875,
            "end_logit": -9.953125,
            "text": "moesin (Moe)",
            "probability": 0.0
        },
        {
            "start_logit": -4.078125,
            "end_logit": -7.625,
            "text": "esin (Moe).",
            "probability": 0.0
        },
        {
            "start_logit": -4.078125,
            "end_logit": -8.3359375,
            "text": "esin (Moe",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -2.91015625,
            "text": "actomyosin complex, which we propose is mediated by Crb recruitment of mo",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -2.91015625,
            "text": "of mo",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_1": [
        {
            "start_logit": 7.6328125,
            "end_logit": 14.515625,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": -2.75,
            "end_logit": 14.515625,
            "text": "dissection",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -6.5625,
            "end_logit": 14.515625,
            "text": "artery dissection",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 14.515625,
            "text": "vertebral artery dissection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.8125,
            "end_logit": 14.515625,
            "text": "and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.515625,
            "text": ": CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.515625,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.515625,
            "text": ") carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.515625,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.515625,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.515625,
            "text": "AIMS: CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.515625,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.515625,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 14.515625,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.515625,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.515625,
            "text": "a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.515625,
            "text": "of onset) carotid and vertebral artery dissection",
            "probability": 0.0
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -7.43359375,
            "text": "carotid and vertebral artery",
            "probability": 0.0
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -7.73828125,
            "text": "carotid",
            "probability": 0.0
        },
        {
            "start_logit": 7.6328125,
            "end_logit": -10.3671875,
            "text": "carotid and vertebral artery dissection.",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_2": [
        {
            "start_logit": 6.03125,
            "end_logit": 14.359375,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": 14.359375,
            "text": "dissection",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 14.359375,
            "text": "artery dissection",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 14.359375,
            "text": "vertebral artery dissection",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.953125,
            "end_logit": 14.359375,
            "text": "AIMS  CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 14.359375,
            "text": "and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.359375,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.359375,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.359375,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.359375,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.359375,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.359375,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.359375,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.359375,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.359375,
            "text": "of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.359375,
            "text": "-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.03125,
            "end_logit": -7.0703125,
            "text": "carotid and vertebral artery",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -8.453125,
            "text": "carotid",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -9.921875,
            "text": "carotid and vertebral artery dissection.",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -7.0703125,
            "text": "artery",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_3": [
        {
            "start_logit": 6.03125,
            "end_logit": 14.359375,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": 14.359375,
            "text": "dissection",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 14.359375,
            "text": "artery dissection",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 14.359375,
            "text": "vertebral artery dissection",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.953125,
            "end_logit": 14.359375,
            "text": "AIMS CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 14.359375,
            "text": "and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.359375,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.359375,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.359375,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.359375,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.359375,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.359375,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.359375,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.359375,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.359375,
            "text": "of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.359375,
            "text": "-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.03125,
            "end_logit": -7.0703125,
            "text": "carotid and vertebral artery",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -8.453125,
            "text": "carotid",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -9.921875,
            "text": "carotid and vertebral artery dissection.",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -7.0703125,
            "text": "artery",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_4": [
        {
            "start_logit": 6.03125,
            "end_logit": 14.359375,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": 14.359375,
            "text": "dissection",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 14.359375,
            "text": "artery dissection",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -7.625,
            "end_logit": 14.359375,
            "text": "vertebral artery dissection",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.953125,
            "end_logit": 14.359375,
            "text": "AIMS CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 14.359375,
            "text": "and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.359375,
            "text": ") carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 14.359375,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.359375,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.359375,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.359375,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.359375,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.359375,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.359375,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.359375,
            "text": "of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.359375,
            "text": "-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.03125,
            "end_logit": -7.0703125,
            "text": "carotid and vertebral artery",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -8.453125,
            "text": "carotid",
            "probability": 0.0
        },
        {
            "start_logit": 6.03125,
            "end_logit": -9.921875,
            "text": "carotid and vertebral artery dissection.",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -7.0703125,
            "text": "artery",
            "probability": 0.0
        }
    ],
    "5e4604d83f54159529000003_5": [
        {
            "start_logit": 5.2109375,
            "end_logit": 14.203125,
            "text": "carotid and vertebral artery dissection",
            "probability": 1.0
        },
        {
            "start_logit": -3.21875,
            "end_logit": 14.203125,
            "text": "dissection",
            "probability": 0.0002200603485107422
        },
        {
            "start_logit": -4.875,
            "end_logit": 14.203125,
            "text": "artery dissection",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 14.203125,
            "text": "vertebral artery dissection",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.203125,
            "text": "and vertebral artery dissection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.203125,
            "text": "CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.203125,
            "text": ") carotid and vertebral artery dissection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.484375,
            "end_logit": 14.203125,
            "text": "acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.203125,
            "text": "within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.203125,
            "text": "in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.203125,
            "text": "controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.203125,
            "text": "randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.203125,
            "text": "(within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 14.203125,
            "text": "-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.203125,
            "text": "of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.203125,
            "text": "a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -7.1796875,
            "text": "carotid and vertebral artery",
            "probability": 0.0
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -8.8125,
            "text": "carotid",
            "probability": 0.0
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -9.984375,
            "text": "carotid and vertebral artery dissection.",
            "probability": 0.0
        },
        {
            "start_logit": -4.875,
            "end_logit": -7.1796875,
            "text": "artery",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_1": [
        {
            "start_logit": 3.125,
            "end_logit": 5.44140625,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity.",
            "probability": 1.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": 5.44140625,
            "text": ".",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": 3.125,
            "end_logit": -7.04296875,
            "text": "Spermidine",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -9.71875,
            "end_logit": 5.44140625,
            "text": "against \u03b1-synuclein neurotoxicity.",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 3.125,
            "end_logit": -8.015625,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 5.44140625,
            "text": "\u03b1-synuclein neurotoxicity.",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 5.44140625,
            "text": "protects against \u03b1-synuclein neurotoxicity.",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 3.125,
            "end_logit": -8.390625,
            "text": "Spermidine protects",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 5.44140625,
            "text": "synuclein neurotoxicity.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -11.3125,
            "end_logit": 5.44140625,
            "text": "-synuclein neurotoxicity.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 3.125,
            "end_logit": -9.75,
            "text": "Spermidine protects against \u03b1-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.71875,
            "end_logit": -8.015625,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -8.015625,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -8.015625,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -8.015625,
            "text": "synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -8.390625,
            "text": "protects",
            "probability": 0.0
        },
        {
            "start_logit": -11.3125,
            "end_logit": -8.015625,
            "text": "-synuclein neurotoxicity",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -9.75,
            "text": "against \u03b1-",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.75,
            "text": "\u03b1-",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -9.75,
            "text": "protects against \u03b1-",
            "probability": 0.0
        }
    ],
    "56c073fcef6e394741000020_2": [
        {
            "start_logit": -3.865234375,
            "end_logit": 5.02734375,
            "text": "Spermidine protects against \u03b1-synuclein neurotoxicity",
            "probability": 0.9951171875
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 5.02734375,
            "text": "against \u03b1-synuclein neurotoxicity",
            "probability": 0.001567840576171875
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 5.02734375,
            "text": "\u03b1-synuclein neurotoxicity",
            "probability": 0.0009074211120605469
        },
        {
            "start_logit": -10.96875,
            "end_logit": 5.02734375,
            "text": "synuclein neurotoxicity",
            "probability": 0.000820159912109375
        },
        {
            "start_logit": -11.234375,
            "end_logit": 5.02734375,
            "text": "-synuclein neurotoxicity",
            "probability": 0.0006289482116699219
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 5.02734375,
            "text": "neurotoxicity",
            "probability": 0.0006237030029296875
        },
        {
            "start_logit": -11.546875,
            "end_logit": 5.02734375,
            "text": "protects against \u03b1-synuclein neurotoxicity",
            "probability": 0.00045990943908691406
        },
        {
            "start_logit": -3.865234375,
            "end_logit": -8.40625,
            "text": "Spermidine",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -3.865234375,
            "end_logit": -8.609375,
            "text": "Spermidine protects",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -11.546875,
            "end_logit": -8.609375,
            "text": "protects",
            "probability": 0.0
        }
    ],
    "606074ab94d57fd87900003e_1": [
        {
            "start_logit": 14.515625,
            "end_logit": 15.2890625,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": 15.2890625,
            "text": "a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.4296875,
            "text": "Rtpc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.9873046875,
            "text": "Rt",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -7.4453125,
            "text": "Rtpca:",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": 15.2890625,
            "text": "pca",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -8.8671875,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation analysis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.90625,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.0234375,
            "text": "Rtpca: an R package for differential",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.0390625,
            "text": "Rtpca: an R package for differential thermal proximity coaggregation analysis",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.1171875,
            "text": "Rtpca: an",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.1328125,
            "text": "Rtpca: an R package for differential thermal proximity coaggr",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.1328125,
            "text": "Rtpca: an R package for differential thermal proximity",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -10.1640625,
            "text": "Rtpca: an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": -7.4453125,
            "text": "a:",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -1.4296875,
            "text": "pc",
            "probability": 0.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": -8.8671875,
            "text": "a: an R package for differential thermal proximity coaggregation analysis.",
            "probability": 0.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": -9.90625,
            "text": "a: an R package for differential thermal proximity coaggregation",
            "probability": 0.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": -10.0234375,
            "text": "a: an R package for differential",
            "probability": 0.0
        },
        {
            "start_logit": -1.724609375,
            "end_logit": -10.0390625,
            "text": "a: an R package for differential thermal proximity coaggregation analysis",
            "probability": 0.0
        }
    ],
    "606074ab94d57fd87900003e_2": [
        {
            "start_logit": 14.5546875,
            "end_logit": 15.3515625,
            "text": "Rtpca",
            "probability": 1.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -0.0972900390625,
            "text": "Rtpc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.5078125,
            "end_logit": 15.3515625,
            "text": "a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.861328125,
            "text": "Rt",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.671875,
            "end_logit": 15.3515625,
            "text": "pca",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -7.90234375,
            "text": "Rtpca is",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.859375,
            "text": "Rtpca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a differential",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": -0.0972900390625,
            "text": "pc",
            "probability": 0.0
        },
        {
            "start_logit": -1.5078125,
            "end_logit": -7.90234375,
            "text": "a is",
            "probability": 0.0
        },
        {
            "start_logit": -1.5078125,
            "end_logit": -9.859375,
            "text": "a is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a differential",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": -7.90234375,
            "text": "pca is",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": -9.859375,
            "text": "pca is an R package implementing methods for inferring protein-protein interactions based on thermal proteome profiling experiments of a single condition or in a differential",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -8.5390625,
            "text": "//bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -8.5390625,
            "text": ": Rtpca is available from Bioconductor (https://bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -8.5390625,
            "text": "available from Bioconductor (https://bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -8.5390625,
            "text": "Rtpca is available from Bioconductor (https://bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.5390625,
            "text": "/bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -8.5390625,
            "text": "AVAILABILITY: Rtpca is available from Bioconductor (https://bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -8.5390625,
            "text": "Bioconductor (https://bioconductor.org",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -9.265625,
            "text": "//bioconductor.",
            "probability": 0.0
        }
    ],
    "513ce494bee46bd34c000009_1": [
        {
            "start_logit": 12.765625,
            "end_logit": 14.7265625,
            "text": "polycystic kidney disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.517578125,
            "end_logit": 14.7265625,
            "text": "disease",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.765625,
            "end_logit": -2.30859375,
            "text": "polycystic kidney disease (PKD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.765625,
            "end_logit": -4.796875,
            "text": "polycystic",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -5.34765625,
            "text": "polycystic kidney disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 14.7265625,
            "text": "kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -7.49609375,
            "text": "polycystic kidney",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 14.7265625,
            "text": "in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.7265625,
            "text": "development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.7265625,
            "text": "of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 14.7265625,
            "text": "kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.7265625,
            "text": "autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 14.7265625,
            "text": "recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.7265625,
            "text": "of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.7265625,
            "text": "the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -9.2109375,
            "text": "polycystic kidney disease (",
            "probability": 0.0
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -2.30859375,
            "text": "disease (PKD",
            "probability": 0.0
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -5.34765625,
            "text": "disease (PKD)",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -2.30859375,
            "text": "kidney disease (PKD",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": -2.30859375,
            "text": "PKD",
            "probability": 0.0
        }
    ],
    "5a885daa61bb38fb24000018_1": [
        {
            "start_logit": 4.35546875,
            "end_logit": 0.408447265625,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 0.99609375
        },
        {
            "start_logit": -1.5537109375,
            "end_logit": 0.408447265625,
            "text": "Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 0.0027008056640625
        },
        {
            "start_logit": -1.48828125,
            "end_logit": -2.14453125,
            "text": "DEAD box proteins are putative RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing.",
            "probability": 0.0002243518829345703
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -8.171875,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which",
            "probability": 0.0001875162124633789
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -8.4921875,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp",
            "probability": 0.00013506412506103516
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.1796875,
            "text": "including Asp(D",
            "probability": 6.788969039916992e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.2578125,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D",
            "probability": 6.276369094848633e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.265625,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif",
            "probability": 6.276369094848633e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.53125,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D)",
            "probability": 4.8160552978515625e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.5390625,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended",
            "probability": 4.738569259643555e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.6875,
            "text": "including Asp(D)-",
            "probability": 4.118680953979492e-05
        },
        {
            "start_logit": 4.35546875,
            "end_logit": -9.7265625,
            "text": "including Asp(D)-Glu-(E)-Ala(A)-",
            "probability": 3.927946090698242e-05
        },
        {
            "start_logit": -8.125,
            "end_logit": 0.408447265625,
            "text": "-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -8.828125,
            "end_logit": 0.408447265625,
            "text": "Asp(D) which is part of a more extended motif.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -9.015625,
            "end_logit": 0.408447265625,
            "text": "(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif.",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 0.408447265625,
            "text": "-Asp(D) which is part of a more extended motif.",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 0.408447265625,
            "text": "more extended motif.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -9.296875,
            "end_logit": 0.408447265625,
            "text": ".",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -2.14453125,
            "text": "RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 0.408447265625,
            "text": "(D) which is part of a more extended motif.",
            "probability": 8.940696716308594e-07
        }
    ],
    "52b2e409f828ad283c00000e_1": [
        {
            "start_logit": 10.4140625,
            "end_logit": 12.3828125,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 12.3828125,
            "text": "with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 12.3828125,
            "text": "antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 12.3828125,
            "text": "for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 12.3828125,
            "text": "the use of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.3828125,
            "text": "use of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.3828125,
            "text": "the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 12.3828125,
            "text": "adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 10.4140625,
            "end_logit": -8.7421875,
            "text": "schizophrenia in",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.3828125,
            "text": "of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.3828125,
            "text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 12.3828125,
            "text": "trends in the use of antipsychotics for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 10.4140625,
            "end_logit": -9.171875,
            "text": "schizophrenia in Canada",
            "probability": 0.0
        },
        {
            "start_logit": 10.4140625,
            "end_logit": -9.3203125,
            "text": "schizophrenia in Canada from 2005 to 2009.",
            "probability": 0.0
        },
        {
            "start_logit": 10.4140625,
            "end_logit": -9.8828125,
            "text": "schizophrenia in Canada from",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -8.7421875,
            "text": "with schizophrenia in",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -9.171875,
            "text": "with schizophrenia in Canada",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -8.7421875,
            "text": "antipsychotics for adults with schizophrenia in",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -9.3203125,
            "text": "with schizophrenia in Canada from 2005 to 2009.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -9.171875,
            "text": "antipsychotics for adults with schizophrenia in Canada",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_2": [
        {
            "start_logit": 9.7578125,
            "end_logit": 11.25,
            "text": "schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 11.25,
            "text": "which schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 11.25,
            "text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -9.0078125,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -9.140625,
            "text": "schizophrenia was listed as the indication",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -9.515625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -9.8671875,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38%",
            "probability": 0.0
        },
        {
            "start_logit": 9.7578125,
            "end_logit": -10.1640625,
            "text": "schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.0078125,
            "text": "which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.140625,
            "text": "which schizophrenia was listed as the indication",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.515625,
            "text": "which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -9.8671875,
            "text": "which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38%",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -9.0078125,
            "text": "listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -9.140625,
            "text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -9.0078125,
            "text": "with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -9.140625,
            "text": "listed as the indication",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -9.0078125,
            "text": ": First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -9.28125,
            "text": "to 454",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -9.0078125,
            "text": "as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -10.1640625,
            "text": "which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased",
            "probability": 0.0
        }
    ],
    "52b2e409f828ad283c00000e_3": [
        {
            "start_logit": 12.59375,
            "end_logit": 14.765625,
            "text": "paranoid schizophrenia",
            "probability": 1.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 14.765625,
            "text": "schizophrenia",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.59375,
            "end_logit": -4.52734375,
            "text": "paran",
            "probability": 0.0
        },
        {
            "start_logit": 12.59375,
            "end_logit": -5.2421875,
            "text": "paranoid",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 14.765625,
            "text": "oid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 14.765625,
            "text": "be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.765625,
            "text": ", serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.765625,
            "text": "Its best indication seems to be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.765625,
            "text": "adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.765625,
            "text": "to be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.765625,
            "text": "-blocking activities. Its best indication seems to be paranoid schizophrenia",
            "probability": 0.0
        },
        {
            "start_logit": 12.59375,
            "end_logit": -10.0859375,
            "text": "paranoid schizophrenia, although some data suggest bipolar action.",
            "probability": 0.0
        },
        {
            "start_logit": 12.59375,
            "end_logit": -10.1640625,
            "text": "paranoid schizophrenia,",
            "probability": 0.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -10.0859375,
            "text": "schizophrenia, although some data suggest bipolar action.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -10.1640625,
            "text": "schizophrenia,",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -4.52734375,
            "text": "be paran",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": -5.2421875,
            "text": "oid",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -5.2421875,
            "text": "be paranoid",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -4.52734375,
            "text": ", serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paran",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -4.52734375,
            "text": "Its best indication seems to be paran",
            "probability": 0.0
        }
    ],
    "6252f496e764a53204000020_1": [
        {
            "start_logit": 11.40625,
            "end_logit": 13.8359375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 1.0
        },
        {
            "start_logit": -2.201171875,
            "end_logit": 13.8359375,
            "text": ".",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 13.8359375,
            "text": "removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 13.8359375,
            "text": "G1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -6.75,
            "text": "ABC",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 13.8359375,
            "text": "ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 13.8359375,
            "text": "excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 13.8359375,
            "text": "cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 13.8359375,
            "text": "from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.5234375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -7.609375,
            "text": "ABCG1 is an ATP binding cassette (ABC) transporter",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.8359375,
            "text": "transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 13.8359375,
            "text": "an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 13.8359375,
            "text": "binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.8359375,
            "text": "peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.8359375,
            "text": "that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 13.8359375,
            "text": "(ABC) transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 13.8359375,
            "text": ") transporter that removes excess cholesterol from peripheral tissues.",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.8125,
            "text": "ABCG1",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.6328125,
            "text": "ABCG1 is",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_1": [
        {
            "start_logit": 13.0703125,
            "end_logit": 13.6875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -3.0078125,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 13.6875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 13.6875,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 13.6875,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -8.953125,
            "text": "1967 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.90625,
            "text": "1967 was performed using a deceased donor heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.9765625,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 13.6875,
            "text": "first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.6875,
            "text": "human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 13.6875,
            "text": "heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 13.6875,
            "text": "transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -3.0078125,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -3.0078125,
            "text": "the first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": -8.953125,
            "text": "7 was performed using a deceased donor heart,",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -3.0078125,
            "text": "first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -3.0078125,
            "text": "human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -3.0078125,
            "text": "heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -3.0078125,
            "text": "transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": -9.90625,
            "text": "7 was performed using a deceased donor heart",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_2": [
        {
            "start_logit": 13.515625,
            "end_logit": 14.078125,
            "text": "1967",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.31640625,
            "end_logit": 14.078125,
            "text": "In 1967",
            "probability": 0.0020198822021484375
        },
        {
            "start_logit": 13.515625,
            "end_logit": -2.78125,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.20703125,
            "end_logit": 14.078125,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -7.98828125,
            "text": "1967, Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -8.328125,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -8.6328125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -2.78125,
            "text": "In 196",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.59375,
            "text": "1967, Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.6953125,
            "text": "1967, Christian Barnard performed",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.8203125,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.9296875,
            "text": "1967, Christian Barnard performed the first successful human-to-human heart transplant",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.125,
            "text": "1967, Christian Barnard performed the first",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.2578125,
            "text": "1967, Christian Barnard performed the first successful human-to-",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -6.66015625,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.98828125,
            "text": "In 1967, Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -8.328125,
            "text": "In 1967, Christian Barnard performed the first successful human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -8.6328125,
            "text": "In 1967,",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -9.59375,
            "text": "In 1967, Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -9.6953125,
            "text": "In 1967, Christian Barnard performed",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_3": [
        {
            "start_logit": 14.265625,
            "end_logit": 14.53125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -1.6025390625,
            "text": "196",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.43359375,
            "end_logit": 14.53125,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 14.53125,
            "text": "Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 14.53125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 14.53125,
            "text": "Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 14.53125,
            "text": "by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 14.53125,
            "text": "nard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 14.53125,
            "text": "istiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 14.53125,
            "text": "Since the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.53125,
            "text": "iaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 14.53125,
            "text": "successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.53125,
            "text": "the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 14.53125,
            "text": "n Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.53125,
            "text": "d in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.90625,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially over the last several decades.",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.9453125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.53125,
            "text": "human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.34375,
            "text": "1967, there has been substantial progress in the field of heart transplantation, especially",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -10.3671875,
            "text": "1967, there has been substantial progress in the field of heart transplantation,",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_4": [
        {
            "start_logit": 12.265625,
            "end_logit": 13.7734375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": -4.02734375,
            "end_logit": 13.7734375,
            "text": "7",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.265625,
            "end_logit": -3.322265625,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 13.7734375,
            "text": "December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.7734375,
            "text": ", 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 13.7734375,
            "text": ") Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 13.7734375,
            "text": "'Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 13.7734375,
            "text": ", Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.7734375,
            "text": "on December 3rd, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -6.90234375,
            "end_logit": -4.97265625,
            "text": "50th",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -3.322265625,
            "text": "December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -3.322265625,
            "text": ", 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": -4.97265625,
            "text": "th",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -3.322265625,
            "text": ") Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -3.322265625,
            "text": "'Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -3.322265625,
            "text": ", Christiaan ('Chris') Barnard at Groote Schuur Hospital in Cape Town on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -3.322265625,
            "text": "on December 3rd, 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": -4.97265625,
            "text": "celebrated the 50th",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -4.97265625,
            "text": "In 2017, we celebrated the 50th",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -4.97265625,
            "text": "the 50th",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_5": [
        {
            "start_logit": 13.7734375,
            "end_logit": 14.2421875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -1.990234375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.166015625,
            "end_logit": 14.2421875,
            "text": "December 1967",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.12890625,
            "end_logit": 14.2421875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 14.2421875,
            "text": "been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 14.2421875,
            "text": "40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 14.2421875,
            "text": "Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.2421875,
            "text": "in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 14.2421875,
            "text": "has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.2421875,
            "text": "since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.2421875,
            "text": "Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.2421875,
            "text": "human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.2421875,
            "text": "istiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.2421875,
            "text": "by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.2421875,
            "text": "the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.2421875,
            "text": "iaan Barnard in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -3.166015625,
            "end_logit": -1.990234375,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -1.990234375,
            "text": "been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -1.990234375,
            "text": "40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -1.990234375,
            "text": "It has been 40 years since the first human-to-human heart transplant performed in South Africa by Christiaan Barnard in December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_6": [
        {
            "start_logit": 14.3359375,
            "end_logit": 14.609375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -1.4345703125,
            "text": "196",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.359375,
            "end_logit": 14.609375,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": 14.609375,
            "text": "Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 14.609375,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": 14.609375,
            "text": "Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 14.609375,
            "text": "by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 14.609375,
            "text": "the first successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 14.609375,
            "text": "istiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.609375,
            "text": "nard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.609375,
            "text": "successful human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.609375,
            "text": "iaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.0703125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.609375,
            "text": "d in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.609375,
            "text": "human heart transplant performed by Christiaan Barnard in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.296875,
            "text": "1967, there has been substantial progress in the field of heart transplantation,",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -1.4345703125,
            "text": "Christiaan Barnard in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": -1.4345703125,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.921875,
            "end_logit": -1.4345703125,
            "text": "Barnard in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -1.4345703125,
            "text": "by Christiaan Barnard in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_7": [
        {
            "start_logit": 14.1484375,
            "end_logit": 14.3125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -1.9130859375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.86328125,
            "end_logit": 14.3125,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 14.3125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": 14.3125,
            "text": "the first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.2578125,
            "text": "1967, the field of heart transplantation has advanced to the point where survival and acceptable quality of life are commonplace.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 14.3125,
            "text": "human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 14.3125,
            "text": "Since the first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 14.3125,
            "text": "performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 14.3125,
            "text": "heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.828125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.3125,
            "text": "first human heart transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.1953125,
            "text": "1967, the field of heart transplantation has",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.3203125,
            "text": "1967, the field of heart",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.3515625,
            "text": "1967, the field",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.3125,
            "text": "transplantation was performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.3828125,
            "text": "1967, the field of heart transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.40625,
            "text": "1967, the field of heart transplantation has advanced",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": -1.9130859375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.890625,
            "end_logit": -1.9130859375,
            "text": "the first human heart transplantation was performed in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_8": [
        {
            "start_logit": 12.796875,
            "end_logit": 13.5078125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 12.796875,
            "end_logit": -3.021484375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.96875,
            "end_logit": 13.5078125,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": 13.5078125,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 13.5078125,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 13.5078125,
            "text": "50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 13.5078125,
            "text": "performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 13.5078125,
            "text": "human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 13.5078125,
            "text": "human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 13.5078125,
            "text": "years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 13.5078125,
            "text": "ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.5078125,
            "text": "to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 13.5078125,
            "text": "-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 13.5078125,
            "text": "first human-to-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.5078125,
            "text": "-human heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 13.5078125,
            "text": "heart transplant was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.5078125,
            "text": "was performed 50 years ago in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -3.021484375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": -3.021484375,
            "text": "The first human-to-human heart transplant was performed 50 years ago in 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -3.021484375,
            "text": "50 years ago in 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_9": [
        {
            "start_logit": 14.1796875,
            "end_logit": 14.3515625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -1.6328125,
            "text": "196",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.83203125,
            "end_logit": 14.3515625,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 14.3515625,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 14.3515625,
            "text": "heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 14.3515625,
            "text": "performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.3515625,
            "text": "human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -9.6015625,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.3515625,
            "text": "the first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 14.3515625,
            "text": "Since the first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 14.3515625,
            "text": "human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -9.8671875,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.03125,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.0703125,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.0859375,
            "text": "1967, advances in organ donation",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.3515625,
            "text": "transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1796875,
            "end_logit": -10.1953125,
            "text": "1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.3515625,
            "text": ", performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.3515625,
            "text": "-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.3515625,
            "text": "first human-to-human heart transplantation, performed in 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_10": [
        {
            "start_logit": 14.0390625,
            "end_logit": 14.375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -1.859375,
            "text": "196",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.8046875,
            "end_logit": 14.375,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 14.375,
            "text": "the first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 14.375,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 14.375,
            "text": "heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.3671875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 14.375,
            "text": "human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.375,
            "text": "first human heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.0,
            "text": "1967 was",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.375,
            "text": "transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.1328125,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.2421875,
            "text": "1967 was performed using a deceased donor heart, the advent of brain death criteria and",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": -1.859375,
            "text": "the first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -1.859375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -1.859375,
            "text": "heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -1.859375,
            "text": "human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -1.859375,
            "text": "first human heart transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -1.859375,
            "text": "transplant in 196",
            "probability": 0.0
        },
        {
            "start_logit": -3.8046875,
            "end_logit": -9.3671875,
            "text": "7 was performed using a deceased donor heart, the advent of brain death criteria and the ability to avoid long warm ischemic times led donation after cardiac death",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_11": [
        {
            "start_logit": 8.390625,
            "end_logit": 11.8671875,
            "text": "1983",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.390625,
            "end_logit": 5.21875,
            "text": "1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0013055801391601562
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 11.8671875,
            "text": "Human Tissue Act of 1983",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.984375,
            "end_logit": 11.8671875,
            "text": "Tissue Act of 1983",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 11.8671875,
            "text": "The Human Tissue Act of 1983",
            "probability": 0.0
        },
        {
            "start_logit": -2.779296875,
            "end_logit": 5.21875,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 11.8671875,
            "text": "of 1983",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 11.8671875,
            "text": "Act of 1983",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -7.9921875,
            "text": "1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 196",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -9.6015625,
            "text": "1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -9.6875,
            "text": "1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -10.046875,
            "text": "1983 had its origin in the first successful heart transplant operation",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -10.1171875,
            "text": "1983 had its origin",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -10.21875,
            "text": "1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team",
            "probability": 0.0
        },
        {
            "start_logit": 8.390625,
            "end_logit": -10.375,
            "text": "1983 had its origin in the first successful heart transplant",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 5.21875,
            "text": "1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": 5.21875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 5.21875,
            "text": "of 1983 had its origin in the first successful heart transplant operation performed by Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 5.21875,
            "text": "in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 5.21875,
            "text": "Professor Christiaan Barnard and his team in December 1967",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_12": [
        {
            "start_logit": 13.59375,
            "end_logit": 14.2265625,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 1.3798828125,
            "end_logit": 14.2265625,
            "text": "December 1967",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 13.59375,
            "end_logit": -2.4453125,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.07421875,
            "end_logit": 14.2265625,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 14.2265625,
            "text": "Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 14.2265625,
            "text": "been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.2265625,
            "text": "since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.2265625,
            "text": "It has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.2265625,
            "text": "50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.2265625,
            "text": "has been 50 years since Dr. Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.2265625,
            "text": "human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.2265625,
            "text": "in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.2265625,
            "text": "human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.2265625,
            "text": "Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.2265625,
            "text": "Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.2265625,
            "text": ". Christiaan Barnard performed the first human-to-human heart transplant in December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.9609375,
            "text": "1967 in South Africa",
            "probability": 0.0
        },
        {
            "start_logit": 1.3798828125,
            "end_logit": -2.4453125,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": 1.3798828125,
            "end_logit": -8.2109375,
            "text": "December",
            "probability": 0.0
        },
        {
            "start_logit": 1.3798828125,
            "end_logit": -9.9609375,
            "text": "December 1967 in South Africa",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_13": [
        {
            "start_logit": 13.9140625,
            "end_logit": 14.4375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -2.185546875,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.6640625,
            "end_logit": 14.4375,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 14.4375,
            "text": "3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 14.4375,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 14.4375,
            "text": "The first successful human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 14.4375,
            "text": "successful human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.4375,
            "text": "on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.7109375,
            "text": "1967, by Christiaan Barnard",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.7109375,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.7109375,
            "text": "1967, by Christiaan Barnard in South Africa.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.4375,
            "text": "reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 14.4375,
            "text": "first successful human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.4375,
            "text": "human heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -10.0859375,
            "text": "1967, by Christiaan Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -10.09375,
            "text": "1967, by Christiaan Barnard in South Africa",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.4375,
            "text": "heart transplantation was reported on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -5.5390625,
            "end_logit": -2.185546875,
            "text": "3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -2.185546875,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": -2.185546875,
            "text": "The first successful human heart transplantation was reported on 3 December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_14": [
        {
            "start_logit": 14.1640625,
            "end_logit": 14.546875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -1.5537109375,
            "text": "196",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.513671875,
            "end_logit": 14.546875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 14.546875,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 14.546875,
            "text": "The world's first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 14.546875,
            "text": "the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 14.546875,
            "text": "2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.3203125,
            "text": "1967.",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 14.546875,
            "text": "Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.546875,
            "text": "human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.546875,
            "text": "human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.546875,
            "text": "on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.546875,
            "text": "heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.546875,
            "text": "s first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.546875,
            "text": "to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.546875,
            "text": "-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.546875,
            "text": "Schuur Hospital on the 2nd December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -1.5537109375,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -1.5537109375,
            "text": "The world's first human-to-human heart transplant was performed at Groote Schuur Hospital on the 2nd December 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -1.5537109375,
            "text": "the 2nd December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_15": [
        {
            "start_logit": 13.3125,
            "end_logit": 14.046875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -3.068359375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.0859375,
            "end_logit": 14.046875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": 14.046875,
            "text": "3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 14.046875,
            "text": "50 years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 14.046875,
            "text": "December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 14.046875,
            "text": "Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 14.046875,
            "text": "by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.046875,
            "text": "have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 14.046875,
            "text": "human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 14.046875,
            "text": "in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.046875,
            "text": "Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 14.046875,
            "text": "years have passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.046875,
            "text": "passed since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.046875,
            "text": "Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.046875,
            "text": "human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.046875,
            "text": "istiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.3125,
            "end_logit": -9.828125,
            "text": "1967.",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.046875,
            "text": "since the first human to human heart transplantation, performed by Christiaan Barnard in Cape Town December 3rd 1967",
            "probability": 0.0
        },
        {
            "start_logit": -5.890625,
            "end_logit": -3.068359375,
            "text": "3rd 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_16": [
        {
            "start_logit": 13.703125,
            "end_logit": 14.0546875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": 14.0546875,
            "text": "In 1967",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 13.703125,
            "end_logit": -2.474609375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.2578125,
            "end_logit": 14.0546875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -8.328125,
            "text": "1967, he led the team that performed the world's first human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -8.7421875,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.625,
            "text": "1967, he led the team",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.6484375,
            "text": "1967, he led the team that performed the world",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.71875,
            "text": "1967, he led the team that performed the world's first human-to-human heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.9140625,
            "text": "1967, he led the team that performed the world's first human-to-human heart transplant",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -9.9453125,
            "text": "1967, he led the team that",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -10.125,
            "text": "1967, he led the team that performed the world's first",
            "probability": 0.0
        },
        {
            "start_logit": 13.703125,
            "end_logit": -10.2421875,
            "text": "1967, he led the team that performed the world'",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -2.474609375,
            "text": "In 196",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -7.01953125,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -8.328125,
            "text": "In 1967, he led the team that performed the world's first human-to-human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -8.7421875,
            "text": "In 1967,",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -9.625,
            "text": "In 1967, he led the team",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -9.6484375,
            "text": "In 1967, he led the team that performed the world",
            "probability": 0.0
        },
        {
            "start_logit": 0.30126953125,
            "end_logit": -9.71875,
            "text": "In 1967, he led the team that performed the world's first human-to-human heart",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_17": [
        {
            "start_logit": 13.8125,
            "end_logit": 14.1875,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -2.234375,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.94921875,
            "end_logit": 14.1875,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -5.23828125,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 14.1875,
            "text": "in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 14.1875,
            "text": "a century. From the repair of the first septal defect in 1953, followed by the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.3203125,
            "text": "1967,",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.453125,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in h",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 14.1875,
            "text": "successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.1875,
            "text": "heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 14.1875,
            "text": "the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -10.1484375,
            "text": "1967, and later to the first infusion of bone marrow",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -10.15625,
            "text": "1967, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -10.1640625,
            "text": "1967, and later",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -10.265625,
            "text": "1967, and later to the first infusion of bone marrow-derived cells to the human myocardium",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.1875,
            "text": "transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 14.1875,
            "text": "by the first successful heart transplant in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -3.94921875,
            "end_logit": -5.23828125,
            "text": "7, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -2.234375,
            "text": "in 196",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": -5.23828125,
            "text": "2002",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_18": [
        {
            "start_logit": 13.7734375,
            "end_logit": 14.3203125,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -2.36328125,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.87109375,
            "end_logit": 14.3203125,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -5.4140625,
            "end_logit": 14.3203125,
            "text": "3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": 14.3203125,
            "text": "December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.3203125,
            "text": "heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.3203125,
            "text": "the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -9.8125,
            "text": "1967.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.3203125,
            "text": ", Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.3203125,
            "text": "on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.3203125,
            "text": "Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.3203125,
            "text": "at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.3203125,
            "text": "Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.3203125,
            "text": "Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.3203125,
            "text": "first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.3203125,
            "text": "transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 1967",
            "probability": 0.0
        },
        {
            "start_logit": -5.4140625,
            "end_logit": -2.36328125,
            "text": "3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -2.36328125,
            "text": "December 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -2.36328125,
            "text": "heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -2.36328125,
            "text": "the first heart transplant, performed at Groote Schuur Hospital, Cape Town, on 3 December 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_19": [
        {
            "start_logit": 13.796875,
            "end_logit": 14.3984375,
            "text": "1967",
            "probability": 1.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -2.25,
            "text": "196",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.693359375,
            "end_logit": 14.3984375,
            "text": "7",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 14.3984375,
            "text": "On December 3, 1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 14.3984375,
            "text": ", 1967",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.3984375,
            "text": "December 3, 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -9.671875,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with the first successful human heart transplant.",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -9.734375,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.3984375,
            "text": "3, 1967",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.0078125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnar",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.0390625,
            "text": "1967, in Cape Town",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.1640625,
            "text": "1967, in Cape Town, South Africa",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.1875,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.28125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with the first successful human heart",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.328125,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.375,
            "text": "1967, in Cape Town, South Africa, Dr. Christian Barnard revolutionized organ transplantation with the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.02734375,
            "end_logit": -2.25,
            "text": "On December 3, 196",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -2.25,
            "text": ", 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -2.25,
            "text": "December 3, 196",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -2.25,
            "text": "3, 196",
            "probability": 0.0
        }
    ],
    "601ee4c61cb411341a000066_20": [
        {
            "start_logit": 9.3515625,
            "end_logit": 12.6171875,
            "text": "1974",
            "probability": 1.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": 12.6171875,
            "text": "1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 12.6171875,
            "text": "Barnard performed the 1st human-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 12.6171875,
            "text": "in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.6171875,
            "text": "human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 12.6171875,
            "text": "in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 12.6171875,
            "text": "performed the 1st human-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 12.6171875,
            "text": "human-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 12.6171875,
            "text": "the 1st human-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 12.6171875,
            "text": "heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 12.6171875,
            "text": "heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.6171875,
            "text": "of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 12.6171875,
            "text": "followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 12.6171875,
            "text": "to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 12.6171875,
            "text": "1st human-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 12.6171875,
            "text": "-to-human orthotopic heart transplantation in 1967 and followed this by introducing the technique of heterotopic heart transplantation in 1974",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -9.8203125,
            "text": "1974.",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -7.5390625,
            "text": "1967",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -7.5390625,
            "text": "Barnard performed the 1st human-to-human orthotopic heart transplantation in 1967",
            "probability": 0.0
        },
        {
            "start_logit": -7.796875,
            "end_logit": -9.6875,
            "text": "1967 and",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_1": [
        {
            "start_logit": 2.6640625,
            "end_logit": -6.13671875,
            "text": "cis-regulatory elements",
            "probability": 0.82470703125
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.5625,
            "text": "cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.026824951171875
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.734375,
            "text": "cis-regulatory elements is",
            "probability": 0.0225830078125
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.796875,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI",
            "probability": 0.021209716796875
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.828125,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion",
            "probability": 0.0205535888671875
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.8515625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements",
            "probability": 0.02008056640625
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -9.9140625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNase",
            "probability": 0.0188751220703125
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -10.34375,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to",
            "probability": 0.01227569580078125
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -10.40625,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity",
            "probability": 0.01152801513671875
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -10.4609375,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold",
            "probability": 0.01091766357421875
        },
        {
            "start_logit": 2.6640625,
            "end_logit": -10.4921875,
            "text": "cis-regulatory elements is central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains",
            "probability": 0.01058197021484375
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -3.123046875,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 8.046627044677734e-05
        },
        {
            "start_logit": -9.65625,
            "end_logit": -3.123046875,
            "text": "gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 7.444620132446289e-05
        },
        {
            "start_logit": -10.328125,
            "end_logit": -3.123046875,
            "text": "locating such elements.",
            "probability": 3.802776336669922e-05
        },
        {
            "start_logit": -10.328125,
            "end_logit": -3.123046875,
            "text": "central to understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 3.802776336669922e-05
        },
        {
            "start_logit": -10.375,
            "end_logit": -3.123046875,
            "text": "understanding gene transcription. Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 3.62396240234375e-05
        },
        {
            "start_logit": -10.546875,
            "end_logit": -3.123046875,
            "text": "the gold-standard approach to locating such elements.",
            "probability": 3.057718276977539e-05
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -3.123046875,
            "text": "of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 2.866983413696289e-05
        },
        {
            "start_logit": -10.625,
            "end_logit": -3.123046875,
            "text": "ating such elements.",
            "probability": 2.8252601623535156e-05
        },
        {
            "start_logit": -10.75,
            "end_logit": -3.123046875,
            "text": "-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 2.491474151611328e-05
        }
    ],
    "5fdb2e23a43ad3127800000a_2": [
        {
            "start_logit": -2.142578125,
            "end_logit": 9.3359375,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.98388671875
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 9.3359375,
            "text": ".",
            "probability": 0.01282501220703125
        },
        {
            "start_logit": -9.0625,
            "end_logit": 9.3359375,
            "text": "regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0009698867797851562
        },
        {
            "start_logit": -9.6875,
            "end_logit": 9.3359375,
            "text": "-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0005192756652832031
        },
        {
            "start_logit": -10.390625,
            "end_logit": 9.3359375,
            "text": "locating such elements.",
            "probability": 0.0002570152282714844
        },
        {
            "start_logit": -10.625,
            "end_logit": 9.3359375,
            "text": "Hypersensitivity of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0002033710479736328
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 9.3359375,
            "text": "standard approach to locating such elements.",
            "probability": 0.0001895427703857422
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 9.3359375,
            "text": "the gold-standard approach to locating such elements.",
            "probability": 0.00018656253814697266
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 9.3359375,
            "text": "of cis-regulatory elements to digestion with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.00017249584197998047
        },
        {
            "start_logit": -10.828125,
            "end_logit": 9.3359375,
            "text": "ating such elements.",
            "probability": 0.0001659393310546875
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 9.3359375,
            "text": "with DNaseI remains the gold-standard approach to locating such elements.",
            "probability": 0.0001571178436279297
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 9.3359375,
            "text": "approach to locating such elements.",
            "probability": 0.00015461444854736328
        },
        {
            "start_logit": -10.953125,
            "end_logit": 9.3359375,
            "text": "-standard approach to locating such elements.",
            "probability": 0.00014650821685791016
        },
        {
            "start_logit": -11.078125,
            "end_logit": 9.3359375,
            "text": "remains the gold-standard approach to locating such elements.",
            "probability": 0.00012922286987304688
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -6.765625,
            "text": "cis-regulatory elements",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -9.328125,
            "text": "cis-regulatory elements to digestion",
            "probability": 0.0
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -9.7265625,
            "text": "cis-regulatory elements to digestion with DNaseI",
            "probability": 0.0
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -9.84375,
            "text": "cis-regulatory elements to",
            "probability": 0.0
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -9.890625,
            "text": "cis-regulatory elements to digestion with DNase",
            "probability": 0.0
        },
        {
            "start_logit": -2.142578125,
            "end_logit": -10.1015625,
            "text": "cis-regulatory elements to digestion with DNaseI remains the gold",
            "probability": 0.0
        }
    ],
    "5fdb2e23a43ad3127800000a_3": [
        {
            "start_logit": -7.92578125,
            "end_logit": 7.890625,
            "text": ".",
            "probability": 0.43212890625
        },
        {
            "start_logit": -9.03125,
            "end_logit": 7.890625,
            "text": "cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.14306640625
        },
        {
            "start_logit": -9.390625,
            "end_logit": 7.890625,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.099853515625
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 7.890625,
            "text": "gene transcription.",
            "probability": 0.08343505859375
        },
        {
            "start_logit": -10.296875,
            "end_logit": 7.890625,
            "text": "understanding gene transcription.",
            "probability": 0.04034423828125
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 7.890625,
            "text": "regulatory elements is central to understanding gene transcription.",
            "probability": 0.0400390625
        },
        {
            "start_logit": -10.421875,
            "end_logit": 7.890625,
            "text": "central to understanding gene transcription.",
            "probability": 0.035614013671875
        },
        {
            "start_logit": -10.5,
            "end_logit": 7.890625,
            "text": "-regulatory elements is central to understanding gene transcription.",
            "probability": 0.032928466796875
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 7.890625,
            "text": "identification of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.0262451171875
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 7.890625,
            "text": "elements is central to understanding gene transcription.",
            "probability": 0.025054931640625
        },
        {
            "start_logit": -10.890625,
            "end_logit": 7.890625,
            "text": "of cis-regulatory elements is central to understanding gene transcription.",
            "probability": 0.02227783203125
        },
        {
            "start_logit": -11.046875,
            "end_logit": 7.890625,
            "text": "to understanding gene transcription.",
            "probability": 0.0190582275390625
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.375,
            "text": "cis-regulatory elements is",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -9.375,
            "text": "The identification of cis-regulatory elements is",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.7734375,
            "text": "cis-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -10.1328125,
            "text": "cis-regulatory elements",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -9.7734375,
            "text": "The identification of cis-regulatory elements is central to understanding gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -10.296875,
            "text": "cis-regulatory elements is central to",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.7734375,
            "text": "gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": -10.1328125,
            "text": "The identification of cis-regulatory elements",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_1": [
        {
            "start_logit": 14.734375,
            "end_logit": 15.328125,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 14.734375,
            "end_logit": -0.65185546875,
            "text": "autosomal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": 15.328125,
            "text": "dominant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 15.328125,
            "text": "AD has an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 14.734375,
            "end_logit": -8.828125,
            "text": "autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 15.328125,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 14.734375,
            "end_logit": -9.4140625,
            "text": "autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head",
            "probability": 0.0
        },
        {
            "start_logit": 14.734375,
            "end_logit": -9.4609375,
            "text": "autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": 14.734375,
            "end_logit": -9.6640625,
            "text": "autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -0.65185546875,
            "text": "AD has an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -8.828125,
            "text": "dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -0.65185546875,
            "text": "an autosomal",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.4140625,
            "text": "dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.4609375,
            "text": "dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.6640625,
            "text": "dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -8.828125,
            "text": "AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head).",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -8.859375,
            "text": "AD",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.4140625,
            "text": "AD has an autosomal dominant mode of inheritance, distinct facial and skeleton features (a hoarse voice and internal notch of the femoral head",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.4609375,
            "text": "AD has an autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.6640625,
            "text": "AD has an autosomal dominant mode",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_2": [
        {
            "start_logit": 14.21875,
            "end_logit": 15.1953125,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": -1.6591796875,
            "end_logit": 15.1953125,
            "text": "dominant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.283203125,
            "text": "autosomal",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -3.734375,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -8.421875,
            "text": "autosomal dominant or an autosomal recessive (AR) mode",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -8.703125,
            "text": "autosomal dominant or an autosomal recessive (AR",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -8.890625,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.03125,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.15625,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5390625,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.1953125,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.1953125,
            "text": "WMS is transmitted either by an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.1953125,
            "text": "by an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.9296875,
            "text": "autosomal dominant or an autosomal recessive",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.96875,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.046875,
            "text": "autosomal dominant or an autosomal recessive (AR) mode of inheritance,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6591796875,
            "end_logit": -3.734375,
            "text": "dominant or an autosomal recessive (AR) mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -1.6591796875,
            "end_logit": -8.421875,
            "text": "dominant or an autosomal recessive (AR) mode",
            "probability": 0.0
        },
        {
            "start_logit": -1.6591796875,
            "end_logit": -8.703125,
            "text": "dominant or an autosomal recessive (AR",
            "probability": 0.0
        }
    ],
    "53318685d6d3ac6a3400003d_3": [
        {
            "start_logit": 14.6875,
            "end_logit": 15.296875,
            "text": "autosomal dominant",
            "probability": 1.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -0.9140625,
            "text": "autosomal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.5732421875,
            "end_logit": 15.296875,
            "text": "dominant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6875,
            "end_logit": -8.6328125,
            "text": "autosomal dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 15.296875,
            "text": "an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.3125,
            "text": "autosomal dominant mode of inheritance.",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -9.4765625,
            "text": "autosomal dominant mode",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.296875,
            "text": "families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.296875,
            "text": "with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.296875,
            "text": "The condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.296875,
            "text": "vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.296875,
            "text": "cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.296875,
            "text": "consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.296875,
            "text": "the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.296875,
            "text": "in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.296875,
            "text": "condition appeared to be sporadic in 16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.296875,
            "text": "16 cases but the observation of vertical transmission in three families was consistent with an autosomal dominant",
            "probability": 0.0
        },
        {
            "start_logit": 14.6875,
            "end_logit": -10.3359375,
            "text": "autosomal dominant mode of",
            "probability": 0.0
        },
        {
            "start_logit": -1.5732421875,
            "end_logit": -8.6328125,
            "text": "dominant mode of inheritance",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -0.9140625,
            "text": "an autosomal",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_1": [
        {
            "start_logit": 14.171875,
            "end_logit": 14.1953125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -1.6025390625,
            "text": "Oh",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.865234375,
            "end_logit": 14.1953125,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -8.375,
            "text": "Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 14.1953125,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 14.1953125,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.1953125,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.1953125,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.1953125,
            "text": "2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.1953125,
            "text": "Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 14.1953125,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.1953125,
            "text": "communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.1953125,
            "text": "include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.1953125,
            "text": "in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -1.6025390625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -1.6025390625,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -1.6025390625,
            "text": "a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -3.865234375,
            "end_logit": -8.375,
            "text": "io,",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -1.6025390625,
            "text": "measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -1.6025390625,
            "text": "2014 measles outbreak in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_2": [
        {
            "start_logit": 13.8984375,
            "end_logit": 13.7890625,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -1.8671875,
            "text": "Oh",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.47265625,
            "end_logit": 13.7890625,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 13.7890625,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 13.7890625,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 13.7890625,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.7890625,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.7890625,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 13.7890625,
            "text": "Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 13.7890625,
            "text": "numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.7890625,
            "text": "communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 13.7890625,
            "text": "with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 13.7890625,
            "text": "in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.7890625,
            "text": "outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 13.7890625,
            "text": "individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -1.8671875,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -1.8671875,
            "text": "a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -1.8671875,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -1.8671875,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -1.8671875,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_3": [
        {
            "start_logit": 14.046875,
            "end_logit": 14.1484375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -1.7822265625,
            "text": "Oh",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.916015625,
            "end_logit": 14.1484375,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 14.1484375,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.921875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.96875,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.1484375,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.1640625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.171875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.1484375,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.1484375,
            "text": "features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -1.7822265625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -1.7822265625,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -1.7822265625,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -1.7822265625,
            "text": "features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -9.921875,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -9.96875,
            "text": "io were",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -10.1640625,
            "text": "io were transmission primarily within households, the small proportion of Amish",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -10.171875,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -9.921875,
            "text": "in Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_4": [
        {
            "start_logit": 14.3125,
            "end_logit": 14.2578125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -1.32421875,
            "text": "Oh",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.79296875,
            "end_logit": 14.2578125,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 14.2578125,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.9921875,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.2578125,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.2578125,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.2578125,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.2578125,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.2578125,
            "text": "Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -1.32421875,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -1.32421875,
            "text": "a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -1.32421875,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": -1.32421875,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -1.32421875,
            "text": "Measles outbreaks in the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -1.32421875,
            "text": "2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -1.32421875,
            "text": "Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -3.79296875,
            "end_logit": -9.9921875,
            "text": "io pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -9.9921875,
            "text": "in Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": -10.2734375,
            "text": "in",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_5": [
        {
            "start_logit": 14.265625,
            "end_logit": 14.3359375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -1.4873046875,
            "text": "Oh",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.6328125,
            "end_logit": 14.3359375,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 14.3359375,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 14.3359375,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.3359375,
            "text": "a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.78125,
            "text": "Ohio, resulting in 368 cases reported.",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.7890625,
            "text": "Ohio,",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.3359375,
            "text": "measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.3359375,
            "text": "Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.3359375,
            "text": "2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.3359375,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 14.3359375,
            "text": "include a 2014 measles outbreak in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -1.4873046875,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -1.4873046875,
            "text": "Recent outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -1.4873046875,
            "text": "a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -1.4873046875,
            "text": "measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -1.4873046875,
            "text": "Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -1.4873046875,
            "text": "2014 measles outbreak in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -1.4873046875,
            "text": "outbreaks in Amish communities include a 2014 measles outbreak in Oh",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_6": [
        {
            "start_logit": 14.046875,
            "end_logit": 14.1484375,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -1.7822265625,
            "text": "Oh",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.916015625,
            "end_logit": 14.1484375,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 14.1484375,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.921875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.96875,
            "text": "Ohio were",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.1484375,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.1640625,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.171875,
            "text": "Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.1484375,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.1484375,
            "text": "features of a measles outbreak in the Amish community in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -1.7822265625,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -1.7822265625,
            "text": "CONCLUSIONS The key epidemiologic features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -1.7822265625,
            "text": "epidemiologic features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -1.7822265625,
            "text": "features of a measles outbreak in the Amish community in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -9.921875,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -9.96875,
            "text": "io were",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -10.1640625,
            "text": "io were transmission primarily within households, the small proportion of Amish",
            "probability": 0.0
        },
        {
            "start_logit": -3.916015625,
            "end_logit": -10.171875,
            "text": "io were transmission primarily within households, the small proportion of Amish people affected, and the large number of",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -9.921875,
            "text": "in Ohio were transmission primarily within households, the small proportion of Amish people affected, and the large number of people in the Amish community",
            "probability": 0.0
        }
    ],
    "5c5312097e3cb0e231000011_7": [
        {
            "start_logit": 14.1953125,
            "end_logit": 14.125,
            "text": "Ohio",
            "probability": 1.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -1.529296875,
            "text": "Oh",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.962890625,
            "end_logit": 14.125,
            "text": "io",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 14.125,
            "text": "in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.96875,
            "text": "Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.125,
            "text": "a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.125,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.125,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.125,
            "text": "2014 outbreak in Amish communities in Ohio",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -1.529296875,
            "text": "in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -1.529296875,
            "text": "a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -1.529296875,
            "text": "United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -1.529296875,
            "text": "the United States continue to occur in subpopulations with sufficient numbers of undervaccinated individuals, with a 2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -1.529296875,
            "text": "2014 outbreak in Amish communities in Oh",
            "probability": 0.0
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -9.96875,
            "text": "io pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": -9.96875,
            "text": "in Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -9.625,
            "text": "Measles Transmission in the North",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -9.625,
            "text": "North",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.96875,
            "text": "a 2014 outbreak in Amish communities in Ohio pushing the annual cases to the highest national number reported in the last 20 years.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -10.0,
            "text": "a 2014",
            "probability": 0.0
        }
    ],
    "61f95f9f882a024a1000004e_1": [
        {
            "start_logit": 13.4375,
            "end_logit": 14.859375,
            "text": "Oguchi disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.50390625,
            "end_logit": 14.859375,
            "text": "disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.4375,
            "end_logit": -3.927734375,
            "text": "Og",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.76171875,
            "text": "Oguch",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.8671875,
            "text": "Oguchi",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 14.859375,
            "text": "i disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 14.859375,
            "text": "uchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 14.859375,
            "text": "cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 14.859375,
            "text": "Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.859375,
            "text": "G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 14.859375,
            "text": "mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.859375,
            "text": "allelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.7265625,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB).",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.859375,
            "text": "Oguchi disease,",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -10.25,
            "text": "Oguchi disease, a rare",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -10.2734375,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -10.3046875,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -10.3125,
            "text": "Oguchi disease, a rare subtype of congenital stationary night blindness (",
            "probability": 0.0
        },
        {
            "start_logit": -2.50390625,
            "end_logit": -9.375,
            "text": "disease, a rare subtype of congenital stationary night blindness (CSNB",
            "probability": 0.0
        }
    ]
}
